



**ADVANCES IN INTERNAL MEDICINE**  
**VOLUME IX**

# ADVANCES IN INTERNAL MEDICINE

VOLUMES I II and VII (out of print)

## VOLUME III

- USE OF ANTI LEWISITE (BAL) IN TREATMENT OF POISONING BY ARSENIC  
MERCURY AND OTHER METALS *by W T Longcope and J A Luetscher Jr*  
CURRENT CONCEPTS OF HEMOLYTIC ANEMIAS *by S Estren*  
HOST DRUG AND PARASITE FACTORS THAT MODIFY THE THERAPEUTIC ACTIVITY OF PENICILLIN *by H Eagle*  
STREPTOMYCIN DEVELOPMENT AND STATUS OF ITS USE IN THE TREATMENT OF TUBERCULOSIS *by H C Hinshaw and W H Feldman*  
HISTOPLASMOSIS *by H Pinkerton*  
TREATMENT OF HYPERTHYROIDISM WITH ANTITHYROID COMPOUNDS *by E B Astwood*  
DIAGNOSIS OF DISEASE BY ENZYMIC METHODS *by C Huggins and P Talalay*  
PLASMA FRACTIONATION *by C A Janeway*  
THE MECHANISM OF ACCLIMATIZATION TO HEAT *by J W Conn*  
MODERN THERAPEUTIC AGENTS IN NEUROLOGIC CONDITIONS *by H H Merritt*

## VOLUME IV

- NITROGEN MUSTARDS IN THE TREATMENT OF NEOPLASTIC DISEASE *by D A Karnofsky*  
USE OF RADIOACTIVE ISOTOPES IN MEDICINE *by L R Wasserman and R Loelinger*  
BRUCELLOSIS *by A I Braude and W W Spink*  
ADVANCES IN NEUROMUSCULAR DISORDERS *by D McEachern and R Rabinovitch*  
USE OF SODIUM DEPLETION IN THERAPY *by W Dock*  
CLINICAL USE OF ANTICOAGULANTS *by I E Estes and E V Allen*  
HEPATITIS AND CIRRHOSIS OF THE LIVER *by A J Patek Jr*  
HEPATIC TESTS *by H Popper and F Schaffner*  
THE VASCULAR PHYSIOLOGY OF HYPERTENSION *by G W Pickering*

## VOLUME V

- DISEASES OF THE PREGNANT WOMAN AFFECTING THE OFFSPRING *by M H Bass*  
CATHETERIZATION OF THE HEART *by R J Sang*  
PORTAL HYPERTENSION AND ITS TREATMENT *by A H Blakemore*  
THE ANEMIA OF INFECTION XVII A REVIEW *by G E Cartwright and M M Wintrobe*  
GOUT A DERANGEMENT OF PURINE METABOLISM *by A B Gutman and T F Yu*

- ✓ CLINICAL ASPECTS OF GANGLIONIC AND ADRENERGIC BLOCKING AGENTS *by R H Lyons and V L Loe*
- ASPECTS OF THE INFLUENZA PROBLEM *by J Mulder*
- EXPERIENCES WITH ADRENOCORTICOTROPIC HORMONE (ACTH) AND CORTISONE, *by C Ragan*
- ✓ ABNORMAL PROTEINS IN MYELOMA, *by J Waldenström*

## VOLUME VI

- ✓ UROPEPSIN *by D C Balfour Jr*
- GLUCAGON THE HYPERGLYCEMIC-GLYCOGENOLYTIC HORMONE OF THE PANCREAS *by P P Föld*
- DIAGNOSIS OF CANCER OF INTERNAL ORGANS BY PAPANICOLAOU TECHNIC, *by R M Graham*
- ✓ SPATIAL VECTORCARDIOGRAPHY *by A Grishman*
- ✓ THE L.E. CELL PHENOMENON *by M M Hargraves*
- BIOPSY STUDIES OF THE LIVER AND KIDNEY *by P Iversen M Bjørneboe and N B Krørup*
- ✓ THROMBOTIC THROMBOCYTOPENIC PURPURA *by K. Singer*
- ✓ PORPHYRIA, *by C J Watson*
- DIAPHRAGMATIC HERNIA, *by S Weintraub*
- THE DETERMINATION OF INSULIN IN BLOOD *by A F Willebrands and J Groen*

## VOLUME VIII

- ✓ DISORDERS OF ESOPHAGEAL MOTOR FUNCTIONS *by Franz J Ingelfinger*
- ✓ PEPTIC ULCER REVIEW OF RECENT LITERATURE PERTAINING TO ETIOLOGY PATHOGENESIS AND CERTAIN CLINICAL ASPECTS *by Joseph B Kirsner Robert S Kasriel and Walter L Palmer*
- DIGITALIS AND POTASSIUM *by Bernard Lown*
- ✓ ALDOSTERONE *by John A Luetscher Jr*
- ✓ ADRENALECTOMY AND HYPOPHYSECTOMY IN THE TREATMENT OF ADVANCED CANCER, *by Olof H Pearson*
- ✓ CHEMOTHERAPY OF TUBERCULOSIS *by William F Russell Jr Sidney H Dressler and Gardner Middlebrook*
- ✓ TRACE METALS AND CHRONIC DISEASES *by Henry A Schroeder*
- HEMOGLOBINS AND DISEASE *by R Janet Watson*





# VANCES *in* INTERNAL MEDICINE

EDITED BY

WILLIAM DOCK, M D

*University of New York College of Medicine at New York City*

JOHN H. NAPPER, M D

*El Hospital Brooklyn*

VOLUME IX 1958

LEA AND FEBER BOOK PUBLISHERS

INC

COPYRIGHT 1958 BY THE YEAR BOOK PUBLISHERS INC

For Great Britain and Northern Ireland  
Inter-science Publishers Ltd.  
28-30 Chancery Lane London WC2

PRINTED IN U.S.A.

# Contents

✓ The Metabolism of Vitamin B <sub>12</sub> in Pernicious and Other Megaloblastic Anemias <i>By</i> SOLOMON ESTREN, EUGENE A. BRODY and LOUIS R. WASSERMAN <i>Department of Hematology The Mount Sinai Hospital New York</i>	11
Technics of Study	12
Measurement of Vitamin B <sub>12</sub> in Body	12
Radioactive Technics	14
Absorption	18
Intestinal Absorption	18
Absorption by Other Routes	20
Transport	20
Summary	25
Distribution Storage and Excretion	25
Role in Cellular Metabolism	28
Role in Megaloblastic Anemias	30
Nutritional Macrocytic Anemia	31
✓ Pernicious Anemia	32
✓ Total Gastrectomy	33
✓ Congenital Absence of Intrinsic Factor	33
✓ Posterolateral Sclerosis Without Anemia	33
Primary Malabsorption Syndrome	34
Intestinal Blind Loop Syndrome	35
Diphyllobothrium Latum Anemia	36
Pernicious Anemia of Pregnancy	37
Megaloblastic Anemia of Infancy	37
Megaloblastic Anemia of Hepatic Disease	38
Megaloblastic Anemia Due to Drugs	38
References	38
Corticosteroids and Infections <i>By</i> EDWARD H. KASS and MAX WELL FINLAND <i>Thorndike Memorial Laboratory Second and Fourth (Harvard) Medical Services Boston City Hos</i>	

For Great Britain & Northern Ireland  
Interline Publishers Ltd.  
88-90 Chancery Lane London WC 2

Treatment	134
Circulating Anticoagulants	140
Hemophilia in the Female	142
Vascular Hemophilia	143
Christmas Disease	145
Plasma Thromboplastin Antecedent Deficiency	149
Tetartoheophilia A Fourth Plasma Thrombo Plastin Com ponent Deficiency	152
Hageman Trait	152
Prothrombin Deficiency	154
Parahemophilia	154
Deficiencies of "Serum" Factors Pro SPCA and Stuart Factor	158
Congenital Afibrinogenemia	161
Congenital Hyperheparinemia	163
Congenital Thrombocytopenia	163
Combined Defects	164
Lennox	166
References	166
<b>Etiology and Pathogenesis of Glomerulonephritis</b> By WILLARD • C SCHMIDT and CHARLES H RAMMELKAMP JR Depart ments of Pediatrics and Medicine Cleveland City Hospi tal and Department of Preventive Medicine Western Re serve University Cleveland Ohio	181
Natural History	182
Problems Presented by Variations in Disease	183
Clinical Features	183
Etiology Bacteriologic and Serologic Studies	186
Pathology	191
Experimental Nephritis	193
Heterologous Protein Nephritis	193
Nephrotoxic Renal Disease	195
Experimental Nephritis After Infection of Streptococci or Streptococci Kidney Tissue Mixtures	200
References	201
<b>Pathophysiology of Carcinoid Tumors</b> By DAVID M SPAIN Beth El Hospital Brooklyn New York and Columbia Uni versity College of Physicians and Surgeons New York	207
Enterochromaffin (Argentaffin) Cells	207

<i>pital and Department of Medicine Harvard Medical School Boston</i>	45
Role of Adrenocortical Hormones in Management of Infectious Diseases	48
Evidence for Depression of Host Resistance by Corticosteroids	49
Use of Corticosteroids with Antimicrobial Agents in Infection	53
Evidence of Beneficial Effects from Corticosteroids	57
Corticosteroids and Inflammation and Repair	67
Corticosteroids and Antibody Response	69
Corticosteroids and Reticuloendothelial Function	71
Conclusions	73
References	73
 Primary and Secondary Hyperparathyroidism By B E C NORDEN <i>The University Department of Medicine Gardiner Institute Western Infirmary Glasgow Scotland</i>	81
Actions of Parathyroid Hormone	81
Phosphaturic Action	82
Calcemic Action	87
Hormone or Hormones?	89
Stimulus to Parathyroids	90
Diagnosis of Primary Hyperparathyroidism	91
Syndromes of Secondary Hyperparathyroidism	94
In Vitamin D Deficiency	94
In Glomerular Failure	96
Primary and Secondary Hyperparathyroidism in Renal Failure	100
References	101
 Hereditary Defects in Clotting Mechanisms By OSCAR D RATNOFF <i>Department of Medicine Western Reserve University School of Medicine and University Hospitals Cleveland Ohio</i>	107
Physiology of Blood Coagulation	109
Some Comments on Laboratory Procedures	114
Classic Hemophilia	120
Hereditary Nature of Hemophilia	120
Nature of Defect	125
Clinical Picture	128
Diagnosis	133

# The Metabolism of Vitamin B<sub>12</sub> in Pernicious and Other Megaloblastic Anemias\*

SOLOMON ESTREN EUGENE A BRODY *and*  
LOUIS R WASSERMAN

*Department of Hematology The Mount Sinai Hospital New York*

IT IS ONLY in the last 10 years that the indispensable role of extremely minute amounts of vitamin B<sub>12</sub> (cyanocobalamin) in normal metabolism has been unequivocally demonstrated. Our knowledge of the nature of pernicious anemia and of other megaloblastic anemias has been increased greatly as a result of such studies. The various concepts of pernicious anemia as (1) a toxic disease (2) a hemolytic disorder (3) a neoplastic process and (4) an infectious disease have now been discarded and its nature as a deficiency disease—first suggested on purely theoretic grounds by Flint (38) and first demonstrated by the therapeutic triumphs of Minot, Murphy and Castle (24 26 27 82)—is universally accepted.

The levels of B<sub>12</sub> in the body are measured in micromicrograms or at most in micrograms; it is the inability of a person to absorb from the food even these minute amounts which causes pernicious anemia. As Castle (25) has stated “this disease would not develop if the

---

\* Studies reported in this paper were supported in part by grants from the Albert A. Lust, Anna Ruth Lowenberg and Frederick Machlin Research Funds.

We wish to thank Merck and Company Rahway New York, and the Squibb Institute for Medical Research New Brunswick, New Jersey for their support of these studies and for generous supplies of test materials.



Carcinoid Tumor	209
Malignancy	212
Secretion	213
Local Effect of Carcinoid of Ileum	214
Malignant Carcinoid Syndrome	215
Cardiovascular Changes	218
Pharmacology and Distribution of Serotonin	221
Serotonin and Cerebral Function	223
Serotonin and Certain Blood Dyscrasias	226
Serotonin and Renal Function	226
References	227
Some Aspects of Disordered Renal Tubular Function <i>By S W</i> <i>STANBURY Department of Medicine University of Man-</i> <i>chester England</i>	231
Renal Amino Aciduria	233
Cystinuria (Cystinelysinuria Cystine Lithiasis)	234
Cystine Storage Disease with Amino Aciduria (Lignac Fanconi Syndrome)	236
Childhood Disorders Simulating Lignac Fanconi Syndrome	241
Fanconi Syndrome in Older Children and in Adults	243
Osseous Disorders Complicating Multifactorial Tubular Defects	245
Functional Renal Tubular Disorders Apparently Caused by Heavy Metals Poisoning	248
Renal Phosphaturia	250
Potassium Deficiency and Renal Tubular Disorders	261
References	272
Author Index	283
Subject Index	297

blood plasma in the amount of 200 to 900  $\mu\text{g}$  per milliliter (41 67 84 106) From 5 to 30 per cent of the circulating B<sub>12</sub> is immediately available to the test organism and is therefore called free the remainder is assayed after heating the plasma to 100 C for 30 minutes a process which presumably separates it from the protein to which it is bound. This B<sub>12</sub> is normally bound chiefly to the serum globulins Vitamin B<sub>12</sub> is present in largest amounts in normal liver (80 112, 115 124) and in lesser amounts in kidney (80 112-115) muscle (111) and

TABLE 1—SERUM LEVELS OF VITAMIN B<sub>12</sub> IN VARIOUS DISORDERS

CONDITION	TOTAL B <sub>12</sub> , $\mu\text{g}$ /ML
Normal	200-900 ✓
Pernicious anemia	
Relapse	0-50
Remission parenteral therapy	200-900 ✓
Remission incomplete oral therapy	100-300
Total gastrectomy relapse	0-50
Malabsorption syndrome	{ 200-900 or 50-100
Diphyllobothrium latum anemia	0-50
Blind loop anemia	0-50
Pernicious anemia of pregnancy	200-900
Posterolateral sclerosis with or without anemia	0-20
Megaloblastic anemia due to anticonvulsant drugs	
Chronic myelocytic leukemia	1 500-17 000
Acute liver disease	800-6 000

other tissues (112) and in pleural ascitic joint and cerebrospinal fluids (84) Normally the urine contains some 0.2  $\mu\text{g}$  per 24 hours all in the free form (84) The stool contains 3 to 20  $\mu\text{g}$  both normally and in certain disease states including pernicious anemia (10 23 42) however some of the fecal B<sub>12</sub> is synthesized *de novo* by bacteria in the colon and is not available for absorption or tissue metabolism (10) ✓

In pernicious anemia in relapse—the prototype of B<sub>12</sub> deficiency—the patient's body in contrast to that of the normal individual contains minimal amounts of B<sub>12</sub> The serum level approaches zero (67 84) the amount in the urine is greatly reduced (84) and the liver contains practically none (43 123) The serum B<sub>12</sub> content may also be reduced in other megaloblastic anemias (sprue nutritional macrocytic anemia intestinal blind loops with anemia) but rarely to the same degree as in pernicious anemia On the other hand in certain megaloblastic

patient could effect daily the transfer of a millionth of a gram of vitamin B<sub>1</sub> the distance of a small fraction of a millimeter across the intestinal mucosa and into the blood stream. This he cannot do."

✓ Vitamin B<sub>12</sub> is a protoporphyrin like complex containing an atom of cobalt in its molecule (59-119). It plays a part in the basic synthesis of nucleoproteins and in the intermediate metabolism of carbohydrate and fat. Its presence is essential to the normal development of cells throughout the body. It is the purpose of the present discussion to examine the metabolism of this substance—its absorption, transport, utilization and excretion—in man and especially to clarify the mechanism by which B<sub>1</sub> deficiency occurs. This deficiency leads to the development of megaloblastic anemia and other disorders.

### TECHNICS OF STUDY

Since the isolation of vitamin B<sub>12</sub> in 1948 and the acceptance of the fact that B<sub>12</sub> is the extrinsic factor of Castle, the laborious assay technics (81) using patients with pernicious anemia in relapse have been largely replaced by newer methods. These new technics, which measure B<sub>12</sub> directly, may be considered as falling into two categories: (1) estimation of the amount of B<sub>12</sub> in the blood and body tissues and (2) determination of the fate of B<sub>12</sub> by radioactive technics.

#### ✓ MEASUREMENT OF VITAMIN B<sub>12</sub> IN BODY (TABLE 1)

The order of magnitude of B<sub>1</sub> levels in body tissues is so low that chemical methods of determination are precluded and microbiologic assay technics are mandatory (12-34-39-51-61-62-84-88-101-109-111). Such technics are based on the use of bacteria and protozoa whose growth under specified conditions is a measure of the amount of B<sub>12</sub> in the medium. Older methods use *Lactobacillus leichmannii* and *Escherichia coli* (12-34-51-101-109); recently more accurate and more specific results have been obtained with the protozoan *Euglena gracilis* var. *bacillaris* (62-67-84-110) and *Ochromonas malhamensis* (39-61). The microbiologic technics have given reliable data on the distribution of B<sub>12</sub> in body tissues.

By bioassay it has been determined that the B<sub>12</sub> content of the average American diet approximates 5 µg daily so that an average meal contains 0.5 to 2 µg. In the normal human body B<sub>12</sub> circulates in the

their radioactivity. The difference between the amount of radioactivity ingested and that excreted in the stool until no further radioactivity appears (approximately 7 days) is a measure of the amount of B<sub>12</sub> absorbed. The normal individual excreted 0 to 42 per cent of the oral dose. The patients with pernicious anemia excreted virtually the entire oral dose (72-96 per cent) when the test was repeated later in patients with pernicious anemia who were given at the same time potent intrinsic factor, the radioactivity in the stool fell toward normal values (14-29 per cent). Presumably the amount of (radioactive) B<sub>12</sub> ab-

TABLE 2—RADIOACTIVE TECHNIQUES FOR STUDY OF INTESTINAL ABSORPTION OF VITAMIN B<sub>12</sub>

TEST	METHOD <sup>a</sup>	TISSUE OR EXCRETA EXAMINED	TIME	NORMAL <sup>b</sup>	PERNICIOUS ANEMIA <sup>b</sup>	
					Without IF	With IF
Heinle Welch Glass	0.5 µg orally 0.5 µg orally	Stool Liver	For 7 d After 5-7 d	0-42% +	90-100% -	0-42% +
Schilling	0.5 µg orally and 1 000 µg non radioactive intramuscularly	Urine	For 24 hr	8-40% →	0-1%	8-40%
Blood	0.5 µg orally	Plasma	After 8-12 hr	+	-	+

<sup>a</sup>Radioactive vitamin B<sub>12</sub> (Co<sup>57</sup>B<sub>12</sub>, Co<sup>58</sup>B<sub>12</sub>, Co<sup>60</sup>B<sub>12</sub>)

<sup>b</sup>+ radioactivity - n radioactivity IF intrinsic factor

sorbed via the intestine rose to normal. This distinction between the normal state and that of pernicious anemia—nonabsorption of a test oral dose of B<sub>12</sub> in the absence of added intrinsic factor—held whether the patient was in clinical and hematologic relapse or remission.

Subsequent studies (53-104) have confirmed the results obtained with the Heinle Welch technique.

**SCHILLING URINARY EXCRETION TECHNIC** (66-116-117)—When a physiologic amount of radioactive B<sub>12</sub> is given by mouth to a normal subject, virtually no radioactivity appears in the urine. But if at about the same time a large dose (1 000 µg) of nonradioactive B<sub>12</sub> is administered parenterally, a detectable portion (8-40 per cent) of the radioactive (oral) dose appears in the 24 hour urine specimen (66-74-99-104-116-117). In patients with pernicious anemia under the same

blastic anemias (sprue, pernicious anemia of pregnancy) the serum  $B_{12}$  level may be normal (85-88-95) /

Thus megaloblastic anemias may be associated with a normal or a reduced level of serum  $B_{12}$ . Since the serum level is probably a reflection of the tissue content of  $B_{12}$  (85) megaloblastic anemias may be of two types in this regard those with reduced stores of  $B_{12}$  and those with normal stores. An obvious corollary borne out by clinical observations and experimental studies is that the development of megaloblastic erythropoiesis may be due to more than one factor in some cases to a tissue deficiency of  $B_{12}$  in others to deficiencies of other substances notably folic acid and possibly ascorbic acid and other materials. In general patients with megaloblastic anemias whose serum (and therefore tissue) levels of  $B_{12}$  are normal do not respond to  $B_{12}$  therapy while those with low serum levels do (85-87) /

### RADIOACTIVE TECHNIQUES

By adding radioactive cobalt to the medium in which a culture of *Streptomyces griseus* is growing it is possible to induce the synthesis not only of normal (nonradioactive)  $B_{12}$  but also of  $B_{12}$  with a radioactive cobalt atom (25-118-120). In this way  $Co^{58}B_{12}$ ,  $Co^{59}B_{12}$  and  $Co^{60}B_{12}$  have been produced and have been made available for tracer studies of the vitamin in the body. All such studies have shown the same general result when  $B_{12}$  is ingested in physiologic amounts its absorption depends on some gastrointestinal substance (intrinsic factor) present in the normal individual but lacking in the patient with pernicious anemia (25). When, however  $B_{12}$  is ingested in larger than physiologic amounts a point is reached at which absorption occurs by a "mass action" effect (31-113) not dependent on intrinsic factor. This manner of absorption occurs not only in the normal person but also in the patient who lacks intrinsic factor i.e. in pernicious anemia. Finally faulty intestinal absorption of  $B_{12}$  may be present despite adequate production of intrinsic factor as part of a generalized mucosal (enzymic?) disorder which also includes impaired absorption of glucose, vitamin A, vitamin K, protein and other substances; this is the condition in the malabsorption syndrome (76-99) /

Several radioactive techniques are of clinical importance (Table 2)

**STOOL METHOD (HEINLE WELCH) (52)**—The original technic for the study of  $B_{12}$  absorption was to give the patient a physiologic (0.5  $\mu$ g) dose of radioactive  $B_{12}$  by mouth, collect all stools and determine

anemia and at least some patients with malabsorption syndrome how ever absorb virtually none

**GLASS HEPATIC UPTAKE TECHNIC (49)**—Both the Heinle-Welch and the Schilling technics measure B<sub>12</sub> absorption indirectly by determining the fraction of an oral dose which appears in the excreta. Glass (49) has suggested a "direct" technic in which a physiologic amount of radioactive B<sub>12</sub> is ingested and the body is then scanned in vivo to determine whether there is localization of radioactivity in the liver. In normal subjects he found radioactivity to be present in the first few days throughout the abdominal cavity some of this came from the B<sub>12</sub> in the intestinal canal which ultimately passed into the feces. After 6 or 7 days, however, all remaining radioactivity was localized in the right upper abdominal quadrant, indicating that the liver had taken up the ingested B<sub>12</sub>. Such hepatic uptake did not occur in the patients with pernicious anemia whether in remission or in relapse however when the test was repeated with the addition of intrinsic factor hepatic uptake—and therefore intestinal absorption—of the ingested B<sub>12</sub> occurred. Again certain patients with sprue showed no hepatic uptake even with the use of intrinsic factor. The hepatic radioactivity in the normal subjects and in the patients with pernicious anemia given intrinsic factor persisted for long periods of time possibly for years (117).

**RADIOACTIVITY IN BLOOD**—A fourth technic measures the presence of radioactivity in the blood after an oral tracer dose of B<sub>12</sub> (15, 34). When normal subjects take radioactive B<sub>12</sub> of exceptionally high specific activity (1 000–5 000  $\mu\text{c}/\text{mg}$ ) by mouth radioactivity in the blood can be demonstrated within hours it is present in the plasma and becomes maximal in 8 to 12 hours. In pernicious anemia radioactivity cannot be detected in the blood but again if the test is repeated with added intrinsic factor radioactivity is found in the plasma just as in the normal subject.

✓ All these methods lead to one general conclusion the absorption of physiologic amounts of vitamin B<sub>12</sub> the amount present in an ordinary meal, for example normally depends on the presence of intrinsic factor in the gastrointestinal tract. Absence of the factor causes the non-absorption of ingested B<sub>12</sub> in pernicious anemia and in patients after total gastrectomy and absorption in both conditions can be effected by adding intrinsic factor to the oral B<sub>12</sub>. However intestinal absorption of B<sub>12</sub> may be faulty for other reasons as discussed below.

conditions no radioactivity is detectable in the urine when the test is repeated with the addition of intrinsic factor the urine shows radioactivity the values approaching the normal range (99-116). In patients with malabsorption syndrome there may also be little or no urinary radioactivity but in such cases addition of intrinsic factor does not increase the radioactivity (99). However this defect does not appear in every patient with sprue nor do all types of megaloblastic

✓TABLE 3—ABSORPTION OF ORAL DOSE OF RADIOACTIVE  $B_{12}$  IN MEGALOBlastic ANEMIAS

CONDITION	ABSORPTION WHEN GIVEN	
	Without Intrinsic Factor	With Intrinsic Factor
Normal	Absorbed	No change
Pernicious anemia		
Relapse	Not absorbed	Absorbed
Remission	Not absorbed	Absorbed
Total gastrectomy	Not absorbed	Absorbed
Malabsorption syndrome	Absorbed not absorbed	No change not absorbed
Intestinal blind loop	Not absorbed <sup>b</sup>	Not absorbed
Diphyllobothrium latum anemia	Not absorbed	Not absorbed (?)
Pernicious anemia of pregnancy	Absorbed	?
Nutritional megaloblastic anemia	Absorbed	No change
Megaloblastic anemia of infancy	?	?
Megaloblastic anemia due to drugs	?	?

<sup>S</sup> footnote T bl 2

<sup>b</sup> After antbot c (t trac y lin blert t ac y l n ) therapy abs rpt n may be ome n rmal

anemia give abnormal results in the Schilling test, i.e. abnormal absorption of orally administered  $B_{12}$  (Table 3)

The appearance of radioactivity in the urine under the conditions of this test indicates that a portion of the orally administered radioactive  $B_{12}$  has been absorbed has entered the blood and has subsequently been excreted into the urine. Callender and Evans (22) have calculated that in the normal subject approximately 33 per cent of an absorbed oral dose of radioactive  $B_{12}$  appears in the urine under these conditions. The normal subject therefore absorbs 27 to 100 per cent of the small test dose; these figures correlate well with those of the Heinle-Welch stool technique (56). The patient with pernicious

B<sub>12</sub> ultimately produces tissue deficiency of B<sub>12</sub>. Such a patient can not absorb the physiologic amount of vitamin B<sub>12</sub> present in food or in the radioactive test dose but when artificial concentrates of intrinsic factor are given together with the oral test dose absorption occurs and tends to be normal (see Table 3)✓

All of the foregoing applies only to "physiologic" amounts of B<sub>12</sub> (up to 1 or 2 µg/day). Beyond these levels the percentage absorbed by normal individuals decreases rapidly (47)

Amount µg	Absorption %
0.5	90
1.0	80
2.0 ✓	40 ✓
5.0	22
50	3
1 000	1.5

As can be calculated the absolute amounts absorbed however rise from 0.45 to 15 µg. This is true both in the normal subject and in the patient with pernicious anemia. Minot and Murphy's success in treating patients with pernicious anemia by feeding them liver was probably due to the intake of such large unphysiologic amounts of vitamin B<sub>12</sub> that absorption although small percentually was quantitatively significant. Absorption of these large amounts of B<sub>12</sub> across the intestinal mucosa does not depend on intrinsic factor and occurs by a sort of mass action effect (113). This effect occurs not only in the normal person and in the patient with pernicious anemia but also in the patient with malabsorption syndrome. Recent reports suggest that in patients with pernicious anemia the threshold for such mass action absorption may vary thus a few patients with pernicious anemia in relapse respond to 5 µg B<sub>12</sub> by mouth daily (37) many to as little as 15 to 50 µg (37) and all to 150 µg (17). Patients given huge (1 000-9 000 µg) single doses e.g. once a week regularly showed absorption of therapeutically effective amounts (31 107) )

✓It is obvious then that the absorption pattern of orally administered B<sub>12</sub> depends on the dosage. In physiologic amounts absorption occurs in stoichiometric relation to the amount of gastric intrinsic factor (4) and cannot occur in its absence this is the normal pattern of absorption. In larger dosages B<sub>12</sub> passes across the intestinal wall independent of the presence or absence of intrinsic factor

The advent of crystalline preparations and solutions of B<sub>12</sub> has pro



## ✓ABSORPTION

### INTESTINAL ABSORPTION

✓When  $B_{12}$  is taken by mouth by the normal individual absorption occurs across the intestinal wall. It has been shown that intrinsic factor produced in man in the corpus of the stomach is essential for normal absorption of physiologic amounts of  $B_{12}$ . The actual absorption occurs not in the stomach but as with other nutrients and vitamins in the small intestine and, specifically, in the duodenum and upper jejunum (25). It is uncertain if any significant absorption occurs in the rest of the small intestine or in the colon. Lack of colonic absorption is further confirmed by the observation that the stools of patients with pernicious anemia in relapse (not to say those of the normal individual) contain significant amounts of  $B_{12}$  amounts so large that could they be absorbed they would produce remission (10, 23).

✓These facts concerning normal  $B_{12}$  absorption have been confirmed by radioactive techniques. The nature of intrinsic factor is not known. That in man it is produced exclusively in the corpus of the stomach is fully established (25, 52). It is thought to be a mucopolysaccharide which possibly binds  $B_{12}$  for a time then releases it to the mucosal cells for absorption (25, 126, 129). Not all substances which bind  $B_{12}$  however can then release it. Most of the binding substances are not intrinsic factor. For example, serum globulin, certain bacteria (22, 33) and the *Taenia Diphyllorhynchus latum* (97) may bind ingested  $B_{12}$ . When the bacteria or *Taenia* have bound the vitamin in competition with intrinsic factor they do not release it for absorption and thus lead to  $B_{12}$  deficient megaloblastic anemias.

Even in the presence of normal amounts of intrinsic factor however and in the absence of competitive binding agents other abnormalities may prevent normal absorption of ingested  $B_{12}$ . This is the case in malabsorption syndrome where the defect in absorption of  $B_{12}$  is merely part of a more generalized absorption defect and in which the addition of intrinsic factor to the oral dose of  $B_{12}$  does not enhance absorption (99).

✓A patient may lack intrinsic factor because of a congenital defect (121) or of a hereditary disorder of the secreting glands of the corpus of the stomach (pernicious anemia) or of surgical ablation of these glands (total gastrectomy). In such a patient it is the lack of intrinsic factor which by causing prolonged malabsorption of ingested

in plasma protein which causes B<sub>12</sub> depletion in the blood but malabsorption of the vitamin itself. Under certain abnormal conditions such as chronic myelocytic leukemia the ability of the blood proteins to bind B<sub>12</sub> increases markedly, so that both serum levels and binding capacity reach extremely high levels. We are not personally aware of any disorder in which binding capacity for B<sub>12</sub> is abnormally low although theoretically such a situation may exist, and 1 such case has been reported (60)

**CHANGES WITH AGE**—The serum B<sub>12</sub> level tends to fall with advancing age (12). This decrease although statistically significant is apparently without clinical importance since even the lower levels remain entirely within the normal range. The mechanism and significance of the decrease are not known. There is some indication however that with advancing age B<sub>12</sub> absorption may sometimes be impaired (48).

**CHANGES IN PREGNANCY**—As pregnancy progresses the serum B<sub>12</sub> level falls (13, 57) but again the levels remain within the normal range. The serum B<sub>12</sub> (cord blood) of newborn infants is statistically higher than that of the mothers and of normal adults (14). Apparently the fetus obtains its tissue (and therefore serum) B<sub>12</sub> at the mother's expense without, however, decreasing her stores to abnormal levels. Pernicious anemia of pregnancy is generally not due to B<sub>12</sub> deficiency the mother's tissues (as measured by the serum levels) are not depleted of B<sub>12</sub> nor does the disorder usually respond to B<sub>12</sub> therapy. However, occasional exceptions have been reported (28, 70). The megaloblastic erythropoiesis of this disorder is due to other causes and responds preferentially to folic acid.

**CHANGES IN CHRONIC MYELOCYTIC LEUKEMIA**—In some untreated cases of this disorder and in cases of acute leukemias the serum level of B<sub>12</sub> is abnormally high (1 000–12 000  $\mu\text{g/ml}$ ) (5, 6, 58, 83). The increase is due chiefly to an increase in the protein bound B<sub>12</sub>. In chronic myelocytic leukemia it has been shown that the B<sub>12</sub> is bound almost entirely to  $\alpha_1$  globulin (84 per cent) with 15 per cent being bound to  $\alpha_2$  globulin (6, 58). The ability of such blood to bind additional B<sub>12</sub> despite the already high B<sub>12</sub> content differs from that of normal serum which binds strictly limited amounts of B<sub>12</sub> (9, 86, 90, 102). Since no quantitative or electrophoretic difference between the proteins of such leukemic blood and those of normal blood have been demonstrated, a qualitative difference of the  $\alpha_1$  globulin may be inferred.

vided a method of by passing normal intestinal absorption by the simple expedient of injecting  $B_{12}$  solution or liver extract instead of giving  $B_{12}$  by mouth. In pernicious anemia small injections (1-2  $\mu\text{g}$ /day) of crystalline  $B_{12}$  have the same effect as large (150  $\mu\text{g}$ /day) oral doses (20 32)

### ABSORPTION BY OTHER ROUTES

The absorption of  $B_{12}$  by still other routes has been demonstrated under experimental conditions. Such routes include the nasal (91) sublingual (19) and subcutaneous tissues

### TRANSPORT

In the normal individual,  $B_{12}$  is present in the plasma partly in a free or unbound form (directly available to the assay microorganism) and partly in a protein bound form (available for assay only after heating which separates it from the protein). The total serum  $B_{12}$  amounts to 200 to 900  $\mu\text{g}$  per milliliter\*. The free serum  $B_{12}$  ranges between 0 and 200  $\mu\text{g}$  per milliliter and constitutes 5 to 30 per cent of the total. The difference between total and free serum  $B_{12}$  is the bound  $B_{12}$  (i.e. 200-700  $\mu\text{g}$ /ml). The bound  $B_{12}$  is normally carried by the globulins largely by  $\alpha_1$  globulin (66 per cent) in part by  $\alpha$  globulin (20 per cent) and some by  $\beta$  globulin (12 per cent) (58). Albumin neither carries nor binds  $B_{12}$  (102) although in the presence of excessive amounts of  $B_{12}$  in vitro nonspecific binding of some of the excess may occur (9). Binding to the  $\alpha$  globulins is generally accepted but some also maintain that there is nonspecific binding to and transport by the  $\gamma$  globulins (64). In the patient with pernicious anemia or with other  $B_{12}$  deficiency disease the serum level approaches zero (50  $\mu\text{g}$ /ml) and whatever amount of  $B_{12}$  is present is globulin bound.

The  $B_{12}$  in normal plasma although largely bound to protein does not completely saturate the proteins to which it is bound i.e. they can bind additional amounts of  $B_{12}$ . This binding power of human blood has been measured by microbiologic technics and has been found to be of the order of 700  $\mu\text{g}$  of  $B_{12}$  per milliliter (9 67 86 106) both in the normal individual and in the patient with pernicious anemia. In the latter therefore it is not some abnormality of or lack

\*  $1 \mu\text{g} = 1 \times 10^{-6} \text{ Gm} = 0.000000000001 \text{ Gm}$

tient with leukemia as in the normal subject. These results conform with the abnormal ability of leukemic blood to bind B<sub>12</sub>.

The abnormality was further demonstrated by repeating the experiment in normal individuals after incubating the radioactive B<sub>12</sub> *in vitro* with a solution of human serum albumin and with serum ob-




FIG 2—Effect of incubating vitamin B<sub>12</sub> with albumin (no binding) and with leukemic plasma (binding of B<sub>12</sub>) before administration of Co<sup>57</sup>B<sub>12</sub> intravenously to a normal subject

tained from the leukemic patient with high serum levels of B<sub>12</sub>. Whereas the serum of the leukemic patient bound B<sub>12</sub> *in vitro* the albumin showed no such binding (Fig 2).

With treatment the serum levels of B<sub>12</sub> in patients with chronic myelocytic leukemia drop toward normal (6, 83).

The source of the increased amounts of protein bound B<sub>12</sub> in the serum of these patients is not known. Presumably both ingested and tissue stored B<sub>12</sub> becomes bound in this way.

CHANGES IN LIVER DISEASE—Hepatic localization of B<sub>12</sub> is demon-

Similar results were obtained by measuring the disappearance of radioactivity after intravenous injection of a tracer dose. In the normal subject, after rapid injection of physiologic ( $0.5 \mu\text{g}$ ) or small ( $1-4 \mu\text{g}$ ) amounts of radioactive  $B_{12}$  the level of radioactivity in the blood falls rapidly (78-90) (Fig. 1) within 2 minutes less than 50 per cent is present in the plasma within 1 hour less than 15 per cent after 8 hours less than 5 per cent. Of the remaining radioactivity less




FIG. 1—Radioactivity in plasma and urine after intravenous administration of  $\text{Co}^{60}\text{B}_{12}$  to a normal subject and to a patient with chronic myelocytic leukemia.

than 10 per cent of the dose appears in the first 24 hour urine and none thereafter. The only site of localization demonstrable by *in vivo* counting technics is the liver which shows immediate uptake and a slow progressive rise (see Fig. 3). In a patient with untreated chronic myelocytic leukemia and high serum levels of  $B_{12}$  (Fig. 1) the rate of disappearance of radioactivity was significantly slower: after 2 minutes 55 per cent remained in the plasma; after 1 hour 32 per cent; after 8 hours 22 per cent. After 24 hours when the plasma of the normal subject showed no appreciable radioactivity, the leukemic patient still retained 18 per cent of the injected dose. The radioactivity in the urine and the localization in the liver was the same in the pa-

B<sub>12</sub> megaloblastic anemias may be divided into those with low and those with normal levels. It is a reasonable inference that the cause of the megaloblastic anemias with normal serum (and therefore tissue) levels is not tissue depletion of B<sub>12</sub>. The megaloblastic anemias with low serum levels of B<sub>12</sub> are in general due primarily to tissue depletion of B<sub>12</sub>, and respond to B<sub>12</sub> therapy.

**Pernicious Anemia**—The serum B<sub>12</sub> is so low ( $< 50 \mu\text{g/ml}$ ) as to approach zero (67-84). Parenteral administration of liver extract or vitamin B<sub>12</sub> effects the return of the serum level to normal. Treatment with sufficiently large oral doses is also successful in all respects—hematologic, clinical and neurologic—including return of the serum level to normal (20-107).

**Malabsorption Syndrome**—In some patients the serum B<sub>12</sub> level is normal; in others it is low ( $< 100 \mu\text{g/ml}$ ) but rarely to the degree found in pernicious anemia.

**Total Gastrectomy**—Approximately 2 to 4 years after total gastrectomy megaloblastic anemia may occur, identical in all clinical and pathogenetic respects with pernicious anemia. When this occurs the serum levels of B<sub>12</sub> are as low as in Addisonian pernicious anemia.

### SUMMARY ✓

Vitamin B<sub>12</sub> is normally present in the serum in a "free" form and in a form bound to the serum  $\alpha$  globulins. It is carried from the sites of absorption in the small intestine to the tissues where it is utilized and stored. In certain disorders, e.g. chronic myelocytic leukemia, abnormal globulins may be present in the blood which both carry and can bind abnormally large amounts of B<sub>12</sub>. In other disorders with protein abnormalities (myeloma, sarcoidosis, chronic lymphocytic leukemia) we have found no such increase in binding capacity. In certain forms of injury to the hepatic cells the serum B<sub>12</sub> level may be high because of its liberation from these cells, but the ability of the serum to bind added B<sub>12</sub> is not increased. In the megaloblastic anemias due to B<sub>12</sub> deficiency the serum B<sub>12</sub> level is extremely low, reflecting the low tissue level.)

### DISTRIBUTION, STORAGE AND EXCRETION

It has long been known that liver obtained from a patient dead of pernicious anemia or of certain related disorders is incapable of caus-

strated not only by the data of the experiments just described (Fig 3) but also by data obtained by the Glass hepatic uptake technic and by the well known fact that healthy liver contains huge amounts of B<sub>12</sub> (112 115 124) The B<sub>12</sub> is contained within the hepatic cells where according to some it is bound to a protein which resembles the  $\beta$  globulin of serum (102 103) It has been shown that the acutely damaged liver of an animal given injections of carbon tetrachloride shows markedly impaired ability to fix B<sub>12</sub> (132)

Related observations of a rise in serum B<sub>12</sub> have been made in pa




FIG 3—Radioactivity in plasma and liver after intravenous administration of Co<sup>57</sup>B<sub>12</sub> in a normal subject and in a patient with liver disease

tients with early acute hepatitis as the hepatitis subsides the B<sub>12</sub> levels return to normal (106) It has therefore been suggested that damage to the hepatic cells which normally store B<sub>12</sub> causes its release into the blood stream (62 106)

Intravenous injection of physiologic amounts (0.5  $\mu$ g) of radioactive B<sub>12</sub> into patients with hepatic disease have also shown that such livers take up less than normal amounts of the vitamin (see Fig 3) and that the serum level of radioactivity is lower at any time than in the normal subject In other words in such patients the injected B<sub>12</sub> remains less readily in the plasma and cannot be accepted in normal fashion by the hepatic cells The reasons for these events are being explored

CHANGES IN MEGALOBLASTIC ANEMIAS—With regard to the serum

radioactive B<sub>12</sub> show the greatest amount of B<sub>12</sub> to be localized within the liver (50%) with lesser amounts in the kidney, heart, pituitary and other organs (personal observations) ✓

The B<sub>12</sub> in the body is in a state of flux. If for example in the Schilling urinary excretion test the oral test dose of radioactive B<sub>12</sub> is not accompanied by injection of nonradioactive B<sub>12</sub>, urinary radioactivity cannot be demonstrated but if 1 000  $\mu$ g of nonradioactive B<sub>12</sub> is given parenterally at the same time some 8 to 40 per cent of the oral dose appears in the urine within 24 hours. However if the administration of the nonradioactive B<sub>12</sub> is delayed for 24 hours after ingestion of the radioactive dose some radioactivity (one half or one third of that in the first experiment) is found in the following 24 hours. Apparently dilution of the body radioactivity with additional B<sub>12</sub> allows in the normal course of its utilization, transport, and storage some radioactivity to be released from the stores to circulate in the blood and to be excreted. If the parenteral dose is delayed for 48 hours after the oral dose there is still excretion in some cases but of even smaller amounts (79).

The excretion pattern is quite definite. The normal individual daily ingests 5 to 15  $\mu$ g in his food (104) and excretes 0.2  $\mu$ g in his urine (84) and some 10 mg in his stool (23). The B<sub>12</sub> in the urine is thought to be entirely endogenous, some of that in the stool represents unabsorbed B<sub>12</sub> and some is formed *de novo* by bacteria in the colon. When the normal subject ingests a test dose of 0.5  $\mu$ g of radioactive B<sub>12</sub> he thus excretes 0 to 42 per cent in his stool (presumably unabsorbed) and none in the urine (that absorbed is distributed to the tissues). As the amounts taken by mouth are increased more and more remains unabsorbed.

The normal individual given a dose of B<sub>12</sub> parenterally excretes none in the stool and all above approximately 500  $\mu$ g (31) in the urine within 24 hours. Similar data obtained in animal experiments confirm that parenterally administered B<sub>12</sub> appears only in the tissues and in the urine but not in the stool whereas ingested B<sub>12</sub> appears mainly in tissues and stool and only a small amount in urine. ✓ In the normal subject and in the patient with pernicious anemia the amounts of B<sub>12</sub> in the feces are large. Apparently the B<sub>12</sub> is formed by colon bacteria and is not available to the body because it is not absorbed (8, 23, 42). The patient with an absorptive defect for B<sub>12</sub> loses nearly all the ingested dietary B<sub>12</sub> in the stool (the urine containing only minute amounts).



ing remission of pernicious anemia in relapse in contrast to liver from a patient dead of other causes (43 108) Microbiologic assay of the liver of a patient with pernicious anemia in relapse shows absence of  $B_{12}$  (43 123) The chief source of the antipernicious anemia factor has always been liver extract Newer studies have confirmed if such confirmation were needed the importance of the liver as the storage depot of  $B_{12}$

Organ analyses of animals given  $B_{12}$  show most of it to be lodged in the liver and kidneys (80 115) In the normal human subject orally administered radioactive  $B_{12}$  rapidly appears in the liver and radioactivity persists for more than a year (117) After intravenous administration of radioactive  $B_{12}$  to a normal subject there is prompt uptake by the liver and persistent localization there of radioactivity (see Fig 3) such localization is not demonstrated by this technic in other organs When the patient with pernicious anemia is given radioactive  $B_{12}$  by mouth together with a potent source of intrinsic factor radioactivity also appears in the liver within 5 to 7 days and persists In patients with chronic myelocytic leukemia (75) or other lymphomas radioactivity appears in the liver immediately after intravenous administration and increases in amount in the course of the next 3 weeks (75 personal observations) In the patient with hepatocellular disease radioactivity still appears promptly in the liver but in smaller amounts than in the normal subject and it tends to fall off rather than to rise (see Fig 3) *In vivo* counting over other sites—heart spleen thigh muscles—fails to show within the limits of the method localization of radioactivity There is thus no question that the liver cell is the prime site of localization of vitamin  $B_{12}$  in the body

However  $B_{12}$  is also present in other tissues (112 115) and is excreted from the body in definite patterns Intravenously injected radioactive  $B_{12}$  appears in minute amounts in the cerebrospinal fluid (84) but none has been found in ascitic fluid (78 personal observations) It remains in the plasma for a period of time which depends chiefly it seems on the ability of the plasma proteins to bind it (see Figs 1 and 2) It normally appears in the urine in small amounts less than 10 per cent of the injected dose in 24 hours Since only 10 to 15 per cent can be accounted for by the amounts in plasma and in urine the remaining 85 per cent must be within the body and largely within the liver Clinical knowledge however compels the conclusion that  $B_{12}$  is present in all body tissues, notably in the cells of the bone marrow and the nervous system Postmortem organ analyses of patients given

essary for the production of cells normal in size appearance and function. A tissue deficiency of B<sub>12</sub> or folic acid (or theoretically of any of the other substances) results in abnormal nucleoprotein synthesis with a series of distinct abnormalities in the cells. The most marked abnormality is seen at the hematopoietic centers where normal normoblastic erythropoiesis is replaced by megaloblastic erythro

TABLE 4—PATHOGENETIC CLASSIFICATION OF MEGALOBLASTIC ANEMIAS

CAUSE	TYPE OF ANEMIA
<i>Tissue deficiency of B<sub>12</sub></i>	
B <sub>12</sub> lack in diet	Nutritional macrocytic anemia
Malabsorption of B <sub>12</sub>	
Absence of intrinsic factor	Pernicious anemia total gastrectomy congenital in children
Multiple defects of intestinal absorption	Primary and secondary malabsorption syndromes
Bacterial utilization of B <sub>12</sub>	Intestinal blind loop syndrome
Parasitic competition for B <sub>12</sub>	Diphyllobothrium latum anemia
Impaired transport of B <sub>12</sub>	Defective α-globulins megaloblastic anemia (60)
Poor utilization of B <sub>12</sub>	Megaloblastic anemia in liver disease (?)
Destruction of B <sub>12</sub>	None known
<i>Tissue deficiency of folic acid</i>	Nutritional macrocytic anemia primary malabsorption syndrome intestinal blind loop syndrome pernicious anemia of pregnancy megaloblastic anemia of infancy megaloblastic anemia due to anticonvulsant drugs
<i>Tissue deficiency of ascorbic acid</i>	Megaloblastic anemia of infancy

poiesis. Related defects occur in other hematopoietic cells (abnormally large granulocytes abnormally maturing megakaryocytes) and in other tissues notably epithelial cells (50) and nerve cells (94). The clinical result of B<sub>12</sub> deficiency i.e. of tissue depletion is therefore a systemic disease involving the gastrointestinal mucosa and the nervous and hematopoietic systems. The systemic nature of the clinical disease is to be expected whatever the cause of the tissue deficiency: lack of intrinsic factor (pernicious anemia, total gastrectomy) malabsorption of B<sub>12</sub> (malabsorption syndrome) competition for B<sub>12</sub> (Diphyllobothrium latum infestation blind loops) or dietary lack of B<sub>12</sub> (nutritional macrocytic anemia). Too the same clinical end results—the systemic picture of megaloblastic anemias—may result from tissue depletion of folic acid ascorbic acid, lack of carbon

## ROLE IN CELLULAR METABOLISM

Multiple metabolic functions have been discovered for vitamin  $B_{12}$  including a role in carbohydrate (29) and fat metabolism (65 69 94 98). Another role is in the synthesis of the nucleoproteins of the tissue cell. The mechanism of its action is not known but it has been shown that it plays a part in the methylation of homocysteine the formation of methionine desoxyribosides and purines the reduction of thiol groups (glutathione homocysteine and perhaps coenzyme A) and presumably in still other as yet unclarified reactions (2). In the




Fig 4—Role of vitamin  $B_{12}$  in nucleoprotein metabolism theoretic schema of some interrelations of vitamin  $B_{12}$ , folic acid and ascorbic acid (Adapted from Girdwood (40) and Mueller and Will (89) )

intermediary metabolism of nucleic acid precursors  $B_{12}$  is associated with folic, folinic and ascorbic acids. Figure 4 presents a schema embodying the current concepts of the formation of normal nucleoprotein (40 93)

Vitamin  $B_{12}$  is thus one of many substances which although essential to the normal formation of the tissue cell, are not synthesized by vertebrates. The schema suggests that several substances are important and necessary for the normal development of the tissue cells proteins folic and ascorbic acids  $B_{12}$  and presumably other substances not shown in Figure 4.

Deficiencies of any of the substances but notably of vitamin  $B_{12}$  or of folic acid may thus result in abnormal nucleoprotein synthesis. The schema applies to the synthesis in any body cell. Hematologically normal nucleoprotein synthesis implies with respect to the erythrocyte normoblastic erythropoiesis. From the point of view of other marrow and tissue cells normal nucleoprotein synthesis is nec-

essary for the production of cells normal in size appearance and function. A tissue deficiency of B<sub>12</sub> or folic acid (or theoretically of any of the other substances) results in abnormal nucleoprotein synthesis with a series of distinct abnormalities in the cells. The most marked abnormality is seen at the hematopoietic centers where normal normoblastic erythropoiesis is replaced by megaloblastic erythro

// TABLE 4 —PATHOGENETIC CLASSIFICATION OF MEGALOBlastic ANEMIAS

CAUSE	TYPE OF ANEMIA
<i>Tissue deficiency of B<sub>12</sub></i>	
B <sub>12</sub> lack in diet	Nutritional macrocytic anemia
Malabsorption of B <sub>12</sub>	
Absence of intrinsic factor	Pernicious anemia total gastrectomy congenital in children
Multiple defects of intestinal absorption	Primary and secondary malabsorption syndromes
Bacterial utilization of B <sub>12</sub>	Intestinal blind loop syndrome
Parasitic competition for B <sub>12</sub>	Diphyllobothrium latum anemia
Impaired transport of B <sub>12</sub>	Defective α-globulins megaloblastic anemia (60)
Poor utilization of B <sub>12</sub>	Megaloblastic anemia in liver disease (?)
Destruction of B <sub>12</sub>	None known
<i>Tissue deficiency of folic acid</i>	Nutritional macrocytic anemia primary malabsorption syndrome intestinal blind loop syndrome pernicious anemia of pregnancy megaloblastic anemia of infancy megaloblastic anemia due to anticonvulsant drugs
<i>Tissue deficiency of ascorbic acid</i>	Megaloblastic anemia of infancy

poiesis. Related defects occur in other hematopoietic cells (abnormally large granulocytes abnormally maturing megakaryocytes) and in other tissues notably epithelial cells (50) and nerve cells (94). The clinical result of B<sub>12</sub> deficiency i.e. of tissue depletion is therefore a systemic disease involving the gastrointestinal mucosa and the nervous and hematopoietic systems. The systemic nature of the clinical disease is to be expected whatever the cause of the tissue deficiency: lack of intrinsic factor (pernicious anemia total gastrectomy) malabsorption of B<sub>12</sub> (malabsorption syndrome) competition for B<sub>12</sub> (Diphyllobothrium latum infestation blind loops) or dietary lack of B<sub>12</sub> (nutritional macrocytic anemia). Too the same clinical end results—the systemic picture of megaloblastic anemias—may result from tissue depletion of folic acid ascorbic acid lack of carbon

## ROLE IN CELLULAR METABOLISM

Multiple metabolic functions have been discovered for vitamin B<sub>12</sub> including a role in carbohydrate (29) and fat metabolism (65 69 94 98) Another role is in the synthesis of the nucleoproteins of the tissue cell The mechanism of its action is not known but it has been shown that it plays a part in the methylation of homocysteine the formation of methionine desoxyribosides and purines the reduction of thiol groups (glutathione homocysteine and perhaps coenzyme A) and presumably in still other as yet unclarified reactions (2) In the




Fig 4—Role of vitamin B<sub>12</sub> in nucleoprotein metabolism theoretic schema of some interrelations of vitamin B<sub>12</sub> folic acid and ascorbic acid (Adapted from Girdwood (40) and Mueller and Will (89) )

intermediary metabolism of nucleic acid precursors B<sub>12</sub> is associated with folic folinic and ascorbic acids Figure 4 presents a schema embodying the current concepts of the formation of normal nucleoprotein (40 93)

Vitamin B<sub>12</sub> is thus one of many substances which although essen tial to the normal formation of the tissue cell, are not synthesized by vertebrates The schema suggests that several substances are impor tant and necessary for the normal development of the tissue cells proteins folic and ascorbic acids B<sub>12</sub> and presumably other sub stances not shown in Figure 4

Deficiencies of any of the substances but notably of vitamin B<sub>12</sub> or of folic acid may thus result in abnormal nucleoprotein synthesis The schema applies to the synthesis in any body cell, Hematologi cally normal nucleoprotein synthesis implies with respect to the erythrocyte normoblastic erythropoiesis From the point of view of other marrow and tissue cells normal nucleoprotein synthesis is nec




FIG 5—Absorption transport and storage of vitamin B<sub>12</sub> schema of the pathogenesis of vitamin B<sub>12</sub> deficiency states

### NUTRITIONAL MACROCYTIC ANEMIA

The megaloblastic erythropoiesis in this disease is probably due to multiple deficiencies vitamin B<sub>12</sub> protein folic acid and other substances. However in some cases the B<sub>12</sub> deficiency is of prime importance. Thus strict vegetarians ("vegans") were found to have low serum levels of B<sub>12</sub> (130) other patients with dietary fads who develop megaloblastic anemia on a nutritional basis have shown low serum levels despite normal intestinal absorption of B<sub>12</sub> (105). In such pa

donors (proteins, amino acids) and perhaps other factors. Table 4 gives a pathogenetic classification of the megaloblastic anemias on this basis. Clinically of course there are differences between the syndromes caused primarily by deficiency of  $B_{12}$  and those due to deficiency of the other substances notably folic acid. Thus involvement of the central nervous system is much more common in the  $B_{12}$  deficiency anemias and especially in pernicious anemia than in folic acid deficiencies such as certain cases of sprue or in nutritional macrocytic anemia. Nevertheless, subacute combined degeneration has been described in sprue (133) and in nutritional macrocytic anemia. Clinically an excess of folic acid in the presence of  $B_{12}$  deficiency (pernicious) anemia may lead to neurologic involvement previously absent, despite hematologic remission apparently the cause is a reciprocal relation between  $B_{12}$  and folic acid so that in a deficiency of one of them administration of the other aggravates the deficiency (55). Vitamin  $B_{12}$  seems to be of special importance to the well being of the nerve cell (94) administration of folic acid by furthering the reactions shown in Figure 4 results in even further depletion of the remaining  $B_{12}$  in the nerve cells with disastrous results.

The data on  $B_{12}$  absorption, transport and storage suggest that its serum levels are merely an index of its tissue stores (85). Observation of patients with pernicious anemia accidentally or deliberately allowed to relapse by withholding therapy confirms that the tissue stores at the height of an induced remission are adequate to supply the patient for several years. Patients with total gastrectomy similarly do not have megaloblastic anemia until after 2 to 4 years. During this time determination of the serum  $B_{12}$  levels by giving a clue to depletion of tissue stores may give notice of impending relapse. Patients treated with oral  $B_{12}$  without intrinsic factor are slow to reach normal serum  $B_{12}$  levels (20) despite complete hematologic and neurologic remission. This suggests that in such cases too the tissue content is precariously low and that relapse may occur swiftly if treatment is discontinued.

### ROLE IN MEGALOBLASTIC ANEMIAS

From the discussion of the absorption and utilization of  $B_{12}$  a hypothetical diagram can be prepared listing theoretic pathogeneses for most of the  $B_{12}$  deficiency megaloblastic anemias (Fig. 5). However not all megaloblastic anemias are attributable to deficiency of  $B_{12}$  (see Table 4).

plete remission in all cases) In our own experience the serum B<sub>12</sub> levels approached normal in most of these cases (20) others also have found normal serum levels of B<sub>1</sub> (107) Orthodox treatment circumvents the intestinal barrier to B<sub>12</sub> absorption by parenteral administration of B<sub>1</sub> or liver extract (a source of B<sub>1</sub>) remission is complete the serum B<sub>12</sub> level returns to normal and the tissues become saturated Progress of the central nervous system lesions is halted and improvement generally occurs although often to a limited degree)

### TOTAL GASTRECTOMY

This operation by removing the glands producing intrinsic factor (100) causes an acquired inability to absorb B<sub>1</sub> comparable to the hereditary defect causing pernicious anemia After 2 years or more a clinical picture develops identical in all respects with that of pernicious anemia (114) The results of B<sub>1</sub> absorption tests are identical with those in pernicious anemia (49 122) (see Table 3) the serum levels of B<sub>1</sub> are low (see Table 1) and treatment is the same as for pernicious anemia Preventive treatment consisting of parenteral administration of B<sub>12</sub> at stated intervals after the operation is now recommended for all patients who have had a total gastrectomy It prevents depletion of tissue stores of B<sub>12</sub> and thus the development of the pernicious anemia picture

If gastrectomy is not truly total the glands which produce intrinsic factor may not be entirely removed and B<sub>1</sub> deficiency does not develop Subtotal gastrectomy is thus inconstantly followed by a B<sub>1</sub> deficiency (3) It has been said that the leaving behind at surgery of a 1 to 2 cm collar of the gastric fundus may be enough to prevent the development of postgastrectomy pernicious anemia (53)

### CONGENITAL ABSENCE OF INTRINSIC FACTOR

Some workers have assumed that in certain children with the hematologic picture of pernicious anemia there was a congenital defect of the gastric mucosa which led to congenital lack of intrinsic factor and thence to pernicious anemia (7 89 121) This situation in our opinion is exceedingly rare

### POSTEROLATERAL SCLEROSIS WITHOUT ANEMIA

In certain cases posterolateral sclerosis due to B<sub>12</sub> deficiency occurs without or before development of the hematologic changes of pernicious



tients,  $B_{12}$  therapy results in remission (105) but generally the use of full diets supplemented by multiple vitamins is recommended.

Penicillin has also produced remissions in such patients (40). Presumably the antibiotic eliminates bacteria which have competed successfully for ingested  $B_{12}$ , thus allowing normal  $B_{12}$  absorption and leading to subsidence of the megaloblastic anemia.)

### ✓ PERNICIOUS ANEMIA

This disorder, the prototype of the entire group of megaloblastic anemias is today known to be the end result of a hereditary defect of the gastric glands as a result of which the gastric fundus sooner or later fails to produce intrinsic factor. Since intrinsic factor is necessary for the normal transport of dietary  $B_{12}$  across the intestinal mucosa progressive depletion of the tissue store of  $B_{12}$  develops with resultant abnormalities of nucleoprotein synthesis in the gastrointestinal tract and nervous and hematopoietic systems. The diagnosis is suggested by the finding of pancytopenia with megaloblastic anemia in the presence of achylia; it is strengthened when other causes of megaloblastic anemia are eliminated and it is established beyond doubt by demonstrating the intestinal inability to absorb physiologic amounts of  $B_{12}$  in the absence of intrinsic factor. The serum and urinary  $B_{12}$  levels are extremely low (approaching zero).

The pathogenesis of pernicious anemia already discussed is the chronic inability to absorb dietary  $B_{12}$  because of the lack of gastric intrinsic factor. Certain recent observations have suggested however that an abnormal intestinal flora may contribute to the development of pernicious anemia; remission after antibiotic therapy has supported this suggestion (68). However such observations are not fundamental to the basic concept of the disorder and such therapy is only of experimental interest.

✓ Folic acid therapy for pernicious anemia in relapse temporarily causes hematologic remission but may precipitate neurologic relapse. Treatment with small amounts of  $B_{12}$  by mouth (5-50  $\mu\text{g}$ /day) without added intrinsic factor is not consistently effective; apparently there is mass action transport of part of the  $B_{12}$  across the intestinal mucosa in some cases (37). Oral treatment with small amounts of  $B_{12}$  together with intrinsic factor is probably always effective provided the intrinsic factor is potent. Large amounts of  $B_{12}$  by mouth (150  $\mu\text{g}$ /day to 1000  $\mu\text{g}$ /week) without intrinsic factor by forcing absorption independent of the intrinsic factor mechanism causes com-

show that the abnormal erythropoiesis responds in some cases only to B<sub>12</sub> in others only to folic acid

The defect in the intestinal absorption of B<sub>1</sub> in this syndrome differs from the defect in pernicious anemia in the former the defect is not related to intrinsic factor (see Table 3). In the patient with sprue who fails to absorb B<sub>1</sub> in oral test doses intrinsic factor has no corrective action. This fact affords an added tool in the diagnosis of megaloblastic anemias (99).

Occasionally a patient with primary sprue may show the same neurologic abnormalities as are found in pernicious anemia (133). Judging by the disastrous results of using folic acid in patients with pernicious anemia and posterolateral sclerosis the assumption that in such cases of sprue it is the depletion of B<sub>1</sub> which causes the central nervous system lesions seems reasonable.

On the basis of the B<sub>12</sub> serum levels in primary sprue the syndrome can be divided into 2 groups, that in which the serum level is low and that in which it is normal (77 85 87). When low the serum level ranges below 100  $\mu$ g per milliliter but rarely approaches the very low values seen in pernicious anemia. Again the patient with sprue whose serum (and therefore tissue) levels of B<sub>12</sub> are low will probably respond to B<sub>1</sub> therapy whereas the patient with normal serum B<sub>1</sub> levels responds better or perhaps exclusively to folic acid (85).

#### INTESTINAL BLIND LOOP SYNDROME (53 125 127 128)

Megaloblastic anemia may occur in association with intestinal resections and anastomoses which create a blind loop of intestine. It may also occur in cases of intestinal diverticulosis (22) a sort of multiplicity of small blind loops. The essential pathogenetic factor seems to be stasis of intestinal contents and overgrowth of bacteria within the blind loops. Absorption studies in such patients have demonstrated impaired intestinal absorption of B<sub>1</sub> and the megaloblastic anemia has been attributed to B<sub>12</sub> depletion in the bone marrow.

The absorption pattern of ingested B<sub>12</sub> is unique (see Table 3). The patient fails to absorb the test dose of radioactive B<sub>1</sub> and intrinsic factor does not improve the absorption. However in some patients given a course of Aureomycin by mouth intestinal absorption of orally administered B<sub>12</sub> becomes normal (53). That this is not due to a direct effect of the antibiotic but to its antibacterial action is suggested by similar effects of orally administered gentian violet (131).

These data compel the conclusion that in such patients the static

anemia. Not all cases of subacute combined degeneration are due to the deficiency some may be caused by lead intoxication some by sypilis and some by vascular abnormalities. Posterolateral sclerosis related to B<sub>12</sub> deficiency may occur not only with pernicious anemia itself but with other B<sub>12</sub> deficiency states malabsorption syndrome (133) nutritional macrocytic anemia blind intestinal loops (125)

Patients with posterolateral sclerosis in pernicious anemia (whether the anemia is present or not) show profound reduction of the B<sub>1</sub> serum levels (87). Radioactive techniques show the same pattern of failure of absorption as in pernicious anemia. Intrinsic factor increases the intestinal absorption of the test doses of B<sub>12</sub> toward normal (1).

Such cases of posterolateral sclerosis without anemia must therefore be considered as B<sub>12</sub> deficiency syndromes in which the depletion of tissue B<sub>1</sub> primarily affects for reasons which are quite obscure, not the hematopoietic tissues but the axons. Intensive saturation of the body (and therefore the nerve cell) with B<sub>1</sub> by parenteral administration of large doses of crystalline B<sub>12</sub> prevents further neural damage and may result in considerable remission of neurologic symptoms.

✓ The adverse effects of administration of folic acid in such cases is proof that folic acid is not the cause of the neural damage. It is postulated (Fig. 4) that an excess of folic acid in a patient depleted of tissue B<sub>1</sub> forces the utilization of still more B<sub>1</sub> and thus increases the neural damage (93).

### PRIMARY MALABSORPTION SYNDROME

✓ A defect in the intestinal absorption of B<sub>1</sub> has been demonstrated in most but not in all cases of primary malabsorption syndrome in nontropical sprue tropical sprue and idiopathic steatorrhea (99) as well as a defect in folic acid absorption (45). However these are merely part of a large group of defects of intestinal absorption including defective absorption of iron vitamins A and K fats and other substances. The resulting clinical and hematologic pictures therefore vary from case to case depending in part on the predominant absorptive defect(s) (36).

Hematologically the characteristic picture of the malabsorption syndrome is a macrocytic anemia with megaloblastic or intermediate megaloblastic erythropoiesis in the bone marrow (36). The pathogenesis of the abnormal erythropoiesis as between B<sub>1</sub> deficiency and folic acid deficiency is not clarified. It is likely that both deficiencies as well as iron and protein deficiencies are important. Therapeutic studies

show that the abnormal erythropoiesis responds in some cases only to B<sub>1</sub> in others only to folic acid

The defect in the intestinal absorption of B<sub>12</sub> in this syndrome differs from the defect in pernicious anemia in the former the defect is not related to intrinsic factor (*see* Table 3). In the patient with sprue who fails to absorb B<sub>1</sub> in oral test doses intrinsic factor has no corrective action. This fact affords an added tool in the diagnosis of megaloblastic anemias (99)

Occasionally a patient with primary sprue may show the same neurologic abnormalities as are found in pernicious anemia (133). Judging by the disastrous results of using folic acid in patients with pernicious anemia and posterolateral sclerosis the assumption that in such cases of sprue it is the depletion of B<sub>1</sub> which causes the central nervous system lesions seems reasonable

On the basis of the B<sub>12</sub> serum levels in primary sprue the syndrome can be divided into 2 groups that in which the serum level is low and that in which it is normal (77 85 87). When low the serum level ranges below 100  $\mu\mu\text{g}$  per milliliter but rarely approaches the very low values seen in pernicious anemia. Again, the patient with sprue whose serum (and therefore tissue) levels of B<sub>1</sub> are low will probably respond to B<sub>12</sub> therapy whereas the patient with normal serum B<sub>1</sub> levels responds better or perhaps exclusively to folic acid (85)

#### INTESTINAL BLIND LOOP SYNDROME (53 125 127 128)

Megaloblastic anemia may occur in association with intestinal resections and anastomoses which create a blind loop of intestine. It may also occur in cases of intestinal diverticulosis (22) a sort of multiplicity of small blind loops. The essential pathogenetic factor seems to be stasis of intestinal contents and overgrowth of bacteria within the blind loops. Absorption studies in such patients have demonstrated impaired intestinal absorption of B<sub>12</sub> and the megaloblastic anemia has been attributed to B<sub>1</sub> depletion in the bone marrow

The absorption pattern of ingested B<sub>12</sub> is unique (*see* Table 3). The patient fails to absorb the test dose of radioactive B<sub>12</sub> and intrinsic factor does not improve the absorption. However in some patients given a course of Aureomycin by mouth intestinal absorption of orally administered B<sub>12</sub> becomes normal (53). That this is not due to a direct effect of the antibiotic but to its antibacterial action is suggested by similar effects of orally administered gentian violet (131)

These data compel the conclusion that in such patients the static

anemia Not all cases of subacute combined degeneration are due to the deficiency some may be caused by lead intoxication some by sypilis and some by vascular abnormalities Posterolateral sclerosis related to B<sub>1</sub> deficiency may occur not only with pernicious anemia itself but with other B<sub>1</sub> deficiency states malabsorption syndrome (133) nutritional macrocytic anemia blind intestinal loops (125)

Patients with posterolateral sclerosis in pernicious anemia (whether the anemia is present or not) show profound reduction of the B<sub>1</sub> serum levels (87) Radioactive technics show the same pattern of failure of absorption as in pernicious anemia intrinsic factor increases the intestinal absorption of the test doses of B<sub>1</sub> toward normal (1)

/Such cases of posterolateral sclerosis without anemia must therefore be considered as B<sub>12</sub> deficiency syndromes in which the depletion of tissue B<sub>1</sub> primarily affects for reasons which are quite obscure, not the hematopoietic tissues but the axons Intensive saturation of the body (and therefore the nerve cell) with B<sub>1</sub> by parenteral administration of large doses of crystalline B<sub>1</sub> prevents further neural damage and may result in considerable remission of neurologic symptoms

✓The adverse effects of administration of folic acid in such cases is proof that folic acid is not the cause of the neural damage It is postulated (Fig. 4) that an excess of folic acid in a patient depleted of tissue B<sub>12</sub> forces the utilization of still more B<sub>12</sub> and thus increases the neural damage (93)

### PRIMARY MALABSORPTION SYNDROME

✓A defect in the intestinal absorption of B<sub>1</sub> has been demonstrated in most but not in all cases of primary malabsorption syndrome in nontropical sprue tropical sprue and idiopathic steatorrhea (99) as well as a defect in folic acid absorption (45) However these are merely part of a large group of defects of intestinal absorption including defective absorption of iron vitamins A and K fats and other substances The resulting clinical and hematologic pictures therefore vary from case to case depending in part on the predominant absorptive defect(s) (36)

Hematologically the characteristic picture of the malabsorption syndrome is a macrocytic anemia with megaloblastic or intermediate megaloblastic erythropoiesis in the bone marrow (36) The pathogenesis of the abnormal erythropoiesis as between B<sub>1</sub> deficiency and folic acid deficiency is not clarified It is likely that both deficiencies as well as iron and protein deficiencies are important Therapeutic studies

✓ The pathogenesis of the megaloblastic anemia of *D. latum* infection is competition between parasite and host for ingested B<sub>12</sub> in which the worm successfully competes against the host's intrinsic factor by binding most of the ingested B<sub>12</sub> (17). The patient therefore does not absorb B<sub>12</sub> and tissue deficiency of B<sub>12</sub> results in megaloblastic anemia. The serum B<sub>12</sub> levels in these patients are extremely low (96-97). The radioactive oral absorption tests (see Table 3) reveal poor absorption of the test dose and most of the ingested radioactivity is found in the worm (18-96). Intrinsic factor does not overcome the malabsorption of the test dose. The presence of free hydrochloric acid also suggests that pernicious anemia is not the correct diagnosis and the finding and expulsion of the worm are followed by remission of the anemia.

### ✓ PERNICIOUS ANEMIA OF PREGNANCY (Folic Acid)

Although the serum levels and tissue content of B<sub>12</sub> fall during pregnancy even the lower levels are within the normal range (13). Pernicious anemia of pregnancy would therefore not be expected to be due to tissue depletion of B<sub>12</sub> and clinical observations have long confirmed this fact. In this disorder the serum levels of B<sub>12</sub> are not low and, with rare exceptions (28-70) the disorder responds not to B<sub>12</sub> therapy but to folic acid administration.

The pathogenesis of pernicious anemia of pregnancy must be sought elsewhere in the schema (see Fig. 4) perhaps in some unexplained deficiency of folic acid (coenzyme) (70-93-125).

Pernicious anemia of pregnancy is not a B<sub>12</sub> deficiency anemia.

### MEGALOBLASTIC ANEMIA OF INFANCY (Vitamin C)

The pathogenesis of the megaloblastic anemia which sometimes occurs in infants is also not to be found in study of B<sub>12</sub> depletion. A megaloblastic anemia which resembles that of infancy can be produced in monkeys maintained on a milk diet deficient in ascorbic acid (71-72). This anemia cannot be prevented or eliminated by administration of B<sub>12</sub> but can be successfully treated with ascorbic acid, folic acid, or folinic acid. It is suggested that a deficiency of ascorbic acid interferes with the metabolism of folic acid and thus leads to megaloblastic anemia (see Fig. 4).

✓ Interference with folic acid metabolism has been postulated as the cause of megaloblastic anemia in infants in the course of infections.

bacteria within the blind loops compete in some manner with the host for the ingested  $B_{12}$ . The manner of competition is not clear, it may be by a distant "toxic" action of the bacteria on the ingested  $B_{12}$  on the intrinsic factor or on the  $B_{12}$ -intrinsic factor complex or by a toxic effect on the upper intestinal mucosa or by a direct action in which the bacteria actually bind the  $B_{12}$  or utilize it and folic acid so that they become unavailable for absorption (125-128). Development of the  $B_{12}$  deficient megaloblastic anemia in experimental animals depends on special features: the blind loop must be at the jejunum not at the ileum (128) for megaloblastic anemia to develop. In such animals the resulting anemia can be cured by the parenteral administration of  $B_{12}$  but it can as well be corrected by sterilizing the bowel by means of antibiotics or by correcting the loop surgically (127-128). Sometimes only surgical correction effects remission.

✓ Depletion of tissue  $B_{12}$  can thus be produced by intestinal bacteria which compete with the body for the ingested  $B_{12}$ . Such bacterial action has also been suggested as part of the pathogenesis of the megaloblastic anemia of nutritional deficiencies (40) and even of pernicious anemia itself (68). The intestinal flora of patients with addisonian pernicious anemia is known to be abnormal; partial remissions in such patients by antibiotics have been reported and attributed to their bacteriostatic action (68). Whether this mechanism plays an important role in the pathogenesis of pernicious anemia is questionable, but variations in flora may be important in accounting for the spontaneous remissions which occur in untreated cases.

### DIPHYLLOBOTHRIUM LATUM ANEMIA

✓ Some patients who harbor *D. latum* have coincidental addisonian pernicious anemia; others have a megaloblastic anemia hematologically identical with pernicious anemia which is the direct result of the parasitic infestation. The latter have a normal content of gastric hydrochloric acid and their gastric juice contains intrinsic factor. The worm must be located in the upper jejunum (16). If the worm is expelled from the body spontaneous remission of the megaloblastic anemia occurs. If the expelled worm is ground up and the resulting material ingested by or injected into a patient with addisonian pernicious anemia, remission is produced (17). Finally analysis of the expelled worm for its  $B_{12}$  content shows large amounts of this substance (18).

anemia and puerperal macrocytic anemia J Lab & Clin Med 33 1477 1948

- 11 Bjorkenheim, G Neurological changes in pernicious tapeworm anaemia Acta med scandinav Supp 260 1951
- 12 Boger W P *et al* Vitamin B<sub>12</sub> Correlation of serum concentration and age Proc Soc Exper Biol & Med 89 375 1955
- 13 Boger W P *et al* Vitamin B<sub>12</sub> Correlation of serum concentrations and pregnancy Proc Soc Exper Biol & Med 92 140 1956
- 14 Boger W P *et al* Differential serum vitamin B<sub>12</sub> concentrations in mothers and infants New England J Med 256 1085 1957
- 15 Booth, C. C and Mollin D L Plasma tissue and urinary radioactivity after oral administration of <sup>57</sup>Co-labelled vitamin B Brit J Haemat. 2 223 1956
- 16 von Bonsdorff B Diphyllbothrium latum und perniziose Anämie Acta haemat 10 129 1953
- 17 von Bonsdorff B Pathogenesis of Vitamin B<sub>12</sub> Deficiency with Special Reference to Tapeworm Pernicious Anaemia in Vitamin B and Intrinsic Factor (Stuttgart Ferdinand Enke Verlag 1957) pp 311-327 (First European Symposium on Vitamin B<sub>12</sub> and Intrinsic Factor Hamburg 1956)
- 18 von Bonsdorff B and Gordin R Antianemic activity of dried fish tapeworm Acta med scandinav Supp 266 283 1952
- 19 Brody E A Estren, S and Wasserman L R Personal observations
- 20 Brody E A Estren S and Wasserman L R The treatment of pernicious anemia by oral vitamin B without added intrinsic factor In preparation
- 21 Burkholder P R Microbiological studies on materials which potentiate oral vitamin B<sub>12</sub> therapy in addisonian anemia Arch Biochem 39 322 1952
- 22 Callender S T and Evans J R Observations on the relationship of intrinsic factor to the absorption of labelled vitamin B<sub>12</sub> from the intestine Clin Sc. 14 387 1955
- 23 Callender S T and Spray G H Preparation of haemopoietically active extracts from faeces Lancet 1 1391 1951
- 24 Castle W B Observations on etiologic relationship of achylia gastrica to pernicious anemia I Effect of administration to patients with pernicious anemia of contents of normal human stomach recovered after ingestion of beef muscle Am J M Sc 178 748 1929
- 25 Castle W B Development of knowledge concerning the gastric intrinsic factor and its relationship to pernicious anemia New England J Med 249 603 1953
- 26 Castle W B and Ham T H Observations on the etiologic relationship of achylia gastrica to pernicious anemia J.A.M.A 107 1936 1936
- 27 Chaet, L Rosenblum C and Woodbury D T Biosynthesis of radioactive vitamin B<sub>12</sub> containing cobalt<sup>60</sup> Science 111 601 1950
- 28 Chaudhuri, S Vitamin B in megaloblastic anaemia of pregnancy and tropical nutritional macrocytic anaemia Brit M J 2 825 1951
- 29 Chow B F and Stone H H The relationship of vitamin B<sub>12</sub> to carbohydrate metabolism and diabetes mellitus Am. J Clin Nutrition 5 431 1957
- 30 Cohn E J *et al* The nature of the material in liver effective in pernicious anemia J Biol Chem 74 69 1927
- 31 Conley C L *et al* Observations on the absorption utilization and excretion of vitamin B<sub>12</sub> J Lab & Clin Med 38 84 1951
- 32 Conley C L *et al* Prolonged treatment of pernicious anemia with vitamin B<sub>12</sub>, Am J Med 13 284 1952.



(73) It has been treated successfully with combined ascorbic acid folic acid and B<sub>12</sub> therapy

Megaloblastic anemia of infancy too is not a B<sub>12</sub> deficiency anemia

### MEGALOBlastic ANEMIA OF HEPATIC DISEASE (92)

In many cases of chronic hepatic insufficiency the macrocytic anemia is not megaloblastic in etiology. Rarely however a true megaloblastic anemia may occur in chronic liver disease. Theoretically (Fig 5) such an anemia might be expected as the result of the liver's inability to store B<sub>12</sub>. Actually the pathogenesis of this anemia in liver disease is not at all clear

### MEGALOBlastic ANEMIA DUE TO DRUGS (46)

Megaloblastic anemia has been described following the use of primidone (Mysoline) and certain other drugs used to control epilepsy. In such cases no defect in B<sub>12</sub> metabolism has been found and folic acid has proved to be therapeutically effective. It has been proposed that the megaloblastic abnormality is the result of competitive inhibition of an enzyme using folic acid. Therefore this is not a B<sub>12</sub> deficiency syndrome

### REFERENCES

- 1 Arias I M Apt L and Pollycove M Absorption of radioactive vitamin B<sub>12</sub> in non anemic patients with combined system disease New England J Med 253 1005 1955
- 2 Arnstein H R V The Function of Vitamin B<sub>12</sub> in Animal Metabolism in *The Biochemistry of Vitamin B* (Cambridge Cambridge University Press 1955) pp 92-108 (Biochemical Society Symposia No 13)
- 3 Badenoch J *et al* Megaloblastic anaemia following partial gastrectomy and gastro enterostomy Brit. J Haemat 1 339 1955
- 4 Baker S J and Mollin D L The relationship between intrinsic factor and the intestinal absorption of vitamin B<sub>12</sub> Brit J Haemat 1 46 1955
- 5 Beard M F *et al* Serum concentrations of vitamin B<sub>12</sub> in acute leukemia Ann Int. Med 41 323 1954
- 6 Beard M F Pitney W R and Sanneman E H Serum concentrations of vitamin B<sub>12</sub> in patients suffering from leukemia Blood 9 789 1954
- 7 Benjamin B Infantile form of pernicious (addisonian) anemia Report of long term study of a case Am J Dis Child 75 143 1948
- 8 Berk L *et al* Observations on the etiologic relationship of achylia gastrica to pernicious anemia X. Activity of vitamin B<sub>12</sub> as food (extrinsic) factor New England J Med 239 911 1948
- 9 Bertscher R W and Meyer L M Co<sup>57</sup> vitamin B<sub>12</sub> binding capacity of normal human serum Proc. Soc Exper Biol & Med. 94 169 1957
- 10 Bethell, E H Meyers M C and Neligh R B Vitamin B<sub>12</sub> in pernicious

- 54 Halsted J A *et al* Mechanisms involved in the development of vitamin B<sub>12</sub> deficiency Gastroenterology 30 21 1956
- 55 Harris J W Aggravation of clinical manifestations of folic acid deficiency by small daily doses of vitamin B<sub>12</sub>, Am J Med 21 461 1956
- 56 Heinle R W *et al* Studies of excretion (and absorption) of Co<sup>60</sup> labeled vitamin B<sub>12</sub> in pernicious anemia Tr A Am Physicians 65 214 1952.
- 57 Heinrich H C Die biochemischen Grundlagen der Diagnostik und Therapie der Vitamin B<sub>12</sub>-Mangelzustände (B<sub>12</sub>-Hypo- und Avitaminosen) des Menschen und der Haustiere II Untersuchungen zum Vitamin B<sub>12</sub>-Stoffwechsel des Menschen während der Gravidität und Lactation, Klin Wchnschr 32 205 1954
- 58 Heinrich H C and Erdmann Oehlecker S Der Vitamin B<sub>12</sub>-Stoffwechsel bei Hamoblastosen II Die intravitale Bindung (Transport) der B<sub>12</sub>-Vitamine an die Serumproteinfraktionen bei Hamoblastosen Clin chim acta 1 311 1956
- 59 Hodgkin D C *et al* Structure of vitamin B<sub>12</sub> The crystal structure of the hexacarboxylic acid derived from B<sub>12</sub> and the molecular structure of the vitamin Nature 176 325 1955
- 60 Horrigan, D L and Heinle R W Refractory macrocytic anemia with defect in vitamin B<sub>12</sub> binding and with response to normal plasma J Lab & Clin Med 40 811 1952
- 61 Hutner S H Provasoli L and Filfus J Nutrition of some phagotrophic fresh water chrysomonads Ann New York Acad Sc 56 852 1953
- 62 Hutner S H *et al* Assay of anti pernicious anemia factor with Euglena Proc Soc Exper Biol & Med 70 118 1949
- 63 Jansen L Zum Vitamin B<sub>12</sub>-Haushalt bei Lebererkrankungen in *Vitamin B und Intrinsic Factor* (Stuttgart Ferdinand Enke Verlag 1957) pp 541-543 (First European Symposium on Vitamin B<sub>12</sub> and Intrinsic Factor Hamburg 1956 )
- 64 Jasianska B Frei, H and Stiefel, G E Bindung Transport und Verteilung von Vitamin B<sub>12</sub> in Organismus in *Vitamin B<sub>12</sub> und Intrinsic Factor* (Stuttgart, Ferdinand Enke Verlag 1957) pp 449-456 (First European Symposium on Vitamin B<sub>12</sub> and Intrinsic Factor Hamburg 1956 )
- 65 Kasbekar D K Rege D V and Sreenivasan, A Protective action of vitamin B<sub>12</sub> in experimental liver injury Nature 178 989 1956
- 66 Klayman M J and Brandberg L Clinical application of cobalt<sup>60</sup> labeled vitamin B<sub>12</sub>, urine test New England J Med 253 808 1955
- 67 Lear A A *et al* The serum vitamin B<sub>12</sub> concentration in pernicious anemia J Lab & Clin Med 44 715 1954
- 68 Lichtman H Ginsberg V and Watson J Therapeutic effect of aureo mycin in pernicious anemia Proc Soc Exper Biol & Med 74 884 1950
- 69 Ling C I and Chow B F Vitamin B in Carbohydrate and Lipid Metabolism, in *Vitamin B and Intrinsic Factor* (Stuttgart Ferdinand Enke Verlag 1957) pp 127-132 (First European Symposium on Vitamin B<sub>12</sub> and Intrinsic Factor Hamburg 1956 )
- 70 Lowenstein L Pick C and Philpott, N Megaloblastic anemia of pregnancy and the puerperium Am J Obst & Gynec. 79 1309 1955
- 71 May C D Hamilton A and Stewart C T Experimental megaloblastic anemia and scurvy in the monkey IV Vitamin B<sub>12</sub> and folic acid compounds in the diet, liver urine and feces and effects of therapy Blood 7 978 1952.
- 72 May C D *et al* Experimental nutritional megaloblastic anemia Relation

- 33 Davidson I S P The gastro intestinal flora in pernicious anemia J Path & Bact 31 557 1928
- 34 Davis B D and Mingoli E S Mutants of *Escherichia coli* requiring methionine or vitamin B<sub>12</sub> J Bact 60 17 1950
- 35 Doscherholmen A and Hagen P S Radioactive vitamin B<sub>12</sub> absorption studies Results of direct measurement of radioactivity in the blood Blood 12 336 1957
- 36 Estren S The blood and bone marrow in idiopathic sprue J Mt Sinai Hosp 24 304 1957
- 37 Estren S and Wasserman L R Pernicious anemia I Remission by small oral doses of purified vitamin B<sub>12</sub> Proc Soc Exper Biol & Med 91 499 1956
- 38 Flint A Clinical lecture on anaemia Am M Times 1 181 1860
- 39 Ford J E The microbiological assay of vitamin B<sub>12</sub> The specificity of the requirement of *Ochromonas malhamensis* for cyanocobalamin Brit J Nutrition 7 299 1953
- 40 Foy H and Kondi A Response of megaloblastic anemia to crystalline penicillin G Brit M J 1 380 1952
- 41 Gaffney G W *et al* Vitamin B<sub>12</sub> serum concentrations in 528 apparently healthy human subjects of ages 12-94 J Geront 12 32 1957
- 42 Girdwood R H The intestinal content in pernicious anemia of factors for the growth of *Streptococcus faecalis* and *Lactobacillus leichmannii* Blood 5 1009 1950
- 43 Girdwood R H Occurrence of growth factors for *Lactobacillus leichmannii* *Streptococcus faecalis* and *Leuconostoc citrovorum* in tissues of pernicious anaemia patients and controls Biochem J 52 58 1952
- 44 Girdwood R H The relationships between vitamin B<sub>12</sub> folic acid and folinic acid Brit J Nutrition 6 315 1952
- 45 Girdwood R H A folic acid excretion test in the investigation of intestinal absorption Lancet 1 53 1953
- 46 Girdwood R H and Lenman J A N Megaloblastic anaemia occurring during primidone therapy Brit M J 1 146 1956
- 47 Glass G B J Biochemistry and physiology of Castle's intrinsic factor and its relationship to the metabolism of vitamin B<sub>12</sub> Rev d'hémat, 10 137 1955
- 48 Glass G B J *et al* Intestinal absorption and hepatic uptake of radioactive vitamin B<sub>12</sub> in various age groups and the effect of intrinsic factor preparations Am J Clin Nutrition 4 124 1956
- 49 Glass G B J *et al* Uptake of radioactive vitamin B<sub>12</sub> by liver in humans Test for measurement of intestinal absorption of vitamin B<sub>12</sub> and intrinsic factor activity Arch Biochem 51 251 1954
- 50 Graham R M and Rheault, M H Characteristic cellular changes in epithelial cells in pernicious anemia J Lab & Clin Med 43 235 1954
- 51 Grossowicz N Aronovitch J and Rachmilewitz M Determination of vitamin B<sub>12</sub> in human serum by a mutant of *Escherichia coli* Proc Soc Exper Biol & Med 87 513 1954
- 52 Halsted, J A. Briggs J D and Gasster M Nutritional problems after total gastrectomy New York State J Med 57 223 1957
- 53 Halsted J A Gasster M and Drenick, E J Absorption of radioactive vitamin B<sub>12</sub> after total gastrectomy relation to macrocytic anemia and to the site of origin of Castle's intrinsic factor New England J Med 251 161 1954

- 91 Monto R W., and Rebeck J W Nasal instillation and inhalation of crystal line vitamin B<sub>12</sub> in pernicious anemia A M A Arch Int Med 93 219 1954
- 92 Movitt E R Megaloblastic erythropoiesis in patients with cirrhosis of the liver Blood 5 468 1950
- 93 Mueller J F and Will J J Interrelationship of folic acid vitamin B<sub>12</sub> and ascorbic acid in patients with megaloblastic anemia Am J Clin Nutrition 3 30 1955
- 94 Nieweg H O Vitamine B<sub>12</sub> en Folliumuurdeficiëntie (s Gravenhage Uitgeverij Excelsior 1953)
- 95 Nieweg H O van Buchem F S P and Kroese W F S Vitamin B<sub>12</sub> and pteroylglutamic acid in the treatment of megaloblastic anemias Acta med scandinav 142 45 1952.
- 96 Nyberg W The Absorption of Radioactive Vitamin B<sub>12</sub> in Persons Infested with the Fish Tapeworm *Diphyllobothrium latum* in Vitamin B<sub>12</sub> und Intrinsic Factor (Stuttgart Ferdinand Enke Verlag 1957) pp 328-332 (First European Symposium on Vitamin B<sub>12</sub> and Intrinsic Factor Hamburg 1956)
- 97 Nyberg W and Östling G Low vitamin B<sub>12</sub> concentrations in serum in fish tapeworm anaemia Nature 178 934 1956
- 98 O'Dell B L et al Effect of a vitamin B<sub>12</sub> deficiency and of fasting on oxidative enzymes in the rat J Biol. Chem 217 625 1955
- 99 Oxenhorn S Estren S and Adlersberg D Intestinal uptake of vitamin B<sub>12</sub> in the malabsorption syndrome J Mt Sinai Hosp 24 232 1957
- 100 Paulsen M Conley C L and Glasden E S Absence of intrinsic factor from intestinal juice of patients following total gastrectomy Am J M Sc 220 310 1950
- 101 Pfander W H et al Citrovorum factor vitamin B<sub>12</sub> and folic acid activity of whole blood of several species Proc Soc Exper Biol & Med 79 219 1952
- 102 Pitney W R Beard M F and Van Loon E J Observations on the bound form of vitamin B<sub>12</sub> in human serum J Biol Chem 207 143 1954
- 103 Pitney W R Beard M F and Van Loon E J The vitamin B<sub>12</sub> content of electrophoretic fractions of liver homogenates J Biol Chem 212 117 1955
- 104 Pollycove M and Apt L Absorption elimination and excretion of orally administered vitamin B<sub>12</sub> in normal subjects and in patients with pernicious anemia New England J Med 255 207 1956
- 105 Pollycove M Apt L and Colbert M J Pernicious anemia due to dietary deficiency of vitamin B<sub>12</sub> New England J Med 255 184 1956
- 106 Rachmilewitz M Aronovitch J and Grossowicz N Serum concentrations of vitamin B<sub>12</sub> in acute and chronic liver disease J Lab & Clin Med 48 339 1956
- 107 Reisner E H Jr et al Oral treatment of pernicious anemia with vitamin B<sub>12</sub> without intrinsic factor New England J Med 253 502 1955
- 108 Richter O Ivy A C and Kim M S Action of human pernicious anemia liver extract, Proc Soc Exper Biol & Med 29 1093 1932
- 109 Rosenthal H L and Sarett H P The determination of vitamin B<sub>12</sub> activity in human serum J Biol Chem 199 433 1952
- 110 Ross G I M Vitamin B<sub>12</sub> assay in body fluids Nature 166 270 1950
- 111 Ross G I M Vitamin B<sub>12</sub> assay in body fluids using *Euglena gracilis* J Clin Path 5 250 1952
- 112 Ross G I M and Mollin D L Vitamin B<sub>12</sub> in Tissues in Pernicious

- ship of ascorbic and pteroylglutamic acid I Nutritional data and manifestations of animals A M A Am J Dis Child 82 282 1951
- 73 May C D *et al* Infection as cause of folic acid deficiency and megaloblastic anemia Experimental induction of megaloblastic anemia by turpentine abscess A M A Am J Dis Child 84 718 1952
- 74 McIntyre P A *et al* Pathogenesis and treatment of macrocytic anemia information obtained with radioactive vitamin B<sub>12</sub> A M A Arch Int Med 98 541 1956
- 75 Meyer L M Arkun S N and Jimenez Casado M Further observations on distribution of radioactivity following parenteral administration of Co<sup>60</sup> vitamin B<sub>12</sub> Proc Soc Exper Biol & Med 92 515 1956
- 76 Meyer L M *et al* Oral administration of Co<sup>60</sup> vitamin B<sub>12</sub> in tropical sprue and hepatic cirrhosis and diarrhea Proc Soc Exper Biol & Med 83 681 1953
- 77 Meynell M S *et al* Serum cyanocobalamin level in chronic intestinal disorders Lancet 1 901 1957
- 78 Miller A Corbus H F and Sullivan J F The plasma disappearance excretion and tissue distribution of cobalt<sup>60</sup> labelled vitamin B<sub>12</sub> in normal subjects and patients with chronic myelogenous leukemia J Clin Invest 36 18 1957
- 79 Miller A Corbus H F and Sullivan J F A modified urinary excretion test for measuring oral cobalt<sup>60</sup> labeled vitamin B<sub>12</sub> absorption and its application in certain disease states Blood 12 347 1957
- 80 Miller A *et al* Tissue distribution of parenteral Co<sup>60</sup> vitamin B<sub>12</sub> in mouse hamster rat and guinea pig Proc Soc Exper Biol & Med 93 33 1956
- 81 Minot G R and Castle W B Interpretation of reticulocyte reactions Their value in determining the potency of therapeutic materials especially in pernicious anemia Lancet 2 319 1935
- 82 Minot G R and Murphy W Treatment of pernicious anemia by special diet J A M A 87 470 1926
- 83 Mollin D L and Ross G I M Serum vitamin B<sub>12</sub> concentrations in leukaemia and in some other haematological conditions Brit. J Haemat 1 155 1955
- 84 Mollin D L and Ross G I M The vitamin B<sub>12</sub> concentrations of serum and urine of normals and of patients with megaloblastic anaemias and other diseases J Clin Path 5 129 1952
- 85 Mollin D L and Ross G I M Serum vitamin B<sub>12</sub> concentrations of patients with megaloblastic anaemia after treatment with vitamin B<sub>12</sub>, folic acid or folic acid Brit M J 2 640 1953
- 86 Mollin D L and Ross G I M Vitamin B<sub>12</sub> concentrations of serum and urine in the first 72 hours after intramuscular injection of the vitamin J Clin Path 6 54 1953
- 87 Mollin D L and Ross G I M Vitamin B<sub>12</sub> deficiency in the megaloblastic anaemias Proc Roy Soc Med 47 428 1954
- 88 Mollin D L and Ross G I M The Pathophysiology of Vitamin B<sub>12</sub> Deficiency in the Megaloblastic Anaemias in *Vitamin B and Intrinsic Factor* (Stuttgart Ferdinand Enke Verlag 1957) pp 413-430 (First European Symposium on Vitamin B<sub>12</sub> and Intrinsic Factor Hamburg 1956)
- 89 Mollin D L Baker S J and Doniach I Addisonian pernicious anaemia without gastric atrophy in a young man Brit J Haemat. 1 278 1955
- 90 Mollin D L *et al* The plasma clearance and urinary excretion of parentally administered <sup>60</sup>Co B<sub>12</sub> Blood 11 31 1956

# Corticosteroids and Infections\*

EDWARD H. KASS *and* MAXWELL FINLAND

*Thorndike Memorial Laboratory Second and Fourth (Harvard) Medical  
Services Boston City Hospital and Department of Medicine  
Harvard Medical School Boston Massachusetts*

THE DISCOVERY of the effect of adrenocortical steroids in altering the manifestations of a variety of clinical disorders was in common with many other important medical discoveries a clinical observation without an adequate theoretic framework for predicting the observed effects. Much of the subsequent investigation of the action of adrenocortical steroids necessarily followed the same pragmatic pattern and coincidentally increasing attention was paid to mechanisms of action.

The initial studies on the role of adrenocortical steroids in infectious disease were therefore undertaken pragmatically. Many of the diseases in which effects of corticosteroids had already been observed were diseases of uncertain etiology in which immunologic mechanisms were presumed to play a role. It was hoped without much logic that by studying the effects of adrenocortical steroids in infectious diseases in which a reasonable amount of information was available concerning etiology pathogenesis and mechanisms of resistance insight into some of the mechanisms of action of these steroids would be obtained. In addition there were many indications of a role of adrenocortical steroids in mechanisms of resistance. The observations on this aspect had for the most part been made before the discovery of the clinical effects of large doses of corticosteroids in various inflammatory diseases and were not as potent a stimulus to investigation as the observed clinical effects.

In the initial studies adrenocorticotropin was given to carefully

---

Some of the authors' studies cited herein were aided by grants from the National Institutes of Health United States Public Health Service

- Anaemia and Other Conditions in *Vitamin B<sub>12</sub> and Intrinsic Factor* (Stuttgart Ferdinand Enke Verlag 1957) pp 437-442 (First European Symposium on Vitamin B<sub>12</sub> and Intrinsic Factor Hamburg 1956)
- 113 Ross G I M *et al* Hematologic responses and concentration of vitamin B<sub>12</sub> in serum and urine following oral administration of vitamin B<sub>12</sub> without intrinsic factor *Blood* 9 473 1954
  - 114 Rowlands R A and Simpson S L Addisonian anemia following gastrectomy and gastrojejunostomy *Lancet* 2 1202 1932
  - 115 Scheid H E and Schweigert B S Vitamin B<sub>12</sub> content of organ meats *J Nutrition* 53 419 1954
  - 116 Schilling R F Intrinsic factor studies II Effect of gastric juice on urinary excretion of radioactivity after oral administration of radioactive vitamin B<sub>12</sub> *J Lab & Clin Med* 42 860 1953
  - 117 Schilling R F The absorption and utilization of vitamin B<sub>12</sub> *Am J Clin Nutrition* 3 45 1955
  - 118 Smith E L Radioactive penicillin and vitamin B<sub>12</sub> *Brit M Bull* 8 203 1952
  - 119 Smith E L Isolation and Chemistry of Vitamin B<sub>12</sub> in *The Biochemistry of Vitamin B<sub>12</sub>* (Cambridge Cambridge University Press 1955) pp 3-16 (Biochemical Society Symposia No 13)
  - 120 Smith, E L Hockenhull D J D and Quilter A R J Tracer studies with the B<sub>12</sub> vitamins 2 Biosynthesis of vitamin B<sub>12</sub> labelled with <sup>14</sup>C and <sup>3</sup>P *Biochem J* 52 387 1952
  - 121 Stevenson T D Little J A and Langely L Pernicious anemia in childhood *New England J Med* 255 1219 1956
  - 122 Swendsen M E Halsted J A and Libby R L Excretion of cobalt<sup>60</sup> labeled vitamin B<sub>12</sub> after total gastrectomy *Proc Soc Exper Biol & Med* 83 226 1953
  - 123 Swendsen M E *et al* Vitamin B<sub>12</sub> liver content in old age *Fed Proc* 14 290 1955
  - 124 Swendsen M E *et al* The vitamin B<sub>12</sub> content of human liver tissue and its nutritional significance a comparison study of various age groups *Blood* 12 24 1957
  - 125 Ungley C C The pathogenesis of megaloblastic anaemias and the value of vitamin B<sub>12</sub> *Brit J Nutrition* 6 299 1952
  - 126 Ungley C C and Thompson R B Gastric Intrinsic Factor and Vitamin B<sub>12</sub> Interrelationships in Tocantins L M ed *Progress in Hematology* (New York Grune & Stratton 1956) Vol 1 pp 1-21
  - 127 Watson G M Cameron D G and Wits L J Experimental macrocytic anemia in the rat *Lancet* 2 404 1948
  - 128 Watson G M and Wits L J Intestinal macrocytic anaemia *Brit M J* 1 13 1952
  - 129 Welch A D and Heinle R W Hematopoietic agents in macrocytic anemias vitamin B<sub>12</sub> binding and intrinsic factors *Pharmacol Rev* 3 360 1951
  - 130 Wokes F Badenoch J and Sinclair H M Human dietary deficiency of vitamin B<sub>12</sub> *Am J Clin Nutrition* 3 375 1955
  - 131 Wolf R Brody E and Estren S Personal observations
  - 132 Wolf R Royer P and Karlin R Variations du taux hepatique de vitamine B<sub>12</sub> dans l'intoxication experimentale par le tetrachlorure de carbone *Bull Soc chim biol* 34 538 1952
  - 133 Woltmann H W and Heck F J Funicular degeneration of the spinal cord without pernicious anemia Neurologic aspects of sprue nontropical sprue and idiopathic steatorrhea *Arch. Int Med* 60 272 1937




FIG. 2.—ACTH therapy in 48 year old man with pneumococcal pneumonia complicated by empyema. Administration of ACTH resulted in gradual but progressive improvement in patient's symptoms and general appearance but despite continued therapy pneumococci persisted in sputum new lung areas became involved and empyema developed. Cessation of ACTH and institution of antibiotic therapy led to gradual improvement. Type specific antibodies developed by end of first week of illness and increased while large doses of ACTH were being given (From Kass *et al* (84) )






Fig 1—ACTH therapy without antibiotics in a 16 year old boy with pneumococcal pneumonia. Administration of ACTH resulted in prompt defervescence with rapid clearing of the signs and symptoms of pulmonary infiltration pneumococci nevertheless persisted in sputum after temperature fall. Blood cultures showed no growth of organisms at start of treatment but yielded pneumococcus type 8 after 12 and 36 hours of therapy although patient looked and felt well. Type specific agglutinins and mouse protective antibodies were not demonstrable until 2 weeks later (From Kass *et al* (84) )




FIG. 2--ACTH therapy in 48 year old man with pneumococcal pneumonia complicated by empyema. Administration of ACTH resulted in gradual but progressive improvement in patient's symptoms and general appearance but despite continued therapy pneumococci persisted in sputum new lung areas became involved and empyema developed. Cessation of ACTH and institution of antibiotic therapy led to gradual improvement. Type specific antibodies developed by end of first week of illness and increased while large doses of ACTH were being given (from Kass et al (81) )

selected patients with lobar and viral pneumonias (43-80). Figure 1 illustrates the nature of the response of a patient with type 8 pneumococcal pneumonia. This and similar observations made it clear that adrenocortical steroids could induce in patients with pneumonia striking defervescence and symptomatic relief with diminution or disappearance of malaise and anorexia. These remarkable symptomatic changes occurred despite the persistence of pneumococci in the sputum, the presence of bacteremia and in one instance the spread of the pneumonia to other lobes with subsequent development of empyema (Fig. 2). The symptomatic changes were independent of gross changes in the antibody response and were not accompanied by reversal of metabolic patterns characteristic of pneumonia and other severe injuries, that is, loss of nitrogen, potassium and phosphorus and retention of sodium and chloride. Indeed, the administration of corticotropin accentuated the metabolic changes while bringing about symptomatic relief.

In subsequent years considerable clinical and laboratory data have been accumulated in an attempt to answer the most obvious questions posed by these observations: (1) Is the administration of corticosteroids to patients with infectious diseases really valuable? Are there specific areas within the broad field of infectious diseases in which they are particularly useful? Are there definable conditions under which they are not helpful or in which they may be harmful? Can the specific action of these agents be so defined that they can be used to advantage without leading to serious untoward consequences? Finally, can the observed effects be utilized as a means for increasing our understanding of mechanisms of resistance to infection and perhaps of mechanisms of action of corticosteroids?

Complete and satisfactory answers to these questions are not yet possible. However, some of the available data, as they relate to the practical clinical problem as well as to the understanding of mechanisms of resistance and of hormonal action, will be summarized here. Many reviews of these aspects have appeared (50, 72, 76, 77, 106, 124, 141).

## ROLE OF ADRENOCORTICAL HORMONES IN MANAGEMENT OF INFECTIOUS DISEASES

Fundamentally two conflicting points of view have developed. On the one hand, there is a substantial body of evidence that corticoste-

roids depress resistance to infection on the other there are potent arguments for the use of corticosteroids in the management of infections)

### EVIDENCE FOR DEPRESSION OF HOST RESISTANCE BY CORTICOSTEROIDS

**CLINICAL.** In the early phases of the study of the problem corticosteroids without antibiotics were used in the treatment of such diverse infections as pneumococcal and other bacterial pneumonias tuberculosis brucellosis, typhoid fever subacute bacterial endocarditis acute streptococcosis leptospirosis peritonitis tetanus rickettsiosis poliomyelitis smallpox mumps viral hepatitis viral pneumonias infectious mononucleosis malaria, trichinosis blastomycosis and undoubtedly others (72 76 77 141) The specific etiologic agents were not always clearly definable and many of the studies consist of reports of single or small numbers of cases Nevertheless a few generalizations can be made from the observations recorded on this great variety of infections /

(1) The administration of corticotropin or corticosteroids to patients with acute febrile illnesses or with severe malaise or anorexia frequently brought about prompt defervescence and amelioration of many of the distressing clinical manifestations of illness

(2) In those infections in which cultivation or demonstration of the infectious agent was possible during the course of treatment with corticosteroids alone for example in bacterial pneumonias typhoid fever tuberculosis brucellosis subacute bacterial endocarditis there was frequently evidence of increased multiplication or spread of the pathogenic agent despite the apparent amelioration of the clinical syndrome

(3) Many of the disease syndromes treated with corticosteroids are of the type in which quantitation of the etiologic agent is difficult or impossible (e g trichinosis viral hepatitis infectious mononucleosis) Most of these are infections in which the mortality rates are low and complications are infrequent Presumably host resistance in these diseases is high and even if significant depression of immunity were to occur detection would be difficult However carefully controlled studies of the effects of corticosteroids in infectious hepatitis have shown that although the use of corticosteroids may lead to more rapid symptomatic improvement increased appetite and more rapid fall in serum bilirubin than in untreated controls relapses occurred in

20 per cent of the treated patients and did not occur in controls. The concurrent administration of human serum  $\gamma$  globulin did not prevent relapses in the treated patients (41-42).

Controlled studies of the effects of corticosteroids on the course of poliomyelitis (27) and of acute streptococcosis (58) have indicated no striking effect on the acute disease nor on the sequelae of these two infections: the patients were neither benefited nor apparently harmed. When live virus was injected therapeutically into patients with malignant disease treated with cortisone, the duration of viremia and the resulting infections were only slightly higher than in similar patients not receiving cortisone (136).

Rapid subsidence of mumps orchitis following the administration of corticosteroids has been reported (110-135-137). More detailed studies have indicated that azoospermia and testicular atrophy nevertheless occurred in some of the patients so treated and that a beneficial influence of corticosteroids on testicular function after mumps orchitis must be considered unproved (89). Although it has been pointed out that those patients with mumps orchitis who became afebrile most slowly were the ones in whom late testicular complications were most likely to develop and that more vigorous treatment might have proved more effective, it is just as reasonable to suppose that late azoospermia and atrophy develop only in the severe cases of mumps orchitis and that corticosteroids are of little value in such cases. In a controlled study by Klemola and Somer (89) no difference in response of mumps orchitis to corticotropin or to placebo was discernible with substantial but not extremely large doses.

Finally, the appearance of infections either spontaneously or as aggravations of pre-existing ones in patients receiving corticosteroids for treatment of other diseases, is well known. Pneumonias, bacteremias of various etiologies, pyelonephritis, staphylococcal endocarditis, localized staphylococcal abscesses, cellulitis, peritonitis, meningitis, tuberculosis, moniliasis, histoplasmosis, and other mycoses, malaria, and even unusual saprophytic infections have appeared in patients who were receiving adrenocortical hormones (76-77). The appearance of infections during the course of treatment with corticotropin or corticosteroids has been a major reason for temporary or permanent cessation of treatment with corticosteroids, and many warnings have been issued to physicians urging circumspection in the use of corticosteroids, particularly in disease states in which pulmonary tuberculosis might be present. Haggerty and Eley (57) collected 12 fatal

instances of varicella in children who were receiving such hormones at the time of exposure to this disease

✓ The precise magnitude of the hazard of infection in patients receiving corticosteroids is difficult to assess. In many cases administration of corticosteroids has so masked the appearance of severe sepsis that the infections were recognized only at autopsy. In other cases patients with fever of unknown etiology have been treated with corticosteroids on the assumption that a disease other than tuberculosis was present, only to show such progression of active tuberculosis as to make it likely that this diagnosis had been missed. Undoubtedly also the magnitude of the hazard of infection varies with the group of patients under treatment. It is reasonable to suppose although there is no clear supporting evidence that intercurrent infections are more likely to develop in patients receiving corticosteroids in the treatment of severe debilitating illness than in those being treated for milder self limited illnesses or for chronic illnesses such as rheumatic fever in which convalescence is prolonged but debility is not commonly a prominent feature.

Thus Benedek and Montgomery (10) did not consider the incidence of infection to be unusually high in their patients and several studies have indicated that the hazard of infection is definite but not very great (53 59 98 100). On the other hand Ragan and co-workers (68 115) reported that they considered it necessary to discontinue treatment with corticosteroids permanently in 10 per cent and temporarily in another 10 per cent of their patients with rheumatoid arthritis. In a Danish study moniliasis was reported to have developed in 15 among 210 patients with various primary diseases while receiving corticosteroids but the disease was relatively mild in 11 and might have gone unrecognized except for the particular interest of the observers (19). In their initial studies of patients with disseminated lupus erythematosus Soffer *et al* (133) observed infections in 43 per cent of patients but in later studies this figure had fallen to 13 per cent, probably as a result of improved methods of management, but possibly due also to the earlier recognition of milder cases of lupus erythematosus in which conceivably there was less hazard of infection.

• It is noteworthy that in spontaneous hypercorticism (Cushing's disease) infection is the leading cause of death accounting for more than half of the deaths in a large series studied by Plotz and co-workers (113) this extraordinary incidence of fatal infections has not

decreased significantly since the advent of modern antibacterial therapy. Some doubt has been expressed concerning the meaning of this high mortality because the incidence of infections in arthritics at autopsy is almost as great (113)

**EXPERIMENTAL**—The demonstration that large doses of cortisone cortisol or corticotropin generally depress resistance to infection is documented about as well as any recent scientific demonstration. It is no longer profitable to list the pathogens that have been tested; most of these have been listed by us elsewhere (76-77). The variety of bacterial viral fungal protozoal and even helminthic agents encompasses most of the commonly studied pathogens and a substantial number of rare esoteric and even previously unknown agents. Furthermore this anaclastic\* effect on resistance has been demonstrated not only in man but also in rabbits rats mice guinea pigs and monkeys. Some generalizations may be drawn from the data.

(1) The effect of cortisone cortisol or corticotropin in depressing resistance is variable and depends on the dose type of hormone used experimental animal and the general nature of the experimental design.

(2) The depression of resistance is frequently great enough to cause the animals to succumb to infections from autochthonous saprophytes.

(3) Latent infections are frequently activated. An illustrative experience is that of Denny and Thomas (30) who showed that the administration of cortisone more than 3 months after the subsidence of acute streptococcal infections in rabbits led to exacerbation of the infection with death of the host animals.

(4) Depression of resistance occurs whether the resistance is native as in the case of rabbits made genetically resistant to tuberculosis or acquired passively or actively by the use of vaccines sera or antibiotics (76-77).

(5) When native resistance of the host to the pathogen is already minimal as in the case of mice infected with virulent pneumococci or of guinea pigs with tubercle bacilli the effect of cortisone is difficult to measure and is necessarily limited to accelerating the progress rate of the infection.

(6) The depression of resistance may be used to facilitate the isolation

---

Anaclastic (Greek ana back + klan to bend) suggested as a term to describe the temporary backward deviation of resistance to infection under the influence of cortisone. The term has been used to describe the bending back of thin glass with a crackling sound.

tion or demonstration of infectious agents. For example cortisone treated monkeys are routinely used in determining the viability of poliomyelitis virus in the manufacture of vaccine. Many similar uses of cortisone treated animals have been suggested (45 71 88 140). It is not clear how cortisone facilitates adaptation of a given agent to a host. Such a method of isolating an infectious agent is inherently open to the suspicion that autochthonous or latent infections may arise in the cortisone treated animal and produce pathologic changes open to misinterpretation.

(7) Frequently depression of resistance to a given pathogenic agent by administration of corticosteroids has been taken as evidence that adrenocortical secretions play a special role in the pattern of resistance to the infection under study. In a general sense such a point of view is undoubtedly true. However the data suggest that the mechanisms of resistance depressed by corticosteroids are not specifically related to a particular infectious agent but rather are broadly non specific in their action.

### USE OF CORTICOSTEROIDS WITH ANTIMICROBIAL AGENTS IN INFECTION

From the foregoing, it may be anticipated that antimicrobial agents would tend to counteract the adverse effects of corticosteroids. Similarly the limitations of the effects of such antimicrobial agents may be surmised. A sufficient dose of antiserum or of a specific antibiotic will usually overcome the adverse effects of a given amount of corticosteroid conversely increasing the dose of corticosteroids may overcome the effect of a given dose of specific protective agent. This interplay is limited by the toxicity of the contrasting substances. For example the protective activity of penicillin in pneumococcal or group A streptococcal infections is diminished by the concurrent administration of cortisone but this effect of cortisone is readily overcome by increasing the dose of penicillin (45 71). However if a tetracycline or chloramphenicol is used instead of penicillin the adverse effect of cortisone is not so readily overcome (71) there are at least two reasons for this (1) the broad spectrum antibiotics are bacteriostatic and not bactericidal and (2) the toxicity of these drugs limits the increase in dosage (Fig 3).

As might be expected the host's resistance plays a large role in determining the relative responses to corticosteroids and to antibacterial drugs. For example relatively small amounts of streptomycin will over



come the effects of cortisone on tuberculosis in rats or rabbits, whose native resistance is relatively high. On the other hand even with large doses of streptomycin it is difficult to overcome all of the adverse effects of cortisone on tuberculosis in guinea pigs (72). Thus the ability of specific agents to overcome the adverse effects of corticosteroids in infection is a function of the host's resistance and the organism's viru-




FIG. 3—Effect of cortisone on therapeutic efficacy of antibiotics in mice infected with *Klebsiella pneumoniae*. All mice were given a uniform inoculum of the organism and were treated with increasing doses of streptomycin or chlorotetracycline. Alternate groups were given daily 0.15 mg cortisone acetate subcutaneously. Cortisone decreased the percentage of survivors; its effect being most significant in the range of moderate antibiotic effectiveness. With antibiotic dosage greatly in excess of minimum effective dosage, depressant effect of cortisone was insignificant. Cortisone interfered more with therapeutic effect of chlorotetracycline (predominantly bacteriostatic and less active) than with that of streptomycin (predominantly bactericidal and more effective). (From Jawetz (71).)

lence as well as the mode of action, specificity, toxicity and dosage of the drug.

Clinical observations on the relative effects of corticosteroids and antimicrobial agents are consistent with the generalizations just expressed.

A carefully controlled study of the effect of simultaneous penicillin and cortisone administration to patients with pneumococcal pneumonia showed that defervescence and symptomatic improvement occurred more promptly in patients receiving steroid and penicillin than in those given penicillin alone (148). There were no adverse bacterio-

logic consequences but renal insufficiency and prolonged hypothermia developed in 1 cortisone treated patient this has been reported by others as a complication of cortisone therapy (84) The penicillin dosages used in this study were clearly sufficient to overcome any possible reduction in host resistance induced by the cortisone The results suggested that the symptomatic relief obtained with cortisone coupled with the ability of penicillin to overcome the potentially adverse effects on resistance to the pneumococci made desirable further study of combined cortisone-penicillin therapy in pneumococcal pneumonia It was recognized that similar effects might be obtained with antipyretics and analgesics such as salicylates and that further controlled study of this problem was necessary

The specific treatment of pneumococcal pneumonia poses no great problems but when corticosteroids and antibiotics have been used for infections in which specific treatment is more difficult, the data have not been so uniformly favorable In typhoid fever, rickettsiosis and brucellosis evidence has accumulated that rapid defervescence follows the combined use of corticosteroids and specific chemotherapy with relatively little hazard to the patient However there are no carefully controlled studies such as those on pneumococcal pneumonia and it is not clear whether the improved symptomatic response does not hide an increased hazard A relation between length of cortisone treatment and the occurrence of relapses in acute brucellosis has been suggested although cortisone for 3 or 4 days was not considered to be harmful in the small series of cases studied (99)

✓ In tuberculosis there is substantial support for combined corticosteroid-antibacterial therapy (2 22 39 72, 109 137) Patients hypersensitive to tuberculostatic drugs have been given cortisone allowing the drugs to be continued the manifestations of hypersensitivity were suppressed, without any apparent adverse effect on the course of the infection Treatment of tuberculous meningitis with corticosteroids has been attempted repeatedly on the assumption that this would decrease the incidence of late fibrotic complications and particularly of spinal block There is little doubt that corticosteroid therapy may be followed by symptomatic improvement and diminished inflammation Unfortunately few of these observations have been controlled and the remarkable improvements in tuberculosis management in the past few years have made it especially necessary to determine whether corticosteroids have actually contributed to the ultimate outcome in patients treated with a combination of corticosteroids and chemo

therapeutic agents In one controlled study on 30 patients neither benefit nor harm was found to result from such combined therapy (7) Further studies of this problem are in progress and additional information on the clinical usefulness of corticosteroids in tuberculosis should soon be forthcoming

Thus although there may be occasional difficulty when corticosteroids are used with effective antibiotics substantial symptomatic relief will commonly occur On the other hand many infections most notably those due to staphylococci and to certain gram negative rods have been hard to manage with the drugs available at present Conceivably corticosteroids may exert a more pronounced adverse effect in such cases simply because the antibacterial drugs are not as effective No adequate clinical data for analysis of this phase of the problem are as yet available

One study has been widely quoted as supporting the thesis that in severe infections judicious use of corticosteroids together with appropriate antibacterial agents is highly beneficial clinically (70) The series consisted of 42 patients with "medical" and 41 with "surgical" infections The medical infections included 14 cases of meningococcal infection with 4 deaths of the 4 children under the age of 18 months (the age group with the highest mortality due to this infection) 3 died Of the 14 patients 2 were considered to have benefited definitely and 3 probably from the use of corticosteroids 1 of the "benefited" group died There were 6 cases of nonmeningococcal meningitis with 2 deaths 3 were due to *Hemophilus influenzae* and 2 of them experienced a slow defervescence These results are not unusual and hardly suggest a particular benefit from combined corticosteroid-antibiotic therapy

In the surgical group of 41 patients the best results were obtained in the patients with ruptured appendices No infants were included in the latter group and only 2 adults 1 of whom was over the age of 65 Since such an age distribution is the optimal one for a favorable outcome in appendicitis it is hard to judge whether any benefit was obtained from the corticosteroid therapy Results in patients with perforated viscera or with breakdowns of resections with sepsis were poor In clinically difficult situations therefore there was no apparent benefit from corticosteroid therapy

The studies as summarized here emphasize the difficulties of evaluating results of treatment of infectious diseases and indicate the need for more controlled observations Despite the enthusiastic claims

made for combined corticosteroid-antibiotic therapy the evidence so far reported is not impressive. These difficulties are also brought out in studies reported recently by Lepper and Spies (93). Corticosteroids were used in their hospital over a 6 year period in over 1 000 patients; no marked benefit could be ascribed to their use, and some of the results might even be interpreted as showing detrimental effects. Although the control methods in their study were not ideal as they realized, there were periods when none of their patients received corticosteroids for comparison. Lepper and Spies are not at all enthusiastic about the value of the adrenal hormones in their patients including those with meningococcemia and tuberculous meningitis.

The use of antibacterial drugs has been advocated as a routine prophylactic measure in patients receiving corticosteroids. The general problem of chemoprophylaxis of infections is too complex to discuss in detail here. Jordan and Dingle (74) have recently reviewed it. Suffice it to say that chemoprophylaxis has proved effective when directed toward eliminating highly susceptible organisms such as group A hemolytic streptococci or meningococci, but has not been effective in dealing with staphylococci or with some of the gram negative bacteria which readily become drug resistant. It is noteworthy that prophylactic regimens were used in many of the clinical studies in which infections were an important complication of corticosteroid therapy. The infections have most commonly been staphylococcal, although coliform, monilial, and similar antibiotic-resistant infections have been encountered. Prophylactic regimens can hardly be expected to confer adequate protection against all of the common antibiotic resistant organisms and the confidence physicians may feel in using such regimens to "cover" the patient whose resistance is being depressed by the use of corticosteroids is unjustified.

The evidence thus far presented indicates strongly that corticotropin, cortisone, cortisol, and related compounds when given in sufficiently large doses depress resistance to infections and that the capacity of antimicrobial drugs to overcome this depressed resistance is limited. When such limitations are not operative, antimicrobial drugs frequently overcome the depressed resistance.

#### EVIDENCE OF BENEFICIAL EFFECTS FROM CORTICOSTEROIDS

**ADRENAL INSUFFICIENCY** The value of adrenocortical hormones in adrenal insufficiency is so well established that detailed comment is

superfluous. Recently the value of adequate replacement therapy in adrenal insufficiency has been reaffirmed (21, 40, 67). The results of a simple experiment from our laboratory (Fig. 4) illustrate the response of the infected adrenalectomized mouse to cortisone. Uninfected adrenalectomized mice of the strain used can be maintained well with 5 to 10  $\mu\text{g}$  cortisone daily. A dose of specific antiserum was selected which protected 50 per cent of nonadrenalectomized mice against approximately 50 000 virulent pneumococci. The same dose of antiserum protected 50 per cent of adrenalectomized mice against only




FIG. 4—Effect of cortisone on pneumococcal infection in mice all given same dose of specific antiserum dose sufficient to protect 50 per cent of intact mice against 50 000 virulent pneumococci. Adrenalectomy markedly enhanced susceptibility to pneumococcal infection as shown by the much lower LD<sub>50</sub>. Cortisone (5 or 25  $\mu\text{g}$ /day) partially restored resistance of adrenalectomized mice whereas dose of 100  $\mu\text{g}$  increased LD<sub>50</sub> essentially to that of control mice. Larger doses of cortisone reduced resistance as shown by decrease in number of pneumococci necessary to produce fatal infection.

about 1 000 pneumococci. Administration of 5  $\mu\text{g}$  cortisone per day to such mice significantly improved their resistance; given about 25  $\mu\text{g}$  per day their resistance returned to nearly that of the intact animals. Effects of doses ranging between 25 and 100  $\mu\text{g}$  cortisone per day were almost optimal, but with larger doses resistance diminished and 500  $\mu\text{g}$  depressed resistance to a degree comparable to that produced by adrenalectomy.

Thus infection places greater demands for steroid on the host as is well known. In addition the optimal dose of corticosteroid is critical and an excess is likely to be harmful. Objective means for determining the optimal dose clinically are not yet available.

✓ Does adrenal insufficiency occur as a consequence of severe sepsis in the absence of pre existing Addison's disease? There are relatively few data bearing directly on this problem. Traditionally, autopsy evidence of tubular degenerative changes and hemorrhages in the adrenal cortex has been taken as evidence of adrenal insufficiency during life. The existence of acute adrenal insufficiency has also been surmised from the clinical appearance of the patient with severe sepsis and vasomotor collapse. However, there is reason to suspect that adrenal insufficiency is relatively rare in severe sepsis. In the first place, tubular degeneration and hemorrhagic changes can be produced by intense stimulation of the adrenal gland with corticotropin (69) and not only as a consequence of exhaustion, hypoxia or of direct attack by toxic agents. Secondly, there is evidence that vascular collapse during severe sepsis is usually not due to adrenal insufficiency (38, 103). Thirdly, the circulating hydroxycorticoid levels in patients in collapse due to sepsis have been measured in this laboratory and the levels have almost always been in the high normal or distinctly elevated ranges. Similar levels have been found in infections without collapse. Levels of hydroxycorticoids comparable to those found in patients with Addison's disease have not yet been recorded in patients with severe sepsis.

✓ Direct effects of bacteria or their toxins on the adrenal cortex conceivably may lead to adrenal insufficiency. However, pretreatment with cortisone protects the adrenals from the damaging effects of diphtheria toxin, but does not protect the animals from the lethal action of the toxin (5, 46). Presumably the damage caused by the toxin is so widespread that protection of the adrenal gland alone is of little benefit to the host.

It has recently been shown that endotoxins from gram negative bacteria inhibit steroidogenesis in the perfused adrenal gland (127). The amounts of endotoxin used in the perfusion experiments are relatively large by *in vivo* standards. Nevertheless, the possibility of direct damage to the adrenal as a cause of adrenal insufficiency cannot be discounted despite the fact that circulating corticosteroid levels in the animals given lethal doses of endotoxin are generally above the normal range (103, 127).

At present the problems posed by the foregoing discussion must be solved by direct observations of patients in the clinic. Perhaps no clinical syndrome is more often considered to be associated with adrenal insufficiency than meningococcemia with collapse and the use of

cortisone and related substances is generally recommended as part of the treatment of this syndrome. However, controlled observations of the value of adrenocortical hormones in this situation are difficult to find. After the introduction of the first adrenocortical extracts which were extremely weak by present standards there was enthusiastic support for the use of such extracts in this condition (110). After desoxy corticosterone was introduced another cycle of enthusiasm built up only to disappear later (110). General enthusiasm for the use of corticosteroids in meningococcemia now runs high but there have been failures after the use of such steroids (93), and the collapse in this infection has been successfully treated with norepinephrine without corticosteroids (134). The largest recent series of cases of meningococcal infection to be reported is that of Tobin (146) who studied 63 cases occurring in a military experience. 9 patients were considered to have Waterhouse Friderichsen syndrome and 5 survived. Tobin did not find the effects of cortisone to be spectacular. The experience of Jahn *et al* (70) already analyzed also does not constitute impressive evidence of the value of corticosteroids in meningococcal infections.)

Relative adrenal insufficiency may occur if infection appears in patients in whom exogenous steroids have suppressed steroidogenesis. Increasing the dose of corticosteroid is justified under such circumstances. On the other hand, when patients have received corticosteroids for a time and then begin to deteriorate the deterioration is often due to unrecognized infections. Increasing the dose of corticosteroids or using corticotropin under such circumstances is likely to aggravate the infection still further unless specific antibacterial therapy is begun. The amount of corticosteroid to be given to patients in whom relative adrenal insufficiency is suspected must still be determined empirically. As methods for determining circulating corticosteroids become simpler it may be possible to achieve a more objective basis for determining optimal dosage level of corticosteroids. Even then determination of the level of circulating steroid at any instant may not necessarily reflect the rate of production or of turn over in the host, so that most detailed study will be needed for an adequate answer to this question.

In summary adrenal insufficiency is apparently a rare complication of severe sepsis. There is relatively little objective support for the concept that adrenal insufficiency is common in severe infections and that therefore the use of corticosteroids is justified on that basis.

EFFECTIVENESS OF SMALL DOSES OF CORTICOSTEROID — Large doses

have been used in most studies of their efficacy in infectious disease. However, a few observations have suggested that relatively small doses may increase resistance to infection in adrenalectomized, as well as intact, animals (124). This effect, when it has been observed, has been elicited in a narrow range of steroidal dosage: a slight increase above the optimal amount led to decreased resistance to infections. The salutary effect of small, carefully chosen doses of cortisone has been explained on the basis that in severe infection there may be mild relative adrenal insufficiency which is overcome by giving small additional amounts of corticosteroid. There is also reason to suppose that, with infection, there is increased turnover of corticosteroid (122).

It has long been recognized that doses of corticosteroid sufficient for maintenance of function in adrenal insufficiency may be inadequate in the presence of infection, trauma and other conditions).

On the other hand, it has already been noted that corticosteroid blood levels are usually elevated in patients during severe infections; hence it must be postulated that (1) adrenal insufficiency is rare or (2) it is species specific or related to some unique feature of the experimental situation or (3) entry of steroid into cells is diminished, or (4) the increased turnover rates during infection are so great that relative insufficiency in tissues might occur in the presence of elevated blood levels. Under certain of these circumstances, small doses of exogenous hormone might conceivably cause more steroid to enter tissue cells. The highly speculative nature of these considerations indicates how little is known about the mechanism of action of steroid hormones (60). Experimental data to support the concept that small doses of corticosteroid may be more effective than large doses in increasing resistance to infection are still inadequate and inconclusive.

**CAN CERTAIN ADVERSE EFFECTS OF CORTICOSTEROIDS BE OVERCOME SELECTIVELY?**—The augmentation of host defensive mechanisms by the use of specific antimicrobial drugs or by specific antisera when corticosteroids are being administered has already been discussed. A few observations have suggested that it may be possible to separate the anaclastic effects of adrenocortical hormones on resistance to infection from some of their other metabolic effects.

Thus, administration of large doses of corticotropin to mice and to hamsters did not substantially depress resistance to infection when compared with the effects of cortisone or cortisol, despite the fact that the doses given caused greater loss of weight than did the cortisone (83). Smith and co-workers have observed that certain doses of corti-



cortropin depressed resistance of rabbits to experimental tuberculosis less than did cortisone although corticotropin caused more marked leukopenia than cortisone (6 149) Similarly amounts of corticotropin causing significant weight changes in rabbits caused relatively little depression of antibody response whereas doses of cortisol causing less change in weight induced greater depression of antibody response (82)

There may be several explanations for these unusual findings. For example the adrenal response to corticotropin varies in different animal species. The adrenal glands of mice react atypically to corticotropin manifesting relatively few morphologic changes even after extensive stimulation (86) thus it is conceivable that their adrenal secretory response to corticotropin is qualitatively as well as quantitatively different from that in other animals. Inferential evidence that this is true is derived from studies on the nature of adrenal secretion in different animal species it varies in different animal species and among individuals within a species (23 62 79). Although cortisol or corticosterone or both may predominate in the adrenal secretion of all animal species studied the two hormones are not necessarily equivalent in their biologic effects. The relative ineffectiveness of corticosterone when compared with cortisone or cortisol in depressing resistance to infection inflammation and antibody formation or in relieving symptoms of acute arthritis is well established (26 85 114). The effects of corticotropin may differ under different circumstances in the rabbit at least, the effects of corticotropin on antibody production and on lymph nodes parallel changes in the corticosterone-cortisol ratio secreted (78). Species differences in the adrenal secretions pattern may therefore explain in part why corticotropin fails to produce changes regularly comparable to those produced by cortisol or cortisone.

By the same token quantitative as well as qualitative differences in the nature of the adrenal response may influence several parameters of the metabolic response to stimulation with corticotropin. The influence of differences in adrenal secretion pattern on resistance to infection cannot be precisely evaluated at present. Evidence suggests that there may be individual differences in the relative amounts of corticosterone and cortisol secreted by the human adrenal cortex (125). There is also evidence that tuberculous rabbits may secrete relatively more corticosterone than cortisol, when compared with uninfected animals (79). However comparisons of the effects of exogenous

steroids on resistance mechanisms have failed to take into full account differences in absorption and metabolism of these steroids. Thus corticosterone and cortisol were approximately equivalent in their protective action in rats given endotoxin when the steroids were injected intravenously but corticosterone was markedly less effective after subcutaneous injection (94). The differences after subcutaneous injection were best explained as being due to a difference in the absorption rates from the local sites of deposition. Differences in the metabolic rates of injected corticosteroids have also been observed in man (112).

Other hormonal and nonhormonal substances may overcome the effects of cortisol or cortisone. The adrenal secretion contains many "trace substances" the activity of which is largely unexplored and the possibility that some as yet unidentified substances may be active in overcoming certain metabolic effects of cortisol or cortisone cannot be discounted. Study of one of the trace substances revealed it to be aldosterone, with electrolyte activity so great that the small amounts secreted are sufficient to account for a large share of adrenal control over mineral metabolism. It is noteworthy that aldosterone exerts antagonistic effects to cortisol in sites of inflammation (31, 131) and has been reported to be effective in maintaining vascular tone under experimental conditions in which cortisol, desoxycorticosterone, corticosterone and corticotropin have failed (101).

Somatotropic hormone has also been reported to overcome the adverse effects of cortisol or cortisone on mechanisms of resistance to infection although the evidence in support of this action is contradictory (46, 54, 76, 77, 92, 93, 130). Once again potency of preparation, method of administration and similar artificial aspects of the experimental approach probably play a large role in determining the results. However, there is no doubt that potent preparations of somatotropin may overcome many metabolic effects of adrenocortical hormones (85). At present there seems to be no clear clinical role for somatotropin as a means of overcoming adverse effects of corticosteroids.

An occasional report has indicated that liver extracts, choline and cobalamine might overcome some actions of cortisone (65, 102) but the data have been seriously challenged and the possibility that these substances might overcome adverse effects of cortisone or cortisol must be considered unproved (128, 139).

Substances which may inhibit corticosteroid action would be of great interest and it is likely that inhibitors of certain metabolic ac

tions of cortisone will be found. Experimental indications that lymphoid cells may contain such a substance have been advanced recently by Berglund and Fagraeus (13) who found that viable cells from the thymus or spleen overcame the inhibitory effect of cortisone on antibody production.

EFFECT OF CORTICOSTEROIDS ON TOXICITY—It is well established that corticosteroids generally diminish clinical manifestations of toxicity such as malaise myalgia fever tachycardia and tachypnea this effect has constituted one of the chief bases for investigating the value of corticosteroids in the treatment of infection. The data relevant to this problem may be summarized briefly as

(1) Cortisone and corticotropin markedly diminish the febrile response to several pyrogens including those derived from gram negative bacteria (51 75 119)

(2) Presumptive evidence of an effect of cortisone on hypothalamic thermoregulating centers may be derived from the finding that hypothermia occurs regularly in experimental animals and occasionally in man after administration of cortisone (33 84 148)

(3) Prolonged administration of cortisone may lead to a rise in the fever or to variable responses to pyrogens the reason for these peculiar effects is so far obscure (11 31)

(4) After pyrogens are injected into rabbits a substance which can be differentiated from the injected pyrogen appears in the blood and is pyrogenic when transferred to other animals. This endogenous pyrogen appears in the cortisone treated and in the untreated animal in response to an injection of pyrogen cortisone therefore does not interfere with the formation of endogenous pyrogen (4)

(5) Larger doses of most bacterial pyrogens are lethal. Cortisone cortisol and frequently corticotropin protect mice rats rabbits and chick embryos against lethal doses of endotoxins and such diverse sources as the coliform organisms *Serratia marcescens* various species of *Brucella* the typhoid paratyphoid group meningococci staphylococci and other related organisms have provided the toxic extracts (16 20 24 25 49 51 79 94 132 138 142)

(6) The protective effect of corticosteroids against bacterial endotoxins depends on increased blood levels of corticosteroids at the time of contact between endotoxin and the susceptible tissues. When the steroid is given 30 minutes or more after the endotoxin the protective effect is distinctly diminished conversely if endotoxin is given after the increased blood levels due to administered corticosteroids have

returned to pretreatment values the protective effect is diminished or absent (49 94, 138)

(7) The protective effect of steroids against endotoxin is demonstrable not only with corticosterone but also with the other steroids (e.g. 11-hydroxyprogesterone 11-dehydrocorticosterone and even 11-deoxycorticosterone) which are generally regarded as having weak, if any anti-inflammatory activity (20 25)

(8) Pretreatment with cortisone does not protect dogs and guinea pigs against endotoxin (16 37 121)

(9) Marked differences in reactivity to endotoxin and to cortisone may occur within a species. In rabbits the protective effect of cortisone is demonstrable primarily in adult animals. Smaller rabbits (0.5 to 1.0 kg) are more resistant to the lethal effects of endotoxin, and endotoxin administration to the cortisone-treated rabbit causes bilateral necrosis of the renal cortex and other evidence of a generalized Shwartzman phenomenon. In the small rabbit, therefore, cortisone supplants the usual preparatory dose of endotoxin in eliciting the Shwartzman response (143 144)

(10) Infections produced by endotoxin-containing bacteria and treated by cortisone were generally aggravated. When the organisms were relatively avirulent and the dose of cortisone small, cortisone gave some protection (17). Attempts to demonstrate such protection in cortisone-treated animals given toxic doses of influenza virus indicated only that cortisone aggravated the degree of injury to the host by permitting greater virus proliferation (87)

(11) Cortisone may inhibit the local response to a preparatory injection of endotoxin (142)

(12) A protective action of cortisone is not demonstrable in toxemias due to exotoxins from *Clostridia*, *C. diphtheriae*, *C. tetani*, *C. botulinum*, *C. perfringens* or *Shigella dysenteriae* (5 17 18 47 56 108 126)

✓ Biologically study of the effects of corticosteroids on the action of pyrogens and endotoxins is of great interest. The immediate therapeutic suggestion is that, by proper use of hormone and appropriate antibacterial agents it may be possible to interfere with the lethal action of endotoxin while controlling the infection. However corticosteroids do protect all animal species against endotoxins and it is not anticipated that they would interfere with the lethal action of endotoxins already fixed to tissues. The potential for harm as illustrated in the experiments on the development of bilateral renal cortical necrosis

cannot be lightly dismissed (143) There would appear to be adequate reasons therefore for considering that corticosteroids may not be helpful or may even have harmful potentials in managing infections due to endotoxin producing bacteria these must be balanced against the positive indications of the beneficial effects demonstrated both in animals and in man The need for detailed and cautious clinical study of this problem is apparent /

Recently chlorpromazine and serotonin too have been found to inhibit the lethal action of endotoxins (155 120) The many complex interrelations involved are far from clear but there is little doubt that altered vascular reactivity, as it is affected by epinephrine and many other substances plays a large role in the physiologic changes induced by endotoxins (145) Demonstration of the effectiveness of these substances may suggest other avenues of approach to the management of severe sepsis

✓ CORTICOSTEROID ENHANCEMENT OF PHARMACOLOGICALLY ACTIVE SUBSTANCES—The lack of understanding of the complex interrelations influencing vascular tone has already been stressed It is clear however that norepinephrine epinephrine and related agents may increase vascular tone in states of collapse or of impending collapse although the full extent of the benefit to the patient is not yet clear Corticosteroids may potentiate the action of norepinephrine in adrenalectomized as well as intact animals thyroxine also may play a role in potentiating the action of norepinephrine and corticosteroids (91 117 151) The observation that serotonin may inhibit the lethal action of endotoxin suggests that this substance may also be involved Conversely a growing body of evidence indicates that the administration of endotoxin leads to increased sensitivity to epinephrine or serotonin so that local tissue responses to the injection of endotoxin are augmented when epinephrine or serotonin is given (145) The apparent contradiction between the increased sensitivity to extremely small amounts of vasopressor agents in endotoxin poisoning and the use of such vasopressor agents therapeutically in large doses to restore failing blood pressure in patients with severe sepsis including those with bacteremia due to endotoxin producing organisms has not been resolved It is not clear whether the usually elevated levels of corticosteroid in severe sepsis are already sufficiently high to permit vasopressor substances to exert maximal activity

The foregoing has presented both sides of the question of corticosteroid use in severe sepsis On the one hand corticosteroids depress

resistance to infection and often limit the effectiveness of antimicrobial agents in overcoming these adverse effects. On the other hand, many observations indicate possible pharmacologic effects of corticosteroids which may augment resistance. The need for controlled clinical observation of the net resultant effect of using steroids in infection is obvious.

Although the value of corticosteroids in the management of infection is still uncertain, the attention focused on the mechanisms of host resistance and on the pathologic physiology of infections has been salutary.

### CORTICOSTEROIDS AND INFLAMMATION AND REPAIR

✓ Adrenal corticosteroids are effective in diminishing the inflammatory response regardless of the stimulus. Such diverse irritants as immunologically active substances (e.g. antigen-antibody complexes, tuberculin), trauma (burns, incisions, cold), chemical irritants (croton oil, formaldehyde, turpentine), viable infectious agents and many others have been used (50, 141).

✓ The general sequence of events in inflammation is well known: injury and destruction to cells at the site of irritation, increased capillary permeability with loss of fluid and formed elements, endothelial swelling and adherence of formed elements of the blood to the capillary endothelium, localization of leukocytes and other cells, and finally repair. Each of these stages of the inflammatory response has been analyzed in an attempt to determine at which level corticosteroids influence the process (32). ✓ The existing evidence indicates that primary focus of cortisone or cortisol action is on vascular responsivity. It has also been suggested that the hormones act by preventing the release or enhancing the removal of substances coming from injured cells and thus influence the progress of the inflammatory process (32). Administration of corticosteroids results in increased vascular tone and decreased loss of fluid and cells from capillaries; adherence of leukocytes to endothelium is virtually eliminated, the subsequent collection of cells and fluid at the site of injury is diminished and as might be expected the subsequent repair is commonly less extensive and less complete (50, 141).

✓ The extent to which inflammatory changes are inhibited appears to be largely the result of an interplay between the intensity of inflammatory stimulus and the reverse action of corticosteroids, although such

factors as animal species site of injection and the nature of the stimulus play a role

Duran Reynals (35) has pointed out the similarities in the response of tumors and infections to corticosteroids and has reviewed the evidence indicating that many experimental tumors are inhibited in their initial growth by hormone treatment but that the development of metastases may be promoted in the process. The prolongation of survival of tissue transplants in cortisone treated animals probably reflects a similar anti inflammatory action of the corticosteroids (14)

Development of semiquantitative methods for studying inflammation has permitted more precise estimation of the relative anti inflammatory effects of various steroids. hydrocortisone and related derivatives such as prednisone have been found to be superior to cortisone corticosterone and other steroids and desoxycorticosterone (aldosterone and somatotrophic hormone overcome the anti inflammatory action of corticosteroids to varying degrees (31 130 131). Whether the antagonism of aldosterone to the anti inflammatory corticosteroids does indeed represent an important biologic balance or is a pharmacologic action induced by excessively large exogenous doses of hormone cannot be decided at present. In any event the anti inflammatory effects have been used as a basis for discovering the influence of changes in the steroidal chemical configurations on reactivity to an inflammatory irritant and several interesting and commercially useful drugs have been found in consequence (66 97)

✓ In the course of tissue destruction and repair many chemical substances appear in the blood and indicate either developing or healing inflammation. The appearance in the serum of such substances as antihyaluronidase C reactive proteins and serum mucoprotein appears to be primarily a nonspecific response to injury. Administration of corticosteroids frequently results in lowered levels of many of these indices of tissue damage but it is not clear whether this decrease reflects any corticosteroid action other than a general anti inflammatory one

The effect of corticosteroids on leukocytic function is not great and generally is of insufficient magnitude to account for the adverse effects of cortisone and related substances on resistance to infection. The failure of leukocytes to accumulate in a lesion is manifestly not due to peripheral neutropenia. Although some diminution of phagocytic function has been noted after the use of cortisone it is not great and it has not been regularly observed. Similarly cortisone causes little

if any effect on the bactericidal action of leukocytes (29 51 104 118)

The eosinopenia which generally occurs after the administration of corticosteroids is well known but the mechanism by which it occurs is obscure. Lysis of the eosinophiles after exposure to cortisol has been observed *in vitro* but the effects require relatively large amounts of hormone (105 106). Lymphopenia atrophy of lymph nodes and histologic evidence of lympholysis too are regularly seen after corticosteroid administration, but the mechanism of this action is still not known and attempts to induce lympholysis *in vitro* by use of corticosteroids have not been very successful (61 63 123 129)

The effect of corticosteroids on fibrogenesis and repair has been extensively studied. Clinically the hazard of delayed wound healing after corticosteroid administration appears to be relatively small, but occasionally ulcerated lesions fail to heal properly and may erode with consequent perforation or hemorrhage. When large amounts of corticosteroids have been given granulations form poorly in wounds and the ingrowth of new vessels is inhibited (3 36 116). Careful observation of the latter effect has suggested that it is due to reduction of blood flow to areas of tissue damage and not to a direct cortisone effect on endothelium (3)

In general the effects of corticosteroids on inflammation and repair can be explained on the basis of their effect on vascular tone and permeability. This conclusion although not yet supported by adequate evidence can provide a unifying view of the observed effects. By the same token the effects of corticosteroids on hypersensitivity reactions and similar tissue responses to immunologically active stimuli probably reflect the general anti-inflammatory effect of these steroids rather than a specific effect on purely immunologic mechanisms

### CORTICOSTEROIDS AND ANTIBODY RESPONSE (Fig 5)

There is now general agreement that cortisone and cortisol depress antibody production but do not alter the degradation rate of preformed antibody (15 44 52 82). The depressing effect of corticosterone on antibody production in rabbits is relatively slight (82)

The mechanism by which antibody production is depressed by corticosteroids is not clear. Several mechanisms may be operative for example (1) the antigen may be held locally due to a vascular effect of the steroids or (2) the antibody forming mechanisms may be directly depressed or (3) the relationship of antibody forming cells to inter






FIG. 5.—Effect of adrenal steroids on antibody production in rabbits. Graph shows mean values for various treatment groups. Cortisol (Compound F) even 25 mg per day markedly depressed antibody response. Corticosterone (Compound B) did not overcome adverse effect of cortisol but actually seemed to have an additive effect. Effect of ACTH varied with dosage. 15 units daily (ACTH I) had little effect. 20 mg (II) and 30 mg (III) per day respectively resulted in progressive decrease of antibody production. (From Kass, Hendrick and Finland (81).)

mediary cells in the process of antibody production may be altered. Berglund and Fagraeus (13) have presented some evidence in support of the last two possibilities. The response of lymph nodes to the injection of antigen is ordinarily that of hypertrophy and hyperplasia with increased concentrations of ribonucleic acid and accumulation of plasma cells. Use of cortisone inhibits the RNA response and the hypertrophy (81).

Recent detailed analyses of the effect of cortisone on antibody production have indicated that the effect of cortisone is greatest during the initial response to antigenic stimulation but that the dose of hor-

more the dose of antigen and the time of hormone administration all affect the extent of the cortisone induced inhibition (12) Of particular interest is the observation that viable spleen or thymus cells protect against cortisone inhibition of antibody production (13) Relatively intensive corticosteroid treatment is required to depress antibody production under most clinical conditions suppression of antibody production plays a relatively minor role in determining the clinical response especially in acute infections

### CORTICOSTEROIDS AND RETICULOENDOTHELIAL FUNCTION

An effect of corticosteroids on reticuloendothelial function was surmised from early studies of cortisone and corticotropin effects in ma




FIG 6—Effect of cortisone (12.5 mg/100 Gm body weight daily for 5 days) on return of normal clearance function in mice after saturating dose of carbon particles (16 mg/100 Gm body weight) intravenously After second dose of 8 mg carbon per 100 Gm the means of the logarithms of carbon concentrations in the blood were plotted against time Line A control after 5 hours line B cortisone treated after 3 days line C control after 3 days (Modified from Benacerraf *et al* (9))

laria tuberculosis and viral infections in which the activity of macrophages and of fixed reticuloendothelial cells rather than polymorpho nuclear responses predominate (50) and in which corticosteroids nevertheless adversely affect resistance of the host A direct corticosteroid effect on the clearance of bacteria from the blood has not been observed (150) although when inert colloidal particles have been ad

ministered to cortisone treated animals a delay of clearance has some times occurred (28 48 64) Studies using subcutaneously injected erythrocytes (81) and tubercle bacilli inhaled by genetically defined rabbits (96) suggested that the effect of cortisone is not so much on the primary uptake of particles by reticuloendothelial cells as on the removal rate of such particles from within the cells The elegant observations of Benacerraf and co workers (9) lend substance to this view They observed that large doses of cortisone did not alter the removal rate of carbon particles from the blood stream of the mouse but that the hormone retarded the recovery rate of this function of the reticuloendothelial system as measured by the clearing of repeated doses of carbon particles (Fig 6) They suggested that the recovery of function after administration of carbon particles was due to the formation of new phagocytes and that cortisone delayed this new cell production

The important observations of Thomas and associates (142 143) on reticuloendothelial function in relation to the action of cortisone have already been cited In rabbits of appropriate size 2 successive doses of endotoxin a day apart, lead to the production of the generalized Shwartzman phenomenon That the reticuloendothelial system plays a role in this phenomenon is suggested by evidence that (1) tolerance to a pyrogenic dose of endotoxin can be reversed by administration of reticuloendothelial blocking agents and (2) administration of such blocking agents as killed streptococcal vaccines or thorium dioxide suspensions serves as a substitute for the preparatory dose of endotoxin in the production of the Shwartzman response Similarly cortisone may prepare the animal so that a single dose of endotoxin is sufficient to evoke this phenomenon

It may be concluded that reticuloendothelial function is disturbed by the administration of corticosteroids and that this disturbance is manifested less in the initial response of reticuloendothelial cells to an injected load than in the capacity of these cells to recover their function (or for new cells to appear) after such a load has been administered

Many attempts have been made to demonstrate *in vitro* effects of corticosteroids on isolated cells Sea urchin eggs tissue cultures of various sorts lymphocytes polymorphonuclear leukocytes macrophages erythrocytes and many other cell systems have been used (8 90 141) In general the effects observed have required the addition of amounts of steroid 10 to 100 times as great as their usual blood

levels Furthermore such *in vitro* studies have often indicated that steroids such as 11-desoxycorticosterone which is virtually inactive as an anti inflammatory agent, may be as active or more so than cortisol in producing direct effects on cells *in vitro* The assumption is that the observed effects however interesting from the point of view of cellular physiology reflect a pharmacologic action of steroids on cells quite unlike that observed in mammals given corticosteroids at physiologically active levels The failure of *in vitro* systems to reflect more precisely the observed actions of corticosteroids on various metabolic functions of the host has been a puzzling aspect of the problem and has hindered more effective studies of the mechanism of corticosteroid action

### CONCLUSIONS

The value of corticosteroids in the management of infections is still not clear Only carefully controlled clinical observations are likely to solve the problem Some insight into mechanisms of host resistance and into the pathophysiology of infections have come from the studies of the effects of corticosteroids on resistance to infection The knowledge derived from these studies may eventually be more useful than the potential value of these agents in the treatment of infections At the present time it may be concluded only that the value of the adrenocortical steroids in the management of infections requires greater definition on the basis of controlled clinical study

### REFERENCES

- 1 Abernathy R S Halberg F and Spink W W Studies on mechanism of chlorpromazine protection against brucella endotoxin in mice J Lab & Clin Med 49 708 1957
- 2 Ashby M and Grant H Tuberculous meningitis treated with cortisone Lancet 1 65 1955
- 3 Ashton N and Cook C In vivo observations of effects of cortisone upon blood vessels in rabbit ear chambers Brit J Exper Path 33 445 1952
- 4 Atkins E *et al* Studies on antipyretic action of cortisone in pyrogen induced fever J Exper Med 101 353 1955
- 5 Atlas L L *et al* The effect of cortisone on survival of guinea pigs inoculated with diphtheria toxin Bact Proc 1952, p 72
- 6 Bacos J M and Smith D T Effect of corticotropin (ACTH) dihydrostreptomycin and corticotropin-dihydrostreptomycin on experimental bovine tuberculosis in rabbit Ann Rev Tuberc 67 201 1953
- 7 Barnard C Tuberculous meningitis cortisone treatment as adjunct to antibiotics effect on clinical features and cerebrospinal fluid South African M J 27 219 1953
- 8 Barron E S G and Kit, S Studies on mechanism of action of adrenal

- cortical hormones inhibition of protein synthesis in lymphatic cells by some corticoid hormones *Tr A Am Physicians* 62 293 1952
- 9 Benacerraf B *et al* Quantitative study of the granulopoietic activity of the reticulo endothelial system effect of cortisone and nitrogen mustard on regenerative capacity of the RES after saturation with carbon *Brit J Exper Path* 35 97 1954
  - 10 Benedek T G and Montgomery M R Influence of ACTH and cortisone on incidence of infections *J Lab & Clin Med* 44 766 1954
  - 11 Bennett I L Jr and Beeson P B Effect of cortisone upon reactions of rabbits to bacterial endotoxins with particular reference to acquired resistance *Bull Johns Hopkins Hosp* 93 290 1953
  - 12 Berglund K Studies on factors which condition effect of cortisone on antibody production the significance of time of hormone administration in primary hemolysin response *Acta path et microbiol scandinav* 38 311 1956
  - 13 Berglund K and Fagraeus A Biological factor inhibiting effect of cortisone on antibody formation *Nature* 177 233 1956
  - 14 Billingham R E Krohn P L and Medawar P B Effect of cortisone on survival of skin homografts in rabbits *Brit M J* 1 1157 1951
  - 15 Bjørneboe M Fischel E E and Stoerk H C Effect of cortisone and adrenocorticotrophic hormone on concentration of circulating antibody *J Exper Med* 93 37 1951
  - 16 Borden C W Hall W H and Gold D Study of experimental shock produced by meningococcus toxin *J Lab & Clin Med* 42 787 1953
  - 17 Boyer F and Chedid L La cortisone dans les infections experimentales de la souris *Ann inst Pasteur* 84 453 1953
  - 18 Brainerd H and Scaparoni M Effect of cortisone on fixation and neutralization of diphtheria antitoxin *Antibiotics & Chemother* 3 693 1953
  - 19 Brathund H and Holten C Moniliasis of mucous membranes and lungs as complication of treatment with antibiotics corticotropin and cortisone *Danish M Bull* 1 79 1954
  - 20 Brooke M Hechter O and Kass E H Unpublished observations
  - 21 Browne J S L *et al* Treatment of coexistent Addison's disease and active pulmonary tuberculosis *Am J M Sc* 228 491 1954
  - 22 Bulkely W C M Tuberculous meningitis treated with ACTH and isoniazid comparison with intrathecal streptomycin *Brit. M J* 2 1127 1953
  - 23 Bush I E Species differences in adrenocortical secretion *J Endocrinol* 9 95 1953
  - 24 Chedid L Boyer F and Saviard M Action de la cortison vis à vis de l'infection experimental avec *Salmonella typhi* chez la souris *Compt rend. Acad sc* 233 713 1951
  - 25 Chedid L Boyer F and Saviard M Nouveaux aspects de la fonction antitoxique de la cortisone *Ann Inst Pasteur* 86 347 1954
  - 26 Copeman W S C *et al* Study of cortisone and other steroids in rheumatoid arthritis *Brit M J* 2 849 1950
  - 27 Coriell L L *et al* Use of pituitary adrenocorticotrophic hormone (ACTH) in poliomyelitis *JAMA* 142 1279 1950
  - 28 Cornwell S Studies of reticuloendothelial function with colloidal gold *Anat. Rec* 115 295 1953
  - 29 Crepea S B Magnin G E and Seastone C V Effect of ACTH and cortisone on phagocytosis *Proc Soc Exper Biol. & Med* 77 704 1951
  - 30 Denny F W Jr and Thomas L Persistence of group A streptococci in

- tissues of rabbits after infection *Proc Soc Exper Biol & Med* 88 260 1955
- 31 Desaulles P Schuler W and Meier R Vergleich der Wirkung des Aldosterons auf das Fremdkörpergranulom der Ratte mit derjenigen von Cortexon Corticosteron Cortison und Hydrocortison *Experientia* 11 68 1955
- 32 Dougherty T F and Schneebeli, G C Use of steroids as antinflammatory agents *Ann New York Acad Sc* 61 328 1955
- 33 Douglas W W and Paton W D M Hypothermic and antipyretic effect of preparations of ACTH *Lancet* 1 342, 1952
- 34 Duffy B J Jr and Morgan H R ACTH and cortisone aggravation or suppression of febrile response of rabbits to bacterial endotoxin *Proc Soc Exper Biol & Med.* 78 687 1951
- 35 Duran Reynals F On parallel behavior of cancer and bacterial cells in same host Experiments with cortisone and transplantable mouse tumor *Yale J Biol & Med* 28 501 1956
- 36 Ebert, R H *In vivo* observations on effect of cortisone on experimental tuberculosis using rabbit ear chamber technique *Am Rev Tuberc* 63 64 1952
- 37 Ebert R V *et al* Study of hypotension (shock) produced by meningococcus toxin *Circulation Res* 3 378 1955
- 38 Ebert, R V and Stead E A Jr Circulatory failure in acute infection *J Clin Invest.* 20 671 1941
- 39 Elsbach P and Edsall, J R ACTH and cortisone as adjuncts to treatment of tuberculous meningitis *Ann Int Med* 46 332 1957
- 40 Esplin D W and Marcus S Relation between antibacterial action of penicillin and mouse host defenses in systemic pneumococcus infection *Antibiotics & Chemother* 4 423 1954
- 41 Evans A S *et al* Adrenal hormone therapy in viral hepatitis effect of gamma globulin and oral cortisone in the acute disease *Am J Med* 19 783 1955
- 42 Evans A S Sprinz H and Nelson, R S Adrenal hormone therapy in viral hepatitis effect of ACTH in acute disease *Ann Int Med* 38 1115 1953
- 43 Finland M Kass E H and Ingbar S H Effects of ACTH in Primary Atypical (Viral) Pneumonia and in Pneumococcal Pneumonia in *Proceedings of the First Clinical ACTH Conference* (Philadelphia: Blakiston Company 1950) pp 529-535
- 44 Fischel, E E Stoerk H and Bjørneboe M Failure of cortisone to affect rate of disappearance of antibody protein *Proc Soc Exper Biol & Med.* 77 111 1951
- 45 Foley E J Therapeutic effect of chlortetracycline and oxytetracycline in immunized mice treated with cortisone *Antibiotics & Chemother* 5 1 1955
- 46 Galliard H Lapiere J and Murard, J Inhibition de l'infection à Plasmodium berghei chez la souris et le rat par l'hormone hypophysaire de croissance (S.T.H.) *Ann parasit* 29 167 1954
- 47 Ganley O H Balch H H and Pulaski E J Effect of ACTH and adreno cortical hormones in experimental gas gangrene toxemia *Proc Soc Exper Biol & Med* 89 485 1955
- 48 Gell P C H and Hinde I T Effect of cortisone on macrophage activity in mice *Brit J Exper Path* 34 273 1953
- 49 Geller P Merrill E R and Jawetz E Effects of cortisone and antibiotics

- on lethal action of endotoxin in mice *Proc Soc Exper Biol & Med* 88 716 1954
- 50 Germuth F G Jr Role of adrenocortical steroids in infection immunity and hypersensitivity *Pharmacol Rev* 8 1 1956
  - 51 Germuth F G Jr Ottinger B and Oyama J Influence of cortisone on evolution of acute infection and development of immunity *Bull. Johns Hopkins Hosp* 91 22 1952
  - 52 Germuth F G Jr Oyama J and Ottinger B Mechanism of action of 17 hydroxy 11-dehydrocorticosterone and adrenocorticotrophic hormone in experimental hypersensitivity in rabbits *J Exper Med* 94 139 1951
  - 53 Good R A Vernier R L and Smith R T Serious untoward reactions to therapy with cortisone and adrenocorticotropin in pediatric practice *Pediatrics* 19 95 1957
  - 54 Gordon L E Miller C P and Hahne H J Effect of somatotrophic hormone and streptomycin on mice exposed to total body X irradiation *Proc Soc Exper Biol & Med* 83 85 1953
  - 55 Gordon P and Lipton M A Beneficial effect of serotonin and compound F on E coli endotoxin mortality in mice *Fed Proc* 16 301 1957
  - 56 Greene A E Ambrus J L and Gershenfeld L Effect of cortisone and desoxycorticosterone on infection with tetanus spores and upon toxicity of tetanus toxin *Antibiotics & Chemother* 3 1121 1953
  - 57 Haggerty R J and Eley R C Varicella and cortisone *Pediatrics* 18 160 1956
  - 58 Hahn E O *et al* Effect of cortisone on acute streptococcal infections and post streptococcal complications *J Clin Invest* 30 274 1951
  - 59 Harris T N *et al* Therapeutic effects of ACTH and cortisone in rheumatic fever Cardiac observations in a controlled series of 100 cases *Pediatrics* 17 11 1956
  - 60 Hechter O Concerning possible mechanisms of hormone action *Vitamins & Hormones* 13 293 1955
  - 61 Hechter O and Johnson S *In vitro* effect of adrenal cortical extract upon lymphocytolysis *Endocrinology* 45 351 1949
  - 62 Hechter O and Pincus G Genesis of adrenocortical secretion *Physiol Rev* 34 459 1954
  - 63 Heilman, D H Effect of 11 dehydro 17 hydroxycorticosterone and 11-dehydrocorticosterone on lymphocytes in tissue culture *Proc Staff Meet Mayo Clin* 20 310 1945
  - 64 Heller J H Effect of cortisone on function capacity and activity of reticuloendothelial system *Fed Proc* 12 65 1953
  - 65 Heller J H and Cowles P B Reversal of cortisone depressing effect on therapeutic efficacy of antibiotics *Clin Res Proc* 2 93 1954
  - 66 Herzog H L *et al* New antiarthritic steroids *Science* 121 176 1955
  - 67 Higginbotham R D and Dougherty T F Mechanism of protective effect of hydrocortisone in staphylococci infected adrenalectomized mice *Proc. Soc Exper Biol & Med* 90 253 1955
  - 68 Howell, D S and Ragan, C Course of rheumatoid arthritis during four years of induced hyperadrenalism (IHA) *Medicine* 35 83 1956
  - 69 Ingle D J Functional interrelationship of anterior pituitary and adrenal cortex *Ann Int Med* 35 632, 1951
  - 70 Jahn, J P *et al* Combination of ACTH-cortisone-hydrocortisone with antibiotics in management of overwhelmingly severe infections theory and practice based on 3 years experience *J Pediat.* 44 640 1954

- 71 Jawetz E Effect of cortisone on therapeutic efficacy of antibiotics in experimental infections Arch Int Med 93 850 1954
- 72 Johnson J R and Davey W N Cortisone corticotropin and antimicrobial therapy in tuberculosis in animals and man A review Am Rev Tuberc 70 623 1954
- 73 Johnson J R *et al* Corticotropin and adrenal steroids as adjuncts to the treatment of tuberculous meningitis Ann Int Med 46 316 1957
- 74 Jordan W S and Dingle J H Control of infection Biological and chemical means of prophylaxis Ann Rev Med 8 19 1957
- 75 Kass E H and Finland M Effect of ACTH on induced fever New England J Med 243 693 1950
- 76 Kass E H and Finland M Adrenocortical hormones in infection and immunity Ann Rev Microbiol 7 361 1953
- 77 Kass E H and Finland M Adrenocortical hormones and management of infections Ann Rev Med 8 1 1957
- 78 Kass E H *et al* Changes in patterns of secretion of corticosteroids in rabbits after prolonged treatment with ACTH Proc Soc Exper Biol & Med 85 583 1954
- 79 Kass E H *et al* Effects of adrenal steroids on resistance to infection differences in relative amounts of corticosterone and hydrocortisone secreted and in their biologic effects Arch Int. Med 96 397 1955
- 80 Kass E H Ingbar S H and Finland M Effects of adrenocorticotrophic hormone in pneumonia Clinical bacteriological and serological studies Ann Int Med 33 1081 1950
- 81 Kass E H Kendrick M I and Finland M Effect of certain corticosteroids and growth hormone on nucleoproteins of lymph nodes Ann New York Acad Sc 56 737 1953
- 82 Kass E H Kendrick, M I and Finland M Effects of corticosterone hydrocortisone and corticotropin on production of antibodies in rabbits J Exper Med 102 767 1955
- 83 Kass E H Lundgren M M and Finland M Effect of adrenal steroids corticotropin and growth hormones on resistance to experimental infections J Exper Med. 99 89 1954
- 84 Kass G H Hypothermia following cortisone administration Am J Med 18 146 1955
- 85 Kendall E C Relation of Chemical Structure of Adrenal Cortical Hormones to Biological Activity in *Transactions of the First Conference [on] Adrenal Cortex 1949* (New York Josiah Macy Jr Foundation 1950) pp 11-16 Discussion pp 17-46
- 86 Kessler W B and Leatham J H Evaluation of adrenal responses to ACTH and stress in mouse Fed Proc 11 362 1952
- 87 Khoobyarian, N and Walker D L Effect of cortisone on mouse resistance to intravenous toxicity of influenza virus Proc Soc Exper Biol & Med 94 295 1957
- 88 Kilbourne E D and Horsfall, F L Jr Lethal infection with Coxsackie virus of adult mice given cortisone Proc Soc Exper Biol & Med 77 135 1951
- 89 Klemola E and Somer P Treatment of mumps orchitis with cortisone and corticotropin Nord med 56 1128 1956
- 90 Koritz S B and Dorfman R I Effect of hormones on *in vitro* incorporation of glycine 1 C<sup>14</sup> into reticulocyte proteins Endocrinology 58 748 1956
- 91 Kurland G S and Freedberg A S Potentiating effect of ACTH and of



- cortisone on pressor response to intravenous infusion of 1 norepinephrine  
Proc Soc Exper Biol & Med 78 28 1951
- 92 Lemonde P Panisset M and Selye H Somatotrophic hormone in tuberculosis Am Rev Tuberc 71 319 1955
  - 93 Lepper M H and Spies H W Clinical Study of the Use of Cortisone Hydrocortisone and Corticotropin in the Treatment of Seriously Ill Patients with Infections in *Antibiotics Annual 1956 1957* (New York Medical Encyclopedia Inc 1957) pp 447-454
  - 94 Levitin H Kendrick M I and Kass E H Effect of route of administration on protective action of corticosterone and cortisol against endotoxin Proc Soc Exper Biol & Med 93 306 1956
  - 95 Li C H *et al* Corticotropins (ACTH) X Biological investigations on a corticotropin J Exper Med 105 335 1957
  - 96 Lurie M B *et al* Constitutional Factors in Resistance to Infection Effect of Cortisone on the Pathogenesis of Tuberculosis in New York Academy of Medicine (106) pp 84-99
  - 97 Lyster S C *et al* Adrenal corticoid activities of 6 methyl  $\Delta$  hydrocortisone Proc Soc Exper Biol & Med 94 159 1957
  - 98 McGehee E H and MacLean K Experiences with ACTH and cortisone note on long term therapy Brit M J 1 1171 1954
  - 99 Magill G B Killough J H and Said S I Cortisone and combined antibiotic therapy of acute brucellosis mellitensis Am J Med 16 810 1954
  - 100 Markowitz M and Kuttner A G Effect of intensive and prolonged therapy with cortisone and hydrocortisone in first attacks of rheumatic carditis Pediatrics 16 325 1955
  - 101 Meier R and Bein H J Der Einfluss der Nebennieren auf die Wirkung kreislaufaktiver Substanzen Helvet physiol et pharm acta 12 C83 1954
  - 102 Meites J and Feng Y S L Prevention by vitamin B<sub>12</sub> of protein catabolic action of cortisone Proc Soc Exper Biol & Med 85 341 1954
  - 103 Melby J C *et al* Production and catabolism of cortisol in experimental endotoxin shock J Clin Invest In press
  - 104 Mogabgab W J and Thomas L Effects of cortisone on bacterial infections Group A hemolytic streptococcal infection in rabbits J Lab & Clin Med 39 271 1952
  - 105 Muehrcke R C Lewis J L and Kark R M Effects of cortisone and heparin on eosinophils in defibrinated human blood Science 115 377 1952
  - 106 New York Academy of Medicine Section on Microbiology *The Effect of ACTH and Cortisone upon Infection and Resistance* (New York Columbia University Press 1953) (Symposia No 6)
  - 107 Padawer J and Gordon A S Hormonal influences upon distribution and fate of eosinophilic leukocyte J Clin Endocrinol 12 922, 1952.
  - 108 Parker R T Snyder M J and Merideth A M Effect of various antibiotics and cortisone upon botulinum tetanal and diphtherial toxins *in vivo* Am J Med 14 753 1953
  - 109 Peerman C G and McGarity W J Cortisone and antibiotic therapy in resistant pelvic inflammatory disease South M J 50 374 1957
  - 110 Perla D and Marmorston J *Natural Resistance and Clinical Medicine* (Boston Little Brown & Co 1941) pp 475-514
  - 111 Petersdorf R G and Bennett I L Jr Treatment of mumps orchitis with adrenal hormones report on twenty three cases with note on hepatic involvement in mumps AMA Arch Int. Med 99 222, 1957
  - 112 Peterson R H *et al* Physiological disposition and metabolic fate of hydrocortisone in man J Clin Invest 34 1779 1955

- 113 Plotz C M Knowlton A I and Ragan C Natural history of Cushing's syndrome *Am J Med* 13 597 1952
- 114 Polley H F and Mason H L Rheumatoid arthritis effects of certain steroids other than cortisone and of some adrenal cortex extracts *J.A.M.A.* 143 1474 1950
- 115 Ragan C *et al* Critical appraisal of current therapy in rheumatoid arthritis *Bull. New York Acad Med* 28 493 1952
- 116 Ragan C *et al* The Effect of Cortisone upon Repair Processes in Dense and Loose Connective Tissue in *New York Academy of Medicine* (106) pp 46-55
- 117 Ramey E R Goldstein M S and Levine R Action of nor-epinephrine and adrenal cortical steroids on blood pressure and work performance of adrenalectomized dogs *Am J Physiol* 165 450 1951
- 118 Rebeck J W and Mellinger R C Interruption by topical cortisone of leukocytic cycles in acute inflammation in man *Ann New York Acad Sc* 56 715 1953
- 119 Recant L Ott W H and Fischel E E Antipyretic effect of cortisone *Proc Soc Exper Biol & Med* 75 264 1950
- 120 Reilly J and Tournier P L'action de la chlorpromazine (4560 RP) sur l'intoxication typhique expérimentale *Bull Acad nat med* 137 385 1953
- 121 Reilly J *et al* La Prévention et le traitement des accidents observés chez les typhiques après administration de chloromycétine Etude expérimentale et deductions thérapeutiques *Ann med* 55 5 1954
- 122 Roberts S and Szego C M Biochemistry of steroid hormones *Ann Rev Biochem* 24 543 1955
- 123 Robertson J S Failure of adrenal cortical extracts to cause lysis of living lymphocytes *in vitro* *Nature* 161 814 1948
- 124 Robinson H J Adrenal cortical hormones and infection *Pediatrics* 17 770 1956
- 125 Romanoff E B Hudson P and Pincus G Isolation of hydrocortisone and corticosterone from human adrenal vein blood *J Clin Endocrinol* 13 1546 1953
- 126 Rosenbaum P and Obrinsky W Effect of cortisone on diphtheria intoxication and Schick test in guinea pigs *Proc Soc Exper Biol & Med* 83 502 1953
- 127 Rosenfeld G *In vitro* influence of bacterial pyrogens in adrenocortical function of perfused calf adrenals *Am J Physiol* 182 57 1955
- 128 Rupp J and Paschkis K E Lack of influence of vitamin B<sub>12</sub> on protein catabolic action of cortisone *Proc Soc Exper Biol & Med* 82 65 1953
- 129 Schrek R Color test to measure toxicity of adrenal cortex hormones to lymphocytes *Proc Soc Exper Biol & Med* 76 557 1951
- 130 Selye H Influence of somatotrophic hormone and cortisol upon development of tissue necrosis *J Endocrinol* 10 347 1954
- 131 Selye H Anticortisol action of aldosterone *Science* 121 368 1955
- 132 Smith R T and Thomas L Lethal effect of endotoxins on chick embryo *J Exper Med* 104 217 1956
- 133 Soffer L S Ludemann H H and Brill G Effect of corticotropin and adrenal steroids in management of acute disseminated lupus erythematosus *Ann New York Acad Sc* 61 418 1955
- 134 Sokoloff L King B D and Wechsler R L Role of 1 norepinephrine in treatment of shock *M Clin North America* 38 499 1954
- 135 Solem J H Effect of corticotropin in orchitis of mumps *Acta med scandinav* 149 341 1954

- 136 Southam C M and Moore A E Anti virus antibody studies following induced infection of man with West Nile Ilheus and other viruses J Immunol 72 446 1954
- 137 Spink W W Adrenocorticotrophic hormone and adrenal steroids in management of infectious diseases Ann Int Med 43 685 1955
- 138 Spink W W and Anderson D Experimental studies on significance of endotoxin on pathogenesis of brucellosis J Clin Invest. 33 540 1954
- 139 Stoerck H C Knowlton A I and Loth E N Failure of liver feeding to counteract cortisone effects other than growth inhibition Proc Soc Exper Biol & Med 85 627 1954
- 140 Syverton J T *et al* Cortisone and roentgen irradiation as synergistic agents for production of lethal infections Proc Soc Exper Biol & Med 80 123 1952
- 141 Thomas L Effects of cortisone and adrenocorticotrophic hormone on infection Ann Rev Med 3 1 1952
- 142 Thomas L Physiological disturbances produced by endotoxins Ann Rev Physiol 16 467 1954
- 143 Thomas L Cortisone ACTH and infections Bull New York Acad Med 31 485 1955
- 144 Thomas L and Smith R T Effect of cortisone on response to endotoxin in mature rabbits Proc Soc Exper Biol & Med 86 810 1954
- 145 Thomas L Zweifach B W and Benacerraf B Mechanisms in production of tissue damage and shock by endotoxins Tr A Am Phys 70 54 1957
- 146 Tobin J L Complications of meningococcus infection in series of 63 sporadic cases Am J M Sc 231 241 1956
- 147 Tonutti E Einfluss von Hormonwirkungen auf das Reaktionsvermogen von Geweben gegen bakterielle Giftstoffe Rev canad biol 12 213 1953
- 148 Wagner H N *et al* Effect of hydrocortisone upon course of pneumococcal pneumonia treated with penicillin Bull Johns Hopkins Hosp 98 197 1956
- 149 Wanzer S H Morgan T E and Smith D T Effect of corticotropin (ACTH) and streptomycin on experimentally induced pulmonary tuberculosis in rabbits J Bact 67 264 1954
- 150 White R C and Marshall A H E Effect of cortisone on pneumococcal bacteremia Lancet 1 891 1951
- 151 Zweifach B E Shorr E and Black M M Influence of adrenal cortex on behavior of terminal vascular bed Ann New York Acad Sc 56 626 1953

# Primary and Secondary Hyperparathyroidism

B E C NORDIN

*The University Department of Medicine Gardiner Institute Western  
Infirmary Glasgow Scotland*

THE ELUCIDATION of the nature and functions of the parathyroid hormone is lagging behind that of the other endocrine secretions. Clinical disorders of the parathyroid glands are not particularly common and with the diminution in resort to operation in the treatment of thyrotoxicosis and improvements in surgical technique surgical hypoparathyroidism is becoming a rarity. The extract of parathyroid hormone commercially available (prepared by a method which has remained virtually unchanged for 30 years) has not proved useful in the treatment of parathyroid insufficiency and the relative efficacy of calciferol in this disorder has removed the stimulus to further research on the subject.)

Nevertheless there are signs now of growing interest in the parathyroid glands and metabolic bone disease dating from the publication in 1948 of Albright and Reifenstein's (2) monograph on this subject and accentuated by other factors such as the appreciation of the danger of the deposition in the skeleton of fission products from nuclear explosions. Above all perhaps it is the discovery confirmed by the use of labeled isotopes that the bone mineral is in a state of dynamic equilibrium with the ions of the tissue fluid which has directed attention to the metabolism of bone and emphasized our ignorance of parathyroid function.

## ACTIONS OF PARATHYROID HORMONE

The actions of the parathyroid hormone have been studied in the same way as those of other endocrine secretions by observing the

manifestations of spontaneous overactivity of the glands by studying the effects of injected glandular extracts, and by recording the results of parathyroid deficiency whether spontaneous or the result of surgical removal of the glands. There appear to be at least two distinct actions of the parathyroid hormone—phosphaturic and calcemic

### PHOSPHATURIC ACTION

✓ ASSESSMENT OF PHOSPHATURIA IN CLINICAL PRACTICE—The phosphate-creatinine clearance ratio (Cp Ccr) is a useful figure which can very easily be derived from the simultaneous measurement of phosphate and creatinine concentration in the serum and in the urine. The ratio is derived from the equation

$$\text{Cp Ccr} = \frac{\text{urine phosphate} \times \text{serum creatinine}}{\text{serum phosphate} \times \text{urine creatinine}} \quad (\text{all in mg / 100 ml})$$

The resultant figure denotes the proportion of filtered-phosphate which is not reabsorbed by the renal tubules.

✓ The clearance ratio does not in itself provide adequate information about phosphate excretion since it normally rises and falls with the serum phosphate (serum P) (68 69 79). This is certainly true after phosphate infusion (56) and appears to be true of changes in serum phosphate induced by variations in diet. No adequate data have been reported which would show whether or not the diurnal changes in serum and urine phosphate correspond in the same way but this may be inferred from the data of Milne *et al* (69). The view to the contrary expressed by Ollayos and Winkler (77) is based on observations on only 1 subject. The true relation between the serum phosphate and the clearance ratio as derived from the data of Milne *et al* is

$$\text{Cp Ccr} = 0.64 \times \log \text{serum P} - 0.25 \pm 0.12$$

This equation is represented by the regression line and 95 per cent limits shown in Figure 1 in which it should be noted the serum phosphate is plotted logarithmically. It is evident that the significance of the clearance ratio and of the serum phosphate in any particular case is greatly increased when the two values are considered in relation to one another. Thus a clearance ratio of 0.20 falls outside the normal range if the serum phosphate is 2.0 mg per 100 ml but is normal for a serum phosphate of 5.0. A serum phosphate of 2.5 mg per 100 ml is not in itself abnormal if the urine phosphate is very low (except perhaps




FIG 1.—The phosphate-creatinine clearance ratio and serum phosphate concentration in normal subjects and in patients with primary hyperparathyroidism, osteomalacia and hypoparathyroidism (Regression line and 95 per cent confidence limits calculated from data of Milne Stanbury and Thomson (69) )

in suggesting a low phosphate intake) but it is abnormal if the clearance ratio is high

If it is assumed however that the relation of the clearance ratio to serum phosphate follows a straight line up to a serum phosphate of 8 mg per 100 ml then the following approximation holds

$$C_p \text{ Ccr} = \frac{\text{Serum P}}{20} - 0.07 \pm 0.12$$

It has therefore been suggested that in any given case the observed clearance ratio should be compared with the predicted value for the

prevailing blood level derived by this formula and that the discrepancy between the two should be taken as an "index" of phosphate excretion (76). When the predicted and observed values are equal this "index" is 0. Values above +0.12 (i.e., when the observed clearance ra




FIG. 2.—Total and ultrafiltrable (UF) serum calcium, urinary calcium/creatinine ratio, serum phosphate, phosphate/creatinine clearance ratio, and phosphate excretion index (PEI) before and after removal of parathyroid adenoma.

to exceeds the predicted figure by more than two standard deviations) suggest an abnormally low rate of tubular reabsorption of phosphate as in hyperparathyroidism, and values below -0.12 an abnormally high rate of reabsorption as in hypoparathyroid states. It is true that high figures are occasionally observed in other conditions than proved or presumed parathyroid overactivity, particularly in patients with renal calculi, and McGeown and Bull (59) have for this reason declared

themselves "unimpressed" by the phosphate clearance as a measure of parathyroid activity. On the other hand, the present writer has not yet seen a normal value in a proved case of primary or secondary hyperparathyroidism.

PHOSPHATE EXCRETION IN PARATHYROID DISORDERS. The lowering of the serum phosphate with increasing degrees of parathyroid activity is associated with and probably largely or wholly due to a lowering of the renal threshold to phosphate (3, 30, 54, 76), presumably produced by a reduction in tubular reabsorption. This is borne out by the observations of Sirota (98) who showed that the phosphate-mulin clearance ratio was high in 2 cases of parathyroid adenoma and that parathyroidectomy was followed by a rise in serum phosphate and a fall in phosphate clearance. Similar results have been reported by Chambers *et al* (20) by Brush (16) and by others. Conversely a low clearance of phosphate by the kidneys has been observed in hypoparathyroidism (1, 68).

Figure 1 shows the phosphate-creatinine clearance ratio and the concentration of serum phosphate in 4 cases of parathyroid tumour, 12 cases of osteomalacia, 35 normal subjects and 5 cases of hypoparathyroidism. All 4 cases of parathyroid tumour have high clearance ratio values with low concentrations of serum phosphate and in all 5 cases of hypoparathyroidism the clearance ratio is low and the serum phosphate high. In 33 of the 35 normal subjects the values were within the normal limits as defined above. The cases of osteomalacia discussed later are believed to be examples of secondary hyperparathyroidism. The phosphate excretion index which takes both the clearance ratio and the serum phosphate into account yields the following figures for the cases represented in Figure 1.

*Parathyroid tumours*

+0.24  
+0.25  
+0.50  
+0.82

*Hypoparathyroidism*

-0.12  
-0.14  
-0.15  
-0.15  
-0.13

Of the 35 normal subjects, 33 fall within the normal range of -0.12 to +0.12.

It should be noted that the cases of hypoparathyroidism were all receiving vitamin D and that much lower values have been observed in untreated patients.

Figure 2 shows the effect of removal of a parathyroid tumour on the



serum calcium and phosphate levels and on the clearance ratio. It is interesting to note that the operation did not materially alter the serum phosphate level but that the clearance ratio which was abnormally high before the operation as shown by the high "index" fell rapidly to below normal levels. Indeed for the next 2 days the urine was virtually phosphate free. The subsequent return of the clearance ratio to its preoperative level will be discussed later.

The effect of clinical parathyroid disorders on the phosphate clearance or more correctly on its normal relation to the serum phosphate is fairly clear and is compatible with the concept that the parathyroid hormone reduces reabsorption of phosphate by the renal tubule. Some confusion has been caused however because the intravenous injection of parathyroid extract does not invariably increase the urinary excretion of phosphate.

**EFFECT OF INJECTING PARATHYROID EXTRACT**—Albright and Ellsworth (1) first reported the phosphate diuresis which can be provoked by the injection of parathyroid extract and they elaborated the hypothesis that this phosphate diuresis was responsible for the calcemic action of the parathyroid hormone because it reduced the level of serum phosphate. Although this hypothesis has been shown to be incorrect, the original observations on which it was based are undoubtedly valid.

The effect of intravenously given parathyroid extract on urine phosphate excretion is variable.

With the extract at present available some workers have definitely observed phosphaturia in normal subjects (17, 75) while others have failed to produce it (60). The absolute magnitude of the response to a standard dose has been found to be fairly constant but its apparent magnitude (expressed as a percentage increase in phosphate output) is inversely related to the rate of phosphate excretion at the time of injection: when urine phosphate was high the injection appeared to have little effect and vice versa (75). This might explain some of the negative results obtained by other workers but it is unlikely to be the complete explanation since negative results with parathyroid extract in normal subjects are reported too frequently (20, 31, 60). Differences in the potency of different batches of the extract are almost certainly a factor. The effect obtained at the present time with parathyroid extract in hypoparathyroidism also appears to be less striking than that observed by Ellsworth and Howard in 1934 (34) but their cases and some of those reported by Albright and Reifenstein (2) had exception

high levels of serum phosphate. Clearly if parathyroid extract exerts its action on the renal tubule the magnitude of such action is likely to be related to the filtered load of phosphate which is of course a function of the serum phosphate level. In this connection it is of interest that Dent (31) found a good response to parathyroid extract only in a patient with a high serum phosphate.

Administration of parathyroid extract also increases the glomerular filtration rate (18-24) and this may account for some of the phosphaturia after injection but it cannot explain the difference between the excretion of phosphate in hyper and hypoparathyroidism. It has been suggested that parathyroid hormone affects the filtrability of the serum inorganic phosphate but Hopkins et al (44) have reported that all the serum inorganic phosphate is ultrafiltrable. It is most likely that the hormone acts directly on the renal tubule, presumably inhibiting phosphate reabsorption but it has also been suggested that parathyroid hormone promotes phosphate excretion by the tubule (57). Surprisingly little attention has been paid to a possible relation between the phosphaturic action of parathyroid hormone and the mechanism of acid-base regulation in the kidney particularly the excretion of titratable acid and the pH of the urine.

### CALCEMIC ACTION

There is no argument about the existence of the calcemic action of the parathyroid hormone. The raised serum calcium of primary hyperparathyroidism is as unmistakable as that which can be induced by injections of the extract.

The calcemic action of the parathyroid hormone cannot, however be explained by its phosphaturic action despite the ingenious arguments which have been put forward to support this concept. The data in Figure 2 which are representative of many other observations demonstrate its fallacy. In this case of primary hyperparathyroidism the serum calcium fell from a preoperative level of 17 mg per 100 ml to a normal level of 10 mg in about 16 hours without any change in the concentration of serum inorganic phosphate. The low level of serum phosphate cannot therefore have been responsible for the high level of calcium. It is of course true that in the typical case of parathyroid tumour the serum phosphate is low and the serum calcium high but neither serial observations in 1 case nor multiple observations in different cases yield a constant product whether calculated in terms of

secondary or tertiary calcium phosphate and there is thus no reason to believe that the changes in serum calcium are the result of changes in serum phosphate

The calcemic action must therefore be an additional effect of the hormone independent of its phosphaturic power This has been confirmed by animal experiments Stewart and Bowen (92) Ingalls *et al* (49) and others have shown that the serum calcium can be raised by parathyroid extract in dogs even after nephrectomy Barnicot (11) and Chang (21) have described the direct effect on bone of parathyroid implants and Gaillard (37) has reported an effect of parathyroid glands on bone in tissue culture In the face of this evidence some of it going back 15 years it is surprising that recent writers should still imply that the lowering of serum phosphate by parathyroid hormone is the cause of the rise in serum calcium

✓ The intimate mechanism of the calcemic action is unknown, but it is unlikely that the hormone directly stimulates the osteoclasts to destroy bone Osteoclasts is a feature of many forms of rapid bone destruction such as Paget's disease vitamin D poisoning (4 10) and hyperthyroidism (6 36) in which there is no reason to suppose that the parathyroids are directly involved Furthermore injection of parathyroid extract raises the serum calcium before there is any histologic evidence of osteoclasts (13 14)

Howard (45) has emphasized the "equilibrium which must exist between the bone and tissue fluid minerals and has suggested that the parathyroids, by some direct action on the bone cell, regulate the level at which serum calcium is in equilibrium with bone mineral Evidence that the hormone has a direct action on the bone cell comes from Heller Steinberg (41) who observed that the first histochemical effect of injection of parathyroid extract took place around the osteocyte

It is hard to believe however that an equilibrium could exist between the bone salt and a particular ion (the calcium ion) it is more probable that some form of "solubility product" of calcium and phosphate must be operating Powdered calf bone has a reproducible  $\text{Ca} \times \text{P}$  "solubility product" (74) At pH 7.4 this product is not as high as the product of calcium and phosphate in the tissue fluids of the living body but at pH 6.6 to 6.8 the product is comparable to that in mammalian tissue fluid this suggests the possibility that the pH at the bone crystal surface might be of this order In this pH range very small changes in pH cause large changes in bone "solubility" and it is conceivable that parathyroid hormone might act in this way and raise

the serum calcium by lowering bone pH Cretin (27) has in fact, suggested that the pH of bone undergoing resorption is below 7.0

There is however one obvious objection to the idea that the parathyroid hormone renders the bone salt more "soluble" it is that the product of  $\text{Ca} \times \text{P}$  may be no higher in primary hyperparathyroidism when the serum calcium is high and the serum phosphate is low than in hypoparathyroidism in which the levels are reversed. It must be remembered however that the bone salt probably approximates to

TABLE 1—PRODUCT OF SERUM CALCIUM AND PHOSPHATE ( $\text{Ca} \times \text{P}$ ) IN TYPICAL HYPOTHETIC NORMAL IN HYPERPARATHYROID AND IN HYPOPARATHYROID SUBJECTS

	NORMAL	HYPERPARATHYROID	HYPOPARATHYROID
Ca	10.0 mg /100 ml.	14 mg /100 ml	5.2 mg /100 ml.
P	3.1 mg /100 ml	2.2 mg /100 ml	6.0 mg /100 ml
$\text{Ca} \times \text{P}$	31	31	31
HPO	$0.8 \times 10^{-3}$ M /L.	$0.6 \times 10^{-3}$	$1.6 \times 10^{-3}$
$\text{Ca}^{++}$	$1.7 \times 10^{-3}$ M /L	$2.5 \times 10^{-3}$	$0.9 \times 10^{-3}$
$\text{Ca}^{++} \times \text{HPO}^{--}$	$1.5 \times 10^{-6}$ M /L	$1.5 \times 10^{-6}$	$1.5 \times 10^{-6}$
$(\text{Ca}^{++})^3$	$5.3 \times 10^{-9}$ M /L	$15.5 \times 10^{-9}$	$0.7 \times 10^{-9}$
$\text{PO}^{--}$	$7.2 \times 10^{-3}$ M /L.	$5.5 \times 10^{-3}$	$13.6 \times 10^{-3}$
$(\text{Ca}^{++}) \times (\text{PO}^{--})$	$27.5 \times 10^{-6}$ M /L	$39.0 \times 10^{-6}$	$13.5 \times 10^{-6}$

tricalcium phosphate ( $\text{Ca}_3(\text{PO}_4)_2$ ). The solubility product of such a salt is a constant related to the cube of the calcium concentration multiplied by the square of the phosphate, the product is therefore higher when the calcium is high and the phosphate low than when the levels are reversed. This is made clear in Table 1 which shows the product of the calcium and phosphate concentrations in a typical normal subject and in cases of hyper and hypoparathyroidism. In terms of secondary calcium phosphate ( $\text{CaHPO}_4$ ), the product is the same in all three, in terms of tertiary calcium phosphate ( $\text{Ca}_3(\text{PO}_4)_2$ ) it is three times as high in the hyperparathyroid as in the hypoparathyroid case.

The concept that parathyroid hormone exerts its effect on the pH of bone appears to conflict with the increasingly popular view that it acts by promoting the production of citrate or some other chelate in bone (63). It is possible however that acidification and chelation occur together (72).

#### HORMONE OR HORMONES?

Knowing that the secretions of the gland possess two distinct actions tempts one to speculate whether there are two parathyroid hor-

mones as has been suggested by Dent (31) The first evidence that it might be possible to separate the two actions came from Davies and Gordon (29) Munson has now succeeded in separating gland extracts into fractions with different degrees of calcemic and phosphaturic action (71) So far however no correlation whatever has been established between the predominant cell type seen in parathyroid adenomas and the degree of calcemic or phosphaturic action as judged by the biochemical data of the cases concerned

### STIMULUS TO PARATHYROIDS

It is clear that the parathyroid glands serve to maintain the serum calcium at about 10 mg per 100 ml in higher animals presumably to protect the neuromuscular system against the effect of a low concentration of calcium ions in the tissue fluid The calcium concentration in an ultrafiltrate of serum is about 65 mg per 100 ml (46) and it is believed that the greater part of this calcium is ionized It is reasonable to suppose that the gland is stimulated by a fall in calcium ions below a certain critical level and suppressed by a rise in calcium concentration Since the range of serum calcium is normally 9 to 11 mg % it is probable that variations above or below the corresponding range of calcium ion levels modify parathyroid activity) There is in direct evidence to support this view Infusions of calcium (47 55 76 77) are followed by a fall in urine phosphate (Fig 3) and infusions of sodium citrate (76) by a rise in urine phosphate these results are believed to signify decreased and increased parathyroid activity respectively Neither of these responses is observed in the hypoparathyroid subject In terms of the "phosphate excretion index" these procedures are followed by a fall and a rise respectively

It has been suggested that a rise in the serum inorganic phosphate is also a stimulus to the parathyroids (19) but since any substantial rise in serum phosphate depresses the serum calcium ion concentration the stimulus might be an indirect one Ham *et al* (40) have sought to solve this problem by comparing parathyroid weights in rats on different dietary regimes all deficient in vitamin D They found enlargement of the parathyroids only in those groups in which the serum calcium was reduced the high calcium and high phosphorus regime yielded high serum calcium and phosphate levels but no parathyroid hypertrophy They concluded that the stimulus to the parathyroids is a fall in tissue fluid calcium rather than a rise in phosphate and no good evidence has since been produced to prove them wrong




FIG 3—Effect of infusion of calcium gluconate (15 mg calcium/kg body weight) on serum phosphate and urinary phosphate and phosphate-creatinine ratio in 12 normal subjects

### DIAGNOSIS OF PRIMARY HYPERPARATHYROIDISM

The clinical syndrome of primary hyperparathyroidism is now well known. Presenting usually with renal calculi, bone pain or nausea and vomiting, but occasionally discovered in other ways, the typical patient has some or all of the following additional features: polyuria, weakness, hypotonia, dyspepsia and constipation. The high incidence of peptic ulceration (48-82) is not always sufficiently appreciated. The

serum and urine calcium levels are of course raised, unless renal failure (commonly present) is too far advanced the urine calcium being probably the more sensitive indicator of the two since a significant rise in serum calcium level presumably does not occur until the stage at which renal excretion fails to keep pace with bone destruction cases have in fact been reported in which the serum calcium was normal (64) If the extreme sensitivity of the kidney to very small changes in serum calcium level produced by calcium infusions is any guide the urine calcium may well rise before the serum concentration has increased sufficiently to be considered significant but it must also be remembered that a normal serum calcium may conceal a high ionized fraction of calcium if the amount of serum protein particularly of the albumen fraction is lowered.

Refinements in diagnosis are constantly being suggested. The phosphate-creatinine clearance ratio (or its converse tubular reabsorption of phosphate) has already been discussed. Its use in the diagnosis of hyperparathyroidism has been suggested by Schaaf and Kyle (85) Brush (16) Chambers (20) and Crawford (24) However none of these workers takes into account the normal relation between the serum phosphate level and the clearance ratio which has been emphasized above.

Howard (46 47) reported that calcium infusions caused a smaller rise in serum phosphate and a smaller fall in urine phosphate in patients with parathyroid adenoma than in normal subjects. Figure 4 shows the effect of a standard calcium infusion on serum and urine phosphate in a case of parathyroid tumour the results should be compared with the normal responses shown in Figure 3. Serum phosphate rises in both cases but the fall in urine phosphate which occurs in normal subjects does not occur in the patient with primary hyperparathyroidism. It is unlikely that the immediate rise in serum phosphate induced by calcium infusion is mediated by the parathyroid glands but the later fall in urine phosphate probably is (47 75) and the absence of such a fall is compatible with the presence of an autonomous parathyroid tumour which cannot be suppressed by artificially raising the serum calcium level. The diagnostic value of this procedure has not yet been defined.

✓ Chambers *et al* (20) have suggested a phosphate deprivation test to confirm the diagnosis of primary hyperparathyroidism in doubtful cases. They report that the rise in the tubular reabsorption of phosphate which follows deprivation in normal subjects is much less




FIG 4—Primary hyperparathyroidism effect of infusion of calcium gluconate (15 mg calcium/kg body weight) on serum phosphate and urinary phosphate and phosphate creatinine ratio in patient with parathyroid adenoma

marked if a parathyroid tumour is present. The suggestion is a reasonable one and deserves further testing.

(+) Roentgenography may be of some assistance. The lesions of osteitis fibrosa are seen only in a minority of cases, the commonest bone lesion being osteoporosis (22) probably due to prolonged negative calcium balance. Since the roentgenographic diagnosis of osteoporosis can be made only in the most advanced cases, biopsy of bone from the iliac crest may prove useful. The degree of osteoporosis present in a case



of primary hyperparathyroidism can be appreciated by comparing the photomicrograph of bone from the iliac crest with a sample of normal bone (Plate 1). It is wrong to dismiss the evidence of bone histology as negative if it does not show the features of osteitis fibrosa.)

Albright's suggestion (2) that the absence of the lamina dura of the teeth is of diagnostic value must be treated with reserve since a similar finding has recently been reported in Cushing's syndrome (96). Wyman and Robbins (97) have recently suggested the use of the barium swallow to demonstrate parathyroid tumours by their indentation or displacement of the oesophagus. Seldinger (86) has advocated arteriography which may demonstrate a highly vascular adenoma, and Steiner *et al* (90) have applied this technic to the location of a tumour at operation. The popular calcium balance test cannot be recommended as a diagnostic procedure. It entails much work for all concerned without yielding more information than can be obtained from measuring the urine calcium excretion on a limited or relatively limited calcium intake.

In this welter of suggested tests all of them contributing something but none of them entirely satisfactory it is well not to forget to examine the patient's neck. In the writer's experience this simple procedure has twice revealed swellings which proved to be adenomas.

## SYNDROMES OF SECONDARY HYPERPARATHYROIDISM

Secondary hyperparathyroidism may occur in vitamin D deficiency and in uremia.

### IN VITAMIN D DEFICIENCY

Erdheim first reported that the parathyroid glands were enlarged in osteomalacia (35) and although some of his cases are now thought to have been examples of primary hyperparathyroidism the observation has since been confirmed by others (59-78). Parathyroid hyperplasia has also been reported in vitamin D deficient animals (43-73).

The stimulus responsible for the parathyroid overactivity comes presumably from the lowered serum calcium which occurs in rickets and osteomalacia and which is attributed by Albright and Reifenstein (2) to the malabsorption of calcium found in states of vitamin D deficiency. Low calcium diets do not however cause parathyroid hyperplasia if adequate vitamin D is given (23) and it is therefore unlikely that malabsorption of calcium alone would do so. The cause of



PLATE 1—Photomicrographs of biopsy specimens from iliac crest. *Top* from subject without bone disease. *Bottom* from patient with osteoporosis due to primary hyperparathyroidism.



the parathyroid overactivity in vitamin D deficiency is probably a fall in serum calcium due to the absence of the "calcemic" effect of vitamin D on the skeleton. This very important action of vitamin D postulated by McLean in 1941 (61) has recently been demonstrated by Carlsson and Landquist (18) in a very convincing manner. They found that the administration of increasing doses of vitamin D to rachitic rats caused a progressive rise in serum calcium concentration even after no further effect was produced on calcium absorption and they conclude that vitamin D sustains serum calcium by a direct action on the skeleton.

✓ Hypertrophy of the parathyroids is not the only evidence of parathyroid overactivity in rickets and osteomalacia. Thus Lang (56) has described histologic osteitis fibrosa in osteomalacia and recently Davies and others (30) have described in osteomalacia secondary to steatorrhoea subperiosteal erosions of the phalanges indistinguishable from those seen in primary hyperparathyroidism (32). Suggestive evidence of parathyroid overactivity is provided by the raised phosphate clearance seen in osteomalacia (12 66 67 76) (see Fig 1) and by the fact that this high clearance can be suppressed by calcium infusion (75).

✓ The secondary hyperparathyroidism of osteomalacia and rickets is probably an integral feature of the disease responsible for the reduced serum phosphate which is its characteristic biochemical feature. Salvesen and Boe (83) have provided some interesting evidence in this respect. They found that in a large series of cases of steatorrhoea there was either a history of tetany or evidence of osteomalacia but rarely both together. They suggest that tetany occurs in vitamin D deficiency only when the parathyroids fail to respond to the stimulus of a reduced serum calcium. When on the other hand the parathyroids do respond they protect the patient from tetany by maintaining the serum calcium but the concomitant reduction in the serum phosphate leads to the development of osteomalacia. One might add that the development of tetany in the presence of rickets suggests parathyroid "exhaustion."

It is possible that the persistent hypophosphatemia frequently seen after removal of a parathyroid tumour in the presence of bone disease should also be explained in terms of secondary hyperparathyroidism. An example of this persistent hypophosphatemia is seen in Figure 2 it shows that 4 days after removal of a parathyroid tumour in a case in which there was severe osteitis fibrosa the serum phosphate was

still low and the clearance ratio high suggesting persistent parathyroid overactivity. Since the serum calcium at this time was well below 10 mg per 100 ml such parathyroid overactivity was presumably secondary rather than primary. A reasonable explanation of this persisting secondary hyperparathyroidism if such it is following parathyroidectomy might be that the depleted skeleton is unable to sustain the normal serum calcium concentration until some repair and remineralisation have taken place. If this is the true explanation persistent hypophosphatemia after parathyroidectomy should be seen only in patients with bone disease as Albright and Reifenstein (2) in fact declared to be the case.

### IN GLOMERULAR FAILURE

Symmetric enlargement of the parathyroid glands in glomerular renal failure was reported by Bergstrand in 1941 (13) and is now familiar to every pathologist. The fact that a form of rickets ("renal rickets") occurs in this type of renal failure is also well known (89). Albright and Reifenstein (2) showed that there were at least two forms of renal rickets and claimed that the type associated with uremia and parathyroid hyperplasia was not rickets at all but osteitis fibrosa. They postulated that the phosphate retention of glomerular failure depressed the serum calcium level and that this in turn stimulated the parathyroid glands and produced the histologic and roentgenographic features of hyperparathyroidism.

It is becoming increasingly clear that this is an oversimplification. It is true that osteitis fibrosa may be seen in glomerular failure but roentgenographic and histologic features of true rickets are also quite commonly seen. Stanbury (89) in particular has emphasized the variety of bone histology that may be found in azotemia and has confirmed the fact that the rachitic element can be cured by large doses of vitamin D.

At present it is impossible to explain the rachitic element in renal osteodystrophy and some metabolic disorder other than hyperparathyroidism must be present affecting bone. It is hard to understand why osteoid should fail to calcify in uremia in the face of a normal or high  $\text{Ca} \times \text{P}$  product. Yendt *et al* (98) have shown that rachitic rat cartilage which will calcify in ultrafiltrates of normal serum at  $\text{Ca} \times \text{P}$  products of about 30 will not calcify in ultrafiltrates of uremic serum until the product reaches about 55 and they suggest that some unspecified in

hibitor may be present in uremic serum The only other circumstance in which rachitic osteoid develops in the face of a high  $\text{Ca} \times \text{P}$  product is hypervitaminosis D (39) but in this condition some degree of renal failure is almost invariably present and the explanation may be the same as in "renal rickets"

As for the osteitis fibrosa seen in uremia the concept that a raised level of serum phosphate depresses the serum calcium by precipitation of calcium phosphate ( $\text{CaHPO}_4$ ) is superficially satisfactory and is compatible with the wide spread metastatic calcification seen in prolonged uremia especially in children (25 87) The solubility product  $\text{Ca} \times \text{HPO}_4^{--}$  in 0.15M solutions is 3.2 when the concentration of each is expressed in millimoles per liter At pH 7.4 80 per cent of the total inorganic phosphate is present as  $\text{HPO}_4^{--}$  and about 65 per cent of the total serum calcium is probably present as  $\text{Ca}^{++}$  (depending on the concentration of albumin and globulin) The molecular weight of Ca is 40 and of P is 31 so that their concentration in milligrammes per 100 ml must be divided by 4 and 31 respectively when converting them into millimoles per liter the product must therefore be divided by 124 Thus the final calculation to arrive at the product of serum Ca and P (mg/100 ml) which is equivalent to the solubility product (S.P.)  $\text{Ca}^{++} \times \text{HPO}_4$  is

$$\text{S.P. } \text{Ca} \times \text{P} \text{ (each in mg/100 ml)} = 3.2 \times 100/80 \times 100/65 \times 12.4 = 75$$

This figure closely corresponds to that derived in a different manner by Herbert *et al* (44) who showed that generalised metastatic calcification only occurred when the figure was exceeded

There is also evidence in the work of Meroney *et al* (65) in cases of acute anuria that the  $\text{Ca} \times \text{P}$  "ceiling" in the serum is about 60 to 70 Their data (Fig 5) show the reciprocal relationship between Ca and P in anuria and suggest a product of about this figure over a large part of the curve It is of course extremely unlikely that this "ceiling" could be less than 60 or even as low as 60 since this figure may be reached in normal children

A  $\text{Ca} \times \text{P}$  product of 75 is exceeded in the great majority of recently reported cases of metastatic calcification with parathyroid hyperplasia and osteitis fibrosa (15 25 70 80 85) and the train of events in these is comprehensible, an elevated concentration of serum P causes generalized precipitation of  $\text{CaHPO}_4$  with depression of the Ca concentration and stimulation of the parathyroid glands The result is mobilisation of mineral from the skeleton and its deposition in other

sites such as the arterial tree where mineral solubility is not governed by the parathyroids. This is more likely to occur in children, perhaps because their  $\text{Ca} \times \text{P}$  is normally higher than that of adults. (Generalised metastatic calcification does not appear to occur in primary hyperparathyroidism unless the  $\text{Ca}$  concentration is excessively high (52-81) or there is associated renal failure) (7-15).

Unfortunately these considerations cannot explain the reduced




FIG. 5—Serum calcium and phosphate levels found in patients with acute anuria and regression curve calculated from observed values (From Meroney and Hernon (65)).

serum  $\text{Ca}$  or even the osteitis fibrosa in all cases of uremia because it is perfectly clear that the serum  $\text{Ca}$  is often reduced below 10 mg per 100 ml before the serum  $\text{P}$  has reached the critical level or even before it is raised at all. This has been the present writer's experience and that of Stanbury (89a) and confirmation of it may be found in the literature. Thus Baird and Lees (8) have reported 3 cases of renal osteodystrophy in adults. The first presented with osteitis fibrosa and a serum  $\text{Ca}$  reduced to 6.4 mg per 100 ml but the serum inorganic  $\text{P}$  was only 5.1 mg per 100 ml. Crawford *et al* (26) reported 3 cases of osteosclerosis associated with chronic renal failure in the first and

third cases the blood urea was over 200 mg per 100 ml but the serum P was only 4.2 in one and 5.6 in the other yet the serum Ca was markedly depressed in both. Similarly the first of Morgan and MacLagans (70) cases presented with osteitis fibrosa when the plasma P was only 5.3 mg per 100 ml. It seems therefore that there is a tendency for the serum Ca to fall in renal failure before the serum P has risen sufficiently to precipitate  $\text{CaHPO}_4$ . Furthermore it appears




FIG. 6—Serum phosphate and phosphate creatinine clearance ratios in renal failure (Calculated from data of Goldman and Bassett (38) )

that the reduced serum Ca may stimulate the parathyroid glands inasmuch as osteitis fibrosa may develop in this situation.

The data of Goldman and Bassett (38) also suggest the possibility that parathyroid overactivity may develop in renal failure before the serum P reaches the level of 7.5 mg per 100 ml. In Figure 6 their data on phosphate excretion in renal failure have been converted into phosphate-creatinine clearance ratios and plotted in such a way that they can be compared with those in Figure 1. It is apparent that the phosphate-creatinine clearance ratio rises out of all proportion to the serum P concentration well before the concentration of the latter reaches 7 mg per 100 ml. In some cases the serum P is not raised at all. This suggests that either there is some other factor present in



renal failure beside a raised serum P which may stimulate the parathyroids or that the abnormally high clearance ratio in renal failure denotes some other abnormality than parathyroid overactivity. Even if the latter is true, the occurrence of osteitis fibrosa before the serum P increases significantly suggests that in chronic uremia there exists some unknown metabolic factor or factors which lower the serum Ca and so stimulate the parathyroid glands. Whether this is the same factor as the one responsible for the rachitic abnormality it is impossible to say but since the latter appears to respond to large doses of vitamin D (89) one is perhaps justified in speaking of a "vitamin D resistant state." It is conceivable that vitamin D is inactivated or antagonised in renal failure but it is also possible that there are other anions besides phosphate which are active in causing depression of the serum Ca or that the raised citrate level in renal failure lowers the ionic calcium (78a). A raised blood citrate could also explain the results of Yendt *et al* (98).

### PRIMARY AND SECONDARY HYPERPARATHYROIDISM IN RENAL FAILURE

It has already been stated that some degree of renal failure is very frequently present in primary hyperparathyroidism. When the primary condition is left untreated the renal failure may progress until the raised serum phosphate level finally forces down the serum calcium and produces a biochemical picture indistinguishable from that of primary renal failure. The presence of the bone lesions of osteitis fibrosa common to both primary and secondary hyperparathyroidism can offer no assistance in the diagnosis.

This diagnostic dilemma remains unsolved but certain observations can nonetheless be made. The history may be decisive. If myeloma sarcoidosis the milk alkali syndrome malignant disease and vitamin D overdosage have been excluded the presence of a raised serum calcium must be taken to indicate a parathyroid tumour. There is no satisfactory evidence that secondary hyperparathyroidism may go on to hypercalcemia (85). The presence of extensive metastatic calcification in the arterial tree probably favours primary renal failure whereas the presence of renal calcification especially in the medulla (5) probably favours primary hyperparathyroidism. The urine calcium excretion cannot of course be high in renal failure but it may be high relative to the glomerular filtration rate and so equivalent to hyper

calciuria in a person with a normal kidney thus a urine calcium of over 100 mg per 24 hours in a patient with a high blood urea suggests primary rather than secondary hyperparathyroidism and it might be possible to devise a "calcium-creatinine clearance ratio" which would be of diagnostic help. It is clear that the phosphate-creatinine clearance ratio cannot be of great assistance since it is raised in renal failure but the effect of calcium infusions on phosphate excretion in renal failure might be worthy of study. Another approach to the problem would be biopsy of the kidney which does not appear to have been used much for this purpose (50). However it must be admitted that the key to this diagnostic dilemma still eludes us and this is unfortunate in view of the improvement in renal function which may follow the successful removal of a parathyroid tumour (9).

## REFERENCES

- 1 Albright F and Ellisworth R Calcium and phosphorus studies on case of idiopathic hypoparathyroidism J Clin Invest 7 183 1929
- 2 Albright F and Reifenstein E *The Parathyroid Glands and Metabolic Bone Disease* (Baltimore Williams & Wilkins Company 1948)
- 3 Albright F *et al* Effect of parathyroid hormone J Clin Invest 7 139 1929
- 4 Anderson W A D (ed) *Pathology* (3d ed St Louis C V Mosby Company 1957)
- 5 Arons W L Christensen W R and Sosman M C Nephrocalcinosis with chronic glomerulonephritis Ann Int Med 42 260 1955
- 6 Askanazy M and Rutishauser E Die Knochen der Basedow Kranken Virchows Arch path Anat 291 653 1933
- 7 Atlas D H Gaberman P and Eisenberg H L Syndrome of masked hyperparathyroidism Ann Int Med 44 1195 1956
- 8 Baird I M and Lees F Renal osteodystrophy in adults A M A Arch Int Med 98 16 1956
- 9 Baker B M and Howard J E Adenoma of parathyroid with renal insufficiency Bull Johns Hopkins Hosp 59 251 1936
- 10 Baker S L The General Pathology of Bone in Shanks S C and Kerley P eds *Textbook of X Ray Diagnosis by British Authors* (2d ed Philadelphia W B Saunders Company 1950) Vol 4 pp 55-96
- 11 Barnicot N A Local action of parathyroids J Anat 82 233 1948
- 12 Bauer W and Marble A Studies on mode of action of irradiated ergosterol J Clin Invest 11 21 1932
- 13 Bergstrand H Parathyreoideastudien Acta med scandnav 54 539 1920-1921
- 14 Bloom W Resorption of Bone in *Transactions of the Third Conference on Metabolic Interrelations* (New York Josiah Macy Jr Foundation 1951) pp 11-24
- 15 Bogdonoff M D *et al* Hyperparathyroidism Am J Med 21 583 1956
- 16 Brush B E Chase W E and Black M A Evaluation of newer methods in diagnosis of hyperparathyroidism A M A Arch Surg 71 342, 1955

- 17 Cargill W H and Witham A C Parathyroid hormone and tubular reabsorption of glucose and phosphate in man *Fed Proc* 8 21 1949
- 18 Carlsson A and Lindquist, B Comparison of intestinal and skeletal effects of vitamin D in relation to dosage *Acta physiol scandinav* 35 54 1955
- 19 Carnes W H Pappenheimer A M and Stoerk H C Volume of parathyroid glands in relation to dietary calcium and phosphorus *Proc Soc Exper Biol & Med* 51 314 1942
- 20 Chambers E L *et al* Tests for hyperparathyroidism *J Clin Endocrinol* 16 1507 1956
- 21 Chang H Localized resorption of bone adjacent to parathyroid grafts *Anat Rec* 106 266 1950
- 22 Cooke A M Osteoporosis *Lancet* 1 877 929 1955
- 23 Crawford J C *et al* The influence of vitamin D on parathyroid activity and the metabolism of calcium and citrate during calcium deprivation *Endocrinol* 61 59 1957
- 24 Crawford J C *et al* Parathyroids and phosphorus homeostasis *J Clin Invest* 29 1448 1950
- 25 Crawford R L and La Zerte G D Chronic renal disease with secondary hyperparathyroidism *AMA Arch Int Med* 96 818 1955
- 26 Crawford T *et al* Osteosclerosis associated with chronic renal failure *Lancet* 2 981 1954
- 27 Cretin A Contribution histochemique à l'étude de la construction et de la destruction osseuse *Presse méd* 59 1240 1951
- 28 Davies B M A and Gordon A H Effect of parathormone on phosphate excretion in the rat *J Endocrinol* 9 292 1953
- 29 Davies B M A and Gordon A H Hormonal nature of extracts of parathyroid gland stimulating phosphate excretion *Nature* 171 1122 1953
- 30 Davies D R Dent C E and Willcox A Hyperparathyroidism and steatorrhoea *Brit M J* 2 1133 1956
- 31 Dent, C E Physiology of parathyroid glands *Proc Roy Soc Med* 46 291 1953
- 32 Duncan J G Radiological manifestations of hyperparathyroidism *Proc Roy Soc Med* 49 283 1956
- 33 Ellsworth R Studies on physiology of parathyroid glands *J Clin Invest* 11 1011 1932
- 34 Ellsworth R and Howard J E Some responses of normal human kidneys and blood to intravenous parathormone *Bull Johns Hopkins Hosp* 55 296 1934
- 35 Erdheim J Über Epithelkörperbefunde bei Osteomalazie *Sitzungsb Akad Wissensch Wien math natur Kl* 116 311 1907
- 36 Follis R H Skeletal changes in hyperparathyroidism *Bull Johns Hopkins Hosp* 92 405 1953
- 37 Gaillard P J Parathyroid gland tissue and bone *in vitro* *Exper Cell Res Supp* 3 154 1955
- 38 Goldman R and Bassett S H Phosphorus excretion in renal failure *J Clin Invest* 33 1623 1954
- 39 Ham A W and Lewis M D Hypervitaminosis D rickets action of vitamin D *Brit J Exper Path* 15 228 1934
- 40 Ham A W *et al* Physiological hypertrophy of parathyroids its cause and its relation to rickets *Am J Path* 16 277 1940
- 41 Heller Steinberg M Ground substance bone salts and cellular activity in bone formation and destruction *Am J Anat* 89 347 1951

- 42 Herbert, F K, Miller H C and Richardson G O Chronic renal disease secondary parathyroid hyperplasia decalcification of bone and metastatic calcification J Path & Bact 53 161 1941
- 43 Huggins G M and Sheard C Vitamin D and parathyroids Am J Physiol 85 299 1928
- 44 Hopkins T R Connor T B and Howard J F Ultrafiltration studies on calcium and phosphorus in pathological human serum Bull Johns Hopkins Hosp 93 249 1953
- 45 Howard J E Present knowledge of Parathyroid Function in Wolstenholme G E W and O'Connor C M eds *Bone Structure and Metabolism* (Boston Little Brown & Company 1956 London Churchill 1956) pp 206-221
- 46 Howard J E Hopkins T R and Connor T B Use of intravenous calcium as measure of activity of parathyroid glands Tr A Am Physicians 65 351 1952
- 47 Howard J E Hopkins T R and Connor T B On certain physiologic responses to intravenous injection of calcium salts into normal, hyperparathyroid and hypoparathyroid persons J Clin Endocrinol 13 1 1953
- 48 Howard J E et al Hyperparathyroidism J Clin Endocrinol 13 997 1953
- 49 Ingalls T H Donaldson G A and Albright F Locus of action of parathyroids J Clin Invest 22 803 1943
- 50 Inversion P and Brun C Aspiration biopsy of kidney Am J Med 11 324 1951
- 51 Jacobs E and Verbanck M Renal action of parathyroids in man Acta med scandinav 145 143 1953
- 52 James P R and Richards P G Parathyroid crisis AMA Arch Surg 72 553 1956
- 53 Klein R and Gow R C Interaction of parathormone and vitamin D on renal excretion of phosphate J Clin Endocrinol 13 271 1953
- 54 Kyle L H Schaaf M and Erdman L A Metabolic effects of intravenous calcium J Lab & Clin Med 43 123 1954
- 55 Lambert, P P Van Kessel E and Leplat C Etude sur l'élimination des phosphates inorganiques chez l'homme Acta med scandinav 123 386 1947
- 56 Lang F G Ostitis fibrosa in ihren genetischen Beziehungen zur Osteomalazie und Rachitis Beitr path Anat 87 142 1931
- 57 Linnewehe F and Stave U Hyperphosphatämie als Symptom tubularer Insuffizienz Klin Wchenschr 34 1024 1956
- 58 Liu S H et al Osteomalacia Chinese M J 58 141 1940
- 59 McGeown M G and Bull G M Pathogenesis of urinary calculus formation Brit M Bull 13 53 1957
- 60 MacGregor M E and Whitehead T P Pseudohypoparathyroidism Arch Dis Childhood 29 398 1954
- 61 McLean F C Activated sterols in treatment of parathyroid insufficiency JAMA 117 609 1941
- 62 McLean F C and Bloom W Calcification and ossification Arch Path 32 315 1941
- 63 McLean F C and Urist, M R *Bone an Introduction to the Physiology of Skeletal Tissue* (Chicago University of Chicago Press 1955)
- 64 Mather H C Hyperparathyroidism with normal serum calcium Brit M J 2 424 1953
- 65 Meroney W and Herndon R F Management of acute renal insufficiency JAMA 155 877 1954

- 66 Miles L M and Feng C T Calcium and phosphorus metabolism in osteomalacia *J Exper Med* 41 137 1925
- 67 Milne M D Observations on the Parathyroid Hormone (M D Thesis Manchester 1951)
- 68 Milne M D Observations of the action of parathyroid hormone *Clin Sc* 10 471 1951
- 69 Milne M D Stanbury S W and Thomson A E Observations on Fanconi syndrome *Quart J Med* 21 61 1952
- 70 Morgan A D and MacLagan N F Renal disease in hyperparathyroidism *Am J Path* 30 1141 1954
- 71 Munson P L Studies on role of parathyroids in calcium and phosphorus metabolism *Ann New York Acad Sc* 60 776 1955
- 72 Neuman W F *et al* On the mechanism of action of parathormone [Letter] *J Am Chem Soc* 78 3863 1956
- 73 Nonidez J F and Goodale H D Histological studies on endocrines of chickens deprived of ultraviolet light *Am J Anat* 38 319 1926-1927
- 74 Nordin B E C Solubility of powdered bone *J Biol Chem* 227 551 1957
- 75 Nordin, B E C and Fraser T R C Effect of intravenous calcium on phosphate excretion *Clin Sc* 13 477 1954
- 76 Nordin B E C and Fraser T R C *The Indirect Assessment of Parathyroid Function in Wolstenholme G E W and O'Connor C M eds Bone Structure and Metabolism* (Boston Little Brown & Company 1956 London Churchill, 1956) pp 222-238
- 77 Ollayos R W and Winkler W Urinary excretion and serum concentration of inorganic phosphate in man *J Clin Invest* 22 147 1943
- 78 Pappenheimer A M and Minor J Hyperplasia of parathyroids in human rickets *J M Research* 42 391 1921
- 78a Pierce J M Guild W R and Merrill J P Citrate metabolism in uremia *J Appl Physiol* 11 231 1957
- 79 Pitts R F Excretion of urine in dog *Am J Physiol* 106 1 1933
- 80 Richards D G B Chronic renal disease with secondary hyperparathyroidism *Brit M J* 1 167 1951
- 81 Rogers H M Parathyroid adenoma and hypertrophy of parathyroid glands *J A M A* 130 22, 1946
- 82 St Goar W T Gastrointestinal symptoms as clue to diagnosis of primary hyperparathyroidism *Ann Int Med* 46 102 1957
- 83 Salvesen H A and Boe J Osteomalacia in sprue *Acta med scandinav* 146 290 1953
- 84 Schaaf M and Kyle L H Measurement of per cent renal phosphorus reabsorption in diagnosis of hyperparathyroidism *Am J M Sc* 228 262 1954
- 85 Secondary hyperparathyroidism *Am J Med* 21 117 1956
- 86 Seldinger S I Localization of parathyroid adenomata by arteriography *Acta radiol* 42 353 1954
- 87 Sinclair K Studies in case of renal rickets *Arch Dis Childhood* 31 140 1956
- 88 Sirota J H Renal tubular reabsorption of phosphate in hyperparathyroidism before and after removal of parathyroid adenoma *Fed Proc* 12 133 1953
- 89 Stanbury S W Azotaemic renal osteodystrophy *Brit M Bull* 13 57 1957
- 89a Stanbury S W Personal communication.
- 90 Steiner R E Fraser R and Aird I Operative parathyroid arteriography for location of parathyroid tumour *Brit M J* 2 400 1956

- 91 Stewart, G S and Bowen H F Urinary phosphate excretion factor of parathyroids: Hormone or artefact? *Endocrinology* 51 80 1952
- 92 Stewart, G S and Bowen H F Parathyroids: Control of serum calcium independent of renal mediation *Endocrinology* 48 568 1951
- 93 Talmage R V and Krantz F W Progressive changes in renal phosphate and calcium excretion in rats following parathyroidectomy or parathyroid administration, *Proc Soc Exper Biol & Med* 87 263 1954
- 94 Talmage R V Krantz F W and Buchanan G D Effect of parathyroid extract and phosphate salts in renal calcium and phosphate excretion after parathyroidectomy *Proc Soc Exper Biol & Med* 88 600 1955
- 95 Tweedy W R Chilcote M E and Patrass M C Distribution, retention and excretion of radiophosphorus *J Biol Chem* 168 597 1947
- 96 Wang C C and Robbins L L Cushing's disease *Radiology* 67 17 1956
- 97 Wyman S M and Robbins L L Roentgen recognition of parathyroid adenoma *Am J Roentgenol* 71 777 1954
- 98 Yendt E R Connor T B and Howard J E In vitro calcification of rachitic rat cartilage in normal and pathological human sera with some observations on pathogenesis of renal rickets *Bull Johns Hopkins Hosp* 96 1 1955



# Hereditary Defects in Clotting Mechanisms\*

OSCAR D RATNOFF

*Department of Medicine Western Reserve University School of Medicine  
and University Hospitals Cleveland Ohio*

*"En de coeur why does it have to be so complicated?"*  
—BIGGS AND MACFARLANE (39)

PERHAPS BECAUSE of some primordial human fear there has always been intense interest in the mechanisms controlling hemostasis and in abnormal bleeding states. There are many early descriptions of inborn hemorrhagic disorders and crude concepts of their hereditary nature were formulated as early as the second century A.D. Until recently most cases of excessive bleeding were grouped under the term "hemophilia," said to have been introduced by Hopff in 1828. The intensive investigation of the physiology of clotting in the last 20 years has led to the subdivision of this syndrome into a number of different disorders. This differentiation has considerable practical importance. Therapy, prognosis, and perhaps prevention of the hereditary transmission of these diseases depend largely upon accurate diagnosis. Unfortunately the physician is confronted with a voluminous literature and is confused by a complex and conflicting terminology which seems to serve as a secret code for the super specialist. The present review attempts to describe the state of knowledge concerning the hereditary hemorrhagic disorders from the point of view of the physician respon-

---

\* This chapter is inscribed to M. The original investigation included in this review was supported in part by a research grant (PHS H1661C4) from the National Heart Institute of the National Institutes of Health and in part by a grant from the Cleveland Area Heart Society.



sible for the care of patients rather than from that of the physiologist. I have borrowed freely from the many excellent reviews which have appeared within the last few years but the material selected reflects a partisan point of view

TABLE I—GLOSSARY OF CLOTTING TERMS

✓ *Fibrinogen* *Profibrin*

• *Thrombin* *Thrombase* *Fibrin Ferment* *Biothrombin*

*Prothrombin* *Prothrombase* *Thrombogen* *Prothrombin B* *Component A*

*Thromboplastin* *Thrombokinas* (some authors make a distinction between these two terms)

*Pro Accelerin-Accelerin* *Accelerin* *Factor VI* *Activated Factor V* *Serum Ac*  
*celerator Globulin (Ac Globulin)* *Serum Accelerator* *Prothrombinase* ↘

The inactive precursor is called *Proaccelerin* *Factor V* *Labile Factor* *Plasma Accelerator Globulin (Ac Globulin)* *Prothrombin Accelerator* *Plasmatic Co Factor of Thromboplastin*, *Prothrombin A* *Thrombobene* *Plasma Prothrombin Conversion Factor*

✓ *Serum Factors Needed for the Conversion of Prothrombin to Thrombin*

The terminology of these factors is currently in a state of great confusion. The activated form which is responsible for the conversion of prothrombin to thrombin in association with accelerin has been called *Convertin* *Serum Prothrombin Conversion Accelerator (SPCA)* *Activated Thromboplastin* and *Stable Factor* but various authors understand these terms somewhat differently. The inactive precursors are called *Proconvertin* *Co Thromboplastin* *Precursor of Serum Prothrombin Conversion Accelerator (Pro SPCA)* *Prothrombin Conversion Factor* *Prothrombin Accelerator* *Co-Factor V* *Serum Accelerator Factors VII* and *X* *Kappa Factor* *Autoprothrombin I*

↘ These factors are probably multiple. ✓ Two groups have been differentiated: those reacting with tissue thromboplastin (*Pro SPCA*, *Co Thromboplastin*) and those which do not appear to react with tissue thromboplastin (*Stuart Factor* *Prower Defect*)

*Antihemophilic Factor* *Antihemophilic Globulin* *Globulin Substance* *Plasma Thromboplastic Factor* *Antihemophilic Factor* *Platelet Co Factor I* *Thromboplastic Plasma Component* *Factor VIII* *Plasma Thromboplastic Factor A* *Prothrombokinas* *Thromboplastinogen*

*Christmas Factor* *Plasma Thromboplastin Component* *Factor IX*, *Platelet Co Factor II* *Antihemophilic Factor B* *Plasma Thromboplastic Factor B* *Auto prothrombin II*

*Plasma Thromboplastin Antecedent* *Plasma Thromboplastic Factor C* *Factor XI*

↘ *Hageman Factor* *Clot Promoting Factor* *Fifth Plasma Thromboplastin Precursor*

*Plasmin*, *Fibrinolysin* *Tryptase* *Lysin* *Serum Trypsin* *Plasma Proteolytic Enzyme*

*Plasminogen* *Proplasmin*, *Profibrinolysin* *Serum Tryptogen*

*Platelets* *Thrombocytes*

## PHYSIOLOGY OF BLOOD COAGULATION

A discussion of the hereditary hemorrhagic disorders requires as a frame of reference a description of the normal physiology of clotting. Since knowledge of the normal state is largely derived from studies of these very disorders some circular logic is inevitable. The following description is meant only as a tentative formulation of the mechanisms involved (Fig. 1).

Essentially, coagulation consists in the transformation of fibrinogen,





FIG. 1—Some concepts of the physiology of clotting. Proaccelerin is probably converted to accelerin during coagulation. The clot accelerating effect of glass may be mediated at several stages but a major role may be its activation of Hageman factor. The inhibitors of the various clotting stages have been omitted from the diagram.

a soluble protein of high molecular weight, into fibrin, an insoluble network of protein fibers which traps the cellular and fluid blood elements within its meshes. This transformation results from the action of thrombin, a substance elaborated when blood is shed. Thrombin behaves like a proteolytic enzyme (33, 151, 235) which alters fibrinogen by digesting the ends of its molecules. The altered molecules then join together to form the interlacing fibrin strands of which the clot is composed.

The action of thrombin upon fibrinogen can take place in the absence of calcium ions. However, addition of calcium ions in the concentration present in circulating blood greatly accelerates the coagulant effect of thrombin (216, 236) and increases the clot's mechanical


strength (80) Thus calcium ions play an important physiologic role in the final stages of clotting In addition a still unidentified substance in plasma may accelerate the reaction between fibrinogen and fibrin (211) Either this accelerator or some other substance must be present in order for calcium to exert its clot toughening effect (241) The final stages of the clotting process may be summarized as



Perhaps calcium and the plasma accelerator affect the first rather than the second of the reactions depicted

Since thrombin clots blood rapidly it cannot be present as such in the circulating blood in significant amounts. Instead it is present in the form of a precursor prothrombin. The synthesis of this substance apparently a glycoprotein (235) depends on the integrity of the liver (246) and requires the presence of vitamin K (190). This vitamin may function as a link in certain oxidation reduction systems (163, 297) but how this results in the synthesis of prothrombin is not known.


The transformation of prothrombin to thrombin when blood is shed is still not clearly understood although the outlines of the mechanisms are becoming clearer. It has been known for over 100 years that particles of animal tissue accelerate clotting. Schmidt postulated that these particles converted prothrombin to thrombin. The active agent of tissue now called thromboplastin requires calcium to effect this transformation. Teleologically speaking the mechanisms described are most useful. If the body is injured the shed blood comes in contact with naked tissue which in turn initiates or accelerates the clotting process. The formation of thrombin may therefore be represented as



✓ In a simpler age this reaction was called the first stage of the clotting process although the naivete of this view was recognized at the turn of the century. When blood is drawn with care to avoid the admixture of tissue juice and is then transferred to glass tubes coagulation still occurs although much more slowly than in the presence of tissue. Thus blood itself appears to have the potentiality for clotting. If thromboplastin is defined as any substance which initiates clotting then the blood must contain thromboplastin or its precursors. The classic view

held that platelets provided this thromboplastin when blood was shed the platelets were disrupted and liberated thromboplastin, which in turn initiated clotting. Since blood clots more rapidly in glass tubes than in tubes lined with paraffin, collodion or silicone the liberation of thromboplastin from platelets was thought to be accelerated by contact with a glass like surface. Actually, however platelets are only poorly thromboplastic (194 285) and their clot promoting function most probably lies in other areas.)


The relative simplicity of this early hypothesis was upset by evidence that the cells are not the only blood elements affected by glass surfaces. If blood is drawn into syringes coated with agents such as paraffin or silicone and centrifuged in the cold, plasma essentially free of all cellular elements can be prepared without addition of an anti-coagulant. When the plasma is incubated in paraffin or silicone lined tubes it clots only after a long delay or not at all. On the other hand, such plasma, incubated in glass tubes clots in about the same time as whole blood. In other words, platelet-deficient plasma contains one or more substances which, when activated by glass, initiate clotting. Cell free plasma itself, then, presumably contains potentially thromboplastic activity (43 60). The platelets may enhance the activation of this thromboplastin (38). It was at first thought that there was only one soluble plasma precursor of thromboplastin, but at least four substances have now been described which may be required for the optimal development of thromboplastic activity in shed blood (1) antihemophilic factor (2) Christmas factor (or plasma thromboplastin component) (3) plasma thromboplastin antecedent, and (4) Hageman factor. Hereditary disorders of blood coagulation attributable to a deficiency of each of these factors have been observed. The conversion of prothrombin to thrombin must therefore be represented as



Which component is the one primarily affected by glass surfaces is disputed but evidence has accumulated that glass acts primarily on Hageman factor (212).

To complicate matters further a number of other factors have been described which seem necessary for the optimal conversion of prothrombin to thrombin. Despite an overwhelming literature the nature and functions of these factors are still unclear. One such substance called among many names accelerin was recognized almost simultane-

ously by investigators using widely different technics (78 176 193 286) In plasma accelerin is present as a labile precursor proaccelerin which is transformed during clotting into its active form perhaps through the action of thrombin. Accelerin then accelerates the conversion of prothrombin to thrombin. It disappears rapidly during the clotting process and cannot be found in the serum of most species. This step may be outlined as



In 1904 Bordet and Gengou reported that diluted serum accelerated the clotting of plasma. Interest in this property of serum was renewed about 10 years ago (18 117). In essence normal plasma contains one or more relatively stable constituents needed to transform prothrombin to thrombin. Vitamin K is required for the synthesis of these substances and synthesis is impaired by hepatic damage or the administration of the coumarin antagonists of vitamin K. Unlike proaccelerin these substances are present in serum as well as in plasma but can be removed readily by such adsorbents as barium sulfate aluminum hydroxide and calcium phosphate.

At first it was thought that a single constituent was responsible for the accelerating property of serum. However evidence of the presence of more than one substance (75 247) has been confirmed very recently by studies of patients with congenital hemorrhagic disorders. As a result the terminology of the stable factors is now in a state of great confusion. One such factor originally called precursor of serum prothrombin conversion accelerator (pro SPCA), is necessary for optimal conversion of prothrombin to thrombin by tissue thromboplastin (18). Another, Stuart factor (113) may be necessary for the action of thromboplastin originating from tissue or from plasma. Still other factors may possibly be present. It is remarkable that the various serum factors as well as prothrombin and Christmas factor all have similar physical and chemical properties all require vitamin K for their synthesis and the synthesis of all is impaired by coumarin like drugs. Lasch and Roka (137) and Alkjaersig and Seegers (22) have raised the pertinent question: Are these substances not different stages in the evolution of a single series of proteins rather than truly separate factors? The reports that hepatic mitochondria can apparently convert proconvertin to prothrombin *in vitro* (22 137) are particularly exciting.

Should this be confirmed, many of the apparent inconsistencies among experiments in this field will be resolved

Inhibitors of each of the steps of clotting have either been assumed or described Tocantins and associates (269 271-273) have studied extensively the lipoid substances in plasma which inhibit the development of thromboplastic activity in shed blood. Moreover, inhibitors of thromboplastin (132 268) and of thrombin (79) have also been observed. It is possible that these inhibitors help prevent the spontaneous formation of intravascular clots )

Once coagulation has occurred, the fibrin network shrinks or retracts. Under ordinary conditions the cellular elements of the blood remain trapped in the retracted clot, but the serum is extruded. The physiologic importance of clot retraction is in doubt. Budtz Olsen (55) believes that retraction is merely an atavistic remnant from an epoch before coagulation evolved and is without significance in hemostasis. However, in some patients with abnormal bleeding the only demonstrable abnormality is defective clot retraction, suggesting that the phenomenon is related to hemostasis.

In addition to a mechanism producing coagulation, blood contains an enzymic system which can digest clots. This plasma proteolytic enzyme plasmin or fibrinolysin is present as an inactive precursor plasminogen or profibrinolysin. It can be activated *in vitro* by treatment with chloroform with streptokinase (a principle found in the filtrates of certain streptococci) and with tissue extracts. Moreover, plasma itself may contain activators of plasminogen. (The enzyme can digest fibrinogen fibrin proaccelerin antihemophilic factor possibly prothrombin and certain other proteins including complement. When clotted plasma is incubated under sterile conditions the clot dissolves after a variable period.) Rapid lysis is seen in plasma obtained from patients with a wide variety of diseases including chronic hepatic disease prostatic and pancreatic carcinoma, and shock. Rapid fibrinolysis has also been noted after exercise after injection of epinephrine and in the hours immediately postpartum. The role of plasmin in the bodily economy is not clear. Potent inhibitors are present in the plasma. There is experimental evidence that the clotting process may enhance the activation of plasmin and one wonders whether plasmin plays a part in the dissolution of small thrombi *in vivo*. Rarely plasmin may become activated to such a degree during life that fibrinogenopenia and hemorrhage may result. Astrup (25) has recently summarized current ideas on the physiology of plasmin.

A bleeding disorder may result from a congenital or acquired deficiency of any of the elements needed for clotting. It may result from the presence in blood of an anticoagulant inhibiting any of the steps in the clotting process. Or it may result from the destruction of the clotting elements or of the clot itself by plasmin or a similar enzyme.

## SOME COMMENTS ON LABORATORY PROCEDURES

### (Table 2)

Although the histories of patients with various hereditary disorders of coagulation differ in certain details, ultimately diagnosis rests upon laboratory examination. A review of certain tests in current use therefore seems pertinent. This problem is discussed in a number of excellent texts (39, 172a, 262, 270).

CLOTTING TIME IN GLASS TUBES—Innumerable methods have been devised to measure the lapse of time until shed blood clots. These tests all attempt to determine the intrinsic capacity of blood to clot in the absence of tissue thromboplastin. Many clinical laboratories still test the clotting time of capillary blood; this technique will uncover only the grossest abnormalities, since capillary blood is inevitably mixed with tissue juices. In wider use are various modifications of the Lee and White method, in which venous blood is transferred to a series of Pyrex tubes and each tube is tilted until its contents are grossly clotted. The clotting time thus obtained is arbitrary; serum expressed from the clot the instant that coagulation seems complete will usually re-clot. For reproducibility, the test must be done in a standardized way using uniform, clean and unetched Pyrex tubes. Some lots of Pyrex tubes come from the manufacturer with a thin water repellent film which must be removed with acetone. The clotting tubes must also be kept free from any silicone which may be used in the laboratory. The blood must be withdrawn with great care to prevent admixture of tissue; for this purpose a large bore needle is of value. Other precautions include uniform filling of the tubes, care not to juggle the tubes unduly, and measurement of the clotting time at a constant temperature. Occasionally the clotting time will be abnormal when measured at 25°C but normal at 37°C; the lower temperature is therefore preferable.

There are innumerable mechanical methods, many of great ingenuity, for measuring clotting time. At the moment the thromboelastograph devised by Hartert (102) is popular. The blood to be tested is placed in

TABLE 2—DIFFERENTIATION OF SOME HEMORRHAGIC DISORDERS USUAL LABORATORY FINDINGS

DISORDERS	CLOTTING TIME	BLEEDING TIME	TOLENIQUET TEST	PROTHROMBIN TIME	SERUM PROTHROMBIN ACTIVITY	SPECIAL TESTS
Classic hemophilia	Long	Normal	Normal	Normal	High	Corrected by BaSO adsorbed plasma ✓
Vascular hemophilia	Long	Long	Normal	Normal	High	Corrected by BaSO adsorbed plasma ✓
Christmas disease	Long	Normal	Normal	Normal	High	Corrected by serum ✓
Plasma thromboplastin antecedent (PTA) deficiency	Long	Normal	Normal	Normal	High	Corrected by serum or BaSO adsorbed plasma
Hageman trait	Long	Normal	Normal	Normal	High	Corrected by serum or BaSO <sub>4</sub> adsorbed plasma
Parahemophilia	Normal	Normal	Normal	Long	High	Corrected by fresh BaSO adsorbed plasma
Pro SPCA deficiency	Variable	Variable	Normal	Long	Normal	Corrected by serum or aged plasma
Stuart factor deficiency	Variable	Variable	Normal	Long	High	Corrected by serum or aged plasma
Hypoprothrombinemia	Normal	Normal	Normal	Long	Normal	Corrected by aged plasma
Congenital thrombocytopenia	Normal	Long	Positive	Normal	High	Thrombocytopenia impaired clot retraction

Distinguished by special tests



a specially designed cup in which a plunger is suspended the cup is then rotated through a small arc. When the clot forms it adheres to the plunger and to the wall of the cup imparting the cup's motion to the plunger. The movement of the plunger is then recorded optically. The utility of this clever instrument is not yet established.

✓ At best the clotting time of blood in glass tubes is a crude measure. Although prolonged clotting times are found in many patients with coagulative disorders in others the clotting times may be normal despite the presence of abnormalities which are readily detectable by other means.

✓ **CLOTTING TIME IN SILICONE-COATED TUBES**—A major advance in the diagnosis of hemorrhagic disease was the introduction of silicone coated tubes for clotting studies by Jacques and co-workers (118). Blood drawn in silicone coated syringes and transferred to silicone coated tubes takes a much longer time to clot than in uncoated tubes. The same precautions needed to insure uniform results with glass tubes must be used with silicone coated tubes. The clotting time is preferably measured at 25 C. At 37 C the end point is often difficult to read since clot retraction may begin before clotting is complete. One serious technical problem is the adequacy of the silicone coat. If silicone is applied thickly the clotting time of normal blood may be so increased as to make the test impractical. To obviate this difficulty the tubes may be given only a partial coating (212). This may be done with Desicote\* but the coating thus obtained varies from lot to lot. A satisfactory coating can be secured by rinsing tubes with 0.1 per cent Dri Film† in petroleum ether and washing away any excess with distilled water. The clotting time by the siliconed tube method is one of the most sensitive indicators of clotting defects and is prolonged in virtually all cases with a detectable coagulative abnormality. It might be argued that this technic should replace the glass tube method for detecting coagulative abnormalities.

**RECALCIFIED CLOTTING TIME**—For many purposes determination of the clotting time of recalcified citrated or oxalated plasma is useful. Introduced by Howell to measure prothrombin results of this test are more likely to be abnormal if there are deficiencies of factors other than prothrombin. The technic employed must be uniform. Its sensitivity is increased if the clotting time is measured at 25 C rather than 37 C. This clotting time is often normal in patients with coagula

\* Beckman Instruments Inc. Mountainside N. J.

† General Electric Company Silicone Products Department Waterford N. Y.

tive disorders of considerable severity. When it is prolonged, the corrective effect of various normal or abnormal plasmas or serum may be tested. Conversely, if the clotting time is normal, the effect of small amounts of the patient's plasma upon the abnormally long recalcified clotting time of plasmas with known defects may be tested. This method requires that the laboratory have available a collection of abnormal plasmas with significantly prolonged recalcified clotting times. Alternately, certain of the abnormal plasmas can be simulated by one or another laboratory manipulation; in this case, one must be constantly on guard lest unsuspected artefacts confuse the result. The storage of plasmas with known defects is not without hazard. Even at  $-70^{\circ}\text{C}$ , antihemophilic factor and proaccelerin deteriorate particularly in oxalated plasma. The recalcified clotting time of oxalated plasma gradually lengthens during storage in the frozen state. On the other hand, for reasons that are not clear, the recalcified clotting time of stored citrated plasma is often shorter than that of fresh citrated plasma. Nonetheless, the cross matching of various plasmas in the recalcified clotting time test is one of the most useful diagnostic procedures.

**THROMBIN TIME**—The final stages of clotting, the conversion of fibrinogen to fibrin, may be tested by measuring the thrombin time, i.e. the clotting time of a mixture of oxalated or citrated plasma and thrombin. Any qualitative or quantitative change of fibrinogen or of the factors influencing its coagulation by thrombin may be reflected in a change in the thrombin time. No arbitrary standard is available, and a direct comparison with normal plasma must be made each time the test is performed. The thrombin time of oxalated plasma lengthens after storage at  $-25^{\circ}\text{C}$ , and that of citrated plasma shortens. The thrombin times of freshly drawn plasmas must therefore be compared, or less satisfactorily, of plasmas stored under reasonably similar conditions.

**PROTHROMBIN TIME**—The middle stages of the clotting process are most readily studied by testing the one stage prothrombin time by Quick's (191) method. Tissue thromboplastin is added to oxalated or citrated plasma, which is then recalcified. The clotting time or prothrombin time of this mixture is prolonged if there is a deficiency of any of the factors required for the formation of thrombin by thromboplastin, prothrombin, proaccelerin, pro-SPCA, or Stuart factor. The prothrombin time is also prolonged in hypofibrinogenemia; in afibrinogenemia, no clot forms at all.

The potency of tissue thromboplastin, it has been recommended,

should be such as to give a normal one stage prothrombin time of approximately 12 seconds. When this is the case decreasing the concentration of prothrombin to 50 per cent of the average normal lengthens the prothrombin time by only 3 seconds. Relatively greater changes will be observed with somewhat weaker suspensions of thromboplastin making it easier to recognize minor abnormalities. Most laboratories compare the plasma under study with only one normal plasma but this does not take into account the considerable variation in prothrombin times among supposedly normal individuals. Finally expression of the results of the prothrombin time in terms of prothrombin itself is inaccurate since the test measures a number of variables and some less committal term such as apparent prothrombic activity might be more accurate.

✓ When the one stage prothrombin time is abnormal the plasma can be analyzed to determine which factors are responsible for the abnormality. The principle underlying these analyses is to mix the plasma to be tested with reagents containing all the clotting factors except the one to be measured.

SERUM PROTHROMBIC ACTIVITY (PROTHROMBIN CONSUMPTION) (201-261) ✓ When venous blood is placed in glass tubes without adding anti-coagulant its prothrombin is gradually converted to thrombin. The rate at which this occurs depends on the rate at which thromboplastic activity develops in the shed blood and on the concentration of those factors influencing the action of the evolved thromboplastin. Clotting occurs when the concentration of thrombin reaches a critical level. At this time not all of the prothrombin will have been converted to thrombin. Thus the prothrombic activity remaining in the blood at some arbitrary time after it is drawn may be an over all measure of the rate at which thromboplastic activity develops and the rate of the consequent conversion of prothrombin to thrombin. For example in hemophilic or thrombocytopenic blood the evolution of thromboplastic activity is thought to be slower than in normal blood. Reflecting this the serum prothrombic activity of such blood is higher than normal (17-201-206). This is often stated conversely namely that "prothrombin consumption is impaired".

✓ Properly performed measurement of the serum prothrombic activity is often helpful in the diagnosis of congenital disorders of coagulation. Meticulous technic is required. The blood must be placed in scrupulously clean unetched Pyrex tubes free of silicone. The tubes must not be agitated during incubation since this will speed the conversion of prothrombin to thrombin. After an arbitrary period,

the clotting process must be stopped by adding an anticoagulant, and time then allowed for the thrombin which has evolved to be inactivated. Finally the concentration of prothrombin remaining in the serum must be determined by a method which measures prothrombin specifically and is uninfluenced by other clotting factors. The test should be performed in duplicate or triplicate to insure accurate results.

The test for serum prothrombic activity is not sensitive and normal values may be obtained in patients with partial deficiencies of clotting factors thought to influence the determination.

**THROMBOPLASTIN GENERATION TEST**—In 1952 Biggs and Douglas (38) introduced a test designed to measure the earliest stages of clotting, the evolution of thromboplastic activity. Serum, citrated plasma, and platelets are prepared from the blood of the patient to be tested and from a normal individual. The plasma is adsorbed with aluminum hydroxide to remove prothrombin, pro-SPCA, Stuart factor and Christmas factor. A mixture of platelets, diluted serum, diluted adsorbed plasma and calcium is prepared. This "incubation mixture" containing all the recognized clotting factors except prothrombin is incubated at 37°C. At intervals samples are removed and added to normal platelet deficient plasma ("substrate"). This second mixture is recalcified and its clotting time determined. Biggs and Douglas postulated that "thromboplastic activity" develops in the incubation mixture and that it is this activity which is measured in the second step. Thus Stage 1: Serum (containing pro-SPCA, Stuart factor, Christmas factor and Hageman factor) + adsorbed plasma (containing proaccelerin, antihemophilic factor and Hageman factor) + platelets + calcium → "thromboplastin".

Stage 2: "Thromboplastin" + platelet deficient plasma (containing prothrombin, fibrinogen and other clotting factors) + calcium → evolution of thrombin and formation of a clot.

By testing successive samples of the incubation mixture the rate of evolution of thromboplastic activity and the intensity of the activity which develops are measured.

In practice the thromboplastin generation test has been most useful. For example, in hemophilia one can demonstrate impairment of "thromboplastin generation" which can be corrected by adding normal adsorbed plasma to an incubation mixture containing hemophilic serum and platelets. However, the theoretic basis of the thromboplastin generation test has been questioned. The principal problem is the difficulty of preparing the ingredients of the incubation mixture free of

prothrombin There is evidence that, in addition to thromboplastin activator and thrombin are generated in the incubation mixture These theoretic considerations do not challenge the great utility of the thromboplastin generation test both as a diagnostic method and as an investigative tool

### CLASSIC HEMOPHILIA

✓Classic hemophilia is a hereditary hemorrhagic disorder occurring primarily in males characterized by a tendency to bleed into soft tissues and joints upon little or no provocation It is distinguished from other hereditary bleeding diseases with similar symptoms primarily on the basis of laboratory tests These tests demonstrate that the plasma of hemophiliacs behaves as if it were deficient in a specific component, antihemophilic factor Until 1952 it was not appreciated that other hemorrhagic diseases particularly Christmas disease may mimic hemophilia For this reason it must be understood in the discussion to follow that in reports which appeared before 1953 hemophilia was lumped together with these other diseases One must be circumspect in attributing to hemophilia itself any particular quality described up to that time

INCIDENCE —The frequency with which hemophilia occurs is by no means clear Estimates vary from an incidence in Great Britain of 1 in 50 000 to 100 000 inhabitants (39) to 1 in 10 000 births in Australia (227) and 1 in 10 000 inhabitants in Holland (175a) We are personally familiar with at least 39 hemophiliacs living in Cuyahoga County the area comprising metropolitan Cleveland This is an incidence of approximately 1 in 45 000 individuals although presumably our experience does not include all the hemophiliacs in this vicinity Differences in different series may represent true geographic differences in incidence but they are certainly greatly influenced by the completeness with which an area is surveyed The difficulties in determining incidence are illustrated by conflicting statements concerning hemophilia in Negroes Albert Schweitzer (233) and others have commented upon its great rarity yet in a large series of cases Lewis and associates (150) observed no difference in the frequency of hemophilia in white and Negro families

### HEREDITARY NATURE OF HEMOPHILIA (Fig. 2)

In the first clear description of hemophilia Otto in 1803 recognized that the disorder was confined to males who inherited the defect from

asymptomatic females A long debate raged during the latter part of the nineteenth and early twentieth centuries concerning the heredity of hemophilia. In part, the difficulty arose from the confusion of hemophilia with other bleeding syndromes. The sex of an individual depends on the inheritance of a pair of sex chromosomes one from




FIG 2 — The pattern of inheritance in hemophilia. The so-called sex chromosomes are represented schematically as Xs and Ys in accordance with convention. The pattern of inheritance in Christmas disease is identical

each parent. The female inherits an X chromosome from each parent, so that the pair consists of two X chromosomes. The male inherits an X chromosome from his mother and a much smaller Y chromosome from his father. An abnormal recessive gene located on that part of the X chromosome which has no counterpart on the Y chromosome will be unopposed by a normal gene and will find expression in the developing individual. In the female the same abnormal recessive gene will ordinarily be opposed by a normal gene on the corresponding portion of the second X chromosome and its effect will therefore be neutralized to a greater or lesser degree.

Classic hemophilia results from the inheritance of an abnormal recessive gene located in the portion of the X chromosome unrepresented

prothrombin There is evidence that in addition to thromboplastin activator and thrombin are generated in the incubation mixture These theoretic considerations do not challenge the great utility of the thromboplastin generation test both as a diagnostic method and as an investigative tool

### CLASSIC HEMOPHILIA

Classic hemophilia is a hereditary hemorrhagic disorder occurring primarily in males characterized by a tendency to bleed into soft tissues and joints upon little or no provocation It is distinguished from other hereditary bleeding diseases with similar symptoms primarily on the basis of laboratory tests These tests demonstrate that the plasma of hemophiliacs behaves as if it were deficient in a specific component, antihemophilic factor Until 1952 it was not appreciated that other hemorrhagic diseases particularly Christmas disease may mimic hemophilia For this reason it must be understood in the discussion to follow that in reports which appeared before 1953 hemophilia was lumped together with these other diseases One must be circumspect in attributing to hemophilia itself any particular quality described up to that time

**INCIDENCE**—The frequency with which hemophilia occurs is by no means clear Estimates vary from an incidence in Great Britain of 1 in 50 000 to 100 000 inhabitants (39) to 1 in 10 000 births in Australia (227) and 1 in 10 000 inhabitants in Holland (175a) We are personally familiar with at least 39 hemophiliacs living in Cuyahoga County, the area comprising metropolitan Cleveland This is an incidence of approximately 1 in 45 000 individuals although presumably our experience does not include all the hemophiliacs in this vicinity Differences in different series may represent true geographic differences in incidence but they are certainly greatly influenced by the completeness with which an area is surveyed The difficulties in determining incidence are illustrated by conflicting statements concerning hemophilia in Negroes Albert Schweitzer (233) and others have commented upon its great rarity yet in a large series of cases Lewis and associates (150) observed no difference in the frequency of hemophilia in white and Negro families

### HEREDITARY NATURE OF HEMOPHILIA (Fig. 2)

In the first clear description of hemophilia Otto in 1803 recognized, that the disorder was confined to males who inherited the defect from

eration and Vogel (283) suggests a rate of 2.7 per 100,000 births. However, these figures should not be taken literally in view of the obvious difficulties in obtaining accurate human data.

Lest the hereditary pattern seem cut and dried, the disturbing report of Quick and Conway (200) on a pair of identical twins similar in many measurable characteristics must be mentioned: one had hemophilia, the other was normal. It is hard to imagine an explanation. From the data, it is possible that the "hemophilic" twin actually had Christmas disease, but this begs the fundamental question since the genetic problem is the same in both diseases. In another pair of supposedly identical twins, both boys had hemophilia (167).

Diseases closely resembling human hemophilia have been described in dogs and swine. In dogs, the pattern of inheritance appears to be the same as in man (81, 98), while in swine the disease occurs in both sexes and is transmitted by both sexes (169). Cross matching experiments have suggested that a similar defect is present in man, dog, and swine (51).

✓The severity of hemophilia is at least partly determined genetically. In some families the cases seem uniformly mild, in others severe (39, 165, 202, 229). Exceptions to this generalization may occur, but the individual with the supposedly severe hemophilia in a family of mild hemophiliacs may have a circulating anticoagulant (see p. 140) or have been subjected to unusual stress such as a surgical procedure. The severity of the defect can often be correlated with the concentration of antihemophilic factor in the plasma (52, 96, 165, 202). Graham Brinkhous and associates (52, 96) have suggested that the different degrees of hemophilia may result from the inheritance of one of a series of allelic genes, each at the same locus as the normal gene, each manifested clinically by hemophilia of a given severity and each associated with a corresponding plasma concentration of antihemophilic factor.

✓Hemophilia has been referred to as a disease of males, and it has been implied that female carriers are asymptomatic. From the point of view of eugenics, it is of great importance to identify these female carriers. Genetically, three groups of individuals may be confidently designated as carriers: (1) all daughters of a hemophiliac; (2) the mother of 2 or more hemophiliacs; and (3) the mother of 1 hemophiliac when she has other hemophilic relatives. However, it is impossible to predict genetically which other female relatives of a hemophiliac are carriers.

Many attempts have been made to identify the female carriers on



in the Y chromosome. A male with hemophilia will have the abnormal gene in the X chromosome inherited from his mother but a normal Y chromosome inherited from his father. The sons of a male hemophiliac will inherit his normal Y chromosomes if their mother is normal their X chromosomes will also be normal and they will neither have hemophilia nor transmit the trait to their offspring. But all of a hemophiliac's daughters will inherit his abnormal X chromosome as well as an X chromosome from their mother. If their mother is normal the hemophiliac's daughters will be heterozygous for the gene of hemophilia. They will all carry the trait but will not have the overt disease. Such female carriers married to normal males will transmit the hemophilic X chromosome to half their sons who will be hemophiliacs and to half their daughters who will be carriers. Only if a hemophilic male marries a female carrier will a female offspring inherit the full blown disorder for she may inherit an abnormal X chromosome from each parent.

This hereditary pattern has been demonstrated repeatedly by the study of large families of hemophiliacs one of the most interesting of which the descendants of Queen Victoria was again reviewed by Skold (245).

✓ In the past patients with severe hemophilia often died before reaching maturity or without offspring. One might suppose that the disorder would become progressively rarer but in fact cases continue to appear with disheartening frequency. Only about 50 to 75 per cent of hemophiliacs give a family history of the disease (42). The remaining cases appear to arise de novo. The assumption that in some of these the family history is inaccurate is a tempting one. Few persons know the medical histories of their families beyond their grandparents' generation. Particularly in mild cases even the immediate family tree may be inaccurate. However an absence of a family history is as common in severe hemophilia as in mild hemophilia. Another possibility considering the small size of human families is that the genetic trait passes from female carrier to female carrier through several generations before a male with the disease appears (83, 192). In several families we have studied the sex distribution among the patient's relatives was such that there was little likelihood of the appearance of another case for several generations. Still another possibility is that hemophilia might arise from spontaneous mutation of a gene. Various calculations of the rate at which such mutations might occur have been made. Haldane (100) estimated that spontaneous mutations inducing hemophilia occur at a rate of 3 per 100,000 births per gen-

niers yet mother and daughter differed grossly in symptoms and their plasma antihemophilic activity. Possibly the variable expression of the carrier state is the effect of genes which modify the activity of the gene determining the synthesis of antihemophilic factor.

### NATURE OF DEFECT

The essential biochemical lesion in classic hemophilia is still disputed. Addis (3) was probably the first to attribute hemophilia to a defect within the plasma itself. He believed that thrombin evolved more slowly than normally and thought that this resulted from a qualitative change in prothrombin. Then in 1931 Govaert and Gratia (94) observed that normal plasma filtered through a Berkefeld filter accelerated the clotting of hemophilic plasma. This observation was confirmed by Patek and Stetson (179). Patek and Taylor (180) then showed that a crude globulin fraction of normal plasma corrected the defect in hemophilic blood both *in vitro* and *in vivo*; a similar fraction prepared from hemophilic plasma was virtually inert. They postulated that the defect in hemophilia was a deficiency of a substance found in normal globulin. Somewhat similar views were expressed independently by Bendien and van Creveld (29). This concept was only slowly accepted. The studies of Conley and co-workers (60) did much to bolster it. Normal platelet deficient plasma prepared in silicone coated tubes without the addition of anticoagulant clotted readily in glass tubes but hemophilic plasma was incoagulable under these conditions. Presumably the hemophilic plasma was qualitatively different from normal plasma.

Experiments with a wide variety of techniques have now demonstrated that hemophilic blood behaves as if deficient in a specific clotting factor. The antihemophilic factor can be found in Cohn's Fraction I of plasma in close association with fibrinogen (265) in Fractions II+III IV 1 (149) and III 2 (265). The antihemophilic activity of plasma decreases during storage at refrigerator temperatures but the rate at which this occurs varies depending on the conditions used (39, 184, 255). Antihemophilic activity disappears during clotting and is absent in serum (71, 97, 179). Antihemophilic factor is not appreciably adsorbed from oxalated or citrated plasma by such substances as calcium phosphate, barium sulfate or aluminum hydroxide and can thus be distinguished from Christmas factor, prothrombin, pro-SPCA and Stuart factor. It is readily destroyed by mild heating for example at

the basis of history or laboratory study (Minor symptoms of bleeding in carrier females have been reported.) Birch (42) noted that some proved or potential carriers had mild or ill defined hemorrhagic symptoms but she minimized their importance. Merskey and Macfarlane (167) found that known carriers claimed to bleed excessively after dental extraction more often than did normal women but other hemorrhagic symptoms occurred no more frequently than in their control group. It is difficult to assess the significance of these histories since relatives of bleeders are often prone to exaggerate bleeding episodes. In our own experience there are a few families in which some of the females describe minor hemorrhagic phenomena such as epistaxes, ecchymoses and menorrhagia but in most families the females are asymptomatic (161).

Many investigators have attempted to identify the carrier state by laboratory technic (161). Characteristic electrophoretic plasma protein patterns have been described in some hemophilic carriers (32) but this finding has not been confirmed (291). In most studies the methods used did not measure antihemophilic factor specifically so that an abnormality in the carrier's blood may have resulted from irrelevant changes. On the other hand when the concentration of antihemophilic factor itself is measured the great variation among normal plasmas must be taken into account (262). Nonetheless in several studies certain carriers have been found to have partial but significant deficiencies in antihemophilic factor (70a, 96, 130, 131, 161). In 3 families in which some carriers could be identified the hemophilia was mild (96, 130, 161) but this need not always be the case (70a). Curiously in a family we have studied several known carriers have had hemorrhagic symptoms but have normal concentrations of antihemophilic factor. Another carrier the daughter of a hemophiliac is asymptomatic but has an abnormally low concentration of antihemophilic factor (161). Her cousin who has an even chance of being a carrier genetically speaking also has a partial deficiency of antihemophilic factor (212) perhaps in her case the carrier state has been identified. In this regard the report of McGovern and Steinberg (158) is of interest. They studied a young girl whose maternal grandfather had mild hemophilia. She bruised readily and bled excessively after dental extractions and tonsillectomy. The concentration of antihemophilic factor in her plasma was about 5 per cent of normal. In contrast, her mother was asymptomatic and had a normal concentration of antihemophilic factor in her plasma. Thus the patient and her mother were both presumably car-

surface of the platelets a phenomenon seen with such other substances as proaccelerin and serotonin

It has been implied that hemophilic blood is deficient in antihemophilic factor Tocantins and associates (269 271-273) and Johnson (123) hold that hemophilia results from an excess of an inhibitor in plasma directed against antihemophilic factor Tocantins (271) envisions that plasma contains a complex of antihemophilic factor and a lipid inhibitor During normal clotting the lipid inhibitor dissociates from the antihemophilic factor which then reacts with a platelet factor to form plasma thromboplastin In hemophilia an excessive amount of the lipid inhibitor is conjugated with the antihemophilic factor when blood is shed the inhibitor prevents the normal formation of thromboplastin His concept evolved when he found (269) that hemophilic plasma was five to eight times as inhibitory as normal plasma against homologous brain thromboplastin suggesting that an excess of antithromboplastin was the primary cause of the delayed clotting More over the difference in the clotting time between normal and hemophilic plasma was minimized or abolished when each was diluted with saline (273) In this experiment the antihemophilic factor in hemophilic plasma might have been dissociated from its inhibitor by dilution Moreover a fraction was separated from hemophilic plasma which shortened the clotting time of hemophilic plasma (273)

There is no doubt that in certain of Tocantins patients an inhibitor is present in the blood for transfusions of such blood into a normal individual prolongs the recipients clotting time However, these hemophiliacs may have the type of acquired circulating anticoagulant which has been described repeatedly in this disease (see p 140) At present no firm conclusion can be drawn concerning this stimulating concept However Patek and Stetson (179) observed that the transfusion of 40 ml of normal plasma shortened a hemophiliac's clotting time and Alexander and Landwehr (16) noted an effect after the administration of as little as 1 ml Crude antihemophilic factor representing as little as 1 per cent of the antihemophilic activity of a normal individual significantly shortened the clotting time of hemophilic plasma Conversely the transfusion of hemophilic blood into normal individuals did not lengthen the recipients clotting time or induce hemorrhagic phenomena (59 263) in contrast to Tocantins findings Finally the prolonged plasma clotting time of patients with Hageman trait was shortened by dilution with saline (213) suggesting that the effect of dilution on hemophilic plasma may not be specific All these data

50 C for 30 minutes but it will partly resist 56 C for 25 minutes which will precipitate fibrinogen (148) permitting the separation of these two proteins. It can be separated from proaccelerin only with difficulty although the bulk of antihemophilic activity is precipitated by one third saturation with ammonium sulfate and the bulk of proaccelerin activity between 33 and 50 per cent saturation (176). Antihemophilic factor can be differentiated from Hageman factor in the same manner but we have been able to prepare antihemophilic factor devoid of Hageman factor only by using the plasma of a patient with Hageman trait as the starting material (212). Methods of preparing concentrated antihemophilic factor from bovine (34, 257), sheep (35) or porcine (35) plasma have been described recently. Their antigenicity for man has hampered the use of these materials in therapy. The site of synthesis of antihemophilic factor remains an enigma (188).

✓ Considerable progress has been made in elucidating the mode of action of antihemophilic factor. In hemophilia the conversion of fibrinogen to fibrin by thrombin measured by the thrombin time and the middle stages of clotting measured by the one stage prothrombin time are normal. However the evolution of thrombin during clotting is extremely slow (3, 48) so that hemophilic serum is rich in prothrombin even in patients in whom the clotting time is normal (165). In severe cases no measurable amount of prothrombin is "consumed" within an hour after blood is drawn (48, 194). This suggests that the defect in hemophilia is in the early stages of clotting and that antihemophilic factor is concerned with the formation of thromboplastin within the plasma itself. Similarly poor "thromboplastin generation" can be demonstrated in the thromboplastin generation test (38).

It has been suggested that antihemophilic factor and platelets react early in clotting to produce thromboplastic activity in shed blood (49, 194, 206). The experiments with platelet deficient plasma referred to earlier are difficult to reconcile with this view. More recent studies have indicated that antihemophilic factor may react with Christmas factor early during the course of clotting and that the product of this reaction in turn may react with platelets. (30)

The early view that the essential defect in hemophilia is in the platelets is no longer tenable. However Mann (159) has shown that normal platelets have weak antihemophilic activity whereas platelets obtained from the blood of hemophiliacs do not. This has been confirmed in our laboratory using the thromboplastin generation test (238). Presumably, the antihemophilic factor is adsorbed onto the

injury but petechiae are unusual (195) As the child begins to crawl and walk, the bleeding episodes become more frequent. Epistaxes, gastrointestinal hemorrhage and hemarthroses may occur. Trivial injuries may be followed by prolonged bleeding. A common site of bleeding in infancy is the frenum of the upper lip which may be cut accidentally during a fall. Any form of surgery may be disastrous.

Bleeding during the eruption or loss of deciduous teeth is usually no greater than in normal children but is often severe with the eruption of the permanent teeth (66). Bleeding at the gingival margins is frequent, and may be responsible for the poor dental hygiene common in hemophiliacs. As a result, dental extractions are often needed, and these may be attended by protracted and even lethal hemorrhage.

Hemarthroses become evident as soon as the child begins to walk, and in most patients represent the most limiting complication of the disorder. They were present in 11 of 20 patients studied by Quick (195) and in 90 per cent of Davidson's series (66). The typical patient with severe hemophilia limps to the doctor on crutches. The joints most frequently involved are the knees, ankles and elbows (267) although bleeding into any joint may occur. Initially the involved joint is stiff and painful, and rapidly becomes swollen and exquisitely tender (66). The muscles crossing the joint may be in spasm. Surprisingly discoloration around the joint is uncommon (42). The blood is gradually resorbed after bleeding stops and the patient slowly regains use of the joint. However, once hemarthrosis has occurred the joint appears to be susceptible to further bleeding as the process repeats itself. Permanent and crippling deformities ensue. The nature of the pathologic process has been reviewed by Key (127) and by De Palma and Cotler (67). Bleeding is apparently followed by vascular hyperplasia of the synovia and thickening of capsular and pericapsular tissues resulting in a loss of elasticity of the tissues around the joint, scarring and contracture. The cartilages within the joint become thinned and their superficial layers eroded. Granulation tissue then invades the joint from the marrow spaces. The cartilage is also invaded by a panus of hyperplastic vascular synovial and subsynovial tissue. Cysts form as the result of enlargement and coalescence of Weichselbaum's lacunae (67). Destruction of subchondral bone and cartilage by vascular connective tissue and, in cancellous bone, breakdown of atrophic trabeculae. Severe atrophy of subchondral bone may lead to fracture, compression and flattening of articular surfaces. In some cases, excrescences of newly formed cartilage and immature

✓ make it difficult to accept the view that hemophilia ordinarily results from excess of an inhibitor in plasma

The possibility that the severe bleeding of hemophiliacs may be due in part to a defect in the tissue thromboplastic activity has been suggested. However Brown (53) found that an extract of a hemophiliac's brain was as effective as normal brain thromboplastin in clotting hemophilic blood.

### CLINICAL PICTURE

✓ The life history of the typical, severe hemophiliac is marked by recurrent bouts of bleeding into soft tissues, muscles, joints, the renal pelvis, and the gastrointestinal tract. Many of the hemorrhagic episodes appear to arise spontaneously, while others seem to be the abnormal response to the common injuries of life. An excellent review of the symptomatology of hemophilia, written before this disorder was distinguished from Christmas disease, is that of Davidson and co-workers (66).

Except for the evidences of past hemarthroses, no physical characteristics mark the hemophiliac between episodes of bleeding (42). Although the hemophiliac tends to be thin (42), no particular habitus has been ascribed to this disease. However, there seems to have been no systematic anthropologic study of hemophiliacs. Physical examination is usually uninformative. The spleen has been palpable in 5 of our patients (212), an observation contrary to the experience of others (294) and one for which we have no explanation.

Hemophilia may manifest itself at birth, the infant bleeding to death from the trauma of birth (167). More often the first evidence of the disease may be severe bleeding after circumcision (195), although some may be circumcised without incident. Bleeding from the umbilicus, common in certain other hemorrhagic disorders, is unusual. This is the more remarkable since Hartmann and Diamond (103) showed that the defect in hemophilic blood is demonstrable in umbilical vein blood obtained at birth, an observation which has been confirmed in our laboratory (44).

✓ The parents gradually become aware of the hemophilic infant's bleeding tendency. Unexplained hematomas may appear anywhere on the infant's body and may reach enormous proportions. A hematoma larger than an orange is not unusual. These gradually resorb without treatment. Ecchymoses may also appear after little or no obvious

tention by clotted blood is common (42) the obstruction may be seen by intravenous pyelography (262) Hematuria tends to be persistent each episode lasting many days or weeks (42) despite treatment which in other situations would seem adequate (39).

Other forms of intra abdominal bleeding are common (23) Bleeding into the psoas muscles is frequent and may simulate acute appendicitis (66) or cause compression and paralysis of the branches of the femoral plexus accompanied by severe abdominal and leg pain (262) Intra peritoneal bleeding may also simulate one or another of the acute inflammatory conditions of the abdomen (239 262) In such cases exploratory laparotomy may provide the *coup de grace*.

Bleeding into the nervous system is not as rare as is usually believed (5 66 103) Hematomas in soft tissues if strategically located may cause peripheral nerve injury which may lead to permanent damage Occasionally extradural subdural, subarachnoid or focal bleeding into the central nervous system may occur (5 254) Birch (42) described the case of a boy who bled into the spinal cord and was paralyzed for 9 months subsequently making a partial recovery Douglas and McAlpine (74) found neurologic lesions in 5 of 75 patients with classic hemophilia In 1 case an apparently spontaneous cerebral hemorrhage occurred in a 10 year old boy resulting in right hemiplegia In another the spinal cord was compressed by a hematoma after a fall the treatment was laminectomy In 3 instances peripheral nerves were compressed by hematomas

Despite this lugubrious description the patient with severe hemophilia does not bleed continually instead there are repeated bouts of bleeding with intervening periods of freedom (198 254) Several sites may be involved during a relapse (66) For example in 1 of our patients hematuria occurred while he was under treatment for a hematoma of the thigh The causes of this apparent deterioration in hemostatic mechanisms are a subject for speculation Stefanini and Dameshek (262) speak of a seasonal incidence of bleeding relapses occurring particularly in the spring and fall while Hartmann and Diamond (103) suggest that exacerbations follow infections Emotional stress has been said to initiate episodes of bleeding (182) but we have not found this to be the case in our patients Pavlovsky (182) suggests that the variations in bleeding tendency are due to changes in the blood vessels rather than in the blood itself As the patients grow older they tend to be more careful perhaps accounting for the decreasing frequency of bleeding with age (23) Time may play a more fundamental role



bone are produced at the margins of joints. Repeated hemarthroses may lead to an irregular increase in the width of the epiphyses resulting in the typical knobby appearance of the joint, incongruity of the articular surfaces, restricted joint motion and eventually fixed deformities. However, bony ankylosis is unusual. Hemorrhage into the hip joint may result in destruction of the head of the femur and shortening of the involved leg (42). The changes may resemble those of coxa plana (293).

The pathogenesis of the articular lesions is not clear. The tissues of patients who have bled into their joints appear laden with blood pigments. Key (127) believed that the changes described might be a reaction to these substances.

✓ In some cases joint deformities may follow massive hemorrhage into the muscles or tendons, resulting for example in flexion deformities of the hip following hemorrhage into the psoas muscles or the development of a "claw hand" after palmar hemorrhage.

The roentgenographic appearance of hemophilic joints is characteristic. During the acute phase a diffuse uniform haziness may be noted, sharply delineated from the surrounding tissues. Later the changes may simulate osteoarthritis. The bony ends of the joints may broaden and the joint spaces narrow. The articular surfaces become irregular with punched out defects (127), not unlike those of gout. Cysts resembling soap bubbles in appearance (262) may be seen in the subchondral and cancellous bones, and the collapse of these cysts may produce angular deformities, particularly in the knee. Angular deformity and shortening of the bone may also arise from premature closure of the epiphyseal plate. The increased density of the synovial and subcapsular tissue may result in sharp demarcation of the affected joint. These tissues may become calcified.

Hemorrhage into soft tissues may occlude the arterial blood supply leading to atrophy or even gangrene (262). The gangrenous part sloughs off without undue bleeding (156, 267). Bleeding in the soft tissues of the floor of the mouth, the neck or the mediastinum may cause death from asphyxiation unless intubation or tracheotomy is performed (39, 66, 254). Soft tissues distended and damaged by a collection of blood may become necrotic and develop persistent and perhaps fatal infections.

✓ In severe hemophilia hematuria is a common incident occurring in up to 90 per cent of cases (66). The bleeding may arise from any part of the urinary tract (42). Severe colic, presumably from ureteral dis-

died within the first year 57 per cent within the first 5 years and 95 per cent by the age of 40 a similarly gloomy prognosis is provided by Andreassen's (23) statistics for Denmark, published in 1943 Current experience however is more favorable and continued progress as our technics improve may be anticipated

✓ The hemophiliac's life is threatened in various ways He may not survive the insults of birth (167) He may become exsanguinated from a wound although loss of blood is only rarely lethal (63 66) He may bleed into a vital area perhaps strangling from hemorrhage into the soft tissues of the neck or mediastinum Rarely bleeding into the central nervous system may be fatal (167) He may succumb to persistent infection within an area made necrotic by hematomas (66) Finally living as he does under a Damoclean sword, he may become depressed and commit suicide.

### DIAGNOSIS

✓ As measured by laboratory methods the severity of the defect roughly parallels the severity of the patient's disorder (39) The clotting time of venous blood in glass tubes may be greatly prolonged, or it may be normal or nearly normal (52, 165 196 262) Surprisingly in the experience of Biggs and Macfarlane (39) there seemed to be no middle ground Among 50 hemophiliacs about half had clotting times of 20 minutes or less and about half of 30 minutes or more but none had clotting times between 20 and 30 minutes. A normal clotting time in glass tubes therefore does not rule out the presence of hemophilia In silicone-coated tubes the clotting time is almost always prolonged ✓ (212)

✓ In classic hemophilia the platelet count, and thrombin and prothrombin times are normal The serum prothrombic activity is usually abnormally high (69 201 248) but a normal value does not rule out the diagnosis (165 260 262) Results of the thromboplastin generation test are abnormal but the defect is corrected by substituting normal aluminum hydroxide-adsorbed plasma for hemophilic aluminum hydroxide-adsorbed plasma in the incubation mixture The diagnosis is established by demonstrating that the patient's plasma does not correct the defect in the blood or plasma of a patient with known hemophilia and vice versa (155) Depending on circumstances one or more modalities may be tested such as the ability of the patient's plasma to correct the abnormal clotting time (165) prothrombin consumption (254 260) thromboplastin generation (38) or partial thromboplastin

however for epistaxes are frequent in childhood but become less frequent or disappear as the hemophiliac reaches the teens

Fortunately not all hemophiliacs present the grim picture described the disease being much milder in perhaps a third of the patients Brinkhous and associates (51) divide their cases into 4 groups, depending on the severity of the disorder classic, moderate and mild hemophilia, and subhemophilia. We have not attempted such a sharp division. Some patients may have no symptoms until they are 4 or 5 years old or older. Bleeding may follow dental extractions, tonsillectomy or other surgical procedures but may not occur during the ordinary buffeting of life. There may be severe and temporarily incapacitating hematomas in soft tissues but hemarthroses are rare and permanent articular changes rarer (96) /

The burdens which hemophilia imposes on the personality are borne in various ways. The child's parents are continually oppressed by his disease and often guilt ridden (262). The mother may sense her husband's accusation that she has caused the disease and thus the family's troubles (92). Sometimes the mother will hide the illness from her relatives or will not admit to her husband that she has a family history of hemophilia. All these forces play upon the developing child. Moreover he is subjected to perpetual admonishments to be careful and may become fear ridden. The frequent hospitalizations punctuated by innumerable venipunctures and intravenous injections must leave their mark. As he grows older the hemophiliac, feeling stigmatized (92) may withdraw into himself, shunning the company of others. He fears any relationship with the opposite sex and if he should marry he dreads passing the trait to his offspring. The chronic shame and depression may lead to suicide: the method 1 of our patients chose was to slash his wrists. Other patients behave as if they were trying to deny the existence of their disease like the royal bleeder who raced automobiles. Some hemophiliacs wisely choose a sedentary occupation while others tempt fate and seek jobs hazardous to the unaffected. An appreciation of the emotional problems which beset these patients is clearly helpful in the management of their lifelong illness.

**PROGNOSIS** —The prognosis of hemophilia is difficult to determine. The disease was confused with other bleeding disorders until so recently that it is impossible to draw conclusions from published data. Moreover mild cases of hemophilia were often overlooked. Now the natural history of the disease is masked by our therapeutic efforts. Birch (42) in 1937 estimated that 35 per cent of 113 hemophiliacs

long as a month before administration may contain adequate amounts of antihemophilic factor. However, there was considerable variability among specimens and others have demonstrated a rather rapid decline in antihemophilic factor concentration in blood bank blood (38, 66). Possibly differences in the technic of obtaining blood from the donors may be responsible for the differences reported (13, 184). In any case, at present it seems wisest to use the freshest available blood.

Unfortunately, once transfused, antihemophilic factor disappears rapidly (134) so that repeated transfusions for the actively bleeding patient are necessary. For this reason, whole blood is only of limited value unless the hematocrit level is low. Instead, citrated plasma has been used effectively, but it is too cumbersome to prepare before each injection. Administration of plasma separated from freshly drawn blood and kept frozen until administered (11, 298) is a more practical method. Finally, lyophilized plasma prepared from freshly citrated plasma may be used (122). Alexander (12) and Penick and Brinkhous (184) have shown that lyophilized plasma\* has reasonably high antihemophilic potency. Treatment with antihemophilic factor of animal origin is in the experimental stage (157a).

In an adult, a typical therapeutic program is the initial administration of 500 ml. of plasma followed by 100 ml. every 4 hours until bleeding has stopped. Proportionately smaller doses may be used in children. Others have recommended much higher dosages, for example, 500 ml. of plasma every 4 hours (262). In the last analysis, the patient's clinical picture determines whether the amount transfused is adequate. Among laboratory tests, the Lee-White clotting time is as helpful as any. Although more subtle tests have been recommended for evaluating therapeutic results (195, 254, 262), they are impractical except under special conditions. In the presence of a weak circulating anticoagulant, certain laboratory tests will be misleading for under such circumstances transfusions may correct the defect measured in the laboratory but be ineffective *in vivo*.

After bleeding has stopped, it is our practice to continue therapy with plasma at a reduced rate using 50 ml. every 6 to 8 hours for several days.

Since the work of Patek and Taylor (180), attempts have been made to treat bleeding by the injection of concentrated antihemophilic factor. Cohn's Fraction I (149, 168), widely used at first, was not uni-

time (52 133) of known hemophilic plasma. When fresh hemophilic blood or frozen hemophilic plasma is not available the diagnosis can be made by preparing crude antihemophilic factor from normal plasma. This fraction should correct the patient's defect while a similar fraction prepared from the patient's plasma should be inert. Appropriate measures must be taken to rule out the presence of a circulating anticoagulant which might vitiate the various tests. Indeed, circulating anticoagulants are a frequent accompaniment of hemophilia and should be sought in every case.

The bleeding time is usually normal in hemophiliacs should it be prolonged, the true diagnosis may be vascular hemophilia (see p 143).

On the other hand the wound inflicted to determine the bleeding time often opens again when the edges of the wound are disturbed. Results of the tourniquet test are usually normal although it has been reported that positive results may be obtained during bleeding episodes.

It cannot be emphasized often enough that normal results of current tests as performed in most laboratories do not rule out hemophilia. We have repeatedly had to treat mild hemophiliacs who have bled severely after dental extraction. These patients have often told us that their story was disbelieved because routine tests showed no abnormalities.

### TREATMENT

The treatment of hemophilic bleeding by the transfusion of blood or blood products was introduced early in this century by Weil (288) although Lane had attempted such measures almost a century before (132a). Weil's use of serum would now be considered inappropriate for cases of classic hemophilia. With the development of techniques for transfusion the treatment of bleeding by intravenous administration of normal blood plasma or purified antihemophilic factor became feasible. Although practice varies from clinic to clinic the following generalizations seem valid. Adequate hemostasis can often be achieved by raising the blood concentration of antihemophilic factor to 5 or 10 per cent of normal (12 13 134). Under some circumstances however levels as high as 30 to 50 per cent of normal may be needed (4 157). These levels are difficult to achieve by transfusion of whole blood if the patient has not lost an appreciable amount of blood. How fresh the transfused blood must be is a debated question. It would be of obvious advantage if stored bank blood were adequate. Spaet and Garner (255) and Penick and Brinkhous (184) have reported that blood drawn as

relief of pain reduction of distention and a rapid return of function (153). However this form of treatment has not found general favor.

As soon as it becomes apparent that bleeding has stopped motion is encouraged within the limits set by pain (67). Diathermy passive exercise and later active exercise are helpful (195). In the case of the knee traction to the lower leg is used after aspiration to minimize contraction deformities (67). The patient is then encouraged to walk on crutches for several weeks until his muscles have become strong enough to stabilize the joint. If complete correction of the deformity at the knee cannot be achieved, a long leg brace with a circular spring at the knee joint is used intermittently. More persistent deformities are treated by continuous skin traction or wedging plaster casts but the genu valgum and external rotation of the tibia on the femur which follow repeated hemarthroses resist treatment (67). Finally corrective operations may be performed in those patients whose bleeding tendency can be readily overcome by blood transfusion. De Palma and Cotler (67) have performed arthrodesis of the knee and hip joints as well as other orthopedic surgical procedures in hemophiliacs. Dr P. Curtiss at the University Hospitals of Cleveland has lengthened the scarred and shortened Achilles tendon of a patient with severe hemophilia after temporarily correcting the hemostatic defect by transfusion of plasma. It cannot be emphasized too strongly that such surgical procedures should be performed only in those patients who respond to administration of normal plasma and under the close supervision of someone familiar with the treatment of hemorrhagic disorders.

Occasionally other surgical procedures must be performed in patients with hemophilia. The serious nature of such operations has been emphasized in a comprehensive review (63). Appendectomy, nephrectomy, gastrectomy, gastroenterostomy, laminectomy, repair of gunshot wounds, amputation of gangrenous limbs or digits and skin grafting have all been performed successfully. Nevertheless surgery should be avoided whenever possible for the over all fatality rate is high (63) and in those who have survived it is often necessary to give repeated transfusions with all the risks attending this procedure. The suggestion of Davidson and associates (66) that acute appendicitis be treated with antibiotics has merit particularly since the differentiation of this disorder from intra abdominal bleeding is difficult. Paradoxically patients with milder hemophilia may be in greater danger from surgery than those with severe disease for the physician may be lulled into a false sense of security by the negligible clotting abnor-

formly effective because of its variable potency (250). Its use has fallen into disrepute because evidence exists that it stimulates the development of circulating anticoagulants directed against antihemophilic factor. Concentrated antihemophilic factor of animal origin (34-35) may be effective but its use is attended by thrombocytopenia (157) and by evidence of the development of antibodies against the heterologous proteins; a dangerous anaphylactoid reaction has been reported (84). A wide variety of drugs and hormones have been proposed for systemic therapy in hemophilia but none has been of any value.

In addition to transfusion treatment must include immobilization of the bleeding area which usually means putting and keeping the patient at rest. Ice bags may relieve the pain attending distention of tissues with blood and perhaps decrease the rate of bleeding by inducing local vasoconstriction (195). Ordinarily localized hematomas should not be treated surgically but one may be forced to aspirate blood from the distended tissues to prevent necrosis. Strict precautions must then be taken to prevent infection. De Palma and Cotler (67) believe that the injection of hyaluronidase into areas of massive hemorrhage in soft tissues will result in more rapid absorption of blood and thus prevent local necrosis.

Local bleeding may be treated by application of bovine thrombin to the area (2). Biggs and Macfarlane (39) recommend the use of Russell's viper venom. They caution against prolonged application of pressure to injured tissues since this may delay healing. They point out that local use of coagulant solutions is effective only if hemorrhage can be temporarily arrested so that the clot may form at the surface which is actually bleeding. Stefanini and Dameshek (262) suggest the use of the cautery in controlling bleeding from the nasal and buccal mucosae but we have been impressed by the frequent recurrence of epistaxes following cauterization. The use of a pledget of absorbable material soaked in thrombin and pressed firmly against the bleeding point (156) may be more effective.

Opinion on the optimal management of hemarthrosis differs. The joint should be immobilized, a compression bandage applied and the part surrounded by ice packs (67-195). If bleeding appears to continue or if the hemarthrosis is massive transfusion should be given and intra-articular tension relieved by aspiration of the joint (67-298) although Stefanini and Dameshek frown upon this procedure (262). The introduction of hyaluronidase into the affected joint has been suggested to promote the reabsorption of blood; the results claimed are the

margin (66) After several weeks the teeth are readily extracted. However this method is said to be dangerous and is not recommended (24 76 183)

✓ Prophylaxis in hemophilia is difficult, since bleeding may occur with out obvious provocation. The physician must steer between restricting the child so that his personality may be warped and allowing a freedom which results in crippling injuries. Before the child can care for himself his environment must protect him. The crib should be lined with soft material such as mattress padding (197) and the crib or bed should be surrounded by deep carpeting to soften the blow when he falls or jumps out. Toys should be selected with an eye to their possible dangers (197). Such accident producers as the pedals of tricycles should be padded. A football helmet offers some protection against hematomas of the scalp, a common lesion. Padded clothing may be helpful. As the child grows older he should avoid body-contact and other dangerous sports. Swimming (196) sailing (262) and golf may usually be pursued without difficulty. Artful persuasion is necessary since the adolescent will try to imitate his peers. The patient and his parents should be advised that he should be trained for a sedentary occupation; it is helpful to point out that many hemophiliacs have become highly valuable citizens; for their number includes musicians, doctors, engineers, teachers and other professional people. Many cities have chapters of the Hemophilia Foundation\*. This group's chief activities include the dissemination of knowledge about bleeding disorders to patients and physicians and provision of blood and frozen plasma for patients.

Johnson (122), Alexander and Landwehr (16) and van Creveld and Paulssen (275) have suggested that repeated transfusions of small amounts of plasma may have prophylactic value in severely affected patients. Alexander and Landwehr (16) inject 100 to 180 ml of plasma three times a week or oftener. They believe this procedure decreases the frequency of bleeding and permits rehabilitation of the patient (16). However the frequent venipunctures required may scar the veins so that transfusions needed to control a bleeding episode may be extremely difficult to give. Furthermore blood transfusion is always attended by the risk of acquiring homologous serum jaundice, a complication which has been reported (16). Except under unusual circumstances therefore such prophylactic treatment is best avoided.



malities revealed by routine testing. The patient's story of a bleeding tendency should be given credence even in the face of supposedly objective data. If surgery is necessary, transfusions of large amounts of plasma should be administered just before, during and after operation.

The extraction of carious teeth is the commonest surgical procedure to which hemophiliacs are subjected. *Opinion varies concerning the best approach.* Biggs and Macfarlane (39) recommend that the patient be admitted to the hospital and that no more than 2 teeth be removed at a time. Preferably extraction is performed under general anesthesia, and a light plug of cotton or fibrin foam soaked in Russell's viper venom or thrombin is laid over the socket and held in place by the dentist's finger for about 5 minutes. A previously prepared dental splint is then applied to keep the dressing in place, replacing it as needed. Tight plugging of the socket is avoided so as to prevent necrosis of the edges of the wound, and the gum margin is not sutured lest hematomas form which may spread and cause asphyxia. Biggs and Macfarlane used transfusions only to compensate for loss of blood. Others believe that the patient should be prepared by the transfusion of blood or plasma (141, 262, 298). After the tooth is extracted and the splint is applied for which Levine (141) uses a rapidly hardening plastic "stent," he immobilizes the jaw by placing an operating room cap on the patient's head and pinning a piece of elastic gauze to the cap to produce a slight posterior pull on the jaw. The cap is not removed for 48 hours, and then only during the day for a week. Transfusions of blood or plasma are continued until all bleeding has ceased.

Lyon (152) points out that the purpose of the dental splint is to protect the tissues in the area from disturbance by the tongue's motion by oral fluids and food, and to hold medication in position. He emphasizes that the splint is not intended to provide pressure upon the area which might actually increase bruising. He uses topical hemostatic agents freely, packing the dental socket with a piece of Gelfoam soaked with Thrombol subcutaneous\* and powdered with topical bovine Thrombin†. To control undue oozing in the days after extraction, Lyon applies ferric subsulfate solution (Monsel's solution) locally as often as needed.

Some have recommended that the teeth be loosened before extraction by placing thin rubber bands around their bases at the gingival

\* Merck Sharp & Dohme

† The Upjohn Company

been treated with Cohn's Fraction I, and they wondered whether these preparations were responsible for the development of anticoagulants. Lawrence and Craddock (62, 138a) and Munro and Munro (171) found that the anticoagulant was associated with the  $\gamma$  globulin fraction, although similar anticoagulants have been localized to the  $\beta$  globulin fraction as well (112). Lawrence and Craddock and many others have reported that the anticoagulant plasma contained precipitins against antihemophilic factor and therefore have proposed that the circulating anticoagulants were antibodies and that the inhibition of clotting resulted from an antigen-antibody reaction. Lewis and co-workers (146) have shown that the anticoagulant specifically destroys antihemophilic factor, an observation which we have corroborated (160) but which is not accepted by all (276). Experimentally human antihemophilic factor is antigenic for rabbits and the rabbit antiserum appears to inactivate human antihemophilic factor and inhibit the formation of thromboplastin during clotting (217).

Nevertheless certain observations raise the question whether circulating anticoagulants in hemophilia are actually antibodies. A number of cases have been described in which precipitins could not be demonstrated (61, 146, 243, 276) and re-examination of others has failed to confirm the presence of precipitins which had been observed earlier (12). Lawrence and Craddock (138a) noted that the inactivation of antihemophilic factor by the anticoagulant serum required a period of incubation. This behavior is as compatible with that of an enzyme as with that of an antibody. Some insight into the nature of this problem comes from studies by Biggs and Macfarlane (39) of circulating anticoagulant against antihemophilic factor found in the blood of a woman with a postpartum hemorrhagic diathesis. They found that the destruction of antihemophilic factor required a considerable time. We have made the same observation in 2 patients with similar anticoagulants in whom the destruction of antihemophilic factor occurred with increasing rapidity as the temperature of the reaction mixture was increased from 0 to 37°C (161). In addition, complement fixation could not be demonstrated during the inactivation of partially purified antihemophilic factor by concentrates of the anticoagulants\*. Nor could we show that the anticoagulants agglutinated tanned erythrocytes coated with antihemophilic factor. Finally we observed that

\* These experiments were carried out in association with Drs. I. Lepow and A. Stavitsky.

- ✓ The hemophiliac risks injury under circumstances in which he is unable to give his history to the attending physicians. For this reason, patients with this disorder should carry a note giving the diagnosis. We suggest to hemophiliacs that when they travel they carry a supply of lyophilized plasma. The chief virtue of this is psychologic: it reassures the patient or his family that emergency therapy can be started wherever blood or plasma is not readily available.
- ✓ Finally the patient or a potential carrier will seek advice concerning marriage and having children. I believe with Davidson and associates (66) that the patient should be taught the statistical risks in having children but that the final decision is one to be made by the patient or carrier. The hemophiliac's daughters will all be carriers but his grandchildren will not be born for another generation at which time our therapeutic measures may be more successful.

### CIRCULATING ANTICOAGULANTS

- ✓ The complication probably most to be feared in hemophilia is the development of a circulating anticoagulant that is a substance in plasma which neutralizes the effect of transfusions of normal blood. Verstraete and Vandenbroucke (282) have reviewed the literature concerning circulating anticoagulants. The earliest description of a circulating anticoagulant is probably that of Pickering and Gladstone (185) who observed that the blood of a patient with severe hemophilia retarded the clotting of an equal volume of normal blood. In 1941 Lawrence and Johnson (139) described a 44 year old hemophiliac who was refractory to blood transfusion. His blood contained a substance prolonging the clotting of normal blood. Since then many similar cases have been reported: indeed the presence of a circulating anticoagulant in hemophilic blood is rather common. For example Frommeyer and co workers (89) observed anticoagulants in 5 of 22 hemophiliacs tested. Lewis and associates (146) in 5 of 52 and Margolus and I (160, 161) in 6 of 28.

✓ The etiology and nature of the circulating anticoagulants in hemophilic blood are not clear. The anticoagulants cannot be extracted with ether (139, 170) and thus seem not to be identical with that which Tocantins and associates (269, 272) postulate to be present in all hemophilic blood. To my knowledge no case has yet been described in a patient who has not previously been transfused with normal blood or a blood fraction. Frommeyer *et al* (89) noted that their 5 patients had all

hemophilia occurs the mating of a hemophilic male and a carrier female does result in the birth of hemophilic females (50)

At least ~~4~~ well-authenticated cases of hemophilia in women have been reported (3 of these were in sisters—the offspring of a consanguineous marriage in a hemophilic family (166) 2 other sisters were affected and 4 were unaffected) but these 6 individuals were not tested in the laboratory. The hemophilic women bled excessively from wounds and after dental extractions bruised easily bled from the urinary and gastrointestinal tracts and had menorrhagia yet they survived childbirth. Their sons were of course hemophiliacs. In this family the Lee White clotting time was normal but the patients' plasmas failed to correct the defect in known hemophilic blood. These patients have been shown to have classic hemophilia and not Christmas disease (166a). The parents of the fourth patient, described by Israels and associates (115) were unrelated but her father and her mother's brother were known hemophiliacs. The patient's clotting time was prolonged and her plasma did not correct the abnormality of hemophilic blood. However she had only minor evidences of a bleeding tendency and menstruation was not abnormal. 10 days after the delivery of a normal infant at term an event unaccompanied by excessive bleeding intractable uterine hemorrhage developed for which hysterectomy was performed. Despite a stormy course the patient recovered. A fifth case was that of a girl whose parents were first cousins her father being a hemophiliac and her mother the daughter of another (48) the patient bruised easily and had hemarthroses but her menses were normal no laboratory tests were performed.

The case of the young girl reported by Quick and Hussey (203) as an instance of hemophilia in the female should be mentioned. Dr. Quick (199) is no longer willing to commit himself concerning the diagnosis although laboratory tests continue to demonstrate abnormalities in the clotting mechanism.

### VASCULAR HEMOPHILIA

A variety of hemophilia has been described in the last few years manifested by bleeding phenomena, a deficiency of plasma antihemophilic activity and evidences of a vascular disorder, principally prolongation of the bleeding time. Unlike classic hemophilia both sexes are affected. For example among 20 cases reviewed by Singer

the circulating anticoagulants were not specifically directed against human antihemophilic factor, as had been reported (256) but destroyed antihemophilic factor of animal origin as well. None of these observations rule out the possibility that these anticoagulants or the indistinguishable anticoagulants found in hemophilic blood are antibodies, but they do suggest that studies of their mode of action must be continued.

✓ The presence of a circulating anticoagulant should be suspected in any hemophiliac who responds poorly to blood transfusion. In such patients bleeding may be more protracted and severe than in the usual hemophiliac and the clotting time is often extraordinarily long (146 160 256). Various technics have been described for the detection of circulating anticoagulants. *The most sensitive methods seem to be those in which the patient's plasma is incubated with normal plasma for several hours without the addition of calcium and then tested* (38 146 161). This technic will demonstrate anticoagulants which may not be detected without the preliminary incubation. After an anticoagulant has appeared it is not invariably present but when it is the patient is refractory to transfusions (89 282).

✓ Treatment of patients with circulating anticoagulants is most unsatisfactory. Large volumes of plasma must be transfused to provide even transient hemostasis (262). Some believe that temporary amelioration of bleeding may result from ACTH or corticosteroid therapy (220 277) but in many cases this regimen has not been helpful (13 112 146 243 262). Fortunately many patients survive what appears to be uncontrollable bleeding. Since transfusions apparently increase the anticoagulant titer they should be avoided when possible (4 13). Further investigation in this area might well include a search for some chemical agent which will neutralize the effect of the anticoagulants.

### HEMOPHILIA IN THE FEMALE

✓ Genetically the union of a hemophilic male and a female carrier should result in a hemophilic female in a fourth of the births (Fig 2). For a long time the rarity of hemophilia in the female was ascribed to the possibility that the homozygous state for the abnormal gene was lethal for the embryo. It seems more likely that the scarcity of cases is due to the infrequency with which a hemophiliac marries a hemophilic carrier. In dogs a species in which a disease comparable to human

The fundamental nature of vascular hemophilia is yet to be discerned. Singer and Ramot (242) and Matter and associates (164) were impressed by the resemblances between their patients and those described by von Willebrand (292) under the name "pseudohemophilia". For this reason Singer and Ramot named the syndrome "pseudohemophilia type B". Perhaps as Matter *et al* suggest, a single gene determines a step in the synthesis of antihemophilic factor and is needed for the development of the vascular tree. This implies that a series of different genes control the sequence of reactions leading to the synthesis of antihemophilic factor. Corroborative evidence for this is found in those patients in whom hereditary deficiencies of antihemophilic factor and proaccelerin co-exist (*see p 164*). Another explanation might be that the lesion is fundamentally vascular and that antihemophilic factor is used for hemostasis at the site of the vascular injury at a faster rate than it is synthesized. However in patients with severe bleeding because of other hemorrhagic disorders a deficiency of antihemophilic factor is not observed.

The prognosis of vascular hemophilia is variable: some patients dying in childhood and others surviving into adult life. Singer and Ramot believed that when transfusion is necessary, fresh blood is most efficacious, while Schulman *et al* (232) found that they could use freshly frozen plasma effectively. It is obvious from the various contradictory statements which have been quoted that this syndrome is just beginning to be unraveled and clarity may be expected only from the study of additional cases.

### CHRISTMAS DISEASE

Until recently the clinical syndrome of hemophilia was thought to result from a single defect in the coagulative mechanisms. With the development of modern techniques this unitary concept became untenable. In 1947 Pavlovsky (181) reported that a mixture of the blood of 2 hemophiliacs clotted more rapidly than either blood alone. Moreover the transfusion of the blood of 1 patient into the other was as effective as the transfusion of normal blood. A similar observation was made by Koller and co-workers (131): the blood of patients of the Moena family corrected the defect of patients they thought at the time to be true hemophiliacs. Then in 1952 the same paradox was observed by 3 separate groups of investigators (9, 41, 231) who divided hemophiliacs into at least 2 groups (1) those deficient in classic

and Ramot (242) 14 were in females 3 of them had no familial history of hemorrhage but 4 others had male relatives who were bleeders

The clinical manifestations of this disorder include the usual symptoms of hemorrhagic disease Singer and Ramot's patient typically had a life long history including epistaxes easy bruisability and the development of apparently spontaneous hematomas bleeding from a tongue bite and menorrhagia (212) Postoperative and postpartum hemorrhages (164) and hemarthroses (135) have been described Epistaxis may be so severe that death from exsanguination results (164) In 1 patient the spleen was just palpable (278)

The laboratory differentiation of vascular hemophilia depends upon the co existence of a deficiency of antihemophilic factor and a vascular abnormality In all the cases described the platelet counts have been normal and the platelets have behaved normally with respect to clot retraction and thromboplastin generation However in 1 of the cases reported by Soulier *et al* (251) the platelets were unusually large With few exceptions (164) the bleeding time has been prolonged At the same time in most cases the plasma has been deficient in anti hemophilic factor The exceptions have been patients with relatives deficient in this substance (15 164) Because of the presence of a dual defect Schulman and associates (232) have suggested the appropriate name "vascular hemophilia" for this disorder

In those instances in which the antihemophilic factor concentration was estimated quantitatively values varying from 3 to 75 per cent of normal have been reported With one exception these concentrations have been considerably higher than those found in most patients with classic hemophilia even of the mild variety Besides the prolonged bleeding time, other evidences of a vascular anomaly have been described Alexander and Goldstein (15) observed an abnormality of the vessels of the nail bed in the mother of 1 of their patients and similar changes were observed in 3 of 7 cases by Matter *et al* (164) The tourniquet test may also give a positive result (164) -

The mode of inheritance of vascular hemophilia is not clear In some families the abnormal gene behaves like an autosomal i.e. nonsex linked mendelian dominant (65 164) Singer and Ramot's (242) patient was the offspring of consanguineous parents but only her elder brother had bleeding phenomena These investigators suggest that the defect in their patient was determined by autosomal recessive genes Since the various patients described do not necessarily have the same disorder these discrepancies are not surprising

been observed in the serum of some carriers or presumed carriers (138 221 222) We have seen 1 woman the daughter of a man with typical but mild hemorrhagic disease who has had minor bleeding phenomena and an abnormally low concentration of Christmas factor in her blood (212)

Christmas disease exists in at least two forms—severe and mild (31)—and, as in the case of classic hemophilia, the intensity of the disorder seems to be the same for all affected members of a family (31) Presumably there is a series of allelic genes each of which is manifested by Christmas disease of a given severity alternately modifying genes may influence the intensity of the defect

The opinion is generally held that Christmas disease is due to a deficiency of Christmas factor This substance is present both in plasma and serum (9 14 41) implying that at most it is only partly consumed during clotting (152) In serum Christmas factor is stable upon prolonged storage at 4 C or in the frozen state and withstands 56 C for 5 minutes (9) It is destroyed by heating serum at 56 C for 10 minutes (41) In common with prothrombin pro-SPCA and Stuart factor Christmas factor is adsorbed from plasma by such substances as barium sulfate and aluminum hydroxide and can then be eluted and partly purified (9) It is associated with the  $\beta$  globulins of plasma (6) is present in Cohn's Fractions III and IV I (289) and can be precipitated between 45 to 50 per cent saturation with ammonium sulfate (289) Partly purified preparations correct the plasma defect of patients with Christmas disease (6 8) However such products also shorten the recalcified clotting time of normal plasma suggesting that they may be contaminated with the ubiquitous Hageman factor (see p 152)

The site of synthesis of Christmas factor is not known Biggs *et al* (41) reported that the concentration of this factor was depressed in patients treated with coumarin like drugs an observation repeatedly confirmed This suggests that vitamin K is needed for its synthesis but I am not aware of any reported direct evidence for this Liver disease therefore might be suspected to impair the synthesis of Christmas factor but a decreased concentration of this substance was present in the plasma of only 3 of 17 patients with cirrhosis (99) Curiously the 3 were the only women in this group but the series was too small to be sure that this was significant.

Christmas factor appears to play a key role in the development of thromboplastic activity in shed blood Evidence gained from the thromboplastin generation test suggests that it reacts with antihemo-



antihemophilic factor and (2) those lacking a second substance variously named plasma thromboplastin component, Christmas factor antihemophilic factor B factor IX, and  $\beta$  prothromboplastin. Since then innumerable reports have appeared describing the properties of this clotting factor and of Christmas disease, the hereditary disease associated with its deficiency. No review can do more than sample the available information.

With the separation of Christmas disease from classic hemophilia, attempts were made to determine the relative incidence of the 2 disorders. Since the number of individuals in a family who may be tested varies, comparison of the number of patients with the 2 disorders is not satisfactory. Summarizing the number of families with one or the other disease in 10 reported series, we found that 84 per cent of some 488 families had classic hemophilia and the remaining 16 per cent Christmas disease (215). However, these data may give a false impression of the relative frequency of the 2 disorders. Biggs and associates (41) found only 1 case of Christmas disease in a systematic study of 35 patients with the hemophilic syndrome. In our own experience (215), 80 per cent of 44 families had hemophilia and 20 per cent Christmas disease. However, among families residing in Cuyahoga County, which comprises the metropolitan area of Cleveland, only 2 of 32 families had Christmas disease. Thus it is possible that Christmas disease is rarer than has been assumed and that undefined influences have led patients with this disorder to the specialized laboratory for diagnosis. ✓ Christmas disease has been reported from laboratories all over the world and there is no evidence that any racial group is particularly susceptible. Cases are seen with comparable frequency in white and Negro families (150-212). The inheritance of Christmas disease follows the same general pattern as that of hemophilia (41, 143, 221, 222, 249). The tendency to development of Christmas disease is transmitted as a sex-linked recessive trait, presumably on the X chromosome. As a result, Christmas disease is a disorder of males who transmit the abnormal gene to their daughters. These women are usually asymptomatic but half their sons will have Christmas disease and half their daughters will carry the trait (Fig. 2). In addition, sporadic instances have been reported—25 per cent or more of cases appear to arise *de novo* (9, 150, 219, 249, 250). As is believed of hemophilia, some of these sporadic cases may result from spontaneous mutation. Instances of bleeding in the female carriers of Christmas disease have been reported (51, 150, 221, 222) and deficient Christmas factor activity has

✓ In keeping with the greater frequency of mild cases of Christmas disease the over all prognosis is probably better than that of hemophilia but definitive data are not yet available. Treatment does not differ in principle from that of hemophilia. However Christmas factor is more stable than antihemophilic factor so that bank blood stored for several weeks, can be used to advantage (221 262) Bradfield and Case (45) dissent from this view they found that under the ordinary conditions of storage the concentration of Christmas factor in citrated blood decreased sharply within 7 days at 4 C although it was stable in plasma kept at -20 C. The amount of blood or plasma needed for therapy appears to be less than that required for the care of hemophiliacs (271). This is consonant with the observation that the defect in Christmas disease may be corrected for 48 hours or longer by the transfusion of a single unit of blood or plasma (6 27 221 290) and that *in vitro* Christmas factor is more stable than antihemophilic factor. Purified antihemophilic factor is of course ineffective (7). White and co workers (290) have used repeated transfusions of plasma to prevent hemorrhage in severe Christmas disease but this practice is accompanied by the risks of homologous serum jaundice and perhaps of the development of circulating anticoagulants ✓

Resistance to the beneficial effects of transfusion (12) and the presence of circulating anticoagulants (146 250 256) have been described in a few cases of Christmas disease. Circulating anticoagulants were found in 2 of 26 patients studied by Lewis and associates (146). In 1 of their patients the anticoagulant titer fell over a period of 6 months during which no transfusions were given only to rise again after another transfusion this anticoagulant was directed specifically against Christmas factor. In another case it was thought to inhibit tissue thromboplastin although the evidence was not clear cut (57). As in the case of hemophilia the effect of the anticoagulant can be demonstrated more easily if the patient's plasma is incubated with normal plasma before the mixture is recalcified (57). Treatment of these patients is as might be expected difficult because the Christmas factor in transfused blood is inactivated by the anticoagulant.

#### PLASMA THROMBOPLASTIN ANTECEDENT DEFICIENCY

✓ In 1953 Rosenthal Dreskin and Rosenthal (226) delineated a mild familial hemorrhagic syndrome occurring in both sexes and characterized principally by bleeding after surgical procedures (56 209 225)

philic factor in the early stages of clotting (40). The resulting product then reacts with platelets. Whether one of these substances is an enzyme and another its substrate has not been determined. However unlike *antihemophilic factor* Christmas factor does not disappear during clotting.

The diagnosis of Christmas disease is made in the laboratory. The clotting time of whole blood in glass tubes is usually prolonged (41, 221, 290) but in mild cases it may be normal (31, 41, 138). However the clotting time in silicone coated tubes is virtually always prolonged (160). The thrombin time and prothrombin time are normal so that the defect appears to be localized in the earlier phases of clotting. The serum prothrombic activity is usually higher than normal (41, 231) but prothrombin "consumption" may not be abnormal if the defect is mild (31, 138, 212). However thromboplastin generation is usually abnormal. As might be expected the defect measured in this test is corrected by normal serum but not by normal plasma adsorbed with aluminum hydroxide since this is deficient in Christmas factor. The diagnosis rests ultimately upon the demonstration that the plasma of a patient known to have Christmas disease does not correct the defect in the plasma under study. A presumptive diagnosis can be made if the patient's defect can be corrected by normal serum but not by normal adsorbed plasma.

The bleeding time and tourniquet tests have almost invariably given normal results (150, 231). Combined defects have been reported, and will be discussed later.

The clinical picture of Christmas disease is indistinguishable from that of classic hemophilia except that the disease may be mild in relatively more cases (95). The only distinguishing feature of which I am aware is the unusual finding of traumatic rupture of the spleen in a boy; the patient survived (160). This complication was also described in an Ohio born Amish boy whose case was reported in 1948 (298). Since Christmas disease occurs with great frequency among the Amish men in Ohio the boy may have had this disease which was not differentiated from hemophilia at that time. Bleeding into the nervous system may occur as in hemophilia. Schulman and Smith's original patient (231) was first seen because of quadriplegia subsequent to hemorrhage. Douglas and MacAlpine (74) described 4 cases of bleeding into the nervous system including 1 lethal episode of spontaneous cerebral hemorrhage and 3 instances of compression of peripheral nerves by hematomas.

at 25 to 33 per cent saturation with ammonium sulfate (223) or at 20 per cent saturation (209) Rosenthal (223) found maximal activity in Cohn's Fraction IV.1 and only slight activity in Fractions I and III others believe the correct activity lies in Fraction I (107 209) When normal serum was subjected to paper electrophoresis a fraction could be eluted between the  $\beta_1$  and  $\gamma$  globulin components which contained the corrective fraction (223) Seitz filtration of normal plasma through 50 per cent asbestos pads is reported to result in only slight (223) or marked (209) loss of activity Heating serum at 58 C (209) or 60 C (223) for 10 minutes also impairs its corrective effect

One other observation of great interest has been made by Rosenthal (220) concerning the nature of PTA deficiency The corrective effect of normal plasma increased during storage at -15 C More important the plasma of a patient with a mild abnormality acquired the property of correcting the defect in PTA deficiency when it was stored at -15 C for 4 to 62 days Rosenthal did not see this phenomenon in cases in which the defect was marked nor did Ramot (209) in her cases

The significance of the studies in these interesting patients is not yet clear The differences reported from different laboratories suggest that the various patients may not have the same disorder A second problem to be resolved is whether this syndrome is due to the deficiency of a clotting factor Although a fraction of normal plasma corrects the defect, no evidence that a similar fraction prepared from a patient's plasma lacks the corrective activity has appeared Possibly the effect of normal plasma fractions is not specific A third problem has been posed by the report that the plasma of a patient with PTA deficiency provided by Rosenthal was deficient both in antihemophilic factor and Christmas factor (124) Ingram (114) has also suggested that such patients have multiple partial deficiencies of other clotting factors It is difficult to reconcile this view with the evidence that plasma obtained from patients with hemophilia or Christmas disease corrects the defect of plasma from patients with PTA deficiency and vice versa It is evident that no adequate definition of this group of patients is yet possible

~~Bleeding in PTA deficient patients is treated by transfusion of blood or plasma~~ Relatively small amounts are said to suffice Rosenthal *et al* (225) demonstrated that the transfusion of plasma shortened the clotting time and in larger amounts corrected the defective serum prothrombic activity in 1 of their patients The plasmas tested included

delivery (85) and dental extractions (226) Epistaxes (222) cutaneous ecchymoses (85 105 225) muscular hematomas (56 173 225) hemarthroses (222 225) bleeding into the brain stem (105) menorrhagia (105) and gingival bleeding (56) have all been reported. The clotting time of venous blood is usually slightly prolonged and the prothrombic activity of serum is abnormally high. Rosenthal et al (226) differentiated this disorder from other coagulative diseases because the abnormal clotting time and serum prothrombic activity were corrected by the blood of patients with hemophilia or Christmas disease. They suggested that the plasma of their patients was deficient in yet another clotting factor which they named plasma thromboplastin antecedent (PTA).

Rosenthal and co workers (225) believe that the disorder is transmitted as an autosomal dominant trait with a high degree of penetrance and variable expressivity. Thus there is an even chance that a carrier will transmit the disorder to his or her offspring. The available data are compatible with this view (56 85 103 209). Sporadic cases have also been observed (209 222).

Only a few reports deal with the frequency of PTA deficiency. Among 105 families with hereditary coagulative defects reported by 3 groups (85 219 222) 6 were deficient in this factor. These data should not be taken too literally; the problems posed by studies of the frequency of coagulative disorders were discussed in relation to Christmas disease.

The coagulative defect in these patients is usually mild. The results of bleeding time (209 222) and tourniquet tests (105) are normal. The clotting time of venous blood is usually only slightly prolonged and may be normal. However in nearly all cases the prothrombic activity of serum has been abnormally high (226) and the thromboplastin generation test abnormal (173 209). The defect seems to be localized to the initial stages of clotting; the prothrombin time is normal (226). Tests for circulating anticoagulants have been positive in only one case (125a). The abnormal serum prothrombic activity has been corrected by oxalated or citrated plasma or serum stored as long as 2 years in the frozen state (56 223) or at room temperature for 4 months (223). The defect can also be corrected by plasma or serum which has been adsorbed with barium sulfate (223); an eluate of the barium sulfate used to adsorb the plasma also corrects the abnormality.

Which fraction of normal plasma corrects the defect is not yet agreed upon. The corrective fraction has been said to be precipitated

the children or parents of any of the patients tested. The evidence gleaned from these few cases then suggests that Hageman trait is transmitted by autosomal recessive genes (162).

The defect in Hageman trait is apparently in the earliest stages of clotting. The thrombin time and prothrombin time are normal. Prothrombin consumption is usually impaired (121 135a 210 213 234) and the results of the thromboplastin generation test have been abnormal (121 135a 210 214 234). The abnormality can be corrected by adding minute amounts of plasma from patients with a wide variety of hemorrhagic diseases. The plasma of patients under treatment with Dicumarol is also effective (121 160). Paradoxically addition of small amounts of plasma from an individual with Hageman trait is either ineffective (87) or only equivocally effective (224) in correcting the abnormal serum prothrombic activity of blood from patients thought to be deficient in PTA. The significance of this observation is not understood.

The abnormality in the plasma of patients with Hageman trait can be corrected by adding a fraction of normal plasma. The same fraction prepared from individuals with Hageman trait, is without effect. The corrective fraction "Hageman factor," is present in plasma obtained from rats horses rabbits dogs sheep mice and guinea pigs but not in duck plasma. It can be separated by appropriate techniques from fibrinogen prothrombin proaccelerin antihemophilic factor pro SPCA Stuart factor Christmas factor and probably PTA. Hageman factor is associated with the globulin fraction of plasma. When normal serum is subjected to paper electrophoresis Hageman factor can be eluted from the paper maximally between the  $\beta$  and  $\gamma$  globulins (87 121 214). Other properties of Hageman factor have been summarized in a recent review (214).

The role played by Hageman factor in initiating clotting has not been explained. Even small amounts accelerate the clotting of normal blood and increase the rate at which prothrombin disappears during clotting. There is evidence that Hageman factor is inert in blood as it is shed and becomes activated during clotting when the blood comes in contact with glass. The mechanism by which glass "activates" Hageman factor has been illuminated by experiments with duck plasma which is devoid of Hageman factor activity (212). Duck plasma or the plasma of patients with Hageman trait, inhibits the clot accelerating effect of glass. However these plasmas do not inhibit the action of plasma which has previously been treated with glass. Thus

1 stored in a refrigerator for a week and then kept frozen for an additional week After a transfusion of 450 ml of plasma 1 of their patients underwent hernioplasty without unusual bleeding

### TETARTOHEMOPHILIA A FOURTH PLASMA THROMBOPLASTIN COMPONENT DEFICIENCY

In 1954 Spaet and co workers (258) described the case of a man with a lifelong hemorrhagic disorder which at the time they believed to be unique. Studies suggested that his blood was deficient in a factor which could not be identified with the known components of the clotting system. They named this factor the fourth plasma thromboplastin-component and the disorder characterized by its deficiency tetartohemophilia. Through the courtesy of Dr Spaet a group of investigators in several cities restudied this patient recently and it is the consensus that he has mild Christmas disease probably complicated by the presence of a weak circulating anticoagulant (259)

### HAGEMAN TRAIT

✓ Hageman trait is an asymptomatic disorder characterized by prolongation of the clotting time. The name derives from the first patient studied. So far 12 cases have been observed (87 100a 121 135a 210 213 228 238) 6 in males and 6 in females. The most remarkable feature is the absence of significant hemorrhagic symptoms despite the usual gamut of injuries operative procedures and deliveries. A possible exception is the unverified case described by Sjøln (244a). All but 2 of the cases were discovered by chance. The remaining cases were found in a survey of the relatives of 2 of the patients. The lack of hemorrhagic symptoms in these patients, whose clotting times are as long or longer than that of most hemophiliacs, illustrates the poverty of our concepts concerning hemostasis.

✓ Hageman trait may be a hereditary abnormality. In 3 cases (87 121 213) the unusually long clotting time is known to have been present for many years suggesting the lifelong presence of the defect. In 2 instances the trait has been familial. In 2 cases the patients are sisters but none of many of their relatives tested are affected. The 2 sisters are the offspring of a consanguineous marriage. In 2 other cases the patients are brother and sister but their parents are unrelated (234). A deficiency of Hageman factor has not been demonstrated in

thromboplastin and calcium It was soon evident that factor V was identical with labile factor (193) plasma accelerator globulin (286) and accelerator factor (78) all of which had been described at about the same time.

Cases of parahemophilia have now been described in about 20 families The disorder occurs in both sexes In many patients the symptoms are mild consisting only of spontaneous epistaxes easy bruisability menorrhagia and at times excessive bleeding after dental extractions or surgical procedures In others the bleeding has been more severe and the patients have had severe hematomas spontaneous gingival bleeding and perhaps as in Owren's first case bleeding into the central nervous system So far as I can tell, hemarthroses have not been observed The bleeding can be lethal (47) The severity of the illness is roughly related to the severity of the defect measured in the one stage prothrombin time Those with the severest bleeding have had prothrombin times between 70 and 110 seconds (normal values 12-15 sec) Quantitative assays have demonstrated the virtual absence of proaccelerin from the plasma of such patients and 1 to 5 per cent of normal in the plasma of patients with milder bleeding

Parahemophilia is usually familial (47 70 128 150) but sporadic cases have been reported (150 160 176) In some cases quantitative assays have demonstrated that the parents of an affected individual have partial deficiencies of proaccelerin, with or without a mild tendency toward excessive bleeding (145) In others such as Owren's original case (176) a proaccelerin deficiency cannot be demonstrated in either parent although the patients have no demonstrable proaccelerin in their plasma The mother of one young man whom we have studied has a plasma proaccelerin concentration of about 50 per cent of normal his father is unavailable for study (160) Consanguinity has been described in the parents of some patients (128) The variable hereditary pattern makes it impossible to deduce any general rule for the inheritance of parahemophilia

It is noteworthy that in 2 instances congenital cardiovascular defects were associated with parahemophilia (110 145) in 1 family syndactylism (70) and in another case epidermolysis bullosa congenitalis (14) A moderate prothrombin deficiency accompanied the proaccelerin deficiency in 1 patient (70) A simultaneous deficiency of antihemophilic factor proaccelerin may occur (see p 164)

Evidence concerning the physiologic role of proaccelerin is conflicting Proaccelerin seems to be a globulin It is precipitated maximally



the plasma of ducks or patients with Hageman trait appears to inhibit the "activation" of Hageman factor by glass.

The relative stability and ubiquitousness of Hageman factor suggest that it may contaminate other supposedly purified clotting fractions. For example, Hageman factor may account for the clot accelerating properties of crude preparations of plasmin which led to the now abandoned view that this enzyme initiates clotting.

Finally, no hints are available as yet concerning the hemostatic mechanisms which protect these patients from bleeding. The explanation of this phenomenon will be of interest.

### PROTHROMBIN DEFICIENCY

A true congenital deficiency of prothrombin is exceedingly rare. Most of the cases originally reported have turned out to be deficiencies of other factors or to be instances of combined deficiencies. However, Quick and associates (205) have described 3 cases in which moderately severe bleeding phenomena were noted from birth. The patients bled after circumcision, dental extractions and injuries, had hematuria, and bled into muscles and joints, though without the development of crippling arthritis. The clotting times were slightly prolonged and the prothrombin times greatly prolonged. It is of interest that in 1 of them vitamin  $K_{10}$  therapy partly corrected the defect measured in the prothrombin time. Several other patients have been studied in whom prothrombin deficiency was combined with deficiencies of other clotting factors (see p. 164).

### PARAHEMOPHILIA

About 15 years ago evidence began to accumulate that the optimal conversion of prothrombin to thrombin by thromboplastin and calcium required the presence of one or more additional factors. Among the more impressive studies was that by Owren (176) of a young woman with a lifelong history of a severe bleeding tendency. The one stage prothrombin time was greatly prolonged but the actual concentration of prothrombin was normal. However, the addition of normal plasma from which the prothrombin had been removed shortened the prothrombin time to normal. Owren showed that the patient's plasma lacked a heat labile factor needed for the conversion of prothrombin to thrombin. He named the patient's disorder parahemophilia and the missing factor factor V, the other 4 being fibrinogen, prothrombin,

the laboratory Invariably the one stage prothrombin time will be abnormally long. Among the causes of a prolonged prothrombin time, prothrombin and fibrinogen deficiencies can be readily excluded by specific assays for these substances. Deficiencies of prothrombin, pro SPCA and Stuart factor can be excluded if the abnormal prothrombin time is corrected on the addition of fresh plasma from which these substances have been removed by adsorption on such substances as barium sulfate. The diagnosis can be confirmed by the inability of aged oxalated plasma or plasma heated at 37° C for 24 hours (295) to shorten the prothrombin time.

A number of other tests may give abnormal results in parahemophilia. In many reported cases the clotting time of venous blood, whether measured in glass or silicone-coated tubes is prolonged. The bleeding time is usually normal, but instances in which it is long have been reported (14, 136). The prothrombic activity of serum is usually elevated, implying that the conversion of prothrombin to thrombin is impaired during the course of clotting. The results of the thromboplastin generation test are also abnormal. However the abnormality is clearly demonstrable only if the incubation mixture contains the patient's platelets or a suspension of crude cephalin instead of normal platelets since the proaccelerin like activity of normal platelets will partly correct the defect.

The blood of 1 patient with congenital parahemophilia contained a circulating anticoagulant which rapidly inactivated either partly purified proaccelerin or the proaccelerin contained in normal plasma (110). The circulating anticoagulant was probably a lipid, and resisted incubation at 56° C for 10 minutes. I am unfamiliar with any similar cases.

The treatment of parahemophilia like that of other hemorrhagic disorders begins with the avoidance of injury. Episodes of bleeding which cannot be checked by local measures may be treated by the transfusion of citrated blood or the plasma separated from such blood. For example Alexander and Goldstein (14) found that 500 ml of citrated blood shortened the abnormally long prothrombin time, bleeding time and clotting time of a patient with parahemophilia, but the effect lasted less than 48 hours. Although there has been some difference of opinion concerning the stability of proaccelerin in citrated blood under the conditions of storage in a blood bank, Fahey and co-workers (77) have shown that the proaccelerin titer remains high for at least 2 weeks under these circumstances. Freshly drawn blood therefore is not needed in treating this disorder.

between 33 and 50 per cent saturation with ammonium sulfate (176) and is found particularly in Cohn's Fraction II III (12). It is labile dis- appearing rapidly when stored in oxalated plasma and more slowly in citrated plasma (77). The prolonged prothrombin time of plasma of patients with proaccelerin deficiency indicates that this substance is needed for the middle stages of clotting i.e. the conversion of prothrombin to thrombin by thromboplastin. During clotting proaccelerin is probably converted to an active form—accelerin. Factor VI or serum accelerator globulin (176, 287). The conversion can be initiated *in vitro* by adding thrombin (284) suggesting that a chain reaction may take place during clotting. As thrombin evolves it converts proaccelerin to accelerin, this in turn resulting in the production of more thrombin from the prothrombin which is still unconverted.

Many schemes have been proposed to explain how proaccelerin or accelerin speed thrombin formation. Basic to any hypothesis is the observation that proaccelerin activity is demonstrable in the presence of tissue thromboplastin. In spontaneous clotting the proaccelerin or accelerin seems to react after the interaction of antihemophilic factor Christmas factor and platelets (72). Apparently, it exerts its effect on the evolved plasma thromboplastin or upon tissue thromboplastin in association with pro SPCA and calcium (82, 178) but the exact order of the reactions involved is in doubt. In any case an active compound is formed which converts prothrombin to thrombin. Proaccelerin and accelerin activity rapidly disappear during clotting (19, 72, 73) the mode of their destruction is unknown. As a result, the serum of most species is devoid of proaccelerin, one exception is bovine serum. The destruction of proaccelerin during clotting is slower than normal in the blood of patients with thrombocytopenia (19), hemophilia (19, 72) and Christmas disease (72).

The relation of platelets to the pathogenesis of bleeding in para hemophilia is of considerable interest. Alexander and Goldstein (14) showed that platelet agglutination is retarded in this disorder. Normally both platelets and plasma contain proaccelerin like activity whereas in patients with parahemophilia the platelets lack this property (111, 145). Experiments of Hjort, Rapaport and Owren (108) indicate that the proaccelerin of normal platelets has been adsorbed from the plasma. Platelets from a patient with parahemophilia incubated with normal plasma acquired the proaccelerin like activity of normal platelets.

✓ Usually the diagnosis of parahemophilia is readily established in

hour after blood is drawn only a small amount of the prothrombin remains in the serum. However, when the conversion of prothrombin to thrombin is impaired, the amount of prothrombin remaining in serum is relatively high, i.e. prothrombin consumption is poor.

In one group of cases, the results of the test for serum prothrombin activity have been normal (20, 58, 106, 119, 126, 129, 177, 205, 253, 264, 279). These cases have occurred in both sexes. With few exceptions (58, 264), the patients have bled from birth or early infancy. The pattern of hemorrhage has been similar to that of hemophilia, with ready bruising, epistaxes, gingival bleeding, intramuscular hematomas, hemarthroses, bleeding into the gastrointestinal tract and central nervous system, bleeding after dental extractions, and in the females, menorrhagia. Surgical procedures have been tolerated surprisingly well (20, 106, 147, 253). Bleeding is usually not as severe as in hemophilia, although fatal cases have been reported (279). In addition to the prolonged prothrombin time, the clotting time has been long in many of the patients (20, 58, 129, 177), and the bleeding time in a few (20).

The pattern of heredity is by no means clear. Both familial and sporadic cases have been observed. In 1 family studied in our laboratory, pro-SPCA deficiency appeared to be inherited as a recessive trait in which the heterozygous state could be detected (212).

To explain the normal serum prothrombin activity in the presence of a prolonged prothrombin time, it has been suggested that these patients lack a factor needed for the action of tissue thromboplastin, but not for that of the thromboplastin derived from blood itself. (1) In certain of these cases, the thromboplastin generation test has given normal results (1, 106, 126, 177, 279), supporting this view. However, this explanation may not prove satisfactory, since the clotting time may be prolonged and results of the thromboplastin generation test have actually been abnormal as often as normal (37, 58, 129, 253, 268). Finally, it is noteworthy that the prolonged prothrombin time in these patients has been corrected by addition of Russell's viper venom (106, 119, 177, 212), which is known to behave as if it contained pro-SPCA (120).

Although this disorder seldom threatens life, treatment is unsatisfactory. The transfusion of fresh or stored blood has been only of the most transient benefit (20). Chevallier *et al.* (58) noted that the pro-SPCA of normal plasma was inactivated when it was incubated for 6 hours with an equal volume of plasma from 1 of their patients, but other cases of circulating anticoagulants have not been reported. We

In animals the injection of aminophylline has stimulated an increase in the plasma proaccelerin concentration (109) but aminophylline is without effect in parahemophilia. Vitamin K therapy is also ineffective (176) a predictable result since Dicumarol and similar compounds do not alter the proaccelerin concentration.

### DEFICIENCIES OF SERUM FACTORS PRO SPCA AND STUART FACTOR

A number of patients thought to have congenital prothrombin deficiencies were described in the 1940s. Surprisingly the plasma defect in certain of these patients was corrected by adding serum supposedly poor in prothrombin (64 90 123). This discrepancy was clarified by the studies of Alexander *et al* (20) on the nature of the severe clotting defect in a young girl. The clotting time of venous blood was normal or slightly prolonged and the bleeding time abnormally long. The one-stage prothrombin time was much longer than normal for example 72 seconds compared with 17 seconds for a control plasma. The addition of human serum devoid of prothrombin or proaccelerin, shortened the prolonged prothrombin time. Presumably then the patient's plasma lacked something present in normal serum which corrected the abnormality measured by the one stage prothrombin time.

Just such a substance had been described by a number of investigators who used the usual barrage of descriptive terms: co thromboplastin stable factor proconvertin and the precursors of factor VII or of serum prothrombin conversion accelerator (pro SPCA). Alexander *et al* showed that the addition of purified pro SPCA corrected the defect in their patient's plasma and concluded that her plasma was deficient in this factor.

Since then other instances have been reported of a congenital hemorrhagic state associated with a long prothrombin time which is corrected by serum. These cases do not form a homogeneous group and from the available literature they cannot be classified rationally. One classification suggested by recent studies of Ackroyd (1) and of Hougie and co workers (113) would divide these cases according to the results of the prothrombin consumption test. In this test the patient's blood is allowed to clot in glass tubes without the addition of tissue thromboplastin. After a standard interval, the amount of prothrombin remaining in the serum is measured. Normally within 1

the basis of the serum prothrombin activity thromboplastin generation, and the reaction to Russell's viper venom fails to account for all the reported cases. For example the patient described by Frick and Hagen (86) has now been restudied by Gonyea and Krivit (92a). Despite the presence of normal serum prothrombin activity appropriate technics showed that the correct diagnosis was Stuart factor deficiency. The seemingly unending complexity is illustrated by the case of identical twins described by Biggs (37). The prothrombin time serum prothrombin activity thromboplastin generation and reaction to Russell's viper venom were all abnormal as in the cases of Stuart defect or Prower defect. However serum of the patient with Prower defect (266) corrected the defect in these twins and vice versa. Thus the distinction between the various cases is in a hopeless jumble and awaits some clarifying concept. These studies are of great theoretic interest, but their practical application is limited at present to the classification of patients and to an appreciation of the limits of our current diagnostic armamentarium.

### CONGENITAL AFIBRINOGENEMIA

Perhaps the most extraordinary familial hemorrhagic disease is congenital afibrinogenemia first described by Rabe and Salomon (207) in which no significant amount of fibrinogen is detectable in the blood whatever the technic used—chemical immunologic or electrophoretic. The reported cases have recently been reviewed (88 189 252 280). Obviously the blood is incoagulable and a clot does not form when thrombin is added. The tissues too are devoid of detectable fibrinogen (91). These patients usually bleed from the umbilicus at birth (68 189 252) and have repeated episodes of severe bleeding throughout life. They may have cutaneous ecchymoses epistaxes hematomas and hemoptyses and may bleed into the central nervous system (230). Intraperitoneal hemorrhage following rupture of the spleen has been described (101). Hemarthroses are relatively rare (252). Trivial injuries may cause protracted bleeding. Death results from blood loss (175) or bleeding into a vital area (230).

Long periods of freedom from bleeding are among the many oddities seen in these patients (21 140 154). Girls who have reached the menarche have had nearly normal menses (140 186) and there have been no exsanguinating hemorrhages such as might be anticipated. The disorder points up the role of mechanisms other than coagulation in control of bleeding.

were unable to corroborate this observation with the plasma of a patient deficient in pro SPCA in a case to be reported by Hewlett and Battle (105a). Although vitamin K is necessary for proconvertin synthesis it is only occasionally effective in congenital pro SPCA deficiency and then only transiently (129, 268).

In summary in a group of cases similar to that reported by Alexander *et al* the prolonged prothrombin time has been ascribed to a deficiency of pro SPCA. Tests in these cases demonstrate normal serum prothrombin activity, variable thromboplastin generation, and in the few instances tested, correction of the abnormality when Russell's viper venom is added.

In a second group of cases the results of the test for serum prothrombin activity have been abnormal (26, 113, 147, 266, 299). Sporadic and familial cases in both sexes have been described. The symptoms do not differ significantly from those of patients in whom serum prothrombin activity is normal. In addition to a prolonged prothrombin time the clotting time has usually been long and thromboplastin generation abnormal (113, 266). Telfer and co-workers (266) differentiated the defect in their patient from pro SPCA deficiency because the prothrombin time was shortened by the plasma of patients under treatment for a short time with phenindione (Dindevan \* Danilone †, Hedulin ‡) a substance with coumarin-like activity. Such plasma is deficient in pro SPCA. They believed that their patient lacked another factor and they named her disorder Prower-defect after her surname. The reaction to Russell's viper venom in her case was equivocal (37, 266). Similarly, Hougie and co-workers (113) restudying a case reported earlier (147) observed that the prothrombin time was shortened by the plasma of patients treated briefly with Dicumarol. Such plasma too is deficient in pro SPCA. Furthermore, the plasma defect of Hougie's patient was corrected by addition of plasma from the patient observed by Alexander *et al* (20) implying that the 2 patients lacked different factors. Finally, Russell's viper venom did not correct the prolonged prothrombin time. They concluded that their patient lacked a property other than pro SPCA which they named "Stuart factor" after their patient. Restudy of the patient of Crockett *et al* (64) indicated that she had the same defect.

Unfortunately the differentiation of these cases into 2 groups on

\* Evans Medical Supplies, Liverpool, England.

† Schieffelin & Co., New York, N. Y.

‡ Walker Laboratories, Inc., Mount Vernon, N. Y.

present in normal concentration although thrombocytopenia (54 68 154) and a slight decrease in proaccelerin (144) have been observed. Thrombocytopenia has also been associated with congenital hypofibrinogenemia (104 218). The bleeding time varies (280) in some it appears to be normal but bleeding starts again when the patient moves the part which has been tested. The result of the tourniquet test is usually normal (88 280). In 1 patient, the plasma albumin level was decreased and the globulin increased but no clinical evidence of hepatic disease was described (280).

✓ Although episodes of bleeding may end without specific treatment transfusion of blood or preferably human fibrinogen is the treatment of choice. Because exsanguination or bleeding into a vital area is possible the prognosis is poor. To the best of my knowledge the oldest living patient is now 26 years old (101).

### CONGENITAL HYPERHEPARINEMIA

Quick and Hussey (204) have recently described the case of a 23 year old woman with a history of abnormal bleeding since the age of 3. Many transfusions had been necessary because of hemorrhage after mastoidectomy after dental extractions and other minor operations and after childbirth. The clotting time was prolonged this abnormality was apparently due to a change in the final stages of clotting since the clotting time of a mixture of thrombin and the patient's plasma was abnormally long. Since the thrombin time was shortened by the addition of protamine sulfate or toluidine blue substances known to neutralize heparin they believe that the patient has chronic hyperheparinemia. Intravenous injection of protamine or toluidine blue did not improve the patient's condition but cortisone and transfusions of freshly frozen plasma were apparently beneficial. This case has been reported only in the form of a brief abstract more detailed proof that the blood actually contains heparin or a heparinoid would be desirable. Other reported cases of congenital hyperheparinemia are not as convincing as this one since the thrombin time which is altered by minute amounts of heparin has not been prolonged.

### CONGENITAL THROMBOCYTOPENIA

An interesting study is that by Aldrich and co workers (10) of a family in which the complex of repeated ear infections eczematoid dermatitis bloody diarrhea and purpura appeared in certain individu



The experiment of nature represented by afibrinogenemia provides an opportunity to study the earlier stages of clotting and vascular hemostatic mechanisms unhampered by the formation of fibrin. For example Pinniger and Prunty (187) observed that agglutination and fragmentation of platelets occurred in the absence of fibrinogen. The clumps of platelets adhered to the walls of a glass tube. They thought their observations to be in agreement with the view that platelet thrombi are important in controlling bleeding from small vessels. Several groups (21, 36, 280) have confirmed these observations. Alexander *et al* (21) believe that the change in platelets is partly due to elaboration of thrombin in the shed blood. Hardisty and Pinniger (101) showed that serotonin is readily released from the platelets in shed blood of a patient with afibrinogenemia in contrast to hemophilic blood in which the release of serotonin is slower than normal (36). They related the relatively mild bleeding in congenital afibrinogenemia to this capacity to release serotonin.

Congenital afibrinogenemia is an inherited disease occurring in both sexes and is ordinarily transmitted by mutant autosomal recessive genes. Multiple cases within a family may occur (140). Many of the patients were offspring of consanguineous marriages (21, 88, 154, 187, 230, 252). The heterozygous state has been undetectable in many cases (187, 280) but some of the heterozygous carriers have had hypofibrinogenemia (88, 140, 154) and some of them have had mild symptoms. Isolated cases of congenital hypofibrinogenemia have been described (218). However, Graham (95) questions the evidence that heterozygous carriers can be detected.

All the observations seem to indicate that congenital afibrinogenemia is probably due to a failure of fibrinogen synthesis rather than to its excessive use or destruction. Fibrinogen transfused in the form of blood (46, 187) or purified preparations (88, 101) can be detected for as long as 17 days although an adequate concentration for hemostasis lasts for a much shorter time. Gitlin and Borges (91) found the half life of the infused fibrinogen to be approximately 4 days, a value comparable to the half life of radioactive fibrinogen in normal individuals. The diagnosis is easily established. The peripheral blood is incoagulable even when thrombin is added; the absence of fibrinogen can then be confirmed by several methods. When antiserum prepared against human fibrinogen is added to such plasma, no fibrinogen (187, 285) or only the merest traces can be detected (91). Of course the one stage prothrombin time is infinite. Other clotting factors are usually

present in normal concentration although thrombocytopenia (54 68 154) and a slight decrease in proaccelerin (144) have been observed. Thrombocytopenia has also been associated with congenital hypofibrinogenemia (104 218). The bleeding time varies (280) in some it appears to be normal but bleeding starts again when the patient moves the part which has been tested. The result of the tourniquet test is usually normal (88 280). In 1 patient the plasma albumin level was decreased and the globulin increased but no clinical evidence of hepatic disease was described (280).

✓ Although episodes of bleeding may end without specific treatment transfusion of blood or preferably human fibrinogen is the treatment of choice. Because exsanguination or bleeding into a vital area is possible the prognosis is poor. To the best of my knowledge the oldest living patient is now 26 years old (101).

### CONGENITAL HYPERHEPARINEMIA

Quick and Hussey (204) have recently described the case of a 23 year old woman with a history of abnormal bleeding since the age of 3. Many transfusions had been necessary because of hemorrhage after mastoidectomy after dental extractions and other minor operations and after childbirth. The clotting time was prolonged this abnormality was apparently due to a change in the final stages of clotting since the clotting time of a mixture of thrombin and the patient's plasma was abnormally long. Since the thrombin time was shortened by the addition of protamine sulfate or toluidine blue substances known to neutralize heparin they believe that the patient has chronic hyperheparinemia. Intravenous injection of protamine or toluidine blue did not improve the patient's condition but cortisone and transfusions of freshly frozen plasma were apparently beneficial. This case has been reported only in the form of a brief abstract more detailed proof that the blood actually contains heparin or a heparinoid would be desirable. Other reported cases of congenital hyperheparinemia are not as convincing as this one since the thrombin time which is altered by minute amounts of heparin has not been prolonged.

### CONGENITAL THROMBOCYTOPENIA

An interesting study is that by Aldrich and co workers (10) of a family in which the complex of repeated ear infections eczematoid dermatitis bloody diarrhea and purpura appeared in certain individu

als all of them males. The syndrome was apparently transmitted by a sex linked recessive gene. Studies of the hemostatic mechanisms in 1 affected child revealed a persistent thrombocytopenia which failed to respond to splenectomy. The boy's bone marrow contained numerous megakaryocytes with little evidence of platelet formation. The existence of this syndrome has been confirmed by Wolff and Bertuccio (295a) and by Huntley and Dees (113a).

Congenital thrombocytopenia has also been described in association with giant hemangiomas in infancy. The available evidence suggests that in this disorder the platelets are sequestered in the tumor. Treatment of the hemangioma results in remission of the thrombocytopenia (93).

Congenital thrombocytopenia at times familial has also been described in the absence of other defects (296). I am unfamiliar with a clear definition of this syndrome.

Qualitative defects in platelets have not been considered in the present review.

### COMBINED DEFECTS

Incredible as it may seem, a number of cases have been described in which the blood seems congenitally deficient in more than one clotting factor. Thus combined deficiencies of antihemophilic factor and Christmas factor, antihemophilic factor and proaccelerin, and of prothrombin, Christmas factor, and "proconvertin" have all been reported. Soulier and Larrieu (250) described the case of a 39 year old man in whom deficiencies of both antihemophilic and Christmas factors were detected. This patient had a family history of a bleeding diathesis but the nature of the disorder in his relatives was not ascertained. Hill and Speer (107) reported the cases of 2 brothers with a severe bleeding disorder which they attributed to a combined deficiency of the same factors; their data, however, are susceptible to other interpretations. Ingram (114) described the same combination in a woman whose father, brother, 2 sisters, and paternal aunts were all bleeders; information about her mother's family was not available. In addition, the patient's bleeding time was prolonged and Ingram thought the platelets to be qualitatively abnormal. Verstraete and Vandenbroucke (281) patient with the same deficiencies had 2 maternal male cousins with classic hemophilia alone.

Combined deficiencies of proaccelerin and antihemophilic factor have also been observed in 4 cases, all male (116, 174, 238). Oeri and

associates (174) have described 2 brothers with relatively mild hemorrhagic symptoms in whom defects in both factors were found. The same combination was noted by Iversen and Bastrup Madsen (116) in a mentally retarded boy; severe bleeding had resulted in hemarthroses and in priapism. Our patient (238) has had only mild hemorrhagic manifestations. The disorder seems to be due to the inheritance of recessive genes which may not be sex linked since 3 patients were offspring of consanguineous unions (116, 174) and the parents of the fourth came from the same small village (238). A sister of 1 patient had hypoproaccelerinemia but the parents and 2 other siblings were normal (116). The mother of our patient had a slight proaccelerin deficiency but the only other available relative, a maternal half brother, was normal. It would thus appear that the defects can be so inherited that one or both deficiencies appear. It remains to be seen if any relatives will have a deficiency of antihemophilic factor alone.

It is noteworthy that antihemophilic factor and proaccelerin have a number of similar properties: (1) both are labile upon storage or gentle heating, particularly in the presence of oxalate; (2) both disappear rapidly during clotting; (3) both are poorly adsorbed by barium sulfate and similar agents; (4) both are adsorbed onto platelets; and (5) both are only poorly inhibited by sulfhydryl containing reagents (212). The findings would be compatible with the view that certain genes influence the synthesis of both proteins but there are no data to suggest the nature of the genetic influences on these syntheses.

In a third type of combined defect, reported by Newcomb and associates (172), the patient's plasma resembles that of individuals under treatment with coumarin like drugs. Their patient, an adult woman, had had a hemorrhagic tendency since the age of 4, characterized by ecchymoses, hematemesis, hemoptysis, melena, hematuria, menorrhagia, cerebral hemorrhage and bleeding after tonsillectomy. It is not clear whether a hereditary defect was present, although several relatives had histories suggestive of a bleeding tendency. In addition to the hematologic abnormalities, a number of bizarre manifestations including arthralgia, splenomegaly and lymphadenopathy were present. The prothrombin time was greatly prolonged, an abnormality shown to be due to simultaneous deficiencies of prothrombin, pro SPCA and Stuart factor (172). A deficiency of Christmas factor was also present (37). All these changes resemble those in patients treated with coumarin like drugs; we have also seen comparable abnormalities in a patient apparently sensitive to relatively small doses of aspirin.

The possibility of self administration of drugs was excluded by Newcomb *et al*. Massive doses of vitamin K<sub>1</sub> were of the most transient benefit but transfusion of 500 ml of fresh plasma resulted in a remission lasting 1 or 2 weeks. On the other hand fresh serum had only a temporary effect. Newcomb *et al* suggested that the patient might lack some substance required for the synthesis of all of the deficient factors. Similar cases may have been observed elsewhere (274).

This summary does not encompass the various combinations of coagulative defects which have been reported. Without laboring the point it is evident that one must guard against dogmatic acceptance of the relatively simple genetic concepts which have dominated our thinking about hemorrhagic disease.

### L'ENVOI

A common human failing is to hope for a return to an earlier day in which peace, prosperity, the various homely virtues and a simplified concept of coagulation all reigned serenely. In our more lucid moments the obstacles in our way to these goals are clear enough. Perhaps a realistic view of the future would include an increasing appreciation of the biochemistry and biophysics of clotting, more rational therapeutics and the emergence of a new strain of clotologists deficient in the enzymes which are responsible for terminology.

### REFERENCES

- 1 Ackroyd J F. Function of factor VII. *Brit J Haemat* 2:397, 1956.
- 2 Adams M A and Taylor F H L. Thrombic activity of a globulin fraction of plasma proteins of beef, swine and human blood. *Am J M Sc* 205:538, 1943.
- 3 Addis T. Pathogenesis of hereditary haemophilia. *J Path & Bact.* 15:427, 1911.
- 4 Aggeler P M. Treatment of hemophilia. *Blood* 11:81, 1956.
- 5 Aggeler P M and Lucia S P. Neurologic complications of hemophilia. *J Nerv & Ment Dis* 99:475, 1944.
- 6 Aggeler P M, Spaet T H and Emery B E. Purification of plasma thromboplastin factor B (plasma thromboplastin component) and its identification as a beta<sub>2</sub> globulin. *Science* 119:806, 1954.
- 7 Aggeler P M, White S G and Spaet, T H. Deuterohemophilia. Plasma thromboplastin component (PTC) deficiency. Christmas disease hemophilia B. *Blood* 9:246, 1954.
- 8 Aggeler P M *et al*. Purification of plasma thromboplastin factor B. *Rev hémat* 9:447, 1954.
- 9 Aggeler P M *et al*. Plasma thromboplastin component (PTC) deficiency. New disease resembling hemophilia. *Proc Soc Exper Biol & Med* 79:692, 1952.

- 10 Aldrich, R A Steinberg A G and Campbell, D C Pedigree demonstrating sex linked recessive condition characterized by draining ears eczema toad dermatitis and bloody diarrhea Pediatrics 13 133 1954
- 11 Alexander B Antihemophilic principle of normal plasma J Clin. Invest. 28 1173 1947
- 12 Alexander B Coagulation, hemorrhage and thrombosis New England J Med 252 432, 484 526 1955
- 13 Alexander B Treatment of hemophilia Blood 11 84 1956
- 14 Alexander B and Goldstein R Parahemophilia in three siblings (Owren's disease) with studies on certain plasma components affecting prothrombin conversion, Am J Med. 13 255 1952.
- 15 Alexander B and Goldstein, R Dual hemostatic defect in pseudohemophilia J Clin. Invest. 32 551 1953
- 16 Alexander B and Landwehr G Studies of hemophilia control of hemophilia by repeated infusions of normal human plasma J A M A 138 174 1948
- 17 Alexander B and Landwehr G Prothrombin consumption, serum prothrombic activity and prothrombin conversion accelerator in hemophilia and thrombocytopenia, J Clin Invest. 28 1511 1949
- 18 Alexander B de Vries A and Goldstein R Prothrombin activator in serum and its significance in certain hemorrhagic diseases J Clin. Invest 27 523 1948
- 19 Alexander B Goldstein, R and Landwehr G Labile factor of prothrombin conversion Its consumption under normal and pathological conditions affecting blood coagulation, J Clin Invest. 30 252, 1951
- 20 Alexander B., et al Congenital SPCA deficiency Hitherto unrecognized coagulation defect with hemorrhage rectified by serum and serum fractions J Clin Invest 30 596 1951
- 21 Alexander B et al Congenital afibrinogenemia Study of some basic aspects of coagulation, Blood 9 843 1954
- 22 Alkjaersig N and Seegers W H Formation of prothrombin from auto-prothrombin by means of liver mitochondria, Am. J Physiol. 183 111 1956
- 23 Andreassen, M K. *Haemofili i Danmark* (Copenhagen E Munksgaard 1943) (Opera ex Domo biologiae hereditariae humanae Universitatis Hafniensis no 6 1943) (Copenhagen theses 1943) [Eng summary]
- 24 Archer W H and Zubrow H J Hemophilic Pre and postoperative treatment a case report, Oral Surg 3 1377 1950
- 25 Astrup T Fibrinolysis in organism Blood 11 781 1956
- 26 Beaumont, J L and Bernard J Syndrome hemorrhagique congenital du au defaut du facteur de coagulation recemment isole sous le nom de facteur VII convertine SPCA Acta med scandinav 145 200 1953
- 27 Beaumont, J L et al Syndrome hemorrhagique congenital du au defaut d'un facteur plasmatique prothromboplastique different du facteur anti hemophilique (hemophilie B) Sang 24 488 1953
- 28 Bell, W N and Alton H G Brain extract as substitute for platelet suspensions in thromboplastin generation test, Nature 174 880 1954
- 29 Bendien W M and van Creveld, S Onderzoekingen over haemophilie Maandschr kindergeneesk 5 179 1936
- 30 Bergsagel, D E and Hougie C Intermediate stages in formation of blood thromboplastin Brit. J Haemat 2 113 1956
- 31 Bergsagel, D E et al Mild PTC (plasma thromboplastin component) deficiency occurring in two brothers Blood 9 866 1954

The possibility of self administration of drugs was excluded by Newcomb *et al*. Massive doses of vitamin K<sub>1</sub> were of the most transient benefit, but transfusion of 500 ml of fresh plasma resulted in a remission lasting 1 or 2 weeks. On the other hand, fresh serum had only a temporary effect. Newcomb *et al* suggested that the patient might lack some substance required for the synthesis of all of the deficient factors. Similar cases may have been observed elsewhere (274).

This summary does not encompass the various combinations of coagulative defects which have been reported. Without laboring the point, it is evident that one must guard against dogmatic acceptance of the relatively simple genetic concepts which have dominated our thinking about hemorrhagic disease.

### L ENVOI

✓ A common human failing is to hope for a return to an earlier day in which peace, prosperity, the various homely virtues, and a simplified concept of coagulation all reigned serenely. In our more lucid moments, the obstacles in our way to these goals are clear enough. Perhaps a realistic view of the future would include an increasing appreciation of the biochemistry and biophysics of clotting, more rational therapeutics, and the emergence of a new strain of clotologists deficient in the enzymes which are responsible for terminology.

### REFERENCES

- ✓ 1 Ackroyd J F. Function of factor VII. *Brit J Haemat* 2:397, 1956.
- 2 Adams M A and Taylor F H L. Thrombic activity of a globulin fraction of plasma proteins of beef, swine and human blood. *Am J M Sc* 205:538, 1943.
- 3 Addis T. Pathogenesis of hereditary haemophilia. *J Path & Bact.* 15:427, 1911.
- 4 Aggeler P M. Treatment of hemophilia. *Blood* 11:81, 1956.
- 5 Aggeler P M and Lucia S P. Neurologic complications of hemophilia. *J Nerv & Ment Dis* 99:475, 1944.
- 6 Aggeler P M, Spaet T H and Emery B E. Purification of plasma thromboplastin factor B (plasma thromboplastin component) and its identification as a beta<sub>2</sub> globulin. *Science* 119:806, 1954.
- ✓ 7 Aggeler P M, White S G and Spaet T H. Deuterohemophilia. Plasma thromboplastin component (PTC) deficiency. Christmas disease hemophilia B. *Blood* 9:246, 1954.
- 8 Aggeler P M *et al*. Purification of plasma thromboplastin factor B. *Rev hemat* 9:447, 1954.
- 9 Aggeler P M *et al*. Plasma thromboplastin component (PTC) deficiency. New disease resembling hemophilia. *Proc Soc Exper Biol. & Med* 79:692, 1952.

- 58 Chevalier P *et al* Deux cas d'hypoconvertinémie familiale Sang 26 650 1955
- 59 Chevalier P *et al* Action paradoxale d'une transfusion de sang d'hémophile à un sujet normal Sang 20 159 1949
- 60 Conley C L, Hartmann R C and Morse W I II Clotting behavior of human "platelet free" plasma evidence for existence of plasma thromboplastin, J Clin Invest. 28 340 1949
- 61 Conley C L *et al* Circulating anticoagulant as cause of hemorrhagic diatheses in man Bull Johns Hopkins Hosp 83 288 1948
- 62 Craddock C G Jr and Lawrence J S Hemophilia report of mechanism of development and action of an anticoagulant in two cases Blood 2 505 1947
- 63 Craddock C G Jr Fenninger L D and Simmons B Hemophilia problem of surgical intervention for accompanying diseases review of literature and report of case Ann Surg 128 888 1948
- 64 Crockett, C L Jr *et al* Hypoprothrombinemia Studies of case of idiopathic type and effect of serum administration Blood 4 1298 1949
- 65 Darte J M M Defect of antihemophilic globulin in von Willebrand's disease A M A Am J Dis Child 90 561 1955
- 66 Davidson C S *et al* Hemophilia clinical study of forty patients Blood 4 97 1949
- 67 De Palma A F and Cotler J Hemophilic arthropathy Clin Orthopaed 8 163 1956
- 68 De Silva C C and Thanabalasundaram R S Congenital afibrinogenemia Brit M J 2 86 1951
- 69 De Vries A Heiman Hollander E and Herz N Studies on serum prothrombin in hemophilia Acta med scandinav 138 225 1951
- 70 De Vries A, Matoth, Y and Shamir Z Familial congenital labile factor deficiency with syndactylism investigation on mode of action of labile factor Acta haemat 5 129 1951
- 70a Didisheim P, Ferguson J H and Lewis J H Hemostatic data in relatives of hemophiliacs A and B A M A Arch Int Med 101 347 1958
- 71 Douglas A S Antihemophilic globulin consumption during blood coagulation Blood 11 423 1956
- 72 Douglas A S Factor V consumption during blood coagulation Brit. J Haemat 2 153 1956
- 73 Douglas A S and Biggs R Consumption of some components involved in physiological blood coagulation Glasgow M J 34 329 1953
- 74 Douglas A S and McAlpine S G Neurological complications of haemophilia and Christmas disease Scottish M J 1 270 1956
- 75 Duckert F, Fluckinger P and Koller F Le rôle du facteur X dans la formation de la thromboplastine sanguine Rev hemat 9 489 1954
- 76 Dunn F S *Care and Treatment of Teeth in Hemophiliacs* (New York The Hemophilia Foundation)
- 77 Fabey J L, Ware A G and Seegers W H Stability of prothrombin and Ac globulin in stored human plasma as influenced by conditions of storage Am J Physiol 154 122 1948
- 78 Fantl P and Nance M H Physiological activation of prothrombin, M J Australia 1 128 1948
- 79 Fell, C *et al* Differentiation of plasma antithrombin activities Proc Soc Exper Biol. & Med 85 199 1954
- 80 Ferry J D, Müller M and Shulman S Conversion of fibrinogen to fibrin rigidity and stress relaxation of fibrin clots effect of calcium Arch Biochem 34 424 1951



- 32 Bernfeld P *et al* Electrophoretic plasma protein patterns in families with hemophilia Proc Soc Exper Biol & Med 83 311 1953
- 33 Bettelheim F R and Bailey K Products of action of thrombin on fibrinogen Biochem et biophys acta 9 578 1952
- 34 Bidwell E Purification of bovine antihemophilic globulin Brit J Haemat 1 35 1955
- 35 Bidwell E Purification of antihemophilic globulin from animal plasma Brit J Haemat 1 386 1955
- 36 Bigelow F S Serotonin activity in blood measurements in normal subjects and in patients with thrombocythemia hemorrhagica and other hemorrhagic states J Lab & Clin Med 43 759 1954
- 37 Biggs R Some observations on blood of patients with factor VII deficiency Brit J Haemat 2 412 1946
- ✓38 Biggs R and Douglas A S Thromboplastin generation test, J Clin. Path 6 23 1953
- ✓39 Biggs R and Macfarlane R G *Human Blood Coagulation and Its Disorders* (2d ed Oxford Blackwell Scientific Publications 1957)
- 40 Biggs R Douglas A S and Macfarlane R G Initial stages of blood coagulation J Physiol 122 538 1953
- 41 Biggs R *et al* Christmas disease condition previously mistaken for haemophilia Brit M J 2 1378 1952
- 42 Burch C LaF Hemophilia—Clinical and Genetic Aspects in *Illinois Medical and Dental Monographs* (Urbana University of Illinois 1935-1937) Vol. I no 4
- 43 Bordet J and Gengou O Recherches sur la coagulation du sang et les sérums anticoagulants Ann inst. Pasteur 15 129 1901
- 44 Borges W H and Ratnoff O D Unpublished observations
- 45 Bradfield A J and Case J Stability of Christmas factor guide to management of Christmas disease Lancet 2 867 1956
- 46 Breckoff E Zur Kenntnis der Pseudohämophilie Monatsschr Kinderh 28 232 1924
- 47 Brink A J and Kingsley C S Familial disorder of blood coagulation due to deficiency of labile factor Quart. J Med n s 21 19 1952.
- 48 Brinkhous K M Study of clotting defect in hemophilia Delayed formation of thrombin Am J M Sc 198 509 1939
- 49 Brinkhous K M Clotting defect in hemophilia Deficiency in plasma factor required for platelet utilization Proc Soc Exper Biol & Med. 66 117 1947
- 50 Brinkhous K M and Graham J B Hemophilia in female dog Science 111 723 1950
- 51 Brinkhous K M *et al* Newer approaches to study of hemophilia and hemophiloid states J A M A 154 481 1954
- 52 Brinkhous K M Morrison F C Jr and Muhrer M E Comparative study of clotting defects in human canine and porcine hemophilia Fed Proc 11 409 1952
- 53 Brown A Cited by Biggs and Macfarlane (40)
- 54 Buček, A Ein Fall der angeborenen familiären Afibrinogenämie Ann. pædiat. 177 111 1951
- 55 Budtz Olsen O E *Clot Retraction* (Springfield, Ill Charles C Thomas 1951)
- 56 Caen, J and Bernard J Syndrome hémorragique dû au défaut du facteur prothromboplastique de Rosenthal (PTA) Sang 27 219 1956
- 57 Chevallier P Fiehrer A and Samama M Hémophilie B avec taux excessif d'antithromboplastine Sang 26 528 1955

- 103 Hartmann J R and Diamond L K Natural history of 73 patients with hemophilia and related hemorrhagic diseases Arch Dis Childhood 90 594 1955
- 104 Heinild S On familial constitutional fibrinopenia some observations with regard to simultaneous appearance of fibrinopenia thrombopenia and hypoprothrombinemia Acta med scandinav 118 479 1944
- 105 Henry E I Rosenthal R L and Hoffman I Spontaneous hemorrhages caused by plasma thromboplastin antecedent deficiency J A M A 162 727 1956
- 105a Hewlett J and Battle J To be published
- 106 Hicks N D Coagulation disorder due to factor VII like defect M J Australia 2 331 1955
- 107 Hill J M and Speer R J Combined hemophilia and PTC deficiency Blood 10 357 1955
- 108 Hjort P Rapaport S I and Owren P Evidence that platelet accelerator (platelet factor I) is adsorbed plasma proaccelerin Blood 10 1139 1955
- 109 Honorato R Changes in prothrombin time induced by methylxanthenes role of plasma cofactor of thromboplastin Arch Biochem 22 345 1949
- 110 Horder M H Isolierter Faktor V Mangel bedingt durch einen spezifischen Häminkörper Acta haemat 13 235 1955
- 111 Horder M H and Sokal G Der Einfluss von Faktor V auf die Plasma Thromboplastinbildung Acta haemat 14 294 1955
- 112 Hougé C and Fearnley M E Nature and action of circulating anti coagulants Acta haemat 12 1 1954
- ✓ 113 Hougé C Barrow E M and Graham J B Stuart clotting defect segregation of hereditary hemorrhagic state from heterogeneous group heretofore called stable factor (SPCA, proconvertin factor VII) deficiency J Clin Invest 36 485 1957
- 113a Huntley C L and Dees S C Eczema associated with thrombocytopenic purpura and purulent otitis media Pediatrics 19 351 1957
- 114 Ingram G I C Observations in case of multiple haemostatic defect Brit J Haemat 2 180 1956
- 115 Israels M C G Lempert H and Gilbertson E Hemophilia in female Lancet, 1 1375 1951
- 116 Iversen T and Bastrup Madsen P Congenital familial deficiency of factor V (parahemophilia) combined with deficiency of antihemophilic globulin Brit J Haemat 2 265 1956
- 117 Jacob R F Studies in activation of serum prothrombin converting factor J Clin Invest 28 492 1949
- 118 Jacques L B et al Silicates and blood coagulation Canad M A J 55 20 1946
- 119 Jenkins J S Haemorrhagic diathesis due to deficiencies of factor VII J Clin Path 7 29 1954
- 120 Jenkins J S Thromboplastic activity of Russell's viper venom and its relationship to factor VII J Clin Path 7 287 1954
- ✓ 121 Jim, R T S and Goldfein S Hageman trait (Hageman factor deficiency) Am J Med 23 825 1957
- 122 Johnson, J B Management of hemophilia with lyophile human plasma intravenously injected, J A M A 118 799 1942
- 123 Johnson S A Activation of purified prothrombin with hemophilic plasma Am J Clin. Path 23 875 1953
- 124 Johnson S A. McClaughry R I and Seegers W H Nature of blood clotting mechanisms in hemophilia J Michigan State M Soc 54 797 1955

- 81 Field R A Ruckard C G and Hutt F B Hemophilia in family of dogs *Cornell Vet* 30 285 1946
- 82 Flynn J E and Coon R W Purification and isolation of certain intermediates formed prior to activation of prothrombin *Am J Physiol* 175 289 1953
- 82a Fono A Die Hamophilie *Ergebn inn Med u Kinderh* 51 443 1936
- 83 Fono A and Passet R Cited by Quirk (195)
- 84 Frankel G J and Horney C E Gunshot wounds in haemophilic patient successful treatment by animal antihemophilic globulin and surgery *Lancet* 2 1117 1955
- 85 Frick P G Relative incidence of antihemophilic globulin (AHG) plasma thromboplastin component (PTC) and plasma thromboplastin antecedent (PTA) deficiency Study of 55 cases *J Lab & Clin Med* 43 860 1954
- 86 Frick P G and Hagen P S Congenital familial deficiency of stable prothrombin conversion factor restudy of case originally reported as idiopathic hypoprothrombinemia *J Lab & Clin Med* 42 212 1953
- 87 Frick P G and Hagen P S Severe coagulation defect without hemorrhagic symptoms caused by deficiency of fifth plasma thromboplastin precursor *J Lab & Clin Med* 47 592 1956
- 88 Frick P G and McQuarrie J Congenital afibrinogenemia *Pediatrics* 13 44 1954
- 89 Frommeyer W B Epstein R D and Taylor F H L Refractoriness in hemophilia to coagulation promoting agents Whole blood and plasma derivatives *Blood* 5 401 1950
- 90 Giordano A S Idiopathic hypoprothrombinemia *Am J Clin Path* 13 285 1943
- 91 Gitlin D and Borges W H Studies on metabolism of fibrinogen in two patients with congenital afibrinogenemia *Blood* 8 679 1953
- 92 Goldstein R and Alexander B Management of certain hemorrhagic disorders *M Clin North America* 35 1403 1951
- 92a Gonyea L M and Kravitz W Congenital coagulation deficiency of Stuart factor activity *J Lab & Clin Med* 51 398 1958
- 93 Good T A Carnazzo S F and Good R A Thrombocytopenia and giant hemangioma in infants *A M A Am J Dis Child* 90 260 1955
- 94 Govaert P and Gratia A Contribution à l'étude de l'hémophilie *Rev belge sc méd* 3 689 1931
- 95 Graham J B Biochemical genetics of blood coagulation *Am J Human Genet* 8 63 1956
- 96 Graham J B McLendon W W and Brinkhous K M Mild hemophilia an allelic form of the disease *Am J M Sc* 225 46 1953
- 97 Graham J B Penick C D and Brinkhous K M Utilization of anti hemophilic factor during clotting of canine blood and plasma *Am J Physiol* 164 710 1951
- 98 Graham J B et al Canine hemophilia Observations on course clotting anomaly and effect of blood transfusions *J Exper Med* 90 97 1919
- 99 Griggs R and Ratnoff O D Unpublished observations
- 100 Haldane J B S Mutation rate of gene for haemophilia and its segregation ratios in males and females *Ann Eugenics* 13 262 1947
- 100a Hardisty R M Personal communication
- 101 Hardisty R M and Panniger J L Congenital afibrinogenemia further observations on blood coagulation mechanism *Brit J Haemat* 2 139 1956
- 102 Hartert H Die Thromboelastographie eine Methode zur physikalischen Analyse des Blutgerinnungsvorganges *Ztsch ges exper Med* 117 189 1951

- 148 Lewis J H Soulier J P and Taylor F H L Chemical clinical and immunological studies on the products of human plasma fractionation coagulation defect in hemophilia J Clin Invest 25 876 1946
- 149 Lewis J H *et al* Chemical clinical and immunological studies on products of human plasma fractionation coagulation defect in hemophilia J Clin Invest 25 870 1946
- 150 Lewis J H *et al* Primary hemorrhagic diseases J Lab & Clin Med 49 211 1957
- 151 Lorand L and Middlebrook W R Studies on fibrino-peptide Biochim et biophys acta 9 581 1952
- 152 Lyon E D Personal communication
- 153 MacAusland W R Jr and Gartland J J Treatment of acute hemophilic hemarthrosis New England J Med 247 755 1952
- 154 Macfarlane R G Boy with no fibrinogen Lancet 1 309 1938
- 155 Macfarlane R G Hemophilia Christmas disease and matters of terminology Blood 9 258 1954
- 156 Macfarlane R G and Biggs R The Diagnosis and Treatment of Hemophilia and Related Conditions (London H M Stationery Office 1955) (Medical Research Council Memorandum No 32)
- 157 Macfarlane R G Biggs R and Bidwell E Bovine antihemophilic globulin in treatment of haemophilia Lancet 1 1316 1954
- 157a Macfarlane R G *et al* Surgery in haemophilia use of animal antihemophilic globulin and human plasma in thirteen cases Lancet 2 251 1957
- 158 McGovern J J and Steinberg A G Anti hemophilic factor deficiency in a female J Lab & Clin Med 51 386 1958
- 159 Mann F D Reactivity of hemophilic plasma to platelet thromboplastin J Lab & Clin Med 48 51 1956
- 160 Margolius A Jr and Ratnoff O D Unpublished observations
- 161 Margolius A Jr and Ratnoff O D Laboratory study of carrier state in classic hemophilia J Clin Invest 35 1316 1956
- 162 Margolius A Jr and Ratnoff O D Observations on hereditary nature of Hageman trait Blood 11 565 1956
- 163 Martus C and Nitz Litzow D Über den Wirkungsmechanismus des Dicumarols und verwandter Verbindungen Biochim et biophys acta 12 134 1953
- 164 Matter M *et al* Vascular hemophilia association of vascular defect with deficiency of antihemophilic globulin Am J M Sc 232 421 1956
- 165 Merskey C Haemophilia associated with normal coagulation time Brit. M J 1 906 1951
- 166 Merskey C Occurrence of haemophilia in human female Quart J Med ns 20 299 1951
- 166a Merskey C Personal communication
- 167 Merskey C and Macfarlane R G Female carrier of haemophilia clinical and laboratory study Lancet 1 487 1951
- 168 Minot G R *et al* Effect in hemophilia of parenteral administration of fraction of the plasma globulins rich in fibrinogen J Clin Invest 24 704 1945
- 169 Muhrer M E Hogan A G and Bogart R Defect in coagulation mechanism of swine blood Am J Physiol 136 355 1942
- 170 Munro F L Properties of anticoagulant found in blood of hemophiliac J Clin Invest 25 422 1946
- 171 Munro F L and Munro M P Electrophoretic isolation of circulating anticoagulant J Clin Invest. 25 814 1946

- 125 Jones H W and Tocantins L M Treatment of hemophilia J A M A 103 1671 1934
- 125a Josephson A M and Lisker R Demonstration of a circulating anti-coagulant in plasma thromboplastin antecedent deficiency J Clin Invest. 37 148 1958
- 126 Jurgens J Kongenitaler Faktor VII (SPCA) Mangel als Ursache einer hamophilieartigen hamorrhagischen Diathese Acta haemat 16 181 1955
- 127 Key J A. Hemophilic arthritis (bleeders joints) Ann Surg 95 198 1932
- 128 Kingsley C S Familial factor V deficiency pattern of heredity Quart. J Med n s 23 323 1954
- 129 Koch F *et al* Beobachtungen bei angeborenem Faktor VII Mangel (Hypoconvertinämie) Ztschr Kinderh 78 208 1955
- 130 Koller F Is hemophilia a nosologic entity? Blood 9 286 1954
- 131 Koller F Krusi G and Luchsinger G Über eine besondere Form hamorrhagischer Diathese Schweiz med Wchnschr 80 1101 1950
- 132 Lanchantin G F and Ware A C Identification of thromboplastin inhibitor in serum and in plasma J Clin Invest 32 381 1953
- 132a Lane S Cited by Quick (196)
- 133 Langdell R D Wagner R H and Brinkhous K M Effect of antihemophilic factor on one stage clotting tests J Lab & Clin Med 41 637 1953
- 134 Langdell R D Wagner R H and Brinkhous K M Antihemophilic factor (AHF) levels following transfusions of blood plasma and plasma fractions Proc Soc Exper Biol & Med 88 212 1955
- 135 Larrieu M J and Soulier J P Déficit en facteur antihémophilique A chez une fille associé à un trouble du saignement Rev hémat 8 361 1953
- 135a Larrieu M J Soulier J P and Culot Y Déficit en facteur Hageman Sang 28 152, 1957
- 136 Larrieu M J *et al* Hypoaccélerinémie congénitale (parahémophilie d'Owren) Sang 27 117 1956
- 137 Lasch H G and Roka L Zur Prothrombinbildung in der Leber Ztschr physiol Chem 294 30 1953
- 138 Lavelle J M Christmas disease Report of family Irish J M Sc 6 176 1955
- 138a Lawrence J S and Craddock C G Jr Hemophilia Mechanism of development and action of anticoagulant found in two cases Science 106 473 1947
- 139 Lawrence J S and Johnson J B Presence of circulating anti-coagulant in a male member of hemophilic family Tr Am Clin & Climat A 57 223 1941
- 140 Lawson H A Congenital afibrinogenemia Report of case New England J Med 248 552 1953
- 141 Levine P Personal communication
- 142 Lewis J H See reference 70a
- 143 Lewis J H and Ferguson J H Hemorrhagic diathesis due to PTC (plasma thromboplastin component) deficiency Proc Soc Exper Biol & Med 82 445 1953
- 144 Lewis J H and Ferguson J H Afibrinogenemia report of case A M A Am J Dis Child 88 711 1954
- 145 Lewis J H and Ferguson J H Hypoaccélerinémie Blood 10 351 1955
- 146 Lewis J H Ferguson J H and Arends T Hemorrhagic disease with circulating inhibitors of blood clotting anti AHF and anti PTC in eight cases Blood 11 846 1956
- 147 Lewis J H Fresh J W and Ferguson J H Congenital hypoconvertinemia Proc Soc Exper Biol & Med 84 651 1953

- 194 Quick A J Studies on enigma of hemostatic dysfunction of hemophilia  
Am J M Sc 214 272 1947
- 195 Quick A J Management of hemophilia in general practice J A M A  
145 4 1951
- 196 Quick A J *The Physiology and Pathology of Hemostasis* (Philadelphia  
Lee & Febiger 1951)
- 197 Quick A J Hemophilia Am J Med 14 349 1953
- 198 Quick A J On nature and diagnosis of hemophilia Blood 9 265 1954
- 199 Quick A J Personal communication
- 200 Quick A J and Conway J P Hemophilia in twins Am J Med 7 841  
1949
- ✓201 Quick A J and Favre Gilly J E Prothrombin consumption test its clinical  
and therapeutic implications Blood 4 1281 1949
- 202 Quick A J and Hussey C V Hemophilia clinical and laboratory observations  
relative to diagnosis and inheritance Am J M Sc 223 401  
1952
- 203 Quick A J and Hussey C V Hemophilic condition in girl A M A Am J  
Dis Child 85 698 1953
- 204 Quick A J and Hussey C V Hyperheparinemia clinical picture and  
treatment, J Lab & Clin Med 48 932 1958
- 205 Quick A J Pisciotto A V and Hussey C V Congenital hypoprothrombinemic  
states A M A Arch Int Med 95 2 1955
- ✓206 Quick A J Shanberge J N and Stefanini M Role of platelets in coagulation  
of blood Am J M Sc 217 198 1949
- 207 Rabe F and Salomon E Über Faserstoffmangel im Blute bei einem  
Falle von Hamophilie Deutsche Arch klin. Med 132 240 1920
- 208 Ramot B Angelopoulos B and Singer K Variable manifestations of  
plasma thromboplastin component deficiency J Lab & Clin Med 46 80  
1955
- ✓209 Ramot B Angelopoulos B and Singer K Plasma thromboplastin antecedent  
deficiency A M A Arch Int Med 95 705 1955
- ✓210 Ramot B et al Hageman factor (HF) deficiency Blood 11 745 1956
- 211 Ratnoff O D Accelerating property of plasma for coagulation of fibrinogen  
by thrombin J Clin Invest 33 1175 1954
- 212 Ratnoff O D Unpublished studies
- 213 Ratnoff O D and Colopy J E Familial hemorrhagic trait associated  
with deficiency of clot promoting fraction of plasma J Clin Invest  
34 602 1955
- 214 Ratnoff O D and Margolus A Jr Hageman trait asymptomatic disorder  
of blood coagulation Tr A Am Physicians 68 149 1955
- 215 Ratnoff O D and Margolus A Jr On epidemiology of hemophilia and  
Christmas disease New England J Med 256 845 1957
- 216 Ratnoff O D and Potts A M Accelerating effect of calcium and other  
cations on conversion of fibrinogen to fibrin J Clin Invest 33 206 1954
- 217 Richards M D and Spaet T H Immunization of rabbits against human  
antihemophilic factor (AHF) Blood 11 473 1956
- 218 Rusak E Die Fibrinopenie Ztschr klin Med 128 605 1955
- 219 Rosenthal M C Deficiency of plasma thromboplastin component its  
incidence in hemophilic population critique of methods for identification  
Am J Clin Path 24 910 1954
- 220 Rosenthal M C Treatment of hemophilia Blood 11 86 1956
- 221 Rosenthal M C and Sanders M Plasma thromboplastin component de-

- 172 Newcomb T *et al* Congenital hemorrhagic diathesis of prothrombin complex Am J Med 20 798 1958
- 172a de Nicola P *The Laboratory Diagnosis of Coagulation Defects* (Springfield Ill Charles C Thomas 1956)
- 173 Oehme J and Hagette C PTA Mangel Haemophilie Klin Wchnschr 33 841 1955
- 174 Oeri J *et al* Angeborener Mangel an Faktor V (Parahaemophilie) verbunden mit echter Haemophilie A bei zwei Brüdern Bibl paed 58 575 1954
- 175 Opitz H and Frei M Über eine Form der Pseudohaemophilie Jahrb Kinderh 94 374 1921
- 175a den Ottolander G H and Hoorweg P G De frequentie van haemophilie A en B Nederl tijdschr geneesk. 99 2037 1955
- 176 Owren O A Coagulation of blood investigation of new clotting factor Acta med scandinav Supp 194 1947
- 177 Owren P A. New Clotting Factors in *Transactions of Fifth Conference [on] Blood Clotting and Allied Problems* (New York Josiah Macy Jr Foundation 1952) pp 92-170
- 178 Owren P A *et al* Biochemistry of thromboplastin its formation and action Sang 25 752 1954
- 179 Patek, A J Jr and Stetson R P Hemophilia abnormal coagulation of blood and its relation to blood platelets J Clin Invest. 15 531 1936
- 180 Patek A J Jr and Taylor F H L Hemophilia some properties of substance obtained from normal human plasma effective in accelerating coagulation of hemophilic blood J Clin Invest 16 113 1937
- 181 Pavlovsky A Contribution to pathogenesis of hemophilia Blood 2 185 1947
- 182 Pavlovsky A Vascular factors in hemophilia Acta haemat 3 65 1950
- 183 Pekarsky R L Oral surgery and hemophiliae New York State Dental J 21 205 1955
- 184 Penick G D and Brinkhous K M Relative stability of plasma anti hemophilic factor (AHF) under different conditions of storage Am J M Sc 232 434 1956
- 185 Pickering J W and Gladstone J R Coagulability of haemophilic blood J Physiol 59 Lxv 1924
- 186 Pinniger J L and Franks R B Haemophilia in female Lancet 2 82 1951
- 187 Pinniger J L and Prunty F T G Some observations on blood-clotting mechanism role of fibrinogen and platelets with reference to case of congenital afibrinogenemia Brit J Exper Path 27 200 1946
- 188 Pool J G and Spaet T H Ethionine induced depression of plasma anti hemophilic globulin Proc Soc Exper Biol & Med 87 54 1954
- 189 Prichard R W and Vann R L. Congenital afibrinogenemia report on child without fibrinogen and review of literature A M A. Am J Dis Child 88 703 1954
- 190 Quick A J Coagulation defect in sweet clover disease and in hemorrhagic chick disease of dietary origin Am J Physiol. 118 260 1937
- 191 Quick A J Clinical application of hippuric acid and prothrombin tests Am J Clin Path 10 222 1940
- 192 Quick A J *The Hemorrhagic Diseases and the Physiology of Hemostasis* (Springfield Ill Charles C Thomas 1942)
- 193 Quick, A J On constitution of prothrombin Am J Physiol 140 212, 1943.

- 194 Quick A J Studies on enigma of hemostatic dysfunction of hemophilia  
Am J M Sc 214 272 1947
- 195 Quick A J Management of hemophilia in general practice J A M A  
145 4 1951
- 196 Quick A J *The Physiology and Pathology of Hemostasis* (Philadelphia  
Lee & Febiger 1951)
- 197 Quick A J Hemophilia Am J Med 14 349 1953
- 198 Quick A J On nature and diagnosis of hemophilia Blood 9 265 1954
- 199 Quick A J Personal communication
- 200 Quick A J and Conway J P Hemophilia in twins Am J Med 7 841  
1949
- ✓201 Quick A J and Favre Gilly J E Prothrombin consumption test its clinical  
and therapeutic implications Blood 4 1281 1949
- 202 Quick A J and Hussey C V Hemophilia clinical and laboratory observations  
relative to diagnosis and inheritance Am J M Sc 223 401  
1952
- 203 Quick A J and Hussey C V Hemophilic condition in girl A M A Am J  
Dis Child 85 698 1953
- 204 Quick A J and Hussey C V Hyperheparinemia clinical picture and  
treatment J Lab & Clin Med 48 932 1956
- 205 Quick A J Pisciotto A V and Hussey C V Congenital hypoprothrom-  
binemic states A M A Arch Int Med 95 2 1955
- ✓206 Quick A J Shanberge J N and Stefanini M Role of platelets in coagu-  
lation of blood Am J M Sc 217 198 1949
- 207 Rabe F and Salomon E Über Faserstoffmangel im Blute bei einem  
Falle von Hämophilie Deutsche Arch klin Med. 132 240 1920
- 208 Ramot B Angelopoulos B and Singer K Variable manifestations of  
plasma thromboplastin component deficiency J Lab & Clin Med 46 80  
1955
- ✓209 Ramot B Angelopoulos B and Singer K Plasma thromboplastin ante-  
cedent deficiency A M A Arch Int Med 95 705 1955
- ✓210 Ramot B et al Hageman factor (HF) deficiency Blood 11 745 1956
- 211 Ratnoff O D Accelerating property of plasma for coagulation of fibrino-  
gen by thrombin J Clin Invest 33 1175 1954
- 212 Ratnoff O D Unpublished studies
- 213 Ratnoff O D and Colopy J E Familial hemorrhagic trait associated  
with deficiency of clot promoting fraction of plasma J Clin. Invest  
34 602 1955
- 214 Ratnoff O D and Margolius A Jr Hageman trait asymptomatic dis-  
order of blood coagulation Tr A Am Physicians 68 149 1955
- 215 Ratnoff O D and Margolius A Jr On epidemiology of hemophilia and  
Christmas disease New England J Med 256 845 1957
- 216 Ratnoff O D and Potts A M Accelerating effect of calcium and other  
cations on conversion of fibrinogen to fibrin J Clin Invest 33 206 1954
- 217 Richards M D and Spart, T H Immunization of rabbits against human  
antihemophilic factor (AHF) Blood 11 473 1956
- 218 Risak E Die Fibrinopenie Ztschr klin Med 128 605 1955
- 219 Rosenthal M C Deficiency of plasma thromboplastin component its  
incidence in hemophilic population critique of methods for identification  
Am J Clin Path 24 910 1954
- 220 Rosenthal M C Treatment of hemophilia Blood 11 86 1956
- 221 Rosenthal M C and Sanders M Plasma thromboplastin component de-



- 222 Rosenthal R L Hereditary deficiency studies on its inheritance and therapy Am J Med 16 153 1951
- 223 Rosenthal R L Hemophilia and hemophilia like diseases caused by deficiencies in plasma <sup>1</sup> <sup>100</sup> laboratory D plasma factors Antihemophilic globulin (AHG) plasma thromboplastin component (PTC) and plasma thromboplastin antecedent (PTA) Am J Med 17 57 1954
- 224 Rosenthal R L Properties of plasma thromboplastin antecedent (PTA) in relation to blood coagulation, Lab & Clin Med 45 123 1955
- 225 Rosenthal R L Personal communication
- 226 Rosenthal R L Dreskin O H and Rosenthal N Plasma thromboplastin antecedent (PTA) deficiency clinical coagulation therapeutic and hereditary aspects of a new hemophilia like disease Blood 10 120 1955
- 227 Rosenthal R L Dreskin O H and Rosenthal N New hemophilia like disease caused by deficiency of third plasma thromboplastin factor Proc Soc Exper Biol & Med 82 171 1953
- 228 Sawers R Genetics of hemophilia M J Australia 2 222, 1955
- 229 Schilling R F Personal communication
- 230 Schloessman H Neue Forschungsergebnisse über Hämophilie Arch klin Chr 137 686 1924
- 231 Schonholzer G Die hereditäre Fibrinogenopenie Deutsche Arch klin Med 184 496 1939
- 232 Schulman I and Smith C H Hemorrhagic disease in infant due to deficiency of previously undescribed clotting factor Blood 7 794 1952
- 233 Schulman I et al Vascular hemophilia familial hemorrhagic disease in males and females characterized by combined antihemophilic globulin deficiency and vascular abnormality A M A Am J Dis Child 90 526 1955
- 234 Schweitzer A Cited by Fomo A (82a)
- 235 Seaman A Personal communication
- 236 Seegers W H Purification of prothrombin and thrombin chemical properties of purified preparations J Biol Chem 136 103 1940
- 237 Seegers W H and Smith H P Factors which influence activity of purified thrombin Am J Physiol 137 348 1942
- 238 Seegers W H Alkjaersig N and Johnson S A Formation of auto prothrombin in solutions containing purified prothrombin and purified platelet factor 3 Am J Physiol 181 589 1955
- 239 Seibert R Margolius A Jr and Ratnoff O D Unpublished observations
- 240 Shelton M and Hussey H H Hemophilia simulating acute surgical abdomen Postgrad Med 8 233 1950
- 241 Sherry S and Troll W Action of thrombin on synthetic substrates J Biol Chem 208 95 1954
- 242 Shulman S Fibrin serum factor Nature 171 606 1953
- 243 Singer K and Ramot B Pseudohemophilia type B hereditary hemorrhagic diathesis characterized by prolonged bleeding time and decrease in antihemophilic factor A M A Arch Int Med 97 715 1956
- 244 Singer K et al Circulating anticoagulants in hemophilia and in hemophilia like disease Blood 5 1135 1950
- 245 Sise H S Kimball D M and Adams D Plasma thromboplastin component (PTC) deficiency produced by prolonged administration of prothrombopenic anticoagulants Proc Soc Exper Biol & Med 89 81 1955
- 246 Sjølin K E Hageman trait in family with hemorrhagic diathesis Acta genet med et gemel 7 541 1958
- 247 Skold E On haemophilia in Sweden and its treatment by blood transfusion Acta med scandinav Supp 150 1944

- 246 Smith, H P Warner E D and Brinkhous K. M Prothrombin deficiency and bleeding tendency in liver disease (chloroform intoxication) *J Exper Med.* 68 801 1937
- 247 Sørbye Ø Kruse I and Dam, H Factor in vitamin K-deficient plasma which accelerates the coagulation of dicumarol plasma *Acta chem scandinav* 4 549 1930
- 248 Soulier J P Nouvelle méthode de diagnostic de l'hémophilie utilisant les sangs veineux et capillaires coagulés *Sang* 19 78 1948
- 249 Soulier J P Étude genetique des syndromes hémorragiques *Sang* 25 355 1954
- 250 Soulier J P., and Larneau, M J Differentiation of hemophilia into two groups a study of 33 cases *New England J Med.* 249 547 1953
- 251 Soulier J P Larneau, M J and Wartelle O La thromboplastinof ormation dans les affections plaquettaires étude de 34 cas à l'aide du test de Biggs et Douglas *Acta haemat.* 14 160 1955
252. Soulier J P *et al* Etude biologique de deux cas d'afibrinogenémie congénitale *Rev hémat.* 10 689 1955
- 253 Soulier J P *et al* Un cas d'hypoconvertinémie congénitale *Sang* 26 660 1955
- 254 Spaet, T H Recent progress in study of hemophilia, *Stanford M Bull* 13 24 1955
- 255 Spaet, T H. and Garner E S Studies on storage lability of human antihemophilic factor *J Lab & Clin. Med.* 46 111 1955
- 256 Spaet, T H and Garner E S Resistance to transfusion in hemophilia and deuterohemophilia, *Stanford M Bull.* 13 188 1955
- 257 Spaet, T H and Kinsell, B G Properties of bovine anti hemophilic factor *Proc Soc Exper Biol & Med.* 84 314 1953
- 258 Spaet, T H Aggeler P M and Kinsell B G Possible fourth plasma thromboplastin component, *J Clin Invest.* 33 1095 1954
- 259 Spaet, T H *et al* Unpublished observations
- 260 Spaet, T H *et al* Atypical blood clotting patterns in hemophilia *Stanford M Bull.* 11 118 1953
- 261 Stefanini, M and Crosby W H. One-stage prothrombin consumption test clinical value in identification of thromboplastin-deficiency diseases *Blood* 5 964 1950
262. Stefanini, M and Dameshek, W *The Hemorrhagic Disorders A Clinical and Therapeutic Approach* (New York Grune & Stratton 1955)
- 263 Stefanini, M Chatterjee J B and Salomon, L Failure of transfusion of hemophilic plasma to induce abnormalities of hemostatic mechanism in normal individuals *Proc Soc Exper Biol & Med* 78 274 1951
- 264 Stefanovic, S Milosavljevic, A and Stefanovic R. Deux cas d'hypoconvertinémie congénitale *Sang* 26 315 1955
- 265 Taylor F H L. *et al* Studies in blood coagulation coagulation properties of certain globulin fractions of normal human plasma *in vitro* *J Clin Invest.* 24 698 1945
- 266 Telfer T P Denson, K W and Wright, D R New coagulation defect, *Brit. J Haemat.* 2 308 1956
- 267 Thomas H B Some orthopedic findings in 98 cases of hemophilia, *J Bone & Joint Surg* 18 140 1936
- 268 Thomas L. Studies on intravascular thromboplastic effect of tissue suspensions in mice factor in normal rabbit serum which inhibits thromboplastic effect of sedimentable tissue component *Bull Johns Hopkins Hosp* 81 26 1947

- 269 Tocantins L. M. Demonstration of antithromboplastic activity in normal and hemophilic plasma. *Am J Physiol* 139:265 1943
- 270 Tocantins L. M. *The Coagulation of Blood. Methods of Study* (New York: Grune & Stratton 1955)
- 271 Tocantins L. M. Treatment of hemophilia. *Blood* 11:89 1956
- 272 Tocantins L. M. and Carroll R. F. Separation and Assay of a Lipid Antithromboplastin from Human Brain. *Blood and Plasma Fractions in Transactions of Second Conference on Blood Clotting and Allied Problems* (New York: Josiah Macy Jr. Foundation 1949) pp 11-28
- 273 Tocantins L. M., Carroll R. T. and Holburn R. H. Clot accelerating effect of dilution on blood and plasma: relation to mechanism of coagulation of normal and hemophilic blood. *Blood* 6:720 1951
- 274 van Creveld S. Congenital idiopathic hypoprothrombinemia. *Acta paediat. Supp* 100:245 1954
- 275 van Creveld S. and Paulssen M. M. P. Plasma transfusions in hemophilia. *Blood* 7:710 1952
- 276 van Creveld S., Hoorweg P. G. and Paulssen M. M. P. Researches on circulating anticoagulant in hemophilic blood. *Blood* 6:233 1951
- 277 van Creveld S., Hoorweg P. G. and Paulssen M. M. P. Researches on circulating anticoagulant in a hemophilic effect of administration of ACTH and cortisone. *Blood* 8:125 1953
- 278 van Creveld S., Jordan F. L. J. and Punt J. Hemorrhagic disease characterized by combination of shortage of anti hemophilic factor and vascular disorder in woman. *Rev. belge path. et med. exper.* 24:310 1955
- 279 van Creveld S., Veder H. A. and Blans M. M. Congenital hypocoagulation. *Ann. paediat.* 187:373 1956
- 280 Vandenbroucke J., Verstraete M. and Verwulghen R. La fibrinogénémie congénitale. *Acta haemat.* 12:87 1954
- 281 Verstraete M. and Vandenbroucke J. Combined antihemophilic globulin and Christmas factor deficiency in haemophilia. *Lancet* 1:869 1955
- 282 Verstraete M. and Vandenbroucke J. Occurrence and mode of action of endogenous circulating anticoagulants. *J. Lab. & Clin. Med.* 48:673 1956
- 283 Vogel, F. Vergleichende Betrachtungen über die Mutationsrate der geschlechtsgebunden rezessiven Hämophilieformen in der Schweiz und in Dänemark. *Blut* 1:91 1955
- 284 Ware A. G. and Seegers W. H. Serum Ac globulin formation from plasma. Ac globulin role in blood coagulation: partial purification, properties and quantitative determination. *Am J Physiol* 152:567 1943
- 285 Ware A. G., Fahey J. L. and Seegers W. H. Platelet extracts: fibrin formation and interaction of purified prothrombin and thromboplastin. *Am J Physiol* 154:140 1948
- 286 Ware A. G., Guest M. M. and Seegers W. H. Factor in plasma which accelerates the activation of prothrombin. *J. Biol. Chem.* 169:231 1947
- 287 Ware A. G., Murphy R. C. and Seegers W. H. Function of Ac globulin in blood clotting. *Science* 106:618 1947
- 288 Weil, E. L'hémophilie pathogénie et sérothérapie. *Presse med.* 13:673 1905
- 289 White S. G., Aggeler P. M. and Emery B. E. Plasma thromboplastin component (PTC): potency of plasma fractions. *Proc. Soc. Exper. Biol. & Med.* 83:69 1953
- 290 White S. G., Aggeler P. M. and Glendening M. B. Plasma thromboplastin component (PTC): hitherto unrecognized blood coagulation factor: case report of PTC deficiency. *Blood* 8:101 1953

- 291 Wilkenson J F Turner R L and Bottomley A C Electrophoretic studies on serum proteins in haemophilia and Christmas disease *Acta med scandinav* 161 59 1957
- 292 von Willebrand E A Über hereditäre Pseudohämophilie *Acta med scandinav* 76 521 1931
- 293 Winston M E Haemophilic arthropathy of hip *J Bone & Joint Surg* 34 B 412 1952
- 294 Wintrobe M M *Clinical Hematology* (4th ed Philadelphia Lea & Febiger 1956)
- 295 Wolf P Modification for routine laboratory use of Stefanini's method of estimating factor V activity in human oxalated plasma *J Clin Path* 6 34 1953
- 295a Wolff J A and Bertuccio M Sex linked genetic syndrome manifested by thrombocytopenic eczema bloody diarrhea recurrent infection anemia and epistaxis *AMA Am J Dis Child* 93 74 1957
- 296 Woolley E J S Familial idiopathic thrombocytopenic purpura *Brit. M J* 1 440 1956
- 297 Wosilait W D and Nason A Pyridine nucleotide menadione reductase from *Escherichia coli*, *J Biol Chem* 208 785 1954
- 298 Wright C S *et al* Hemophilia current theories and successful medical management in traumatic and surgical crisis *J Lab & Clin Med* 33 708 1948
- 299 Wurzel H A Roth K and Zubrow S Mild familial hypoconvertinemia *J Lab & Clin Med* 44 403 1954



# Etiology and Pathogenesis of Glomerulonephritis\*

WILLARD C SCHMIDT and  
CHARLES H RAMMELKAMP JR

*Departments of Pediatrics and Medicine Cleveland City Hospital and  
Department of Preventive Medicine Western Reserve University  
Cleveland Ohio*

MANY clinicians and pathologists have a rather clear concept of the etiology and pathogenesis of acute glomerulonephritis. However careful analysis of published reports on nephritis both in man and in the experimental animal reveal many gaps in our knowledge as well as many facts which are difficult to reconcile with present theories of the causation of nephritis.

There is general agreement that acute glomerulonephritis is not a result of direct bacterial invasion of renal tissue. On the other hand it is generally accepted that the syndrome is etiologically related to an antecedent infection of the respiratory tract or of the skin caused chiefly by the hemolytic streptococcus. Because nephritis follows rather than accompanies this infection it seems likely that the renal reaction is not directly due to bacterial toxins or bacterial metabolites. In view of the latent period of 1 to 3 weeks between the "triggering" infection and the onset of nephritis it has been proposed that this renal inflammatory reaction represents a hypersensitivity to bacterial protein or an autoimmune response to renal components altered by reaction with bacterial products.

\* This investigation was conducted under the sponsorship of the Commission on Streptococcal Diseases, Armed Forces Epidemiological Board, and was supported by the Cleveland Area Heart Society and by the Office of the Surgeon General, Department of the Army, Washington, D. C.

We propose to describe the natural history of glomerulonephritis and to emphasize some of the difficulties in establishing a clear cut diagnosis of the disease to describe and discuss the epidemiologic evidence relating antecedent streptococcal infection to glomerulonephritis to summarize the methods that have been employed to produce experimental nephritis and to discuss briefly the resulting experimental syndromes and their applicability to the study of human nephritis and to emphasize the potential value of newly developed pathologic technics in the diagnosis and in etiologic investigations of nephritis

### NATURAL HISTORY

Classically the initial attack of acute glomerulonephritis begins with the appearance of dark brown or smoky urine often accompanied by swollen ankles or hands and swelling of the face around the eyes. These signs characteristically appear 1 to 3 weeks after a respiratory infection or occasionally following infection of the skin. They may be accompanied by vague lumbar soreness pain in the abdomen or groins and anorexia vomiting and oliguria. These symptoms and signs prompt the patient to seek medical attention and the demonstration of proteinuria, hematuria red blood cell casts and frequently hypertension establish the diagnosis.

Usually the disease is not severe and clinical improvement is noted within a few days or weeks. The mortality rate of hospitalized patients during the acute phase is less than 5 per cent (11). In the absence of hypertension or edema death rarely occurs. Symptomatically most patients are usually well within several weeks but the urine may show moderate numbers of red blood cells and albumin for several weeks or months. Most patients recover completely and no evidence of permanent damage to the kidney remains. In 5 to 15 per cent, chronic glomerulonephritis develops, according to Earle (11). In such patients albuminuria may at first be the only manifestation of continuing renal disease but later signs of decreased renal function appear.

The factor responsible for the initiation of an attack of acute glomerulonephritis seems to be infection with group A streptococci. This relation seems to be well established although other bacterial agents have been incriminated in a few cases. Since infections with group A streptococci involve the respiratory tract and less commonly the skin the patient with nephritis usually has a history of sore throat,

scarlet fever or skin infection. The signs of nephritis usually develop after recovery from the acute phase of the bacterial infection.)

### PROBLEMS PRESENTED BY VARIATIONS IN DISEASE

As a physician's experience with Bright's disease broadens his original concept of the uniformity of glomerulonephritis is modified. He becomes aware of the wide variations in the intensity of the disease varying from the patient with microscopic hematuria detected only as a result of the physician's diligence in obtaining and examining a urine specimen to the patient hospitalized with hypertension convulsions anuria and azotemia. Instead of the sudden onset, 1 to 3 weeks after a respiratory infection of well delineated symptoms and signs that persist for several weeks and then subside completely the physician also observes patients in whom the onset of renal signs and symptoms is insidious, patients with marked proteinuria and edema and patients in whom persistent or progressive renal disease develops. Thus it becomes evident that nephritis is a complex disease process of man of diverse clinical nature and etiology.

### CLINICAL FEATURES

One of the intriguing features of acute glomerulonephritis is the factor responsible for the initiation of the disease. It has been recognized for years that scarlet fever respiratory infections including tonsillitis or pharyngitis skin infections otitis media sinusitis and pneumonia may precede nephritis. For example Winkenwerder and co workers (96) found that 71 per cent of 78 patients with nephritis had recently experienced an attack of sore throat tonsillitis pharyngitis sinusitis or otitis media. A diagnosis of scarlet fever was established in only 2 per cent. In addition in 7 per cent pneumonia preceded the nephritis and in 4 per cent an attack of rheumatic fever appeared to be related to the kidney complication. In this group 85 per cent of those who did not have a history of a preceding acute respiratory infection or who had a chronic infection showed progressive renal disease. In contrast the course in patients in whom onset was preceded or accompanied by an acute infection with constitutional symptoms was almost invariably favorable. In the pediatric age group the relation of the preceding infection to the course of the disease appears even more clear cut. Aldrich (1) found that chronic



renal disease did not develop among 400 patients with hemorrhagic nephritis following an acute respiratory infection. In addition it is common experience to see patients with chronic nephritis without a history of an acute episode. These clinical observations suggest that signs of nephritis may be produced by at least two different mechanisms: (1) the disease usually follows an acute infection of the respiratory tract and is associated with an extremely favorable prognosis and (2) the acute episode of nephritis is either related to chronic infection or to no infection whatsoever. In the latter group signs of chronic renal disease frequently develop. In the present discussion

TABLE 1—RELATION OF ACUTE GLOMERULONEPHRITIS TO ACUTE PHASE  
HEMATURIA IN TYPE 12 INFECTIONS (85)

ACUTE-PHASE HEMATURIA	NUMBER OF PATIENTS	NUMBER WITH NEPHRITIS
Present	44	12
Absent	140	9

primary consideration will be given to that form of nephritis which follows an acute respiratory infection.)

During the acute phase of glomerulonephritis erythrocytes and usually erythrocyte casts can be demonstrated in the urine. However it does not follow that all patients whose urine contains erythrocytes actually have glomerulonephritis. Red cells may appear in the urine because of pathologic lesions in the urethra, bladder, ureters and renal pelves. In addition hematuria usually mild is associated with the acute phase of febrile disease caused by viruses or bacteria as well as with other illnesses such as cardiac failure. Erythrocytes derived from the glomerulus frequently are distorted so that occasionally the source of bleeding can be ascertained by careful microscopic examination of the urine.)

Because the microscopic urinalysis has been routinely delegated to inexperienced technicians the physician knows little about the nature and interpretation of hematuria (66). Not only is the precise identification of each cellular component important but some quantitation is required for proper interpretation. Recognition of distorted erythrocytes and stroma erythrocyte casts or casts stained with hemoglobin enables the physician to judge reliably whether glomerulonephritis is present. Quantitative studies have been used only on a limited scale probably because of the difficulties in performing Addis counts.

The fact that moderate transient hematuria has been observed in a few patients with scarlet fever (44) has created doubt about the value of quantitative erythrocyte enumeration in the diagnosis of acute nephritis.

The adoption of a modified Addis count whereby a *fresh* concentrated urine specimen is studied directly in a hemocytometer without




FIG 1—Pattern of hematuria and albuminuria in a patient with type 12 streptococcal infection

prior centrifugation) makes possible the examination of large numbers of specimens. Experience with this technic suggests that most normal subjects excrete less than 10 erythrocytes per cubic millimeter (79). Those whose urine contains more than 10 erythrocytes usually have had recent experience with nephritogenic streptococci or show some other cause for the hematuria (79). In patients with respiratory infection including streptococcal disease and scarlet fever the daily enumeration of excreted erythrocytes revealed that the number of cells increases during the febrile period (85). In the patients in whom signs of glomerulonephritis subsequently develop hematuria is especially

likely to appear during the first few days of the respiratory illness (Table 1) These observations which require confirmation indicate immediate damage of the glomerulus by some product of the streptococcus which does not depend on an immune mechanism. However the initial hematuria disappears only to return at the time of the onset of nephritic symptoms (Fig 1) The latter phenomenon may be caused by a different mechanism. It should be emphasized that the hematuria observed in these patients is not transitory but persists for several days or weeks.)

It has been said that the diagnosis of acute glomerulonephritis cannot be made in the absence of albuminuria (2) This appears to be a sound observation when based on studies of patients with edema or hypertension but in their absence albuminuria may be slight or nonexistent during the period of hematuria (Fig 1) Indeed persistent severe albuminuria which begins during an acute infection may indicate chronic renal disease. For example during a food borne epidemic of type 5 streptococcal disease only 1 of 100 patients observed showed signs of nephritis (10) This patient had hematuria erythrocyte casts and large amounts of albumin in the absence of hypertension or edema. It was easy to establish that this was an example of an acute exacerbation of chronic nephritis the patient had a history of repeated episodes of acute hematuria and albuminuria after tonsillitis. The emphasis on albuminuria as an important diagnostic criterion may possibly be responsible for much of the confusion concerning the natural history of acute nephritis.

#### ETIOLOGY BACTERIOLOGIC AND SEROLOGIC STUDIES

✓ The facts that scarlet fever may precede nephritis (89) that group A streptococci may be isolated from many patients after symptoms of nephritis develop (96) and that the antistreptolysin titer of a serum specimen obtained during the first few weeks of illness is usually high (40 75) attest that acute glomerulonephritis is a complication of a streptococcal infection. The studies of Seegal and co workers (76) showed that the number of hospital admissions for acute rheumatic fever a known complication of streptococcal disease bore no relation to the number of admissions for acute nephritis. This observation, as well as the epidemic occurrence of nephritis and the variable attack rate following proved streptococcal infections indicated that strains of group A streptococci might vary in their ability to produce renal disease.

✓ The first method used to determine whether strains of streptococci varied in their nephritogenic capacities was the serologic classification of organisms isolated from the oropharynx of patients with acute glomerulonephritis (63) With this technic most strains obtained from sporadic cases of nephritis were found to belong to type 12 (62) Furthermore type 12 was frequently isolated during epidemics of nephritis from both patients and contacts (64-79) The association of type 12 streptococci with nephritis has been recorded throughout the United States (62) and in Canada (64) Australia (50) England (94) Chile (77) and Japan (35) In one epidemic in Minnesota (33) a new serologic type named Red Lake (86) was recognized the same strain has been isolated from a patient in Chile (77) Type 4 streptococci have occasionally been isolated from sporadic cases in this country (62) and have been identified in cultures from patients and their contacts in epidemics in Honolulu (61) and Japan (35) Type 25 has also been isolated from a few cases of nephritis in this country (63) and in Denmark (3) Other serologic types have occasionally been isolated from patients with nephritis (35, 23, 77, 93)

This is not an entirely satisfactory method of establishing the nephritogenic character of various types of group A streptococci since by the time signs of nephritis develop (on the average about 10 days after the respiratory infection) few organisms may be present in the nasopharynx and in some cases the isolated organism may represent an old infection or a recent cross infection A more difficult problem for interpretation is presented by the isolation of group A streptococci which do not belong to a known nephritogenic type In such cases it is safer to suspect that the current illness is an exacerbation of chronic disease In the presence of epidemics of streptococcal infections due to any serologic type individuals with chronic nephritis may be expected to experience exacerbations As an example an acute exacerbation with a type 5 streptococcal infection developed in a patient with chronic nephritis (10) but no nephritis occurred among the other 99 men with similar infections

A second and more accurate method for establishing the relative role of various serologic types in the production of nephritis is the study of streptococcal infections throughout the period in which the renal complication develops Under these circumstances the original infecting strain can be identified before the onset of nephritis and regular cultures and clinical and laboratory observations will assure that a cross infection with a new serologic type did not occur ✓ In one

likely to appear during the first few days of the respiratory illness (Table 1) These observations which require confirmation indicate immediate damage of the glomerulus by some product of the streptococcus which does not depend on an immune mechanism. However the initial hematuria disappears only to return at the time of the onset of nephritic symptoms (Fig 1) The latter phenomenon may be caused by a different mechanism. It should be emphasized that the hematuria observed in these patients is not transitory but persists for several days or weeks.

It has been said that the diagnosis of acute glomerulonephritis cannot be made in the absence of albuminuria (2). This appears to be a sound observation when based on studies of patients with edema or hypertension but in their absence albuminuria may be slight or nonexistent during the period of hematuria (Fig 1). Indeed persistent, severe albuminuria which begins during an acute infection may indicate chronic renal disease. For example during a food borne epidemic of type 5 streptococcal disease only 1 of 100 patients observed showed signs of nephritis (10). This patient had hematuria erythrocyte casts and large amounts of albumin in the absence of hypertension or edema. It was easy to establish that this was an example of an acute exacerbation of chronic nephritis the patient had a history of repeated episodes of acute hematuria and albuminuria after tonsillitis. The emphasis on albuminuria as an important diagnostic criterion may possibly be responsible for much of the confusion concerning the natural history of acute nephritis.

#### ETIOLOGY BACTERIOLOGIC AND SEROLOGIC STUDIES

✓ The facts that scarlet fever may precede nephritis (89) that group A streptococci may be isolated from many patients after symptoms of nephritis develop (96) and that the antistreptolysin titer of a serum specimen obtained during the first few weeks of illness is usually high (40-75) attest that acute glomerulonephritis is a complication of a streptococcal infection. The studies of Seegal and co-workers (76) showed that the number of hospital admissions for acute rheumatic fever a known complication of streptococcal disease bore no relation to the number of admissions for acute nephritis. This observation, as well as the epidemic occurrence of nephritis and the variable attack rate following proved streptococcal infections indicated that strains of group A streptococci might vary in their ability to produce renal disease.

The first method used to determine whether strains of streptococci varied in their nephritogenic capacities was the serologic classification of organisms isolated from the oropharynx of patients with acute glomerulonephritis (63). With this technic, most strains obtained from sporadic cases of nephritis were found to belong to type 12 (62). Furthermore type 12 was frequently isolated during epidemics of nephritis from both patients and contacts (64-79). The association of type 12 streptococci with nephritis has been recorded throughout the United States (62) and in Canada (64), Australia (50), England (94), Chile (77) and Japan (35). In one epidemic in Minnesota (33) a new serologic type named Red Lake (86) was recognized; the same strain has been isolated from a patient in Chile (77). Type 4 streptococci have occasionally been isolated from sporadic cases in this country (62) and have been identified in cultures from patients and their contacts in epidemics in Honolulu (61) and Japan (35). Type 25 has also been isolated from a few cases of nephritis in this country (63) and in Denmark (3). Other serologic types have occasionally been isolated from patients with nephritis (35, 23, 77, 93).

This is not an entirely satisfactory method of establishing the nephritogenic character of various types of group A streptococci since by the time signs of nephritis develop (on the average about 10 days after the respiratory infection) few organisms may be present in the nasopharynx and in some cases the isolated organism may represent an old infection or a recent cross infection. A more difficult problem for interpretation is presented by the isolation of group A streptococci which do not belong to a known nephritogenic type. In such cases it is safer to suspect that the current illness is an exacerbation of chronic disease. In the presence of epidemics of streptococcal infections due to any serologic type individuals with chronic nephritis may be expected to experience exacerbations. As an example, an acute exacerbation with a type 5 streptococcal infection developed in a patient with chronic nephritis (10) but no nephritis occurred among the other 99 men with similar infections.

A second and more accurate method for establishing the relative role of various serologic types in the production of nephritis is the study of streptococcal infections throughout the period in which the renal complication develops. Under these circumstances the original infecting strain can be identified before the onset of nephritis and regular cultures and clinical and laboratory observations will assure that a cross infection with a new serologic type did not occur. In one

such study four serologic types were responsible for an epidemic of streptococcal infections it was clear that type 12 was nephritogenic, whereas types 3 6 and 19 were not followed by acute nephritis (85) In this epidemic severe hematuria occurred in 2 patients early in the streptococcal infections which were caused by types 6 and 19 respectively the hematuria and albuminuria were observed early and persisted for many weeks indicating an exacerbation of mild chronic




FIG 2—Persistence of antibody to type 12 streptococcus in 2 patients after infection

nephritis Neither patient gave a history of a preceding attack of nephritis

A third method not used widely is the determination of type specific antibodies in serums or whole blood obtained from patients who have recovered from an attack of acute nephritis. Type specific antibodies which persist for several years develop in individuals infected with group A streptococci (Fig 2) Thus many patients with nephritis should show antibodies against one of the nephritogenic strains were these strains etiologically related to the disease Patients in the Cleveland area have been studied by this method (57) Most of those who recovered from an acute attack of hemorrhagic nephritis showed antibody against type 12 streptococci whereas serums from patients with nephrosis and chronic nephritis revealed no antibody as measured in the bacteriostatic test. Another study of serums collected in the Chicago area from patients with acute nephritis failed

to show antibody against type 12 suggesting that some other type was responsible for the complication (78). Recently Braude et al (5) by the use of bacteriostatic mouse protection and complement fixation technics demonstrated antibodies against the Red Lake strain in individuals with nephritis in Minnesota and antibodies against type 12 in serums from patients with nephritis in Texas. Since antibodies to specific serologic types may persist for several years an increase in type specific antibody against a nephritogenic organism is the best indication of its etiologic significance

Demonstration of the presence of type specific protective antibody in the blood of patients who have recovered from a classic attack of acute glomerulonephritis may help to explain certain clinical observations on recurrences of this disease. The presence of this antibody indicates immunity against infection with a specific type (90). It has been frequently said (42) and occasionally recorded (40) that the patient who completely recovers from acute glomerulonephritis rarely if ever suffers a second attack. Knowing that only a few serologic types are able to produce nephritis it would be surprising if many patients became infected with more than one nephritogenic type. Certainly the individual who has experienced one attack of nephritis should be immune against a second attack due to the serologic type responsible for the original attack. Thus freedom from recurrences in patients who recover from an attack of nephritis may be due to type specific immunity or to the statistical improbability of acquiring a second infection with a nephritogenic type. In addition the product of nephritogenic streptococci which may initiate nephritis may be antigenic so that in a second infection the nephritogenic substance would be neutralized *in vivo*.

It is more difficult to explain recurrences in patients with chronic nephritis. Exacerbations are said to occur after a short latent period (11, 74) and this has been used as evidence in support of an immunologic mechanism in the causation of nephritis (14). While it is true that many exacerbations appear to be initiated by streptococcal infections (74) it might be asked why a second attack develops in these patients whereas in the patient who has recovered completely there is no recurrence after a streptococcal infection (74). Perhaps in the former patients the recurrences are nonspecific since there is evidence that recurrences do follow nonstreptococcal infections (74). Study of the serologic types of streptococci isolated from patients with chronic nephritis experiencing recurrences would help to clarify this problem.



Preliminary studies indicate that the serums from patients with chronic nephritis do not contain type specific antibodies against nephritogenic streptococci (60). These data suggest that the pathogenetic mechanisms in exacerbations of chronic nephritis differ from those involved in the initial acute attack of glomerulonephritis.)

Perhaps one of the most puzzling features of acute glomerulonephritis is the fact that many patients exhibiting classic signs of the disease fail to show  $\beta$  hemolytic streptococci on culture. This fact alone has probably led to more confusion concerning etiology than any other observation. If all cases of initial attacks of acute nephritis are caused by nephritogenic streptococci, why is the organism difficult to isolate? The situation is somewhat reminiscent of the difficulty in isolating streptococci from cases of rheumatic fever in which only 50 to 70 per cent of the oropharyngeal cultures show group A streptococci (6). Occasionally  $\beta$  hemolytic streptococci are isolated from only 15 per cent of patients with rheumatic fever (51). Bacteriologic data (59) suggest that the number of streptococci decreases rather rapidly following an acute streptococcal infection so that a single oropharyngeal culture cannot be considered sufficient to exclude the possibility of infection with these organisms. In addition certain biologic characteristics of nephritogenic streptococci may be responsible for these variable bacteriologic results. Colonies of the organism on sheep blood agar are not typically large and mucoid but are small and white (58). Even more striking is the absence of wide zones of  $\beta$  hemolysis. In a recent outbreak resulting in several thousand cases of nephritis in Japan (35) type 12 streptococcus was found to produce such small zones of hemolysis that many of the colonies could be overlooked by the average bacteriologist. This is not a new observation as shown by earlier studies of streptococcal infection epidemics caused by nonhemolytic variants of group A streptococci. In each instance, type 12 streptococci were involved. In 1941 Coburn and Pauli (9) described a nonhemolytic type 12 streptococcus responsible for an epidemic among infants. Francis (17) reported an epidemic of type 12 infections on a plastic surgery ward; cultures of the organism obtained from those patients failed to produce  $\beta$  hemolysis on horse rabbit, or human blood agar. He has isolated a nonhemolytic type 25 streptococcus. Apparently therefore failure to demonstrate typical  $\beta$  hemolytic colonies in cultures obtained from patients with glomerulonephritis may be due to failure to recognize nonhemolytic or poorly hemolytic colonies. It is possible that infection with such strains may stimulate

little antistreptolysin production since *in vitro* evidence suggests that production of streptolysin O is slight'

Because of the difficulties involved in bacteriologic studies and the lack of careful correlation of bacteriologic data with clinical and pathologic findings it has not been possible to evaluate reports claiming that other microorganisms produce acute glomerulonephritis. The pneumococcus for example has long been implicated as a cause of acute glomerulonephritis (52 56 73). It is true that excretion of albumin and red blood cells may be increased in cases of nephritis attributed to pneumococcal infection but hypertension and edema are not common (73). This observation alone might indicate that the nephritis in some patients with pneumonia may be an exacerbation of chronic nephritis. In the most detailed study Seegal (73) reported 7 cases of nephritis among 1 004 patients with lobar pneumonia. The prominent features included marked albuminuria in the absence of significant hypertension anemia was found in 6 patients edema in 3 patients only. Throat cultures for  $\beta$  hemolytic streptococci were negative in 2 of the 7 cases studied and in 1 of these the antistreptolysin titer was normal. It is apparent, therefore that no adequate studies were done to exclude infection with nephritogenic streptococci in addition the clinical features of the illnesses were somewhat unusual. Final conclusions concerning the production of initial attacks of acute glomerulonephritis by agents other than the streptococcus must await further study.)

We have presented only selected data bearing on the natural history of nephritis and the precipitating factors in order to emphasize some of the problems encountered by the investigator interested in pathogenesis and etiology. Since the response of the kidney to noxious stimuli is limited the clinician can only suggest that nephritis is produced by several different mechanisms. With the more precise bacteriologic and serologic methods now available it should be possible to define various forms of renal disease. Much of the present confusion arises from lack of knowledge of the etiologic agent and of the natural course of the disease.

## PATHOLOGY

Many of our concepts of nephritis have come from the extensive contributions of pathologists. The lesion in the kidney is considered to be limited to the glomerulus. There is proliferation of the endo-

thelium infiltration of the glomeruli with polymorphonuclear leukocytes escape of erythrocytes into the capsular space and thickening of the basement membrane. There may be obliteration of the capsular space and the development of crescents. The latter Ehrlich (12) considers to represent subacute glomerulonephritis. Although these pathologic features have been frequently described it is obvious from the literature that the evolution of the cellular changes has not been precisely defined and this is especially true of those patients in whom nephritis is known to develop after an infection with nephritogenic streptococci. Furthermore according to Bell (2) the changes in the glomerulus may be seen during the course of several infectious diseases and therefore may not be specific. Since the course of illness following infection with nephritogenic streptococci may be different from that observed after nonstreptococcal illnesses the evolution of the renal changes may likewise be different. By employing modern bacteriologic and serologic technics together with the recently developed technic of renal biopsy it should soon be possible to define the course of acute streptococcal glomerulonephritis. In addition since streptococcal infections caused by nephritogenic or by presumably non-nephritogenic organisms may precipitate acute exacerbations of chronic nephritis biopsy specimens obtained early in the disease should help in the recognition of chronic nephritis. Consider for example the case of a 12 year old boy in whom hypertension edema and hematuria developed after a type 12 streptococcal infection (88). A renal biopsy was obtained 10 days after the onset of the sore throat. There were large numbers of leukocytes in the glomerulus marked proliferation of the endothelium and glomerular ischemia, and in addition, glomerular hyalinization tubular atrophy and interstitial infiltration. The latter Vernier (88) interpreted as evidence of chronic changes which must have existed before the onset of the acute disease. Thus this patient may have had two diseases acute hemorrhagic nephritis due to type 12 streptococci superimposed on chronic glomerulonephritis. Further serial biopsy studies designed to include specimens taken within a few days of the onset of illness should permit a description of the sequence of histopathologic changes typical of acute nephritis. Correlation of these findings with the clinical disease and with bacteriologic and serologic data should make possible a precise differentiation of acute nephritis from chronic nephritis and from other forms of renal disease. Such an integrated study may possibly also provide some insight into the pathogenesis of glomerulonephritis.

## EXPERIMENTAL NEPHRITIS

For many years investigations of the etiology of nephritis have been based on the concept that the pathogenesis of this disease is a manifestation of hypersensitivity. Since acute glomerulonephritis as it occurs in man is not a natural disease of animals the investigator has used in animal studies several laboratory models resembling the human disease but not duplicating it. The techniques have consisted of the injection into a variety of animals of heterologous protein, nephrotoxic serums, mixtures of bacteria and homologous renal tissue or bacteria specifically hemolytic streptococci alone. The clinical and pathologic manifestations after these procedures have been compared with the corresponding features of human renal disease. Since the manifestations of these experimental nephritides have been described in detail in several reviews (13 43 67 70) only their major characteristics will be summarized here.

HETEROLOGOUS PROTEIN NEPHRITIS

Glomerulonephritis and cardiovascular lesions have been reported in rabbits in which serum sickness was induced by administration of horse serum (46 67 97) purified serum albumin (18 24 97) or serum  $\gamma$ -globulin (18 24, 50 97). A single large dose or several small doses of these antigens resulted, after a latent period of 8 to 10 days in the appearance of fever, proteinuria, hematuria, and cylindruria. Histologic examination of the rabbit tissues obtained at various intervals after induction of the hypersensitivity reaction revealed, in the early acute state glomerular enlargement with swelling and proliferation of endothelial and epithelial cells of the tuft as well as thickening of the glomerular basement membrane. Occasionally at this time but usually later in the course of the inflammatory reaction, adhesions between glomerular tuft and capsule as well as glomerular crescents appeared. Some (67) reported the accumulation of polymorphonuclear leukocytes in the glomeruli but this was not a consistent finding. Tubular lesions were uncommon, and when found were minimal in degree (18 24 46 50 97). The lesions consisted of patchy hyaline or granular changes in tubular cells and, sometimes atrophy of tubular cells and dilatation of tubular spaces. Some tubules contained sizable amounts of amorphous staining material. Excepting those animals that succumbed to anaphylactic shock after repeated injections of antigen, most survived.

thelium infiltration of the glomeruli with polymorphonuclear leukocytes escape of erythrocytes into the capsular space and thickening of the basement membrane. There may be obliteration of the capsular space and the development of crescents. The latter Ehrlich (12) considers to represent subacute glomerulonephritis. Although these pathologic features have been frequently described it is obvious from the literature that the evolution of the cellular changes has not been precisely defined and this is especially true of those patients in whom nephritis is known to develop after an infection with nephritogenic streptococci. Furthermore according to Bell (2) the changes in the glomerulus may be seen during the course of several infectious diseases and therefore may not be specific. Since the course of illness following infection with nephritogenic streptococci may be different from that observed after nonstreptococcal illnesses the evolution of the renal changes may likewise be different. By employing modern bacteriologic and serologic technics together with the recently developed technic of renal biopsy it should soon be possible to define the course of acute streptococcal glomerulonephritis. In addition since streptococcal infections caused by nephritogenic or by presumably non-nephritogenic organisms may precipitate acute exacerbations of chronic nephritis, biopsy specimens obtained early in the disease should help in the recognition of chronic nephritis. Consider for example the case of a 12 year old boy in whom hypertension edema, and hematuria developed after a type of 12 streptococcal infection (88). A renal biopsy was obtained 10 days after the onset of the sore throat. There were large numbers of leukocytes in the glomerulus marked proliferation of the endothelium and glomerular ischemia and in addition glomerular hyalinization tubular atrophy and interstitial infiltration. The latter Vernier (88) interpreted as evidence of chronic changes which must have existed before the onset of the acute disease. Thus this patient may have had two diseases acute hemorrhagic nephritis due to type 12 streptococci superimposed on chronic glomerulonephritis. Further serial biopsy studies designed to include specimens taken within a few days of the onset of illness should permit a description of the sequence of histopathologic changes typical of acute nephritis. Correlation of these findings with the clinical disease and with bacteriologic and serologic data should make possible a precise differentiation of acute nephritis from chronic nephritis and from other forms of renal disease. Such an integrated study may possibly also provide some insight into the pathogenesis of glomerulonephritis.

foreign protein during the period when antigen is rapidly disappearing from the circulation and renal lesions are appearing offers additional suggestive evidence that these nephritic lesions are the result of antigen-antibody reaction (69 91) A similar fall in serum complement titer in human glomerulonephritis has been reported (15 92)

✓ The hypothesis that glomerulonephritis is related to the reaction of host antibody to injected foreign protein is further supported by the observation that suppression of antibody formation after injection of antigen by treatment with roentgen rays or nitrogen mustard prevents the appearance of renal and cardiovascular lesions (69 91) Cortisone and ACTH also apparently suppress the development of glomerulonephritic and cardiovascular lesions by interference with antibody formation (20) Other workers using ACTH have reported that these lesions can be suppressed without interference with antibody formation indicating that the hormones may function by changing tissue reactive capacity (67 91) It is noteworthy that ACTH and cortisone have been reported to be without effect on the course of nephrotoxic renal disease in rats (22, 34 71)

### ✓ NEPHROTOXIC RENAL DISEASE

✓ The production of nephritis in animals with nephrotoxic or anti kidney serums has been extensively studied as an experimental model of human renal disease The nephrotoxic serum reagent is prepared by the injection as antigen of homogenized kidney tissue or isolated fractions of kidney tissue from one animal into another animal species To produce nephrotoxic renal disease, the antikidney serum is then injected into the animal species from which the kidney tissue was originally obtained Nephritis has been produced by this technic in rats (13 27 28 39 70 81-83) rabbits (13 32 70 80) and dogs (4 16 70, 72) with nephrotoxic serum made in ducks chickens and rabbits Although the renal disease produced in these animals with different nephrotoxic serums has many similarities certain differences have been discerned

CLINICAL MANIFESTATIONS—In the rat, a form of nephritis characterized by severe proteinuria, hypoproteinemia hypercholesterolemia and edema has been described (13 27 28 39 70 81-85) The close similarity of the clinical and urinary findings of this disease with the nephrotic syndrome as it occurs in children has been pointed out (27) These manifestations appear almost immediately after the injection of

this hypersensitivity reaction. Relatively complete healing of the glomerular lesion was found in animals followed for several months (18 24, 50 97). Azotemia occurred in a small proportion of animals receiving injections of antigen over long periods of time (46).

In addition to the renal lesions in foreign protein nephritis myocarditis endocarditis generalized arteritis accompanied by lymph node hyperplasia, and granulomas occur with variable frequency (18 19 24 50). The nature and incidence of the lesions produced by heterologous protein injections vary with the nature and dosage of the antigen and the frequency and duration of its administration (19 24 25). Glomerular lesions are reported to appear earlier after the injection of  $\gamma$  globulin than of albumin (24). Arteritis is more likely to be a prominent pathologic feature of prolonged sensitization where as glomerulonephritis is more frequently seen shortly after a single or relatively few doses of either antigen (19 25). A significant degree of unpredictable variation in the production of glomerulonephritis in individual animals has also been emphasized (67).

Concurrent immunologic and histologic studies in heterologous protein hypersensitivities have shown that the lesions of glomerulonephritis after a single intravenous injection of antigen appear during the last stages of antigen elimination and are maximal just before the appearance of free circulating antibody (18 21 24). After free antibody appears the renal lesions as well as the cardiac lesions regress (18 21 24). These findings indicate that renal and cardiovascular lesions occur at a time when antigen and antibody may both be present in tissues and extracellular fluid (18 21 24) and are consistent with the hypothesis that the lesions result from antigen-antibody combination.

Efforts have been made to demonstrate histochemically the localization of antibody in renal lesions in experimental animals given foreign protein (47) and in sections of human kidney obtained at autopsy from patients with nephrosis and several types of nephritis (48 87). Gamma globulins have been shown to concentrate in damaged glomeruli in kidney sections from cases of nephrosis and in several types of nephritis but proof that this is specific antibody has not yet been obtained.

Complement fixation is a well known feature of in vitro antigen-antibody reaction and there is evidence that it occurs in vivo after the reinjection of antigens into specifically sensitized animals (84). The demonstration that serum complement decreases in animals given

that the variations noted with different types or amounts of serum are quantitative (26 27) The clinical disease in rabbits and dogs appears to resemble glomerulonephritis (13 31 32 70) It is possible that the pattern of host response is a characteristic of a given animal species

Evidence has been accumulated that glomerular tissue (36 37 70 83) and more specifically glomerular basement membrane (36 37) contains the nephrotoxic antigen Glomerular basement membrane produces more potent nephrotoxic serum when compared with other kidney components on a weight basis (37) Glomeruli absorb nephrotoxic activity from antikidney serums (37 83) Radioautography and fluorescence microscopy using antikidney or antiglomerulus serums with radioactive (55) or fluorescein (29 49) labels demonstrate the localization of labeled antibodies in glomeruli particularly in glomerular basement membrane in tissue sections from treated animals The latter evidence may indicate the participating antigen and the site of reaction of nephrotoxic serums The ability of placental tissue to stimulate the production of nephrotoxic serum (70) probably results from the presence in placenta of basement membrane material antigenically related to glomerular basement membrane The localization of components of labeled antiplacenta serums in glomerular basement membranes (70) is evidence for this antigenic relation

In general, attempts to measure nephrotoxic antibody in nephrotoxic serums (38 68) and to achieve a quantitative correlation between the amount of this antibody in a given serum and the severity of nephritis produced by it have been unsuccessful. Inability to obtain more than a rough correlation by precipitation complement fixation or hemagglutination is probably due to failure to identify and isolate the specific antigen responsible for nephrotoxicity)

It has been suggested that the lesion of nephrotoxic nephritis is the result of the union of specific antibody in injected antikidney serum with homologous antigen in renal tissue cells (13 43) This hypothesis is supported by the demonstration with fluorescein labeled chicken antiserum against rabbit antibody that injected rabbit antibody against rat kidney localizes in the glomeruli (49) It has been proposed that in the rabbit nephrotoxic nephritis produced with duck antikidney serum, in view of the latent period consists of two phases in the first, injected antikidney antibody in duck serum is bound by rabbit kidney in the second antibody formed by the rabbit against duck globulin reacts with the bound duck antikidney antibody globulin and causes the nephritic inflammatory reaction (31 32) The acceleration of



rabbit antirat kidney serums Hematuria and hypertension are common and transient (27 39 70) In many instances the disease becomes chronic and progresses to uremia and death (28 39 70 81 82)

It has become increasingly apparent that the severity as well as the qualitative variations in several of the clinicopathologic features of nephrotoxic nephritis in the rat depend upon the dosage potency source and method of administration of the antirat kidney serums and on the age sex and strain of rat used in these studies (28 38 43 70 81, 83)

Nephritis produced in the rabbit with antirabbit kidney serums made in ducks has been described as closely resembling glomerulo-nephritis in man (13 31, 32 70) Hematuria and mild or moderate proteinuria accompanied by cylindruria are reported to appear after a latent period of about 5 to 8 days after the injection of nephrotoxic serums hypertension is a more frequent manifestation and hypercholesterolemia and edema are notably less prominent in nephrotoxic nephritis in the rabbit (13 70) than in the rat Chronic progressive lesions as well as azotemia and uremia also develop in rabbits (13 43 70)

In dogs, the intravenous injection of nephrotoxic serums produced disease resembling that seen in the rabbit The manifestations consisted of hematuria proteinuria cylindruria nitrogen retention and in some dogs mild hypertension and hypercholesterolemia (4 16) With rabbit antidog kidney serums no latent period was noted (4) using fowl antikidney serums there was a latent period before the onset of nephritis (16) As in the rabbit disease some dogs died in the acute phase of nephritis in some chronic nephritis developed and some appeared to recover completely In dogs too a form of heterologous protein nephritis similar to that described in the rabbit may develop (4)

IMMUNOLOGIC MANIFESTATIONS—The nature of the antigen-antibody reaction postulated in the pathogenesis of nephrotoxic nephritis has not been elucidated Inability to isolate and characterize the antigen or antigens involved has greatly hindered progress in resolving the differences in incidence and manifestations of nephrotoxic nephritis in various species after injection of antikidney serums of varying reactive capacity from fowls or rabbits It has been reported that renal disease resembling nephrosis is produced in rats by large doses of potent antirat kidney rabbit serum whereas nephritis like disease is said to follow the injection of small doses of this type of serum (13 43) Conflicting data have been presented by other workers who feel that nephrotoxic renal disease in rats generally resembles nephrosis and

of the interstitial tissues by mononuclear cells lymphocytes and polymorphonuclear cells. These cells sometimes form aggregates around vessels and around glomeruli (4 27 81). Vascular and perivascular foci of cells have also been reported in other organs (4 81).

① During the subacute and chronic stages 1 to 6 months after the onset of nephrotoxic disease the basement membrane becomes markedly thickened (13 27 39 70 81). Hyalinization of glomeruli accompanied by cellular proliferation and infiltration with the formation of adhesions between the glomerular tuft and the capsule are characteristic findings in some instances the adhesions partly or completely obliterate the glomerular capsular space (27 70 81). "Crescents" may occur earlier but are more prominent during this stage (39 70 81). Tubules are often dilated and may contain casts (27 39 70 81). Tubular cells may show hyaline or fatty degenerative changes and may be atrophied. Interstitial infiltration continues to be present. Finally glomeruli may become obliterated tubules markedly dilated or atrophied and a relative increase in interstitial tissue may be seen (27 70 81).

Many of the microscopic lesions described are not found in mild nephrotoxic disease (27 39 70). Lesions may consist of early changes in the basement membrane with minimal cellular proliferation. If more extensive changes develop they may involve only a few glomeruli. Restoration of essentially normal kidney cytoarchitecture has been noted after mild disease.

It has not been possible to differentiate, by classic histopathologic studies, nephrotoxic renal disease resembling glomerulonephritis from that which simulates the nephrotic syndrome (70). Renal biopsy has recently been developed and used in studies of the natural history of renal disease. Electron microscopy has also been applied to this problem. With these tools chronologic studies of human glomerulonephritis and nephrosis and comparative studies of nephrotoxic nephritis are being carried on in much greater histopathologic detail than formerly (53 54 88). Changes in glomerular structure consisting of a change of the cement substance between the basement membrane and the epithelial cells of glomerular capillaries changes in the density of foot processes of epithelial cells and thickening of the basement membrane have been reported in initial studies with the electron microscope of nephrotoxic disease in rats (54). These changes are said to parallel closely changes noted by means of the electron microscope in renal tissue obtained by biopsy from children with nephrosis (53).

this form of nephrotoxic nephritis by a previous injection of duck serum and suppression of the reactions with roentgen rays are consistent with this theory (32) Histologic and histochemical observations of the proliferation and increased activity of mesenchymal cells in the rabbit kidney during the latent period following the injection of duck antikidney serum may indicate that antibody formed locally against bound duck antirabbit kidney antibody globulin is a reactant in nephrotoxic nephritis in the rabbit (80)

**PATHOLOGY OF NEPHROTOXIC NEPHRITIS**—The histology of the renal lesion in nephrotoxic nephritis like other features of this experimental disease, varies considerably depending on the size and the number of the doses of antikidney serum given (13 38) Small differences are noted in different strains of rats and in the lesion in the dog and rabbit as compared with the rat (13 38 70) Also it is apparent that there is a definite factor of individual variation among animals of the same strain or species (13 27 28 38 70) A composite chronologic picture of the histopathology of nephrotoxic renal disease cannot be compiled therefore The following description represents an abridged summary of the reports of the various investigations

Early in the acute stage, after the injection of antikidney serum swelling or thickening of the glomerular capillary basement membrane occurs accompanied by infiltration of the glomerular tuft by leukocytes (13 27 39 70) During the first few days of nephrotoxic nephritis swelling of endothelial and epithelial cells is observed in the glomerular tuft (27 39 70 81) and eosinophilic hyaline, and fibrin thrombi have been found in glomerular capillaries (27 70 81) The latter is a more prominent finding in severe nephrotoxic disease and is sometimes associated with partial or complete necrosis of glomerular tufts (27 70 81) Fibrin is seen in the capsular space and frequently in the dog and rabbit erythrocytes are present in Bowman's capsule (4 16 31 72) In kidneys of animals sacrificed or dead during the first or second week of the disease the capillary basement membrane is prominently thickened exudation into the glomerular capsule occurs and adhesions are found between the glomerular tuft and the capsule (13 27 70 81) Tubular changes are less pronounced than the glomerular lesions Swelling and granularity of some tubular cells accompanied by desquamation has been described (13 39 70 81) Eosinophilic hyaline casts are found in tubules (39 70) in the rabbit and dog red blood cell casts are occasionally seen (4 13 70) Tubular dilatation occurs (13 27 39 70) There is a varyingly intense infiltration

kidney antibody formation by collodion particle agglutination complement fixation and precipitation was unsuccessful (30)

From a review of the experimental data the conclusion that acute human glomerulonephritis following infection with nephritogenic streptococci has not been reproduced in animals seems reasonable. It is also apparent that unequivocal experimental evidence supporting the hypothesis that autoantibodies to renal tissue components play a role in the pathogenesis of glomerulonephritis has not been obtained. While many of the clinical and pathologic aspects of nephrotoxic and foreign protein nephritis in animals resemble corresponding features of acute nephritis in man, the fidelity and applicability of these experimental models as a means of investigating the pathogenesis of acute human glomerulonephritis appear to have one major limitation. Although the assumption that human glomerulonephritis may be a hypersensitivity reaction is reasonable it would seem pertinent to intensify efforts to establish nephritogenic hypersensitivity in animals with group A streptococci rather than nephrotoxic sera or unrelated foreign proteins in view of the epidemiological evidence of the role of nephritogenic group A streptococci in this disease.)

#### REFERENCES

- 1 Aldrich C A Nephritis in Brennemann J ed *Practice of Pediatrics* (Hagerstown, Md W F Prior Company 1943)
- 2 Bell E T Pathology and pathogenesis of clinical acute nephritis *Am J Path* 13 497 1937
- 3 Bennike T *et al* Penicillin therapy in acute tonsillitis phlegmonous tonsillitis and ulcerative tonsillitis *Acta med scandinav* 139 253 1951
- 4 Bevans M Seegal B C and Kaplan R Glomerulonephritis produced in dogs by specific antisera pathologic sequences following injection of rabbit antidog placenta serum or rabbit antidog kidney serum *J Exper Med* 102 807 1955
- 5 Braude A *et al* Type specific antibody response to M protein of nephritogenic streptococci in glomerulonephritis *J Clin. Invest* 36 876 1957
- 6 Catanzaro F J *et al* Role of streptococcus in pathogenesis of rheumatic fever *Am J Med* 17 749 1954
- 7 Cavelti P A Studies on technique of collodion agglutination influence of certain qualities of collodion particles and of proportions of antigen and collodion on sensitivity and specificity of reaction, *J Immunol* 49 365 1944
- 8 Cavelti P A and Cavelti E S Studies on pathogenesis of glomerulonephritis *Arch Path* 39 148 1945 40 158 163 1945
- 9 Coburn A F and Paul R H Interaction of host and bacterium in development of communicability by *Streptococcus haemolyticus* *J Exper Med* 73 551 1941
- 10 Commission on Acute Respiratory Diseases Study of food borne epidemic of tonsillitis and pharyngitis due to B hemolytic streptococcus type 5 *Bull. Johns Hopkins Hosp* 77 143 1945

88) Such changes have not been found in preliminary examinations of renal biopsy tissues obtained by biopsy from patients with glomerulonephritis (88)

#### EXPERIMENTAL NEPHRITIS AFTER INJECTION OF STREPTOCOCCI OR STREPTOCOCCI-KIDNEY TISSUE MIXTURES

Because of the epidemiologic evidence of the apparent role of certain types of group A streptococci in the etiology of glomerulonephritis a number of attempts have been made to produce nephritis in animals by infecting them with streptococci or by injection of streptococcal products. In a few instances, signs indicative of a renal inflammatory reaction have been noted in experiments designed for other purposes (95), as well as in experiments planned specifically to produce nephritis (65). In general, these have been isolated observations and have not been reproduced by other investigators. In a recent unconfirmed study hypertension, microscopic hematuria and albuminuria were reported to have developed in rabbits given single or multiple subcutaneous injections of type 12 streptococci isolated from patients during an outbreak of glomerulonephritis (65). Similar results were described following the injection of filtrates of broth cultures of this strain of streptococcus. Histopathologically however, the lesions were more compatible with minimal lower nephron nephrosis than with glomerulonephritis.

Other attempts have been made to produce glomerulonephritis by stimulating experimental animals to produce autoantibodies which would react with their own kidney tissues. Immunization with mixtures of streptococci and homologous kidney homogenates was the method used to produce renal autoantibodies. In the most detailed study with this method (8) the development of nephritis was reported to occur in a high percentage of rats given streptococcus-kidney mixtures but rarely in similarly treated rabbits. Antibody reacting with saline extracts of homologous kidney emulsions was demonstrated in the serum of the rats in which nephritis developed as well as in serum from rabbits in which nephritis did not develop (8). Antibody titrations were made with the sensitive but capricious collodion particle technic (7). The antibody titers were not quantitatively related to the presence or the severity of the nephritis. A careful attempt to reproduce these findings employing some of the same strains of streptococci but with a different strain of rats was completely unsuccessful demonstration of anti

- 32 Kay C F Mechanism of a form of glomerulonephritis nephrotoxic nephritis in rabbits *Am J M Sc* 204 483 1942.
- 33 Kleinman H Epidemic acute glomerulonephritis at Red Lake Minnesota *Med* 37 479 1954
- 34 Knowlton A I *et al* Development of hypertension and nephritis in normal and adrenalectomized rats treated with cortisone *Proc Soc Exper Biol & Med* 72 722, 1949
- 35 Kodama T *et al* To be published
- 36 Krakower C A Physical and chemical properties of the canine renal glomerulus and its nephrotoxic antigen, *Proc Inst Med Chicago* 19 26 1952
- 37 Krakower C A and Greenspon S A Localization of nephrotoxic antigen within isolated renal glomerulus *Arch Path* 51 629 1951
- 38 Lippman R W *et al* Nephrotoxic globulin nephritis effect of certain biological variables *Arch Path* 57 254 1954
- 39 Lippman, R W Marti H U and Campbell D H Nephrotoxic globulin nephritis course after single intravenous injection *Arch Path* 53 1 1952
- 40 Loeb E N *et al* On permanence of recovery in acute glomerulonephritis *J Clin Invest* 17 623 1938
- 41 Longcope W T Studies on variations in antistreptolysin titer of blood serum from patients with hemorrhagic nephritis *J Clin Invest* 15 277 1936
- 42 Longcope W T Some observations on course and outcome of hemorrhagic nephritis *Internat Clin* 1 1 1938
- 43 Luetscher J A Jr Piel C F and Curtis R H Nephrotic syndrome *J Chron Dis* 1 442 1955
- 44 Lytle J D Addis count in scarlet fever *J Clin Invest* 12 95 1933
- 45 Manser R W E and Wilson M M Epidemic of haemolytic streptococcal (group A) infection associated with considerable incidence of acute nephritis *M J Australia* 2 339 1952
- 46 McLean C R *et al* Diffuse glomerulonephritis induced in rabbits by small intravenous injections of horse serum *Arch. Path* 51 1 1951
- 47 Mellors R C *et al* Histopathologic demonstration of glomerular localizing antibodies in experimental glomerulonephritis *Am J Path* 31 687 1955
- 48 Mellors R C and Ortega L C Analytical pathology new observations on pathogenesis of glomerulonephritis lipid nephrosis periarteritis nodosa and secondary amyloidosis in man, *Am J Path* 32 455 1956
- 49 Mellors R C Siegel M and Pressman D Analytic pathology histochemical demonstration of antibody localization in tissues with special reference to antigenic components of kidney and lung *Lab Invest* 4 69 1955
- 50 More R H and Waugh D Diffuse glomerulonephritis produced in rabbits by massive injections of bovine serum gamma globulin *J Exper Med* 89 541 1949
- 51 Mortimer E A *et al* To be published
- 52 Neale A V Kidneys in pneumococcal infections *Brit. M J* 2 391 1928
- 53 Piel C F Nephrosis and Nephritis in Childhood in *Mesenchymal Diseases in Childhood Report of the Twenty second Ross Pediatric Research Conference* (Columbus Ohio Ross Laboratories 1957)
- 54 Piel C F *et al* Glomerulus in experimental renal disease in rats as observed by light and electron microscopy *J Exper Med* 102 573 1955
- 55 Pressman D Hill, R F and Foote F W Jr Zone of localization of anti mouse-kidney serum as determined by radioautographs *Science* 109 65 1949

- 11 Earle D B Natural history of glomerulonephritis J Chron. Dis 5 3 1957
- 12 Ehrlich W E Glomerular nephritis and lipid nephrosis Identities and mechanisms J Chron Dis 5 14 1957
- 13 Ehrlich W Forman C W and Seifer J Diffuse glomerulonephritis and lipid nephrosis Arch Path 54 463 1952
- 14 Fischel E E Immune reactions in human glomerulonephritis J Chron Dis 5 34 1957
- 15 Fischel E E and Gajdusek D C Serum complement in acute glomerulonephritis and other renal diseases Am J Med 12 190 1952
- 16 Fouts P Corcoran A C and Page I Observations on the clinical and functional course of nephrotoxic nephritis in dogs Am J M Sc 201 313 1941
- 17 Francis A E Sulphonamide resistant streptococci in plastic surgery ward Lancet 1 408 1942
- 18 Germuth F G Jr A comparative histologic and immunologic study in rabbits of induced hypersensitivity of the serum sickness type J Exper Med 97 237 1953
- 19 Germuth F G Jr and Heptinstall R H Development of arterial lesions following prolonged sensitization to bovine gamma globulin Bull Johns Hopkins Hosp 100 58 1957
- 20 Germuth F G Jr Oyama J and Ottinger B Mechanism of action of 17 hydroxy 11 dehydrocorticosterone (compound E) and of adrenocorticotrophic hormone in experimental hypersensitivity in rabbits J Exper Med. 94 139 1951
- 21 Germuth F G Jr Pace M G and Tippet J C Effect of sensitization to homologous and cross reactive antigens on rate of antigen elimination and development of allergic lesions J Exper Med 101 135 1955
- 22 Hackel D B Almerindo G P and Finney T D Experimental nephrotoxic nephritis in rat treated with ACTH or cortisone Proc Soc Exper Biol & Med 74 458 1950
- 23 Hardin R A Quinn R and Avery R C Survey of hemolytic streptococci from patients with rheumatic fever glomerulonephritis pharyngitis and the carrier state J Infect Dis 99 84 1956
- 24 Hawn C V Z and Janeway C A Histological and serological sequences in experimental hypersensitivity J Exper Med 85 571 1947
- 25 Heptinstall R H and Germuth F G Jr Experimental studies on immunologic and histologic effects of prolonged exposure to antigen Bull. Johns Hopkins Hosp 100 71 1957
- 26 Heymann W and Hackel D B Nephrotic Syndrome in Puppies in *Proceedings of the Fifth Annual Conference on the Nephrotic Syndrome* (New York National Nephrosis Foundation Inc 1954)
- 27 Heymann W and Lund H Z Nephrotic syndrome in rats Pediatrics 7 691 1951
- 28 Heymann W Lund H Z and Hackel D B Nephrotic syndrome in rats with special reference to progression of the glomerular lesion and to use of nephrototic sera obtained from ducks J Lab & Clin Med 39 218 1952
- 29 Hill A G S and Cruickshank B Study of antigenic components of kidney tissue Brit J Exper Path 34 27 1953
- 30 Humphrey J H Pathogenesis of glomerulo nephritis re-investigation of auto immunisation hypothesis J Path & Bact 60 211 1948
- 31 Kay C F Mechanism by which experimental nephritis is produced in rabbits injected with nephrotoxic duck serum J Exper Med 72 559 1940

- 81 Smadel J E Experimental nephritis in rats induced by injections of anti kidney serum pathological studies of acute and chronic disease J Exper Med 64 541 1937
- 82 Smadel J E and Farr L E Experimental nephritis in rats induced by injections of anti kidney serum clinical and functional studies J Exper Med 65 527 1937
- 83 Solomon D H *et al* Nephrotoxic nephritis in rats J Exper Med 90 267 1949
- 84 Stavitsky A B Stavitsky R and Ecker E E Loss of hemolytic-complement activity and of granulocytes following reinjection of an antigen into the rabbit J Immunol 63 389 1949
- 85 Stetson C A *et al* Epidemic acute nephritis studies on etiology natural history and prevention Medicine 34 431 1955
- 86 Updyke E L Moore M S and Conroy E Provisional new type of group A streptococcus associated with nephritis Science 121 171 1955
- 87 Vazquez J J and Dixon F J Immunohistochemical analysis of amyloid by the fluorescence technique J Exper Med 104 727 736 1956
- 88 Vermer R L Renal Biopsy in the Study of Chronic Renal Disease in Children in *Mesenchymal Diseases in Childhood Report of the Twenty second Ross Pediatric Research Conference* (Columbus Ohio Ross Laboratories 1957)
- 89 Wahrer C F Epidemic of hemorrhagic nephritis following scarlet fever J A M A 51 1410 1908
- 90 Wannamaker L W The Epidemiology of Streptococcal Infections in McCarty M ed *Streptococcal Infections* (New York Columbia University Press 1954)
- 91 Wedgewood R J Hawn C Van Z. and Janeway C A The Mechanism of Action of ACTH in Experimental Nephritis Due to Foreign Protein, in *Proceedings of the Second Clinical ACTH Conference* ed by J R Mote (New York The Blakiston Company 1951) Vol I pp 108-114
- 92 Wedgewood R J and Janeway C A Serum complement in children with collagen diseases Pediatrics 11 569 1953
- 93 Wertheim A R *et al* Association of type specific hemolytic streptococci with acute glomerulonephritis at the Presbyterian and Babies Hospitals New York N Y in the years 1936-1942 J Clin Invest 32 359 1953
- 94 Wilmers M J Cunliffe A C and Williams R E O Type 12 streptococci associated with acute hemorrhagic nephritis Lancet 2 17 1954
- 95 Wilson H E *et al* Reactions of monkeys to experimental mixed influenza and streptococcus infections J Exper Med 85 199 1947
- 96 Winkenwerder W L McLeod N and Baker M Infection and hemorrhagic nephritis Arch Int Med 56 297 1935
- 97 Wissler R W Smull K and Lesh J B Effects of various horse serum fractions in producing cardiovascular and renal lesions in rabbits J Exper Med 90 577 1949



- 56 Rake G Nephritis in pneumococcal infections *Guys Hosp Rep* 83 430 1933
- 57 Rammekamp C H Jr Glomerulonephritis *Proc Inst. Med Chicago* 19 371 1953
- 58 Rammekamp C H Jr Microbiologic aspects of glomerulonephritis *J Chron Dis* 5 28 1957
- 59 Rammekamp C H Jr Epidemiology of streptococcal infections *Harvey Lect* 51 113 1955-1956
- 60 Rammekamp C H Jr To be published
- 61 Rammekamp C H Jr and Choy D C To be published
- 62 Rammekamp C H Jr and Weaver R S Acute glomerulonephritis significance of the variations in the incidence of the disease *J Clin Invest.* 32 345 1953
- 63 Rammekamp C H Jr Weaver R S and Dingle J H Significance of epidemiological differences between acute nephritis and acute rheumatic fever *Tr A Am Physicians* 65 168 1952
- 64 Reed R W Epidemic of acute nephritis *Canad M A J* 68 448 1953
- 65 Reed R W and Matheson B H Experimental nephritis due to type specific streptococci, *J Infect Dis* 95 191 202 1954
- 66 Relman A S Lost art of urinalysis *Boston M Quart.* 8 6 1957
- 67 Rich A R Pathology and pathogenesis of experimental anaphylactic glomerulonephritis in relation to human acute glomerulonephritis *Bull Johns Hopkins Hosp* 98 120 1956
- 68 Rothenberg M B Stavitsky A B and Heymann W In vitro evaluation of nephrotoxic sera in experimental nephrosis *Pediatrics* 18 455 1956
- 69 Schwab L, *et al* Effect of inhibition of antibody formation by x radiation or nitrogen mustards on histologic and serological sequences and on behavior of serum complement following single large injections of foreign proteins *J Exper Med* 91 505 1950
- 70 Seegal B C and Bevans M Production of glomerulonephritis by immunologic methods *J Chron Dis* 5 153 1957
- 71 Seegal B C and Hasson M W Nephrotic nephritis in rat produced by duck antirat kidney serum effect of cortisone on course of disease *Fed Proc* 13 443 1954
- 72 Seegal B C *et al* Glomerulonephritis produced in dogs by specific anti sera course of disease resulting from injection of rabbit antidog placenta serum or rabbit antidog kidney serum *J Exper Med* 102 789 1955
- 73 Seegal D Acute glomerulonephritis following pneumococcal lobar pneumonia analysis of seven cases *Arch Int Med* 56 912, 1935
- 74 Seegal D *et al* On exacerbation in chronic glomerulonephritis *J Clin Invest* 19 569 1940
- 75 Seegal D and Lytle J D Antistreptolysin titer in serum in acute glomerulonephritis *Proc Soc Exper Biol & Med* 31 211 1933
- 76 Seegal D Seegal E B C and Jost E L Comparative study of geographic distribution of rheumatic fever scarlet fever and acute glomerulonephritis in North America *Am J M Sc* 190 383 1935
- 77 Schuster A C Krause R M and Rammekamp C H Jr To be published
- 78 Siegel A C and Rammekamp C H Jr To be published
- 79 Siegel A C Rammekamp C H Jr and Griffeath H I Epidemic nephritis in a school population relation of hematuria to group A streptococci *Pediatrics* 15 33 1955
- 80 Simonsen M Studies on pathogenesis of experimental glomerulonephritis *Acta path et microbiol scandinav* 32 85 1953

# Pathophysiology of Carcinoid ✓      Tumors

DAVID M. SPAIN

*Beth-El Hospital Brooklyn New York and Columbia University  
College of Physicians and Surgeons New York New York*

IN THE SHORT time since the recognition of the malignant carcinoid syndrome and the subsequent isolation of 5 hydroxytryptamine (5-HT serotonin) from the carcinoid tumor serotonin has become the current romance substance of medical research. Experiments with this substance are being conducted at an intense and rapid pace that is only exceeded by speculations about its possible functions in the human body. Currently it is often difficult to separate fact from fancy and any discussion bearing on the subject must be judged within such a frame of reference.

✓ Proper orientation requires a consideration of the enterochromaffin system, the carcinoid tumor, the malignant carcinoid syndrome, the nature and pharmacology of 5-HT and related substances, as well as the possible functions of 5-HT in the human body.

## ENTEROCHROMAFFIN (ARGENTAFFIN) CELLS

(The cells believed to be responsible for the formation and secretion of 5-HT are known as the enterochromaffin cells). Various other names have been used from time to time for the cells that constitute the enterochromaffin system, such as gelbe zelle Kultschitzky cells, the argentaffin cells. Heidenhain (20) in 1870 was the first to recognize and describe them. He isolated these cells from the stomachs of rabbits and dogs and demonstrated their chromaffin nature. In man, normal enterochromaffin cells are present in the stomach particularly



phylogenesis. Similar cells have been observed in the thymus of birds and the posterior salivary glands of Octopoda (10)

(The function of these cells has long been the source of much speculation and has included such concepts as endocrine, exocrine, absorptive and excretory (48). In 1897 Kultschitzky postulated that they played a role in protein absorption. Practically all of the hypotheses with the exception of the endocrine one are at present only of historic interest. The recent claim that glucagon was a product of the argentaffin cell has received insufficient confirmation. There is also inadequate evidence that any significant amount of histamine is either carried or secreted by them. It is now recognized that these cells manufacture 5-HT from tryptophan and then secrete it into the circulation (11). Recent studies have also hinted at some relation between mast cells and 5-HT (3). In order to procure sufficient cell material for quantitative cell content studies it becomes necessary to study tumors derived from these cells. Sjoerdsma and co-workers in an exhibit at a meeting in 1957 showed the following quantities of 5-HT and histamine to be present in mast cell tumors and carcinoids:

Tumor	5-HT $\mu\text{g}/\text{Gm}$	Histamine $\mu\text{g}/\text{Gm}$
Mast cell tumor (dog)	< 0.2	315-160
Carcinoid tumor (man)	360-570-800	3.4-2.0-0.8

At present, therefore, the only hormonal substance that has clearly been demonstrated within these cells in significant amounts is 5-HT.

## CARCINOID TUMOR

Tumors that today would undoubtedly be classified as carcinoids were observed over 100 years ago in the ileum and appendix, and were at that time considered to be atypical and undifferentiated carcinomas. For years the tumor was called a "little cell carcinoma." In 1888 Lubarsch (26) reported 2 cases of *primären Krebs des Ileum*. The description given at that time unequivocally indicates that they were examples of carcinoid tumors. Oberndorfer (35) in 1907 suggested the term "carcinoid" for this form of neoplasm because of its relatively benign behavior and its carcinoma-like histologic appearance. The literature in the United States on the subject of these tumors was confused until 1925 when Forbus (14) redescribed and clarified some of their aspects. The German pathologists were in agreement that

at the base of the cardiac and pyloric glands in the villi and crypts of the small and large intestines and in the appendix the mucosa of the gallbladder and in the pancreatic ducts. They are believed to form a diffuse endocrine gland. Gosset and Masson (18) anticipated the recent discoveries by ascribing a neuroendocrine function to these cells over 40 years ago. Erspamer (10) while studying the nature of the granules in these cells isolated a substance from gastrointestinal mucosa which caused contraction of smooth muscle and named it enteramine. Rapport and co workers (42) independently discovered a substance in serum while searching for a vasoconstrictive factor and named it serotonin. With the identification of 5-HT it was realized that enteramine and serotonin were the same substance (10).

The body of the enterochromaffin cell usually adheres closely to the basement membrane and bulges into its outer surface. A constricted continuation extends from the cell toward the lumen. Its nucleus is large and spherical, while the oval nuclei of the surrounding epithelial cells project beyond it. The cytoplasm at the base of the cell is filled with granules which so intrigued Erspamer and associates. They stain easily with eosin, acquire a brownish yellow color on exposure to chromates and show the classic argentaffin reaction when treated with ammoniacal silver nitrate. The argentaffin reaction has at times been confused with silver impregnation in which reducing agents are used, but the latter is correctly called an argyrophilic reaction. In the true argentaffin reaction the silver salts are reduced by the tissue component stained. However this will occur only if the tissue is fixed in formalin; if alcohol is used the ability of the tissue to reduce ammoniacal silver salts disappears. The authentic/argentaffin reaction, not the argyrophilic one, is characteristic of the enterochromaffin cell and the cells of the carcinoid tumor. Many investigators have studied the detailed histochemistry which indicates that the vacuoles in the cells contain a mixture of neutral fats, cholesterol esters, and a little lecithin. Various opinions about the granules implicate a pterin, a carbohydrate, a derivative of resorcinol, and a freely conjugated  $\beta$  carboline derivative (43).

Some claim that the cells arise from entoderm while others, notably Lewis and Geschickter (25) believed their origin to be from neuroectoderm. Among the vertebrates the Cyclostomata lack typical enterochromaffin cells but they do have cells referred to as pre enterochromaffin cells. These cells may have lost their 5-HT content during

be the favored site Carcinoid tumors of the appendix are generally found in young individuals because in this region the tumor more often produces symptoms and almost any significant lower abdominal discomfort in a young individual often results in an appendectomy

Without adequate explanation it has been noted that carcinoids of the appendix occur more often in females than in males whereas in the other sites of origin there is no sex predilection.

In the appendix the carcinoid is most often located at or near the tip and often appears as a submucosal intramural yellow nodule The overlying epithelium is intact In the intestine, too, the tumor is intramural, and often consists of a small submucosal nodule At times it

TABLE 2—SITES OF ORIGIN OF 509 CARCINOIDS AS REPORTED IN LITERATURE

SITE	CARCINOID	
	Number	Per Cent
Appendix	341	67
Ileum	77	15
Jejunum	7	2
Small intestine, undetermined	33	7
Colon	18	4
Rectum	13	3
Stomach	9	2
Duodenum	5	1
Gallbladder	1	0.2
Unknown origin	5	1

may be as large as 15 cm in diameter Polypoid annular, and constricting patterns of growth may also occur Sometimes as the tumor enlarges central umbilication with ulceration of the overlying mucosa is seen

(It is now established that the carcinoid tumor arises from the cells of the enterochromaffin system) This was first proposed in 1910 according to Rutchie (43) but it was Gosset and Masson (18) who supplied the necessary supporting data and who evolved a theory of origin for these tumors Because rectal carcinoids do not exhibit the characteristic granules seen in the cells of the tumor in other sites Stout (56) has suggested that rectal carcinoids may originate from the pre enterochrome type of cell observed in other animal species This is significant because malignant rectal carcinoids even with extensive hepatic metastasis have to date not been associated with the malignant carcinoid syndrome

The tumor typically consists of well defined solid clumps or strands

these tumors arose from the enterochromaffin cells of the gastrointestinal tract. For a long time these tumors were regarded as medical curios without much clinical importance. Their malignant nature was not appreciated nor was there any suspicion of any clinical syndrome secondary to chemical secretions from these tumors.

The carcinoid tumor or argentaffinoma may occur at any point within the gastrointestinal tract from the cardiac end of the stomach to the anus. It is frequently observed in the appendix and ileum occasionally in a Meckel's diverticulum or the gallbladder and rarely in teratomas of the ovaries and testes. Such cases as are reported as primary carcinoid of the mesentery and pancreas must be regarded

TABLE 1—APPENDICEAL AND NONAPPENDICEAL SITES OF CARCINOID IN SURGICAL AND AUTOPSY MATERIAL AS REPORTED IN LITERATURE

Site	SURGICAL MATERIAL		AUTOPSY MATERIAL	
	Number	Per Cent	Number	Per Cent
Appendiceal	181	92	8	11
Nonappendiceal	15	8	65	86
Undetermined	0		2	3
Total	196		75	

as unproved because there is insufficient evidence in the records that primary tumors elsewhere such as in the ileum had been definitely excluded.

A form of bronchial tumor designated as the carcinoid type of bronchial adenoma is unrelated in its histogenesis to the argentaffinoma of the gastrointestinal tract. The continued use of this term in reference to a particular type of bronchial adenoma is confusing and is better discontinued. Recently however a carcinoid like tumor has been described in the bronchial tree associated with the syndrome (33).

Tables 1 and 2 list the sites of origin of carcinoid tumors as reported in the literature. The relative incidence of occurrence in the appendix as compared with the intestine will depend on the source of the material analyzed. If the series consists entirely of surgically removed specimens the vast majority will be in the appendix. If the study is based on autopsy material the intestine and especially the ileum will

noids 33 per cent were found to be noninvasive 27.3 per cent had invaded muscle 23.3 per cent involved the regional lymph nodes and 16.7 per cent had metastases in distant organs a total of 67 per cent revealed either local invasion or metastases (43)

Although local invasion of muscular coats is often noted in appendiceal carcinoids only a few authenticated cases with distant metastases have been reported This low incidence of metastasis from appendiceal carcinoids may be explained in part by the relatively slow growth of the tumor combined with frequent early removal of the appendix In the appendix, as well as in other sites local infiltration is often accompanied by hyperplasia of adjacent muscular tissue Distant metastases are found commonly in the liver, but almost any organ may become involved )

The microscopic appearance is of little aid in the prognosis of the rate of growth or the development of metastases The cellular pattern is usually uniform, but variations in cell type and bizarre cells may be present in both the "benign" and malignant variants Atypical cells are at times more numerous in the more invasive tumors (37)

Survival in the presence of liver metastases has been as long as 25 years Carcinoid tumors occur at all ages and there is 1 reported case in a 10 day old infant Those with metastases are almost always seen after the age of 45 This is further indication of the sluggish growth and slow tendency to spread (34 40)

The current tendency is to consider all carcinoids potentially malignant ✓

### SECRETION

Evidence that carcinoid tumors secrete an active physiologic or pharmacologic substance has been known since 1924, when extracts from an appendiceal carcinoid exhibited properties similar to epinephrine (7) Since then, others have extracted pressor materials from these tumors (13 46) A most significant contribution was made by Lembeck (24) who isolated considerable amounts of 5-HT from carcinoid metastases and from a "benign" appendiceal carcinoid. This has since been repeated by others (49) The 5-HT so obtained is identical to the enteramine isolated by Erspamer and the serotonin of Page (36) and Rapport et al (42)

5-HT or serotonin as it is most commonly known, belongs to the family of indolealkylamines and has the formula shown in Figure 1.

The 5-HT content varies from one tumor to another and in different



of rather small closely packed polyhedral cells. There may be scattered areas of small glandular lumens or distinct acini. The more actively growing tumors show varying degrees of anaplasia. Mitoses are usually rare and it is practically impossible on histologic evidence alone, to determine their benign or malignant potentialities. Variations in cell types may have functional significance. The special staining characteristics reflect those found in the cell of origin (enterochromaffin cell). Many of the stains depend on artifacts associated with formalin fixation. The tumor itself gives (1) a positive chromaffin reaction, (2) stains with iron hematoxylin and with acid and alkaline diazonium salts (3) is argentaffin with silver nitrate (4) shows yellow fluorescence with ultraviolet light and (5) on frozen section reveals droplets that stain partly with scarlet red Sudan IV and osmic acid. Doubly refractile crystals are observed under polarized light (44-45).

The frequency with which the tumor arises in the same individual from multiple sites raises the question whether it may be developmental in origin. This view was among the earliest held concerning the pathogenesis of these tumors. Such terms as *hamartomatige Bildung* and *mucous membrane naevy* have been used in this connection (50). In support of this are reports of association with minor congenital cardiovascular abnormalities (4 cusped pulmonary valves, Chiari's networks, dextrocardia), Meckel's diverticulum, cleft palate and cystic teratoma (12-53). In fact, these tumors may arise in cystic teratomas of the ovaries or testes and are second in frequency only to squamous cell carcinoma in tumors growing from dermoid cysts of the ovary (12). Some have reported a significant association with other malignant tumors (37).

### MALIGNANCY

✓ The malignant potential of the carcinoid tumor was not fully recognized until the past decade, although such a tumor with metastases was described in 1890 by Ransom (41). Despite the fact that over 400 cases with metastases have been reported as late as 1939, Cohen and associates (6) claimed that the tumor did not metastasize.

✓ Primary carcinoid of the ileum metastasizes more often than those arising from other sites. The tumor at first grows intramurally beneath the mucosa. It may spread into the adjacent muscular coats, then into the regional lymph nodes, into the blood vessels and finally to the liver and other organs. In one study, on 146 extra-appendiceal carci-

secondary to hyperserotonemia. Many carcinoids are asymptomatic and are only discovered as incidental findings at autopsy; others may show recurrent or chronic partial intestinal obstruction. The incidence of obstructive manifestations varies between 25 and 50 per cent of all small bowel carcinoids (23-37). Intermittent diarrhea, pain and loss of weight complete the picture. The tumor is seldom palpable through the abdominal wall. The diarrhea is often bloodless because the growth is intramural and usually without ulceration of the overlying mucosa. Intussusception is an occasional complication.

In general, the clinical features which depend on the presence of the mass itself or at sites of metastases are no different than those due to masses of the same size and location but of a different histogenesis.

Rectal carcinoids may be locally extensive and infiltrate into the surrounding perirectal tissue. Their behavior simulates that of rectal carcinoma, from which they are as a rule clinically indistinguishable. Bleeding is more common at this site. A biopsy specimen of such a lesion may be mistaken for carcinoma or else reveal no tumor cells because of the deep submucosal location of the tumor. It has already been mentioned that rectal carcinoids may not display the tinctorial characteristics of an argentaffinoma. Since the affinity of the cellular granules for certain stains is related to the presence of 5-HT, it is not to be expected that rectal carcinoids even with extensive hepatic metastases will be functional in the sense of producing the "malignant carcinoid syndrome."

Anemia is a late manifestation of the localized form of intestinal carcinoid, and in this respect the carcinoid differs from other malignant neoplasms of the intestine.

### MALIGNANT CARCINOID SYNDROME

The clinical picture of the malignant carcinoid with metastases in which there is significant hyperserotonemia has been extensively described in the last few years (33-49, 58). For the pharmacology and distribution of serotonin, see page 221.

The specific signs and symptoms are believed to be related to excessive production and secretion of 5-HT. Although a "benign" carcinoid may form and secrete increased amounts of serotonin, the clinical syndrome has so far only been described in association with metastatic malignant carcinoid in which larger numbers of functioning cells are present. Recent study of a "benign" appendiceal carcinoid

parts of the same tumor. In one instance a metastatic nodule contained 360  $\mu\text{g}$  per gram while the primary tumor contained 61  $\mu\text{g}$ . Most tumors so far analyzed have yielded over 200  $\mu\text{g}$  per gram (49).

✓ In the normal individual, 5 HT is usually detected in the blood, spleen, gastrointestinal tract and central nervous system. Elevated




FIG. 1

serum levels of 5 HT have been found in the presence of the tumor. Urinary 5 HT and 5 hydroxyindoleacetic acid, i.e., the breakdown product of 5 HT, are increased in individuals with metastatic carcinoid tumors. This finding is used as a diagnostic aid for the clinical detection of carcinoid. A simple test, based on the development of a specific purple color reaction for 5 hydroxyindoles when 1 nitroso 2 naphthol and nitrous acid are added, has been devised by modifying and simplifying the method for quantitative assay of 5 hydroxyindoleacetic acid (60).

### LOCAL EFFECT OF CARCINOID OF ILEUM

The clinical picture of carcinoid tumors may be divided into two parts—that associated with the local mechanical and space-occupying effects in the intestine, and that associated with the systemic effects

the malignant carcinoid syndrome depends only slightly on local mechanical irritation. In all probability it is related to the stimulation of smooth muscle by 5-HT and to the associated localized intestinal muscular hyperplasia. The diarrhea is often an early and persistent manifestation. The stools are watery and may number as many as 30 a day.

The changes in the skin especially of the face include teleangiectasia and dilatation of the small vessels. This imparts a plethoric appearance to the individual, although there is no increase in the total number of red blood cells. In most cases there are episodic attacks of flushing associated with extreme cyanosis. At times they are combined with such vasomotor manifestations as sweating and hot sensations. The hemodynamic changes during the flushing period have been studied in detail (57). During the early stage of the flush the cardiac sounds, murmurs and contractions and the ballistocardiographic waves are diminished. As cutaneous vasodilatation is completed all of the above increase considerably. This is usually accompanied by tachycardia, rise in blood pressure, hyperpnea and tachypnea. With the appearance of cyanosis the findings revert to those seen at the onset of the flushing episode. These manifestations are not always constant. The episodes may be fleeting or last many hours and may be evoked by a variety of stress situations.

In some there are recurrent episodes of cyanosis together with respiratory symptoms akin to bronchial asthma; the patient is dyspneic, wheezes and has an expiratory stridor. The blood pressure remains relatively normal during the attack.

At a meeting in 1957 Weissbach discussed the implications of the presence of 5-HT in the lung and the anaphylactic reaction in general. The enzymes which build and destroy 5-HT are also present in relatively high concentration in the lung in normal animals of various species. It has been shown that the addition of purified antigen and antibody to normal rabbit platelets releases 5-HT and histamine. Guinea pig lung is low in histamine and high in 5-HT. Antihistamines are practically useless in the guinea pig while lysergic acid diethylamide (LSI) which has an antiserotonin action may protect the animal against anaphylaxis. 5-HT plasma levels may be increased tenfold in experimentally induced anaphylaxis in rabbits. Further studies on the quantitative determination of the metabolites of 5-HT in the urine of patients with various allergies may yield valuable data and insight into the general problem of allergy.

revealed a 5 HT content 1 000 times greater than that of normal tissue, and an enzymic ability to synthesize 5 HT from its precursor substance 35 times that of normal human appendiceal tissue

The basic findings of this syndrome consist of chronic diarrhea flushes and cyanosis respiratory distress and right sided cardiac disease. Thorson *et al* (58) were the first to suggest that these protean manifestations might be secondary to the presence of excessive amounts of 5 HT. Since 5 HT acts on the smooth muscle of blood vessels bronchi and intestine he was justified in implicating this substance. Sjoerdsma *et al* (49) in extensive metabolic studies on tryptophan intake and utilization in normal individuals and patients with this syndrome demonstrated a marked depletion of the body reserves of tryptophan as a result of the synthesis of large amounts of 5-HT

5 HT is formed as a result of a ring oxidation and decarboxylation of tryptophan. In the formation of 5 hydroxytryptophan by means of a hydroxylase 60 per cent of the tryptophan in the body may be utilized. As a result of this there may be inadequate niacin and other protein synthesis. In this condition a nutritional deficiency may develop indeed a pellagra like picture has been reported (31). The concept that tryptophan is a precursor of 5 HT and of 5 hydroxy indolacetic acid was supported in man through tracer experiments with  $C^{14}$  labeled tryptophan (see Fig 1)

✓ Palpation and massage of the tumor have precipitated characteristic flushes and respiratory distress. In the same individual histamine injections apparently also produced some aspects of the clinical syndrome. It is postulated that histamine may stimulate the carcinoid to release its secretion just as it stimulates a pheochromocytoma to release norepinephrine (34)

\* Thus both excessive secretion of 5 HT and tryptophan depletion must be considered in any attempt to provide a rational basis for the entire clinical picture and the anatomic changes in the cardiovascular system

✓ Ordinarily the blood concentration of 5 HT ranges from 0.1 to 0.4  $\mu$ g per milliliter, and the 24 hour urinary output of 5 hydroxyindole acetic acid normally ranges between 3 and 8 mg. But in the carcinoid syndrome the serum levels of 5 HT have been as high as 4  $\mu$ g per milliliter and the urinary output of 5 hydroxyindolacetic acid as high as 330 mg

✓ The diarrhea in patients with the "benign" carcinoid as well as with

coagulum or a nonbacterial type of vegetation has been associated with the lesion (30-53). However, these may be nonspecific secondary changes and not necessarily pathogenetically related to the lesion. The chordae tendinae may be surrounded by a uniformly cellular fibrous thickening. At the base of the valves a few lymphocytes and macrophages may be noted. MacDonald and Robbins (28) have observed increased numbers of mast cells and have speculated on their relation to the development of the valve changes. The lesion appears to be distinct and can generally be distinguished from congenital valve changes, fibroelastosis, rheumatic valvulitis, collagen disease, and thrombotic or bacterial endocarditis.

The tricuspid and pulmonic valves appear to be involved with equal frequency. In 1 series the mitral valve was reported to be involved in 12 of 35 cases and the aortic valve in 5 cases (it is not clear whether coincidental rheumatic involvement of the mitral valve was excluded in some of these cases). The pulmonary artery was involved in at least 3 cases and the endocardium of the right auricle revealed fibrous thickening in about one third of the cases (51).

The occurrence of hypertrophy and dilatation of the right auricle and ventricle with or without congestive failure depends on the extent and type of valve deformities. The other clinical features of a functioning malignant carcinoid tumor may be present without any evidence at autopsy of anatomic cardiovascular changes. In a review of 26 carcinoids—benign and malignant—found at autopsy, 10 of the cases revealed various degrees of right-sided endocardial or valvular changes, some of them in the absence of metastases (53). On the other hand, it has been claimed that the specifically characteristic cardiac lesion occurs only in the presence of hepatic metastases. It has also been maintained that the characteristic left-sided cardiac lesion can occur only in the presence of a patent foramen ovale. This is not borne out by our personal experience.

The pathogenesis of the cardiovascular changes is still obscure. Various mechanisms have been proposed to explain the predominantly right-sided endocardial involvement. Gobel and co-workers (17) offer at least a partial explanation: after collecting blood simultaneously from the brachial and the pulmonary arteries they found the plasma 5-HT content of the brachial artery to be much lower than that of the pulmonary artery; they estimated that about two thirds of the unbound 5-HT was removed in the passage through the lungs. This finding, however, remains unconfirmed. They attributed this to the high pulmonary con-

✓Edema of the legs pleural effusion and arthritis have also been observed. The finger joints were the main site of involvement. However, all of the cases with arthritis are in that age group where degenerative joint changes are frequent (33-43).

✓It is difficult to evaluate evidence of mental disturbances because most of the patients were seriously ill. However, in the clinical records of these patients such phrases as uncooperative, unreliable, contradictory, and very nervous are not uncommon. ✓The main anatomic manifestation of this syndrome with its resultant symptomatology is localized in the cardiovascular system. In the advanced form it consists primarily of fibrostenotic lesions of the pulmonic and tricuspid valves.

### CARDIOVASCULAR CHANGES

At least 70 acceptable cases of valvular right sided lesions have been reported in association with malignant carcinoid tumors with hepatic metastases (27-33-43). The gross and microscopic changes in the valves, endocardium and pulmonary arteries in this syndrome have recently been described in detail (28-30-51).

✓Lesions are found chiefly in the pulmonic and tricuspid valves. The auricular and ventricular endocardium of the right cardiac chambers as well as the intima of the major pulmonary arteries may also be affected. The question whether specific lesions of the left cardiac chambers occur in the absence of a patent foramen ovale is still being debated.

The lesion consists of a plaque of moderately cellular tissue intimately adherent to the surfaces of the valves or the other involved sites e.g. pulmonary artery intima. The valve itself appears to be intact, although adhesions between the cusps or leaflets may form eventually and finally lead to marked valvular distortion. The process may extend to the adjacent endocardium and the chordae tendinae. The plaques are made up of a relatively acellular ground substance containing fibrous tissue cells, most of which are spindle shaped. The ground substance is homogeneous and basophilic and contains delicate fibers. Elastic fibers are few or absent entirely. There is no lipid within the lesion and special stains fail to reveal surface or incorporated fibrin. Periodic acid stain is only slightly positive. Foci of distended capillaries are present in the subendothelial thickening superimposed upon a relatively intact endocardium (28). In a few cases a fibrin

the more rapid growth rate of the carcinoid might be secondary to the valvular lesion, which they regarded as congenital.

At present, it is generally held that excessive amounts of 5-HT circulating through the right cardiac chamber and pulmonary circulation are pathogenetically related to the endocardial sclerosis but the mechanism of its action remains obscure

## PHARMACOLOGY AND DISTRIBUTION OF SEROTONIN

At present, it is believed that 5-HT is elaborated by the enterochromaffin system. It is found in the cells of this system in the blood, especially within the platelets in the spleen and in some cerebral and peripheral nervous structures (10). Serotonin may be identified quantitatively in tissue by specially designed spectrofluorometric techniques. Chemical isolation, color reactions, paper chromatography and pharmacologic bioassay methods have all been used. The spectrofluorometric method is especially useful for central nervous system tissues (61).

The substance is released from the cells in the gastrointestinal tract into the blood where most of it is taken up by the platelets. Tryptophan is probably the parent substance of most of the naturally occurring indole derivatives. Enzymic destruction of 5-HT into an indol acetic acid is accomplished by monamine oxidase. The monamine oxidases are present in greatest concentration in the lung and brain (10).

It is claimed that there is a threshold rate for every animal species which limits the capacity of the blood thrombocytes to take up 5-HT. Little is understood about the conditions which regulate possible physiologic release by intact thrombocytes. Cellular disintegration is probably not essential to the liberation of 5-HT from the platelets (10).

The estimated normal serum level of 5-HT is 0.1  $\mu$ g per milliliter. The metabolic rate of endogenous 5-HT as determined by the urinary output of 5-hydroxyindolacetic acid is sufficiently intense not to support the theory of disintegrating platelets as the only source of plasma 5-HT. Most of the 5-HT in the circulating plasma can be attacked by the monamine oxidases particularly as the blood circulates through the lung (10).

The identity of synthetic serotonin and the naturally occurring material has been demonstrated by numerous pharmacologic reactions. Only scant data are available on the toxicity of 5-HT. The intravenous



tent of monoamine oxidase, the enzyme which converts the  $\text{CH}_2\text{NH}_2$  group of 5-HT to  $\text{CO}_2\text{H}$  and thereby produces hydroxyindoleacetic acid. The latter substance is a urinary excretion product and is pharmacologically inactive. They found monoamine oxidase in other organs as well.

It is also possible that the liver has a role in 5-HT metabolism. Extensive amounts of 5-HT, secreted by metastatic carcinoid nodules in the liver, enter the right side of the heart before passing through the lungs so that presumably large amounts of 5-HT may then act on the endocardium and produce the observed changes. On the other hand the changes need not be the result of a specific 5-HT effect on the endocardium but rather of hemodynamic disturbances in the heart and pulmonary circulation. In animals 5-HT has produced a marked rise in pulmonary blood pressure. This has been confirmed by means of pulmonary arterial catheter studies in a few patients with the malignant carcinoid syndrome (30). It is therefore possible that the anatomic lesion may be secondary to the mechanical stress of disturbed hemodynamics. The latter concept of course cannot explain left-sided cardiac lesions in the absence of a patent foramen ovale. Another point of view holds the tryptophan deficiency to be at least a contributing factor in the development of the cardiac lesions. It is well known that in the South African Bantu who subsists on a diet of mealy meal (corn meal) and suffers from essential amino acid deficiencies endomyocardial fibrosis may develop. Whether the excess tryptophan utilization with depletion of its reserves can effect a similar change is problematic.

There are no reports as yet of the experimental production of the cardiac lesion by long term administration of 5-HT. Rabbits given massive daily doses for 3 months failed to show any comparable cardiovascular lesion (53). Prolonged administration of 5-HT might possibly result in valvular changes but this would not answer the question whether the substance acts directly on the endocardium or by way of changed hemodynamics. Because 5-HT is carried by the platelets thrombosis has been suggested as a possible factor in the pathogenesis of the sclerotic plaques. However evidence so far does not support this thesis. Furthermore platelet adhesiveness does not seem to be increased in this condition. In rats subcutaneously administered 5-HT produces a localized edema rich in protein whether this is the initial change in the valve remains to be demonstrated. Hedinger and Gloor's (19) thesis, a view not generally accepted is that

mines may be classified by their effects on (1) systemic blood pressure (2) special vascular areas (pulmonary vessels) (3) isolated artery strips (4) the heart (5) extravascular smooth vessels such as urinary bladder and smooth muscle (6) respiration (7) impulse transmission in ganglions (8) central nervous system (9) development of cutaneous pain (10) certain metabolic effects (11) adrenal medulla (12) histamine releasing activity and (13) participation in hemostatic mechanisms

Serotonin seems to form complexes readily many of which are quite stable This may be of significance in its biologic activity

### SEROTONIN AND CEREBRAL FUNCTION

Twarog and Page (59) were among the first to note that 5-HT is present in cerebral tissue they like other investigators at that time used bioassay methods Development of a specific spectrophotometric technic has now made possible rapid advances in knowledge of the metabolism and the pharmacologic properties of 5-HT in cerebral tissue Its high concentration in certain areas of the brain and the marked effects of indole compounds on the central nervous system suggest that it may play an important part in cerebral function The largest amounts of 5-HT are found in the so-called primitive cerebral areas such as the midbrain and especially the hypothalamus the cortex and cerebellum contain much smaller amounts Decarboxylase and monoamine oxidase the enzymes necessary for 5-HT synthesis and destruction respectively are also present in the brain Significantly monoamine oxidase although found throughout the brain, is present in highest concentration near the hypothalamus) The distribution of decarboxylase which converts 5-hydroxytryptophan to 5-HT also parallels that of 5-HT (15 61)

It is not yet known whether the brain can synthesize 5-HT from its basic precursor tryptophan) In animals the cerebral 5-HT content has been raised by administration of large doses of 5-hydroxytryptophan Since 5-HT does not readily penetrate the blood brain barrier but 5-hydroxytryptophan does (61) administration of the latter substance has been proposed as possibly a practical method of increasing the cerebral 5-HT content in man Reactions to excessive amounts might be controlled by the use of antimetabolites \*

In the experimental animal it is possible to obtain 5-HT levels

LMD<sub>50</sub> is 160 mg per kilogram for mice and 30 mg per kilogram for rats. Dogs and human beings tolerate relatively large amounts administered by rapid intravenous infusion—0.01 to 0.2 mg per kilogram. However, disagreeable symptoms appear with the larger dosages. To date, experimental duplication of dosages quantitatively similar to those occurring with an actively secreting metastatic carcinoid has not been feasible in man (10).

The variable behavior as well as variation in dose response in different species renders any analogies to man based on animal studies uncertain.

Among the protean pharmacologic findings, action of 5-HT on smooth muscle is the most readily reproducible, and was the first to be discovered. In animals it may raise the blood pressure and cause uterine and intestinal contraction. The renal blood vessels of the dog are highly sensitive to 5-HT. One pronounced serotonin effect is evacuation of the bowels, with increased peristaltic sounds, and increased tone of the urinary bladder.

Its effects on the respiratory system differ according to the animal tested. In some there is immediate respiratory standstill. In rabbits a marked increase in right ventricular pressure occurs. In guinea pigs dyspnea develops and is followed by convulsions. In man the response to intravenously administered 5-HT resembles somewhat the response in the dog: exaggerated respiratory movements, cough and tachycardia with urination. In addition the symptoms in man range from none at all to a feeling of tightness of the chest, generalized tingling and prickling, itchy nostrils, difficulty in breathing, desire to empty the bladder associated with pain in the stomach as well as the bladder weakness, nausea, desire to sneeze, generalized numbness and burning of the throat, mouth and hands.

✓ The response of patients with hypertension varies. It is noteworthy that the 5-HT serum levels in hypertensive patients is no higher than that found in normotensive individuals and in some is even lower. This finding certainly does not support the view that 5-HT maintains increased vascular tone in individuals with hypertension (8, 21). In analyzing the physiologic action of 5-HT, only those reactions can be considered physiologic which are provoked in an intact animal by doses lower than the total 5-HT content of the organism. All other reactions must be considered pharmacologic.

Various physiologic or pharmacologic actions of the indolealkyla

mines may be classified by their effects on (1) systemic blood pressure (2) special vascular areas (pulmonary vessels) (3) isolated artery strips (4) the heart (5) extravascular smooth vessels such as urinary bladder and smooth muscle (6) respiration (7) impulse transmission in ganglions (8) central nervous system (9) development of cutaneous pain (10) certain metabolic effects (11) adrenal medulla (12) histamine releasing activity and (13) participation in hemostatic mechanisms

Serotonin seems to form complexes readily many of which are quite stable This may be of significance in its biologic activity

### SEROTONIN AND CEREBRAL FUNCTION

Twarog and Page (59) were among the first to note that 5-HT is present in cerebral tissue they like other investigators at that time used bioassay methods Development of a specific spectrophotometric technic has now made possible rapid advances in knowledge of the metabolism and the pharmacologic properties of 5 HT in cerebral tissue Its high concentration in certain areas of the brain and the marked effects of indole compounds on the central nervous system suggest that it may play an important part in cerebral function The largest amounts of 5-HT are found in the so-called primitive cerebral areas such as the midbrain and especially the hypothalamus the cortex and cerebellum contain much smaller amounts Decarboxylase and monoamine oxidase the enzymes necessary for 5-HT synthesis and destruction respectively are also present in the brain Significantly monoamine oxidase although found throughout the brain, is present in highest concentration near the hypothalamus The distribution of decarboxylase which converts 5 hydroxytryptophan to 5-HT also parallels that of 5-HT (15 61)

It is not yet known whether the brain can synthesize 5-HT from its basic precursor tryptophan In animals the cerebral 5-HT content has been raised by administration of large doses of 5-hydroxytryptophan Since 5-HT does not readily penetrate the blood brain barrier but 5 hydroxytryptophan does (61) administration of the latter substance has been proposed as possibly a practical method of increasing the cerebral 5-HT content in man Reactions to excessive amounts might be controlled by the use of antimetabolites \*

In the experimental animal, it is possible to obtain 5 HT levels

that are 20 times the normal level animals with these high levels become excited and reveal tremors. The simultaneous administration of reserpine and ipromazid (monoamine oxidase inhibitor) produces the same picture in animals. The effects are attributed in both instances to an excessive amount of unbound 5 HT. Administration of 5-hydroxytryptophan to animals pretreated with ipromazid raises the 5-HT levels but not that of its precursor. The cerebral manifestations of the animals therefore cannot be ascribed to an excess of 5 hydroxytryptophan. It is also interesting that the cerebral 5 HT content of pyridoxine-deficient chickens is only 30 per cent of normal and the level in the other tissues is even more drastically reduced. Perhaps some of the neurologic disturbances in this type of deficiency may be due, in part to a change in 5 HT content. However oversimplification of this problem is hazardous because the same chemical and enzymic systems are involved in the formation of epinephrine and histamine (61).

✓ In 1943, Hoffman (22) while working in his laboratory, noticed peculiar sensations of vertigo and restlessness he was in a dreamlike state and appeared drunk his imagination became exaggerated and when he closed his eyes he saw fantastic and vividly colored pictures this state lasted for 2 hours. As it turned out, he had been working with d lysergic acid diethylamide (LSD) and had accidentally inhaled a small quantity. It is now known that tiny doses of LSD or of its bromine derivative block the action of 5-HT. Other antagonists of 5-HT action on uterine smooth muscle exert the same effect on the brain. Among these naturally occurring alkaloids that are antimetabolites of 5 HT are the harmala alkaloids (harmine and yohimbine) and the ergot alkaloids. All of these are structurally related and contain the indole nucleus. Reserpine is an analogue of yohimbine (16 47). The antagonism of chemical substances of a similar molecular structure has been likened to that of a lock and key. The right key is needed to produce an effect. A similar key can fit into the lock and block the keyhole even though it cannot open the door.

✓ The fact that in man LSD produces schizophrenia like symptoms such as change in perception changes in body image and time sense impairment of integration and fragmentation of mental processes is significant. Only a minute amount of drug is needed to induce these phenomena comparable to effective doses of the most potent hormones and vitamins suggestive that LSD has a highly selective action on the central nervous system. It is now believed that the mechanism of LSD

action is its antagonism to 5-HT (59). Psychic effects may be observed after administration of only 1  $\mu\text{g}$  LSD per kilogram body weight, but Waldenstrom (62) administered up to 1500  $\mu\text{g}$  of LSD to a patient with malignant carcinoid without the occurrence of any psychic changes. In a similar situation Snow and co-workers (52) gave 7.5 mg of LSD daily for several weeks without observing any mental changes; the effect on the symptoms of the malignant carcinoid syndrome, however, were insignificant. It is therefore premature to attribute the mental aberrations produced by LSD entirely to its antimetabolic action on 5-HT. At a meeting of the American Psychiatric Association 2 years ago (1) it was concluded, "The psychotic state produced by lysergic acid diethylamide was felt not to be identical with that found in schizophrenia but there were sufficient similarities to suggest a biochemical factor is involved in schizophrenia." Changes in 5-HT metabolism may eventually prove to be one of the keystones in the possible biochemical factors which play a role in the causation of schizophrenia. At this stage, however, the administration of 5-HT to schizophrenic patients has failed to produce any beneficial effects (32).

There is considerable evidence that the primary pharmacologic effect of reserpine is to impair 5-HT binding sites, thereby releasing 5-HT from the enterochromaffin system and preventing its storage. Reserpine disappears from the brain rapidly in contrast to its persistent effects. For these and other reasons it is believed that the reserpine effects are mediated through the release of 5-HT (38). The observation that an LSD-induced deficiency of free 5-HT and an excess of free 5-HT may result in similar central nervous system effects is provocative. It is postulated that 5-HT may act as the chemical transmitter of nerve impulses to the centers of the parasympathetic division (5).

Attempts to construct a scheme showing the relations of the possible balances and imbalances between cholinergic excitation and adrenergic inhibition as these are related to 5-HT metabolism are still premature but the answer to many unsolved problems of mental derangement may lie in this scheme.

Evidence for a key role of 5-HT as a chemical mediator in nerve impulse transmission may be noted in a wide variety of animals. 5-HT is found in the venom of the wasp and in the tentacles of stinging nematocysts. The function of 5-HT at these sites may be to aid in defense or help in the capture or relaxation of prey. In many crustaceans 5-HT or a closely related substance has been found in leg nerves. The decapod

crustacean's heart is neurogenic and an indolamine substance (either 5 HT or one quite similar) acts as a cardiac regulator in these invertebrates (63)

### SEROTONIN AND CERTAIN BLOOD DYSCRASIAS

Experimental studies on hemostasis in animals reveals that 5 HT released from the platelet plug partly accounts for the vasoconstriction which helps to prevent bleeding. Certain reports have indicated the existence of a 5 HT deficiency in the serum of patients with thrombocytosis and thrombopenia (64). Subnormal concentrations have also been noted in a few patients with thrombocytopathia and pseudohemophilia however patients with the severest hemorrhages in these conditions have had normal serum 5 HT levels (4). Thus, in all these conditions the major cause of the bleeding cannot be ascribed to a 5-HT deficiency although in some it may through interference with vasoconstriction contribute toward the bleeding tendency.

### SEROTONIN AND RENAL FUNCTION

Erspamer (10) believes that a basic physiologic action of 5 HT is the regulation of renal circulation and function. An antidiuretic action of 5 HT has been demonstrated in man, dog, rat, guinea pig, and rabbit. The mechanism of this action in the various species is not entirely similar or clear. In the rat it appears to be mediated through a reduction in the glomerular filtration rate. With excessively large doses of 5-HT the afferent glomerular arterioles becomes markedly constricted.

Some investigators have disagreed with the concept of both of the above mechanisms and claim that the antidiuretic action is mediated through the posterior pituitary (55). In dogs it has been demonstrated that much of the antidiuretic action may be due to increased tubular reabsorption of water. However, chronic intravenous infusion with physiologic doses in unanesthetized dogs produced a definite antidiuretic effect at a threshold dose of 10  $\mu$ g per kilogram per minute and became more pronounced until a dose of 20  $\mu$ g was reached; there after further increases in dosage were without effect. Analysis of the data in relation to urine clearance supported the concept of an increase in the rate of tubular reabsorption of water. The antidiuretic action occurs in the absence of any change in systemic blood pressure.

## REFERENCES

- 1 American Association for the Advancement of Science Reports of sections and societies Berkeley meeting American Psychiatric Association (N3) Science 121 262, 1955
- 2 Amin A. H Crawford T B B and Gaddum J H The distribution of substance P and 5 hydroxytryptamine in the central nervous system of the dog J Physiol 126 596 1954
- 3 Benditt, E. P *et al* 5 Hydroxytryptamine in mast cells Proc Soc. Exper Biol. & Med 90 303 1955
- 4 Bigelow F S Serotonin activity in blood measurements in normal subjects and in patients with thrombocythemia hemorrhagica and other hemorrhagic states J Lab & Clin Med 43 759 1954
- 5 Brodie B B and Shore P A Concept for a role of serotonin and nor epinephrine as chemical mediators in the brain Ann New York Acad Sc 66 631 1957
- 6 Cohen, S Landy J A. and Richter M. A. M A Arch. Surg 39 647 1939
- 7 Dansch F Zur Histogenese der sogenannten Appendixkarzinoide Beitr path Anat 72 687 1924
- 8 Daugherty G W *et al* Malignant carcinoid with hyperserotoninemia occurring spontaneously or induced by palpation of the tumor or by intravenous histamine Proc Staff Meet Mayo Clin 30 595 1955
- 9 DeShon H J Runkel M and Solomon H C Mental changes experimentally produced by L S D (*d* lysergic acid diethylamide tartrate) Psychiat Quart 26 33 1952
- 10 Erspamer V Pharmacology of indolealkylamines Pharmacol. Rev 6 425 1954
- 11 Erspamer V and Asero B Identification of enteramine the specific hormone of the enterochromaffin cell system as 5-hydroxytryptamine Nature 169 800 1952
- 12 Falkmer S Examples of gastrointestinal carcinoids with apparently congenital malformations Gastroenterologia 86 73 1956
- 13 Feyrter F and Unna K Ueber den Nachweis eines blutdrucksteigernden Stoffes im Carcinoid Virchows Arch. path Anat 298 187 1936
- 14 Forbus W D Argentaffine tumors of appendix and small intestine, Bull. Johns Hopkins Hosp 37 130 1925
- 15 Gaddum J H Serotonin LSD interactions Ann. New York Acad. Sc. 66 643 1957
- 16 Gaddum J H and Hameed K. A Drugs which antagonize 5 hydroxy tryptamine Brit J Pharmacol. 9 240 1954
- 17 Gobel, A J Hay D R. and Sandler M 5-Hydroxytryptamine metabolism in acquired heart disease associated with argentaffine carcinoid Lancet 2 1016 1955
- 18 Gosset A and Masson P Tumeurs endocrines de l'appendice Presse med 22 237 1914
- 19 Hedinger C and Gloor R Metastasiernde Dunndarmkarzinoide Tricuspidalklappenveränderungen und Pulmonalstenose—ein neues Syndrom Schweiz med Wchnschr 84 942 1954
- 20 Heidenham R Cited by Macklin and Macklin (29)
- 21 Heimark, J J and Parken, T W Syndrome associated with metastatic carcinoid tumor report of case Proc Staff Meet. Mayo Clin. 31 56 1956
- 22 Hoffman A Cited by Page (36)



crustacean's heart is neurogenic and an indolamine substance (either 5-HT or one quite similar) acts as a cardiac regulator in these invertebrates (63)

### 1. SEROTONIN AND CERTAIN BLOOD DYSCRASIAS

Experimental studies on hemostasis in animals reveals that 5-HT released from the platelet plug partly accounts for the vasoconstriction which helps to prevent bleeding. Certain reports have indicated the existence of a 5-HT deficiency in the serum of patients with thrombocytosis and thrombopenia (64). Subnormal concentrations have also been noted in a few patients with thrombocytopathia and pseudohemophilia; however, patients with the severest hemorrhages in these conditions have had normal serum 5-HT levels (4). Thus, in all these conditions the major cause of the bleeding cannot be ascribed to a 5-HT deficiency although in some it may through interference with vasoconstriction, contribute toward the bleeding tendency.

### SEROTONIN AND RENAL FUNCTION

Erspamer (10) believes that a basic physiologic action of 5-HT is the regulation of renal circulation and function. An antidiuretic action of 5-HT has been demonstrated in man, dog, rat, guinea pig, and rabbit. The mechanism of this action in the various species is not entirely similar or clear. In the rat it appears to be mediated through a reduction in the glomerular filtration rate. With excessively large doses of 5-HT the afferent glomerular arterioles become markedly constricted.

Some investigators have disagreed with the concept of both of the above mechanisms and claim that the antidiuretic action is mediated through the posterior pituitary (55). In dogs it has been demonstrated that much of the antidiuretic action may be due to increased tubular reabsorption of water. However, chronic intravenous infusion with physiologic doses in unanesthetized dogs produced a definite antidiuretic effect at a threshold dose of  $10 \mu\text{g}$  per kilogram per minute and became more pronounced until a dose of  $20 \mu\text{g}$  was reached; thereafter further increases in dosage were without effect. Analysis of the data in relation to urine clearance supported the concept of an increase in the rate of tubular reabsorption of water. The antidiuretic action occurs in the absence of any change in systemic blood pressure.

- 49 Sjoerdsma A, Weissbach, H and Udenfriend S Clinical physiologic and biochemical study of patients with malignant carcinoid (argentaffinoma) *Am J Med* 20 520 1956
- 50 Slaughter D P Multiplicity of origin of malignant tumors collective review *Internat Abstr Surg* 79 89 1944
- 51 Smith J P and Campbell A C Cardiac changes associated with malignant argentaffinoma *J Path. & Bact.* 72 673 1956
- 52 Snow P J D *et al* Humoral effects of metastasizing carcinoid tumors *Lancet* 269 1004 1956
- 53 Spain, D M Association of gastrointestinal carcinoid tumor with cardiovascular abnormalities *Am J Med* 19 367 1955
- 54 Spain D M and Glagov S Unpublished data.
- 55 Spinazzola A J and Sherrod T R Effects of serotonin (5 hydroxytryptamine) on renal hemodynamics *J Pharmacol & Exper Ther* 119 114 1957
- 56 Stout A P Carcinoid tumors of the rectum derived from Espartero's pre-enterochrome cells *Am J Path* 18 993 1942
- 57 Thorson A H Hemodynamic changes during "flush" in carcinoidosis *Am Heart J* 52 444 1956
- 58 Thorson A *et al* Malignant carcinoid of small intestine with metastases to liver valvular disease of right side of heart (pulmonary stenosis and tricuspid regurgitation without septal defects) peripheral vasomotor symptoms Bronchoconstriction and unusual type of cyanosis clinical and pathologic syndrome *Am Heart J* 47 795 1954
- 59 Twarog B M and Page I H Serotonin content of some mammalian tissues and urine and a method for its determination *Am J Physiol.* 175 157 1953
- 60 Udenfriend S Titus E and Weissback H Identification of 5 hydroxy 3-indoleacetic acid in normal urine and a method for its assay *J Biol Chem* 216 499 1955
- 61 Udenfriend S Weissback H and Gogdanski, D F Biochemical findings relating to the action of serotonin *Ann New York Acad Sc* 66 602 1957
- 62 Waldenstrom J Cited by Rothlin (45)
- 63 Welsh J H Serotonin as a possible neurohumoral agent evidence obtained in lower animals *Ann New York Acad Sc* 66 618 1957
- 64 Zucker M B and Borrelli, M S Concentration of serotonin in serum in thrombocytopathia pseudohemophilia and thrombocytosis *Am J Clin Path* 26 13 1956

- 23 Humphreys E M Carcinoid tumors of small intestine *Am J Cancer* 22 780 1934
- 24 Lembeck, F 5 Hydroxytryptamine in carcinoid tumor *Nature* 172 910 1953
- 25 Lewis D and Geschickter C F Tumors of sympathetic nervous system Neuroblastoma paraganglionoma ganglioneuroma *Arch Surg* 29 18 1934
- 26 Lubarsch O Ueber den primären Krebs des Ileum nebst Bemerkungen über das gleichzeitige Vorkommen von Krebs und Tuberculose *Virchows Arch path Anat* 111 280 1888
- 27 MacDonald R A Study of 356 carcinoids of the gastrointestinal tract, report of four new cases *Am J Med* 21 867 1956
- 28 MacDonald R A and Robbins S L Pathology of the heart in the carcinoid syndrome *A M A Arch Path* 63 103 1957
- 29 Macklin C L and Macklin M T The Intestinal Epithelium in Cowdry E V ed *Special Cytology* (2d ed New York Paul B Hoeber Inc 1932) Vol 1 p 269
- 30 McKusick V A Carcinoid cardiovascular disease *Bull. Johns Hopkins Hosp* 98 13 1956
- 31 McNeely R C D and Jones N W Secondary pellagra caused by multiple argentaffin carcinoma of ileum and jejunum *Gastroenterology* 6 443 1946
- 32 Marrazzi A S and Hart E R Relationship of hallucinogens to adrenergic cerebral neurohumors *Science* 121 365 1955
- 33 Mattingly T W Functioning carcinoid tumor—a new clinical entity *M Ann. District of Columbia* 25 239 1956
- 34 Miller E R and Hermann W W Argentaffin tumors of the small bowel roentgen signs of malignant change *Radiology* 39 214 1942
- 35 Oberndorfer S Karzinoide tumoren des dunndarms *Frankfurt Ztschr Path* 1 426 1907
- 36 Page I H Neurochemistry and serotonin A chemical fugue *Ann New York Acad Sc* 66 592 1957
- 37 Pearson C M and Fitzgerald P J Carcinoid tumors—re-emphasis of their malignant nature *Cancer* 2 1005 1949
- 38 Fletscher A Shore P A and Brodie B B Serotonin as a mediator of reserpine action in brain *J Pharmacol & Exper Therap* 116 84 1956
- 39 Porter J E and Whelan C S Argentaffine tumors report of 84 cases 3 with metastases *Am J Cancer* 36 343 1939
- 40 Raiford T S Carcinoid tumors of the gastrointestinal tract (so-called argentaffine tumors) *Am J Cancer* 18 803 1933
- 41 Ransom W B Case of primary carcinoma of the ileum *Lancet* 2 1020 1890
- 42 Rapport M M Green A A and Page I H Crystalline serotonin (crystalline substance from beef serum which may be responsible for the vasoconstrictor activity) *Science* 108 329 1948
- 43 Ritchie A C Carcinoid tumors *Am J M Sc* 232 311 1956
- 44 Ritchie G and Stafford W T Argentaffin tumors of gastrointestinal tract, *Arch Path* 38 123 1944
- 45 Rothlin E Lysergic acid diethylamide and related substances *Ann New York Acad Sc* 66 668 1957
- 46 Selberg W Beitrag zur Klinik und Pharmacologie des Darmcarcinoids, *Klin Wchnschr* 20 1271 1941
- 47 Shaw E and Wooley D W Yohimbine and ergot alkaloids as naturally occurring anti metabolites of serotonin *J Biol Chem* 203 979 1953
- 48 Singer M and Sternlieb I Argentaffine cell of the gastrointestinal tract and pancreas Some clinical features *J Mt Sinai Hospital*, 22 328 1955

# Some Aspects of Disordered Renal Tubular Function

S W STANBURY

*Department of Medicine University of Manchester England*

ALTHOUGH IT IS NOW customary to speak of "disorders of renal tubular function" or of "renal tubular dysfunction," these terms are often applied after only the most casual attempt to prove that an observed renal abnormality originates in disturbance of specific tubular mechanisms. There are many obstacles in the way of establishing such proof not the least of which is our almost total ignorance of the intimate cellular mechanisms that mediate the transport of substances across the renal tubular wall. It is however possible to define approximately the magnitude of the reabsorptive processes effected by the tubules. Collectively in the normal individual they return to the blood 99 per cent of the water and most of the mass of solutes contained in the 180 litres of ultrafiltrate formed daily by the glomeruli. The renal tubule can thus be regarded primarily as an organ of conservation and, through the selective reabsorption of various substances and the secretion of hydron (166) and probably of potassium (23) it plays a major role in homeostasis.

In clinical practice the appearance in the urine of substances that normally are completely reabsorbed, or the development of some obvious disturbance of renal homeostatic function, is too readily taken to indicate tubular malfunction. For example since a normal individual reabsorbs all the glucose filtered by the glomeruli in the course of the day the occurrence of glycosuria in the presence of normal plasma levels of glucose is commonly ascribed to impaired transport of glucose by the tubular cells and, since a minor deficiency of sodium



But in other congenital disorders, such as the Lignac Fanconi syndrome the innate defect may be complicated by progressive destructive changes in the kidney it may then prove as difficult to recognise a true tubular defect as it is in any other form of destructive renal disease. Moreover when renal tubular involvement is a secondary consequence rather than a primary manifestation of a genetic disorder the extent of tubular malfunction may vary from patient to patient. This is best seen in Wilson's disease. Such varying degrees of secondary "toxic" effect must be distinguished from the qualitative or quantitative differences that sometimes may occur between homozygous and heterozygous individuals.

An attempt to survey all the conditions thought to involve disordered tubular function would entail consideration of almost all aspects of renal disease and necessitate many incursions into pure physiology. Consequently the following discussion is selective choice of topics has been determined partly by personal interests and experience and partly by their relevance to the clinical practice of internal medicine. Several important subjects have been omitted but renal glycosuria (30 123 173) and the tubular lesion of "pseudohypoparathyroidism" (112) have recently been discussed elsewhere. A more significant omission—the renal and metabolic aspects of renal tubular acidosis (3)—is remedied by the report of Wrong and Davies (228) from this laboratory. The interesting problem of renal diabetes insipidus (33 40 142a, 179) could not be discussed adequately without a detailed consideration of the recent physiologic observations of Wirz (223 224) but limitation of space forced the omission of this and certain other topics.

## RENAL AMINO ACIDURIA

Since the technic of paper chromatography was first applied to the analysis of urine (54) pathologic amino-aciduria has been found in a host of conditions. In some of these such as  $\beta$  aminoisobutyric aciduria (48) the finding is without clinical significance in others amino-aciduria has resulted from severe (73) but sometimes reversible (201) acute damage to the renal tubules. Still others are of major clinical and metabolic interest, and it is with some of these that the following account is concerned. Until recently distinction of a tubular origin for any particular amino-aciduria was uncertain. It depended on the finding of a normal plasma level of total  $\alpha$  amino nitrogen together with a qualitatively normal amino acid chromatogram in the

normally leads to the virtually complete tubular reabsorption of this ion the continued excretion of sodium by a nephritic patient with such a deficiency is generally taken to signify failure of its tubular reabsorption. These crude clinical approximations to the definition of a tubular defect are inadequate and often fallacious.

Wherever it has been possible to make quantitative studies of the active transport mechanisms of the renal tubule it has been found that the reabsorptive process has a limiting maximal rate (194 195). Although the demonstration of such reabsorptive maxima has been made by study of the whole intact kidneys it must be assumed that the reabsorptive capacity of each tubule is also individually limited. In a population of nephrons known to be anatomically heterogeneous it is to be expected that tubular functions such as absorptive maxima will vary from nephron to nephron (29). It becomes necessary therefore to enquire whether certain renal phenomena commonly attributed to defective tubular function may not rather be phenomena of "glomerular tubular imbalance" in which a functionally intact tubule is loaded beyond its absorptive capacity by virtue of its possessing an excessively filtering glomerulus.

The concept of glomerular tubular imbalance has been applied with some success to the study of renal glycosuria (28 123 173) whereas some such cases may result from a metabolic fault in the tubular transport mechanisms there are others that can only be explained satisfactorily by heterogeneity of the nephron population (213). It has also been suggested that a similar mechanism may underlie the amino aciduria in some cases of the Fanconi syndrome without cystinosis (28).

The same problem arises in assessing functional disturbances in patients with organic renal disease leading to progressive destruction of the kidneys. In chronic azotaemic renal failure there is some evidence that impaired osmolar concentrating capacity, isosthenuria (167 168) and even the phenomenon of salt wasting (206) may result from excessive glomerular filtration into intact surviving tubules.

With the recent emergence of precise chemical techniques (55 77 150) it has become possible to define tubular disorders in which the reabsorption of either a single amino acid e.g.  $\beta$ -aminoisobutyric aciduria (48 77) or group of amino acids e.g. cystinuria is defective. These can be regarded as the pure tubular disorders which being genetically determined may reflect the absence of a single particular system of enzymes from the tubular cells; they need not produce either structural or general functional disorganisation of the kidney.

cystinuria in failure of the tubular reabsorption of cystine is thus established and it would appear from the observations of Dent and associates (63) that there is no disorder of the intermediary metabolism of the sulphur containing amino acids in this syndrome.

Evidence concerning the significance of the associated excretion of lysine arginine and ornithine has come from two quite different avenues of study. First Robson and Rose (178) have applied the concept of competitive inhibition in an experimental study of the renal excretion of these amino acids. They elevated the plasma level of lysine by infusing L lysine (5 Gm /70 kg body weight) into normal subjects patients with cystinuria and "heterozygous carriers of recessive cystinuria". In the normal individuals and the heterozygous carriers the infusion increased the renal clearances of cystine arginine and ornithine as would be expected if the 4 amino acids share a common pathway of tubular absorption which was saturated by the increased filtered load of lysine. In the cystinuric patients the infusion of lysine had no effect on cystine clearance as would be expected from its apparent prior identity with the rate of glomerular filtration. Secondly Harris (96) has recently summarised in simplified form the many detailed observations that he and his collaborators have made on the urinary output of cystine lysine and arginine by the healthy relatives of cystinuric patients. Among such relatives the output of cystine may vary from the normal to the frankly cystinuric level but throughout this range there is a close correlation between the output of cystine and that of lysine. On the other hand abnormally increased excretion of arginine (and perhaps of ornithine) is found only when the output of cystine and lysine is high, an observation that Harris and co-workers have taken to suggest that arginine and ornithine are absorbed preferentially to cystine and lysine. The genetics of the disorder are complicated by the occurrence in different families of two patterns of recessive inheritance. The original publications (97-99) must be consulted for the details but most instructive is the finding that homozygous individuals always show the complete syndrome by excreting all 4 amino acids whereas the incompletely recessive heterozygous (semicystinuric) subjects appear to have a less severe tubular lesion and excrete considerably less lysine and cystine together with normal quantities of arginine and ornithine. This again supports the notion that the common absorptive pathway has a greater affinity for arginine and ornithine than for the other 2 amino acids.

Cystinuria is unique in being the one renal amino aciduria in which



plasma ultrafiltrate This crude method sufficed to separate off the amino acidurias of overflow type such as phenylketonuria and that of severe liver disease in which the appearance of amino acids in the urine was due to increase in their levels in the plasma Evered (77) using ion exchange column chromatography has now measured the renal clearance of individual amino acids and he has also obtained amino acid clearances in patients with the adult Fanconi syndrome  $\beta$  aminoisobutyric aciduria and the Hartnup syndrome These new data in general confirm the views formed earlier on the basis of investigation with the qualitative and semiquantitative paper chromatographic methods,

Two important topics—galactosaemia and the so-called Hartnup syndrome—have been deliberately omitted from consideration in the following account Any account of the first would merely echo the recent publications of the author's pediatric colleagues in Manchester (105-107 118 169) The full significance of the second also characterized as hereditary pellagra like skin rash with temporary cerebellar ataxia constant amino aciduria and other bizarre biochemical features is not yet apparent and it suffices to draw attention to the one excellent report so far written on the subject (12)

### CYSTINURIA (CYSTINELYSINURIA, CYSTINE LITHIASIS)

In 1951 Dent and Rose (61) re examined the problem of cystinuria with renal calculus formation and for the first time drew a clear distinction between this genetically determined disorder and other conditions in which cystine is excreted in the urine They showed that, in addition to excreting quantities of cystine affected individuals excreted large amounts of lysine, arginine, and ornithine, and it was suggested that a single enzyme system which was deficient in cystinuric subjects was responsible for the renal tubular reabsorption of these 4 basic amino acids Stein (210) found that the average daily output in affected subjects was 0.73 Gm cystine 1.8 Gm lysine 0.83 Gm arginine and 0.37 Gm ornithine The subsequent and recent advances in the study of this syndrome have been both exciting and complex First, it was shown by polarographic measurement that the plasma level of cystine was normal or somewhat low (59) and later that the renal clearance of cystine in cystinuria was up to 30 times that of normal subjects the absolute values approximating closely to the measured (63) or assumed (178) glomerular filtration rate The origin of familial

cystinuria in failure of the tubular reabsorption of cystine is thus established and it would appear from the observations of Dent and associates (63) that there is no disorder of the intermediary metabolism of the sulphur containing amino acids in this syndrome.

Evidence concerning the significance of the associated excretion of lysine arginine and ornithine has come from two quite different avenues of study. First, Robson and Rose (178) have applied the concept of competitive inhibition in an experimental study of the renal excretion of these amino acids. They elevated the plasma level of lysine by infusing L lysine (5 Gm /70 kg body weight) into normal subjects patients with cystinuria and "heterozygous carriers of recessive cystinuria". In the normal individuals and the heterozygous carriers the infusion increased the renal clearances of cystine arginine and ornithine as would be expected if the 4 amino acids share a common pathway of tubular absorption which was saturated by the increased filtered load of lysine. In the cystinuric patients the infusion of lysine had no effect on cystine clearance as would be expected from its apparent prior identity with the rate of glomerular filtration. Secondly Harris (96) has recently summarised in simplified form the many detailed observations that he and his collaborators have made on the urinary output of cystine lysine and arginine by the healthy relatives of cystinuric patients. Among such relatives the output of cystine may vary from the normal to the frankly cystinuric level, but throughout this range there is a close correlation between the output of cystine and that of lysine. On the other hand abnormally increased excretion of arginine (and perhaps of ornithine) is found only when the output of cystine and lysine is high an observation that Harris and co-workers have taken to suggest that arginine and ornithine are absorbed preferentially to cystine and lysine. The genetics of the disorder are complicated by the occurrence in different families of two patterns of recessive inheritance. The original publications (97-99) must be consulted for the details but most instructive is the finding that homozygous individuals always show the complete syndrome by excreting all 4 amino acids whereas the incompletely recessive heterozygous (semicystinuric) subjects appear to have a less severe tubular lesion and excrete considerably less lysine and cystine together with normal quantities of arginine and ornithine. This again supports the notion that the common absorptive pathway has a greater affinity for arginine and ornithine than for the other 2 amino acids.

✓ Cystinuria is unique in being the one renal amino aciduria in which

it is certain that the excretion of amino acids is directly harmful (There is no direct evidence to support the suggestion that chronic amino aciduria in other conditions may give rise to bone disease or to hepatic cirrhosis)) Within the range of physiologic change in urinary pH, cystine has a solubility between 300 and 400 mg per litre (62), it tends to come out of solution when the rate of urinary flow is low and the urine acid. These conditions obtain physiologically during the night (207) when the urine of cystinuric subjects is actually supersaturated with cystine (62). Since the urinary output of cystine is determined solely by its plasma level and the rate of glomerular filtration the only possible prophylactic therapy is to alkalinize the urine and maintain a high urinary flow by water drinking. To be effective alkalinization must maintain the urinary pH as high as 7.6 (62) and this is therapeutically difficult. Dent and Senior (62) recommend that patients should drink at least 3 litres of water daily taking 500 ml every 4 hours during the day and 750 ml in each 4 hours during the night. In patients with calculi some dissolution may occur when the rate of urinary flow is high and the increased output of cystine will then produce a spuriously high cystine clearance. It has also been suggested (62) that dissolution of cystine calculi may accompany the development of renal failure with its attendant fall in glomerular filtration and acquired polyuria.

The patient with cystinuria is exposed to the same hazards as any other calculous patient he is in danger of pyelonephritis, hydronephrosis and death as a result of progressive renal damage. Knowledge of the genetics of the disease may allow earlier diagnosis and the earlier institution of prophylactic measures.

#### CYSTINE STORAGE DISEASE WITH AMINO ACIDURIA (LIGNAC-FANCONI SYNDROME)

Cystinosis, cystine storage disease or the Lignac-Fanconi syndrome with an incidence of approximately 1 case per 40 000 of the general population (18) has acquired a theoretic importance out of all proportion to its rarity. It is a genetically determined disorder inherited as a simple mendelian recessive character (18) in which the primary defect is unknown but which may involve the general metabolism of proteins and amino acids (8, 19) and which is characterized pathologically by the deposition of cystine in many tissues (22, 92). Clinically

it has long been confused with cystine lithiasis and some still believe that the two conditions are related (92 165). However, most authorities now agree that cystinosis with amino aciduria and cystinylsineuria are separate entities (59). However the two conditions may rarely occur together by chance in the same family (22 59) and confusion is furthered by the occasional development of microliths of cystine in the kidneys of patients with cystinosis (8). Whereas cystine lithiasis is associated with the renal excretion of 4 basic amino acids the amino aciduria of the Lignac-Fanconi syndrome is massive or generalised and is usually associated with renal glycosuria. As many as 20 amino acids may be excreted in excess in the urine and characteristically among these are valine leucine phenylalanine tyrosine proline lysine serine cystine aspartic acid and threonine (19 22).

Fanconi (78) first proposed the concept of an innate defect of the renal tubules to account for his finding of renal glycosuria phosphaturia and the wasting of base in the urine. The discovery of amino aciduria by McCune and associates (134) extended the theory to include the defective reabsorption of amino acids (55 79 80 134). Dent (55) by using paper chromatography revealed the extent of the amino aciduria since the plasma level of total  $\alpha$  amino nitrogen and the chromatogram of an ultrafiltrate of plasma were both normal, he concluded that the amino aciduria was of renal origin. He has persisted in this belief and has shown that the renal clearances of "total  $\alpha$  amino nitrogen" may approach the glomerular filtration rate in this syndrome (57 58). In contrast, others (19 225) have found plasma levels of  $\alpha$  amino nitrogen increased by up to 100 per cent and they claim that the amino aciduria is of the "overflow" type. This dispute has not yet been resolved conclusively but in the genetically determined adult type of Fanconi syndrome it is now certain that the amino aciduria results from defective tubular reabsorption. In such patients Evered (77) has measured quantitatively the plasma levels of some 21 individual amino acids by ion exchange chromatography and has found them within normal limits. The total urinary output of amino acids by the same patients was 2 to 5 times the average normal, and the renal clearances of individual amino acids was greatly increased. Robson and Rose (178) report a cystine clearance approximating the inulin clearance in another adult patient. The strongest support for the hypothesis of a renal origin of the amino aciduria has thus come from study of adult patients and comparable

quantitative measurements of amino acid clearances in children with cystinosis are urgently needed. In the meantime Bickel (17) who has been the principal protagonist of an extrarenal origin for the aminoaciduria now admits that a tubular defect must also be a factor.

Although the genetic basis of the Lignac Fanconi syndrome is established beyond doubt, the evidence that the renal tubular disorder itself is innate remains conflicting. The patient is usually quite well in the first 6 months of life and the characteristic disturbances of electrolyte and water metabolism may develop even later than this (22). It has been shown recently that the amino aciduria is not present at birth but develops somewhere between the fourth and sixth months (17). Since there is a physiologic amino aciduria in the newborn (20) which is exaggerated in prematurity (68) Bickel's (17) recent observation is of considerable importance. It suggests that amino aciduria in the Lignac Fanconi syndrome may be acquired, in a fashion analogous to the acquisition of amino aciduria in galactosaemia.

It is extremely difficult to rationalize these biochemical observations with the finding of apparently congenital anatomic abnormalities of the renal tubule. By microdissection technique Clay and associates (39) discovered a short hypoplastic proximal tubule which in most cases examined (8 out of 11 up to January 1957 (52)) was converted in its proximal third into a thin and narrow swan neck. Many observers have considered this anatomic abnormality to be the basis of the functional tubular defects but its significance becomes questionable with the recent finding of a similar swan neck in the proximal renal tubules of congenital familial nephrosis (52) a disorder in which generalised amino aciduria and glycosuria apparently do not occur. Moreover in patients with the Lignac Fanconi syndrome dying early in the course of the disease the renal tubules were histologically normal (67-108) /

Any satisfactory hypothesis for the renal manifestations of this syndrome must explain the delayed development of amino aciduria, the fact that renal damage commonly progresses to a severe degree of renal failure and the claim (22, 182, 191) that in the established case prolonged treatment with alkalis and vitamin D may result in amelioration or disappearance of the glycosuria and amino aciduria. As yet no single hypothesis can meet these requirements it would however seem most reasonable to ascribe the development of renal tubular disorder to a general metabolic disturbance of which cystine

{storage in the reticuloendothelial system is another expression. This would bring the Lignac Fanconi syndrome into the same group of secondary genetic disorders of the renal tubule as galactosaemia and Wilson's disease /

It can be said with some confidence that no functional significance can safely be attached to the absence of phosphatase from the proximal renal tubules (44 212). This abnormality has certainly been seen in cases of classic cystinosis (8) but it is also a commonplace finding in many kinds of renal disease (8 136). The reduced phosphatase reaction in spleen liver and bone marrow (8) and the claim that the erythrocytes are abnormally permeable to phosphate (170) may be more significant. If the claim is confirmed a clue may be provided to the fundamental nature of the primary metabolic defect /

Much attention has been directed to the supposed occurrence of organic acidemia in the Lignac Fanconi syndrome and Bickel and collaborators (8 19) have inferred that these organic acids may contribute to the production of renal damage. Recognition of organic acidemia depends on the indirect calculation of "undetermined anion" this is fraught with cumulative analytic error and doubtful physicochemical assumptions. Moreover the development of an anion gap is met frequently in renal insufficiency of many different types and it is more likely that this finding in the Lignac Fanconi syndrome is a result rather than a cause of renal damage. Until the matter has been adequately documented by identification of individual organic acids in the plasma this aspect of the syndrome will remain of doubtful significance.

✓The amounts of glucose and amino acids excreted by patients with the Lignac Fanconi syndrome varies from case to case and is probably never sufficient of itself to promote an osmotic diuresis. Yet all authorities include thirst and polyuria among the earliest and most prominent symptoms (22 92 134) and there is often impairment of osmolar concentrating capacity in the absence of conventional renal failure (Table 1). ✓A metabolic acidosis is usually present, often of great severity and is commonly associated with a disproportionately high urinary pH continued excretion of bicarbonate and wasting of cation in the urine. Each of these anomalies reflects additional tubular disorder in the one instance an impairment of the absorption of free water and in the other impairment of hydrogen ion secretion. Detailed observations of renal function in these sick children have been too

quantitative measurements of amino acid clearances in children with cystinosis are urgently needed. In the meantime Bickel (17) who has been the principal protagonist of an extrarenal origin for the amino-aciduria now admits that a tubular defect must also be a factor.

Although the genetic basis of the Lignac Fanconi syndrome is established beyond doubt, the evidence that the renal tubular disorder itself is innate remains conflicting. The patient is usually quite well in the first 6 months of life and the characteristic disturbances of electrolyte and water metabolism may develop even later than this (22). It has been shown recently that the amino-aciduria is not present at birth but develops somewhere between the fourth and sixth months (17). Since there is a physiologic amino-aciduria in the newborn (20) which is exaggerated in prematurity (68) Bickel's (17) recent observation is of considerable importance. It suggests that amino-aciduria in the Lignac Fanconi syndrome may be acquired, in a fashion analogous to the acquisition of amino-aciduria in galactosaemia.

It is extremely difficult to rationalize these biochemical observations with the finding of apparently congenital anatomic abnormalities of the renal tubule. By microdissection technique, Clay and associates (39) discovered a short hypoplastic proximal tubule which in most cases examined (8 out of 11 up to January 1957 (52)) was converted in its proximal third into a thin and narrow "swan neck". Many observers have considered this anatomic abnormality to be the basis of the functional tubular defects but its significance becomes questionable with the recent finding of a similar swan neck in the proximal renal tubules of congenital familial nephrosis (52) a disorder in which generalised amino-aciduria and glycosuria apparently do not occur. Moreover in patients with the Lignac Fanconi syndrome dying early in the course of the disease the renal tubules were histologically normal (67, 108) ✓

Any satisfactory hypothesis for the renal manifestations of this syndrome must explain the delayed development of amino-aciduria, the fact that renal damage commonly progresses to a severe degree of renal failure and the claim (22, 182, 191) that in the established case prolonged treatment with alkalis and vitamin D may result in amelioration or disappearance of the glycosuria and amino-aciduria. As yet, no single hypothesis can meet these requirements; it would, however, seem most reasonable to ascribe the development of renal tubular disorder to a general metabolic disturbance of which cystinosis

storage in the reticuloendothelial system is another expression. This would bring the Lignac Fanconi syndrome into the same group of secondary genetic disorders of the renal tubule as galactosaemia and Wilson's disease.

It can be said with some confidence that no functional significance can safely be attached to the absence of phosphatase from the proximal renal tubules (44 212). This abnormality has certainly been seen in cases of classic cystinosis (8) but it is also a commonplace finding in many kinds of renal disease (8 136). The reduced phosphatase reaction in spleen liver and bone marrow (8) and the claim that the erythrocytes are abnormally permeable to phosphate (170) may be more significant. If the claim is confirmed a clue may be provided to the fundamental nature of the primary metabolic defect.

Much attention has been directed to the supposed occurrence of organic acidaemia in the Lignac Fanconi syndrome and Bickel and collaborators (8 19) have inferred that these organic acids may contribute to the production of renal damage. Recognition of organic acidaemia depends on the indirect calculation of "undetermined anion" this is fraught with cumulative analytic error and doubtful physicochemical assumptions. Moreover the development of an anion gap is met frequently in renal insufficiency of many different types and it is more likely that this finding in the Lignac Fanconi syndrome is a result rather than a cause of renal damage. Until the matter has been adequately documented by identification of individual organic acids in the plasma this aspect of the syndrome will remain of doubtful significance.

The amounts of glucose and amino acids excreted by patients with the Lignac Fanconi syndrome varies from case to case and is probably never sufficient of itself to promote an osmotic diuresis. Yet all authorities include thirst and polyuria among the earliest and most prominent symptoms (22 92 134) and there is often impairment of osmolar concentrating capacity in the absence of conventional renal failure (Table 1). A metabolic acidosis is usually present, often of great severity and is commonly associated with a disproportionately high urinary pH continued excretion of bicarbonate and wasting of cation in the urine. Each of these anomalies reflects additional tubular disorder in the one instance an impairment of the absorption of free water and in the other impairment of hydrogen ion secretion. Detailed observations of renal function in these sick children have been too



quantitative measurements of amino acid clearances in children with cystinosis are urgently needed. In the meantime Bickel (17) who has been the principal protagonist of an extrarenal origin for the amino-aciduria now admits that a tubular defect must also be a factor.

Although the genetic basis of the Lignac Fanconi syndrome is established beyond doubt the evidence that the renal tubular disorder itself is innate remains conflicting. The patient is usually quite well in the first 6 months of life and the characteristic disturbances of electrolyte and water metabolism may develop even later than this (22). It has been shown recently that the amino aciduria is not present at birth but develops somewhere between the fourth and sixth months (17). Since there is a physiologic amino-aciduria in the newborn (20) which is exaggerated in prematurity (68) Bickel's (17) recent observation is of considerable importance. It suggests that amino aciduria in the Lignac Fanconi syndrome may be acquired in a fashion analogous to the acquisition of amino aciduria in galactosaemia.

It is extremely difficult to rationalize these biochemical observations with the finding of apparently congenital anatomic abnormalities of the renal tubule. By microdissection technique Clay and associates (39) discovered a short hypoplastic proximal tubule which in most cases examined (8 out of 11 up to January 1957 (52)) was converted in its proximal third into a thin and narrow "swan neck". Many observers have considered this anatomic abnormality to be the basis of the functional tubular defects but its significance becomes questionable with the recent finding of a similar swan neck in the proximal renal tubules of congenital familial nephrosis (52) a disorder in which generalised amino aciduria and glycosuria apparently do not occur. Moreover in patients with the Lignac Fanconi syndrome dying early in the course of the disease the renal tubules were histologically normal (67 108) /

Any satisfactory hypothesis for the renal manifestations of this syndrome must explain the delayed development of amino aciduria the fact that renal damage commonly progresses to a severe degree of renal failure and the claim (22 182 191) that in the established case prolonged treatment with alkalis and vitamin D may result in amelioration or disappearance of the glycosuria and amino aciduria. As yet no single hypothesis can meet these requirements it would however seem most reasonable to ascribe the development of renal tubular disorder to a general metabolic disturbance of which cystinosis

storage in the reticuloendothelial system is another expression. This would bring the Lignac Fanconi syndrome into the same group of secondary genetic disorders of the renal tubule as galactosaemia and Wilson's disease.

It can be said with some confidence that no functional significance can safely be attached to the absence of phosphatase from the proximal renal tubules (41 212). This abnormality has certainly been seen in cases of classic cystinosis (8) but it is also a commonplace finding in many kinds of renal disease (8 136). The reduced phosphatase reaction in spleen, liver and bone marrow (8) and the claim that the erythrocytes are abnormally permeable to phosphate (170) may be more significant. If the claim is confirmed, a clue may be provided to the fundamental nature of the primary metabolic defect.

Much attention has been directed to the supposed occurrence of organic acidaemia in the Lignac Fanconi syndrome and Bickel and collaborators (8 19) have inferred that these organic acids may contribute to the production of renal damage. Recognition of organic acidaemia depends on the indirect calculation of "undetermined anion" this is fraught with cumulative analytic error and doubtful physicochemical assumptions. Moreover the development of an anion gap is met frequently in renal insufficiency of many different types and it is more likely that this finding in the Lignac Fanconi syndrome is a result rather than a cause of renal damage. Until the matter has been adequately documented by identification of individual organic acids in the plasma, this aspect of the syndrome will remain of doubtful significance.

The amounts of glucose and amino acids excreted by patients with the Lignac Fanconi syndrome varies from case to case and is probably never sufficient of itself to promote an osmotic diuresis. Yet all authorities include thirst and polyuria among the earliest and most prominent symptoms (22 92 134) and there is often impairment of osmolar concentrating capacity in the absence of conventional renal failure (Table 1). A metabolic acidosis is usually present, often of great severity and is commonly associated with a disproportionately high urinary pH continued excretion of bicarbonate and wasting of cation in the urine. Each of these anomalies reflects additional tubular disorder in the one instance an impairment of the absorption of free water and in the other impairment of hydrogen ion secretion. Detailed observations of renal function in these sick children have been too

TABLE 1.—POTASSIUM DEPLETION AND SECONDARY TUBULAR FUNCTIONAL DISTURBANCES IN FANCONI SYNDROME\*

CASE No.	AGE Mo.	POTASSIUM SERUM LEVEL	THIRST	POLYURIA <sup>b</sup>	URINARY OSMOLALITY <sup>c</sup> SP GR.	URINARY pH <sup>d</sup>	AMMONIA PRODUCTION
1	15	Low in 12-14 assays (as low as 2.1 mEq/L)	+++ 4 pt daily	Up to 3.2 L	Fixed 1.010-1.012	5.3 after CaCl <sub>2</sub>	Increased with acidosis
2	10	< 3.9 mEq/L in 9-14 assays 2.9 mEq/L during glucose tolerance test EKG suggestive	+++	Up to 3 L	1.003-1.015	6.7	Normal or slightly raised
5	30	2.7-2.8 mEq/L in 2 assays	First word was "drunk" 2 qt daily	Up to 2 L same after pitressin	1.001-1.004	6.2	Increased
6	15	3.3 mEq/L in 1 assay	+++	1-1.4 L same after pitressin	1.002-1.010	5.0	Increased
8	78	3.1 mEq/L or less in 7 assays EKG positive	3 pt daily at 3 mo drank enormously at 6 mo	Up to 2.2 L 1.3 L output at 0.39 L intake	1.005-1.010	6.1	Normal or increased

From initial presentation to the following dates: (22) and for case 6 from October and Thursday (21) of the following year. \* Serum potassium levels were measured daily in the morning. † Observed loss of sodium in the urine. ‡ Observed loss of sodium in the urine. § Data obtained at a time of severe spontaneous metabolic acidosis. || Normal or increased renal output.

few to permit any definite statement concerning the cause of these tubular defects. In some patients the mechanisms of osmotic concentration appear to be congenitally defective (204) (see Fig 6)

It has become apparent recently that hypokalaemia, and presumably a potassium deficiency are frequent in this disease. Pitressin-resistant hyposthenuria and defective hydrogen ion secretion are characteristic of the tubular disorder in potassium deficiency (see p 270). Data abstracted from the clinical protocols of Bickel *et al* (22) illustrate the association of potassium deficiency and these particular tubular lesions (Table 1). We believe that many of these defects could result directly from potassium deficiency. The preservation of a relatively normal capacity for ammonium excretion in spite of submaximal urinary acidification would also be compatible with the effects of potassium deficiency. However the general belief (134) that ammonium excretion is high in the Lignac Fanconi syndrome is unfounded. When examined critically the output has sometimes been found to be subnormal (19 111 120) as would be expected in a disease associated with progressive renal damage. Some of the described histologic changes in the renal tubules of patients with the Lignac Fanconi syndrome appear to be identical with the vacuolar nephropathy of potassium deficiency (see Plate 1) (8 94 134). It therefore seems certain that potassium deficiency contributes to the production of renal lesions in this syndrome and it may indeed be responsible for the progressive renal failure. This begs the question of the mechanisms responsible for production of the potassium deficiency itself. The author is not aware of any study which clearly documents this matter. It is more than likely that anorexia coupled with renal loss is responsible and some data of Bickel and Hickmans (19) suggest that the renal clearance of potassium can be very high. Whether a secondary increase of aldosterone production plays a part in facilitating the loss of potassium in these children is not known. However in an adult patient with the genetically determined Fanconi syndrome and renal wasting of potassium Dr A H Gowenlock has found the urinary output of aldosterone to be 15 times the average normal value (204).

#### CHILDHOOD DISORDERS SIMULATING LIGNAC FANCONI SYNDROME

There is a tendency at present to attach the label "Fanconi syndrome" or the more ponderous "nephrotic glycosuric aminoaciduric

dwarfism with hypophosphataemic rickets" to almost any condition in young children in which amino aciduria and glycosuria are associated with systemic upset and retardation of growth. This is to be deprecated since the juvenile amino acidurias, even in children with rickets, are by no means homogeneous. Failure to demonstrate cystine in the cornea or in aspirated bone marrow does not exclude cystinosis which can only be eliminated by chemical analysis of the viscera and

TABLE 2—POTASSIUM DEPLETION AND SECONDARY TUBULAR FUNCTIONAL DISTURBANCES IN NEPHROTIC SYNDROME\*

	CASE 1	CASE 2
Age	8	5
Potassium serum level	1.5-3.5 mEq/L before therapy	Sustained hypokalaemia 2.3-2.4 mEq/L, low exchangeable K, paresis retention of administered K
Thirst	No comment	Constant
Polyuria	Very high diuresis, often in presence of oedema	1.0-1.3 L, even in pres- ence of oedema
Urinary osmolality sp gr	Not recorded	220-315 mOsm/L, 440 mOsm/L after therapy
Urinary pH	Alkaline in state of acidosis	6.8 when acidotic
Ammonia production	Low	5 mEq/day

Both patients were dwarfed, osteoporotic and liable to attacks of tetany, both had marked metabolic acidosis, glycosuria and generalised amino-aciduria. Clinical picture closely resembled Lignac Fanconi syndrome but neither patient had cystinosis. Amino-aciduria in case 1 was reduced by alkali therapy. Postmortem examination of case 2 revealed evidence of pyelonephritis in addition to type 2 nephritis (this secondary renal lesion may be a consequence of the potassium deficiency) but showed evidence of osteomalacia.

\* From Tager and Tiddens (215).

\* From Stanbury and Macaulay (205).

especially the spleen<sup>†</sup>(60). Nonetheless young patients have been described in whom characteristic renal functional disorders and various abnormalities of electrolyte metabolism were present but cystinosis absent (28, 120, 134, 183, 191). It seems likely that new and distinctive syndromes will be separated from among such patients and it is suggested that each case merits detailed study. Already the so-called Fanconi syndrome has been seen as a complication of glycogen storage disease (81), of vitamin D intoxication (219), of lead poisoning (36) and possibly of hepatolenticular degeneration (220). Recently 3 patients have been described in whom classic juvenile nephrosis

evolved into a clinical state closely resembling the Lignac Fanconi syndrome<sup>2</sup> (205 215) as in that syndrome potassium deficiency has been implicated in the production of certain of the observed tubular defects (205) (Table 2) (A fourth very similar case has been described recently (107a) ) The situation is further complicated by the finding in nutritional rickets of a distinctive pattern of renal amino aciduria which disappears after treatment with vitamin D (113) and by the occurrence of amino aciduria in coeliac disease which is often associated with rickets and dwarfism (22) )

Finally metabolic acidosis and urinary abnormalities similar to those of the Lignac Fanconi syndrome have been described in association with a totally different clinical syndrome (130) The principal clinical features are mental retardation cataracts glaucoma and in some cases rickets Some or other of these clinical stigmata may be absent (21) and probably the condition is genetically determined (60) As with cystine storage disease this would seem to be a metabolic disorder in which the effects of an abnormal gene are clinically evident in the kidney and other tissues The occurrence of cataracts suggests an affinity with galactosaemia but nothing is yet known of the fundamental metabolic disturbance

✓ The very multiplicity of primary disorders that can be associated with massive or generalised amino aciduria and glycosuria suggests that these may be relatively nonspecific indices of renal tubular damage Their occurrence adds indirect support to the hypothesis that amino-aciduria in the Lignac Fanconi syndrome may not be innate but an early acquired consequence of some innate generalised metabolic disorder

#### FANCONI SYNDROME IN OLDER CHILDREN AND IN ADULTS

✓ Just as several distinct disorders in infancy have been called the Fanconi syndrome so in the adult and in older children the same term is applied to a heterogeneous mixture of clinical conditions Most of the patients to whom this diagnostic label has been attached have had late rickets or osteomalacia and hypophosphataemia together with renal glycosuria renal amino aciduria and probably renal phosphaturia A metabolic acidosis is usual but apparently not invariable (124 154) and when present it may be associated either with a somewhat reduced capacity for acid and ammonia excretion (5 111 182) or with gross impairment of this tubular function and resulting

dwarfism with hypophosphataemic rickets" to almost any condition in young children in which amino aciduria and glycosuria are associated with systemic upset and retardation of growth. This is to be deprecated, since the juvenile amino acidurias even in children with rickets, are by no means homogeneous. Failure to demonstrate cystine in the cornea or in aspirated bone marrow does not exclude cystinosis which can only be eliminated by chemical analysis of the viscera, and

TABLE 2—POTASSIUM DEPLETION AND SECONDARY TUBULAR FUNCTIONAL DISTURBANCES IN NEPHROTIC SYNDROME

	CASE 1	CASE 2
Age	8	5
Potassium serum level	1.5–3.5 mEq/L before K therapy	Sustained hypokalaemia 2.3–2.4 mEq/L low exchangeable K paresis retention of administered K
Thirst	No comment	Constant
Polyuria	Very high diuresis often in presence of oedema	10–13 L even in pres- ence of oedema
Urinary osmolality sp gr	Not recorded	220–315 mOsm/L 440 mOsm/L after K therapy
Urinary pH	Alkaline in state of acidosis	6.8 when acidotic
Ammonia production	Low	5 mEq/day

Both patients were dwarfed osteoporotic and liable to attacks of tetany both had moderate metabolic acidosis glycosuria and generalised amino-aciduria. Clinical picture closely resembled Lignac Fanconi syndrome but neither patient had cystinosis. Amino-aciduria in case 1 was reduced by alkali therapy. Postmortem examination of case 2 revealed evidence of pyelonephritis in addition to type 2 nephritis (this secondary renal lesion may be a consequence of the potassium deficiency) bones showed evidence of osteomalacia.

From Tegelaers and Tiddens (215)

From Stanbury and Macaulay (205)

especially the spleen<sup>†</sup>(60). Nonetheless young patients have been described in whom characteristic renal functional disorders and various abnormalities of electrolyte metabolism were present but cystinosis absent (28 120 134 183 191). It seems likely that new and distinctive syndromes will be separated from among such patients and it is suggested that each case merits detailed study. Already, the so-called Fanconi syndrome has been seen as a complication of glycogen storage disease (81) of vitamin D intoxication (219) of lead poisoning (36) and possibly of hepatolenticular degeneration (220). Recently 3 patients have been described in whom classic juvenile nephrosis

evolved into a clinical state closely resembling the Lignac Fanconi syndrome (205 215) as in that syndrome potassium deficiency has been implicated in the production of certain of the observed tubular defects (205) (Table 2) (A fourth very similar case has been described recently (107a)) The situation is further complicated by the finding in nutritional rickets of a distinctive pattern of renal amino-aciduria which disappears after treatment with vitamin D (113) and by the occurrence of amino aciduria in coeliac disease which is often associated with rickets and dwarfism (22))

Finally metabolic acidosis and urinary abnormalities similar to those of the Lignac Fanconi syndrome have been described in association with a totally different clinical syndrome (130) The principal clinical features are mental retardation cataracts glaucoma and, in some cases rickets Some or other of these clinical stigmata may be absent (21) and probably the condition is genetically determined (60) As with cystine storage disease this would seem to be a metabolic disorder in which the effects of an abnormal gene are clinically evident in the kidney and other tissues The occurrence of cataracts suggests an affinity with galactosaemia but nothing is yet known of the fundamental metabolic disturbance

The very multiplicity of primary disorders that can be associated with massive or generalised amino-aciduria and glycosuria suggests that these may be relatively nonspecific indices of renal tubular damage Their occurrence adds indirect support to the hypothesis that amino aciduria in the Lignac Fanconi syndrome may not be innate but an early acquired consequence of some innate generalised metabolic disorder

#### FANCONI SYNDROME IN OLDER CHILDREN AND IN ADULTS

Just as several distinct disorders in infancy have been called the Fanconi syndrome so in the adult and in older children the same term is applied to a heterogeneous mixture of clinical conditions Most of the patients to whom this diagnostic label has been attached have had late rickets or osteomalacia and hypophosphataemia together with renal glycosuria renal amino-aciduria and, probably renal phosphaturia A metabolic acidosis is usual but apparently not invariable (124 154) and when present it may be associated either with a somewhat reduced capacity for acid and ammonia excretion (5 111 182) or with gross impairment of this tubular function and resulting



hyperchloraemia (59 147 192) It is often forgotten that glomerular filtration may be severely reduced as it may be in the infantile syndrome and insufficient attention has been given to progressive renal destruction as a factor contributing to the development of metabolic acidosis (120) Less common accompanying disorders include hypokalaemia with renal wasting of potassium (74 147 183 192) low serum levels of urate (147, 154) with renal uricuria (192) and impaired osmolar concentrating capacity or renal diabetes insipidus (204)

Among these adult patients are some in which evidence of renal involvement can be traced back to early life (204) and in which a genetic origin is likely (60 204) but they differ from the Lignac Fanconi syndrome in having no deposits of cystine in the viscera These patients may have suffered from thirst and polyuria in early childhood (183 204) and although there may be osseous involvement at that time it may be minimal and easily overlooked or manifest only in some degree of growth retardation Osteomalacia (60 204) evidence of hepatic cirrhosis (212) or renal failure develop in early adult life

Another group of patients come to attention for the first time in middle age with symptoms of osteomalacia and varying combinations of tubular defects (60 102 124 147) In many of these cases no causative factor has been identified but in others a genetic origin is established and like the Lignac Fanconi syndrome the disease is inherited as a simple mendelian recessive (59 60) In addition to their sharing this common pattern of inheritance it has been claimed that both the infantile and adult cases exhibit the swan neck deformity of the proximal tubule (39) but no adult has been found with cystine storage disease (60) The adult and infantile i.e. Lignac Fanconi syndrome types appear to be clearly distinct each runs true to type within a given family and cystinosis has not been seen in the infantile relatives of the genetically determined adult Fanconi syndrome (60)

It has always been thought that among the sporadic adult cases of this syndrome there may be some in which the multifactorial tubular defects develop as a result of some form of primary renal disease Actual proof of this happening has been lacking until recently when characteristic features of the Fanconi syndrome have been described in adults with the nephrotic syndrome (26 27) and with myelomatosis (74 192) The author is aware of another myelomatous patient with renal glycosuria and amino aciduria (190) and the cases in children with nephrosis to which reference has already been made may come into the same general category (205 215) Any attempt to interpret

these complications of renal disease with gross proteinuria is necessarily speculative. On the one hand all these patients had gross disorders of protein metabolism and possibly severe protein deficiency, and the effects of such on the renal tubule are unknown. On the other hand it might be argued that the renal tubules were reabsorbing excessive amounts of filtered protein or even of abnormal myeloma protein and that this may initiate the sequence of cytoarchitectural events described by Oliver and co workers (159 161) as occurring in the proximal tubules of rats with proteinuria following the injection of protein. Since the principal changes noted by them involved the apparent disorganisation of the mitochondria—the cellular locus of energy production—some disturbance of reabsorptive function might reasonably be expected; this has been discussed briefly elsewhere (171). The finding of crystal like inclusions in the renal tubular epithelium of the myelomatous patient of Engle and Wallis (74) is of the greatest interest in this respect; the author is aware of another case of myeloma with similar findings (27). The development of amino aciduria in children with nephrosis appears to be not uncommon (110 226); a deliberate study of its evolution should throw further light on these problems (205).

#### OSSEOUS DISORDERS COMPLICATING MULTIFACTORIAL TUBULAR DEFECTS

✓Frequently it is the development of rickets or osteomalacia that brings the patient to clinical attention and leads to the diagnosis of a multifactorial tubular defect or of the Fanconi syndrome. The osseous lesions are usually ascribed to the low serum level of inorganic phosphorus which is considered to result from loss of phosphorus in the urine. This is an undue simplification. Among different patients of this heterogeneous group at least three distinct mechanisms may contribute either alone or in combination to the production of negative external balances and low serum levels of calcium and phosphorus. These are defective absorption of calcium and phosphorus from the intestine (19 204), excessive excretion of phosphorus in the urine (124) and an abnormally high renal output of calcium (60 102 183).

It has yet to be proved that renal phosphaturia is innate in any of the conditions designated as Fanconi syndrome. In the specific instance of the Lignac Fanconi syndrome in which many workers consid

hyperchloraemia (59 147 192) It is often forgotten that glomerular filtration may be severely reduced, as it may be in the infantile syndrome and insufficient attention has been given to progressive renal destruction as a factor contributing to the development of metabolic acidosis (120) Less common accompanying disorders include hypokalaemia with renal wasting of potassium (74 147 183 192) low serum levels of urate (147 154) with renal uricuria (192) and impaired osmolar concentrating capacity or renal diabetes insipidus (204)

Among these adult patients are some in which evidence of renal involvement can be traced back to early life (204) and in which a genetic origin is likely (60 204) but they differ from the Lignac Fanconi syndrome in having no deposits of cystine in the viscera These patients may have suffered from thirst and polyuria in early childhood (183 204) and although there may be osseous involvement at that time it may be minimal and easily overlooked or manifest only in some degree of growth retardation Osteomalacia (60 204) evidence of hepatic cirrhosis (212) or renal failure develop in early adult life

Another group of patients come to attention for the first time in middle age with symptoms of osteomalacia and varying combinations of tubular defects (60 102 124 147) In many of these cases no causative factor has been identified but in others a genetic origin is established and like the Lignac Fanconi syndrome the disease is inherited as a simple mendelian recessive (59 60) In addition to their sharing this common pattern of inheritance it has been claimed that both the infantile and adult cases exhibit the swan neck deformity of the proximal tubule (39) but no adult has been found with cystine storage disease (60) The adult and infantile i.e. Lignac Fanconi syndrome types appear to be clearly distinct each runs true to type within a given family and cystinosis has not been seen in the infantile relatives of the genetically determined adult Fanconi syndrome (60)

It has always been thought that among the sporadic adult cases of this syndrome there may be some in which the multifactorial tubular defects develop as a result of some form of primary renal disease Actual proof of this happening has been lacking until recently when characteristic features of the Fanconi syndrome have been described in adults with the nephrotic syndrome (26 27) and with myelomatosis (74 192) The author is aware of another myelomatous patient with renal glycosuria and amino aciduria (190) and the cases in children with nephrosis to which reference has already been made may come into the same general category (205 215) Any attempt to interpret

clearances to normal after correction of acidosis (192) or following the administration of alkalis and vitamin D (147) would favour this explanation

In a small group of patients with cystinosis Bickel and Hickmans (19) found no evidence of excessive phosphate excretion in the urine they attributed the development of rickets to impaired absorption of calcium and phosphorus from the intestine. The author has obtained results agreeing with their hypothesis in the genetically determined Fanconi syndrome of early adult life (Fig 1) in this patient, the lesions of osteomalacia healed during therapy with dihydrotachysterol without appreciable elevation of the low serum phosphate level (204). This particular metabolic lesion which leads to inadequate utilisation of dietary calcium and phosphorus appears to be essentially the same as that which occurs in azotaemic renal osteodystrophy (128 202 203). The mechanisms responsible for defective alimentary absorption have not yet been defined but in azotaemic renal osteodystrophy it has been suggested renal failure leads to an acquired vitamin D resistance which can be overcome by the use of sufficiently high doses of calciferol (202) or dihydrotachysterol (128 203). The apparent occurrence of a similar metabolic lesion in nonspecific azotaemic renal failure (128 203) cystinosis (19) nephrosis (72 205) and the adult Fanconi syndrome (204) suggests that a single responsible factor may be common to all. The only common feature that is immediately obvious is the presence of renal disease with destruction of renal tissue whatever its nature this factor may be as important for the production of osseous changes as are phosphaturia and calciuria.

In most children with cystinosis even when there is a severe metabolic acidosis and an impaired capacity for urinary acidification the renal output of calcium is relatively low (19 111) and it cannot be considered to contribute to the development of rickets. In other patients with multifactorial tubular defects either genetically determined (60) or of uncertain origin (102 183) the renal output of calcium has been high as in the syndrome of renal tubular acidosis (3) it is possible that calciuria plays some part in the production of defective skeletal mineralisation. Some of these patients do in fact, have "renal tubular acidosis" as one of their many tubular disorders (59 147 192). But, although it has been demonstrated that correction of acidosis in the adult Fanconi syndrome results in a reduced urinary output of calcium (183) it has not been proved that the administration of alkalis alone would correct the osteomalacia. Indeed in the litera

er phosphaturia to be invariably present Bickel (17) has found both the plasma level and the urinary output of phosphorus to be normal during the early months of the disease). Gross renal phosphaturia has however, been demonstrated in some older children (120 case 2) and adults (44 147) with multifactorial tubular defects, in 2 patients with




FIG 1—Calcium and phosphorus balance data in patient with adult Fanconi syndrome. With two entirely different diets calcium and phosphorus absorption from bowel was defective during treatment with dihydrota/hysterol calcium and phosphorus were retained in ratio of 2:1 and the osteomalacia healed without a return of the serum phosphate level to normal (From Stanbury [204]).

/normal glomerular filtration rates the phosphate  $T_m$  was significantly reduced (44 124). In other, essentially similar patients both older children (111 120 case 1) and adults (5 212) there appeared to be no demonstrable phosphaturia. This suggests that impairment of phosphate reabsorption is present irregularly and perhaps acquired as a secondary consequence of metabolic acidosis, hyperparathyroidism or even of potassium depletion. The reversion of high phosphate

to be a hyperchloraemic acidosis associated with the excretion of neutral or slightly alkaline urine. It thus seems possible that a specific intoxication can give rise to all the clinical features of the Fanconi syndrome.

Future investigation into the effects of heavy metals may prove critical to the understanding of the many clinical and theoretical problems posed by the multifactorial tubular disorders. At present, it is possible only to indicate a few tenuous or potential links between totally different investigations. At the one extreme we have the clinical experience of Chisolm *et al* and the distinct probability that osteomalacia has developed in a few patients (45-220) with the chronic copper intoxication of Wilson's disease. On the other hand the observations of Clarkson and Kench (38) suggest that it may be possible to distinguish specific pathways of amino acid absorption by their differential sensitivity to heavy metal ions. It is tempting if speculative to seek a connexion between the observation that the renal tubule is particularly sensitive to cadmium ion (38) and the clinical fact that an apparent osteomalacia may develop in men with chronic cadmium intoxication (122-156). The recent claim (34) that the liver protein of patients with Wilson's disease differs from the normal suggests another possible and distant link between cadmium intoxication and hepatolenticular degeneration. The proteinuria of cadmium intoxication (197) may not be primarily of renal origin, but a result of the circulation and glomerular filtration of proteins of low molecular weight (196). Smith and Kench (196) take this to suggest an interference by cadmium with the hepatic synthesis of proteins. This provokes the speculation that the oligopeptides excreted in the urine in Wilson's disease (216-218) may originate in a comparable way.

Wilson's disease although it is a genetically determined disorder is included among the effects of heavy metals since there is little doubt that its various clinical features result from intracellular deposition of copper. It is inherited in an autosomal recessive fashion (13-142) and the primary metabolic defect is not precisely known. The plasma concentration of the specific copper binding protein, caeruloplasmin is greatly reduced (185) and it has been suggested that there is a primary failure of the synthesis of this protein. Why such a deficiency should lead to an apparent increase in the absorption of dietary copper (141-230) is by no means clear but retention of copper and its deposition in tissues produces hepatic, cerebral, and renal abnormalities.

Amino aciduria in patients with hepatolenticular degeneration was

ture on pure renal tubular acidosis the author has been unable to find a single documented instance of cure of osteomalacia by means of alkali therapy alone. All cured cases appear to have received large doses of vitamin D. This suggests the possibility that the homeostatic defect—the failure of base conservation—could be less important in the production of osteomalacia than the unknown factor to which reference has been made previously.

The author has permitted himself this digression to suggest that insufficient attention has been given to the causation of the rickets and osteomalacia associated with renal tubular disorders and to plead for a more critical attitude to this problem. To demonstrate the presence of hypophosphataemia or of renal phosphaturia is not to establish the cause of defective mineral deposition in bone.

#### FUNCTIONAL RENAL TUBULAR DISORDERS APPARENTLY CAUSED BY HEAVY METALS POISONING

Experimental intoxication of animals with the salts of uranium and mercury has long been used for the production of an acute renal necrosis in which damage is largely restricted to the proximal tubules (133 71). In human poisoning with corrosive sublimate epithelial necrosis occurs predominantly in the proximal tubule (15 160). In children dying of lead poisoning nuclear inclusions, giant nuclei, and fatty vacuolation have been described in the cells of the proximal renal tubules and of the looped tubules (25 140); the collecting tubules remaining apparently healthy. Recent observations (38) indicate that less severe intoxication with mercury and lead and more especially with uranium and cadmium may induce functional disorders of the renal tubules. Arguing by analogy with the histologic findings in more severe intoxications it may be inferred cautiously that these functional defects involve the proximal tubule. Glycosuria, apparently of renal origin, was recorded in chronic lead poisoning by several earlier workers (see references in 38 95) and more recently the occurrence of amino aciduria has been recognised (140 221). Cystine, taurine and especially  $\beta$  aminoisobutyric acid were found in the urine in excess while the plasma level of total  $\alpha$  amino nitrogen was normal (221). More extensive tubular disorders were present in a single case of lead poisoning described by Chisolm et al (36). This child in addition to having glycosuria and amino aciduria was also rachitic and had a low serum level of phosphate and there appeared

renal tubular cell. The latter hypothesis remains unproved on the other hand it is sometimes possible to demonstrate a reduced tubular reabsorption of phosphate in patients who are excreting normal amounts of phosphorus in the urine (180). The tubular reabsorption of phosphate appears to be influenced by so many extrarenal factors that it may at times be impossibly difficult to establish the cause for a given instance of renal phosphaturia.

It has been assumed apparently on the basis of observations made originally on a single subject (186) that phosphate reabsorption at high plasma levels of phosphate is limited by a stable maximum rate ( $T_m$ ) as it is in the dog (7). Smith (194-195) suggests that when the dietary intake is normal the plasma level of phosphate is such that the load of phosphate filtered is near to the maximal rate of reabsorption. Recent observations on young adults (6) in which meticulous care was taken to maintain basal and constant conditions of study support the concept of a stable  $T_m$ . Similar and equally careful experiments (129) in which conditions were *not* basal, revealed wide variations of  $T_m$  in the same subject. Phosphate reabsorption appeared to vary with the rate of glomerular filtration and the authors explain their results in terms of the perfusion of unpredictably varying numbers of nephrons. These two groups of observations are of the utmost importance for they underline the fundamental difficulties involved in assessing the renal handling of phosphate in disease. In placid patients it may be possible to make observations under reproducible and basal conditions by the use of these techniques it has been claimed that the phosphate  $T_m$  of postmenopausal women is regularly reduced following the administration of oestrogens (155). But in most patients and especially in children the emotional effects of the investigative procedure and the infusion of phosphate salts itself are likely to influence renal haemodynamics in varying degree and the results obtained are correspondingly difficult of interpretation. Effects on renal haemodynamics and accompanying changes in phosphate  $T_m$  are clearly evident in the experiments of Rupp and Swoboda (180-181) which were designed to explore the action of vitamin D in children with refractory rickets. Similar haemodynamic effects produced when crude extracts of parathyroid gland (parathormone) are administered intravenously may account for the continued dispute as to whether or not the parathyroid glands influence phosphate excretion by varying the reabsorption of phosphate by the tubules. This question is discussed by Nordin in this



first recorded by Uzman and Denny Brown (217) and its probable origin in defective tubular reabsorption was suggested by the later observations of Cooper *et al* (45) and Matthews *et al* (142). A renal tubular origin has now been proved by the demonstration of massive amino aciduria in patients with a plasma pattern of amino acids that is both qualitatively and quantitatively normal (211). This renal defect is presumably nonspecific as with poisoning by other metals or with the intracellular accumulation of galactose 1 phosphate or glycogen. Some genetically or clinically involved individuals may not exhibit amino aciduria and one may perhaps infer that the tubular disorder will progress as accumulation of copper increases. A few patients have been found to have renal glycosuria (45) others may have impairment of urate reabsorption and attention has already been directed to the occasional occurrence of apparent osteomalacia. A systematic survey of discrete renal functions in a group of patients with Wilson's disease has been reported recently (14a).

Many aspects of this disease remain obscure. The paradoxical occurrence of copper retention relatively low plasma levels of copper and an increased urinary output of copper has not yet been fully explained. Matthews *et al* (142) found a positive correlation between the urinary output of copper and the excretion of amino acids. They inferred that there may be an impairment of the renal tubular reabsorption of filtered copper, a hypothetical moiety of plasma copper that was not bound to protein and consequently filterable at the glomerulus. This factual observation has been confirmed (14) and increasing knowledge of the state of plasma copper in this disease is providing some direct support for the hypothetical formulation. Uzman (216) and Uzman and Hood (218) believe that copper is filtered in a chelation complex with oligopeptides which remain unabsorbed in the tubule and carry copper to the urine in this form.

## RENAL PHOSPHATURIA

The term "renal phosphaturia" is widely and indiscriminately used to imply a state of affairs in which excessive amounts of phosphorus are excreted in the urine through impairment of the reabsorption of phosphate by the renal tubules. In certain genetically determined disorders it has been further inferred that the impaired phosphate reabsorption is based on a deficiency of some unspecified system of enzymes in the

renal tubular cell The latter hypothesis remains unproved on the other hand it is sometimes possible to demonstrate a reduced tubular reabsorption of phosphate in patients who are excreting normal amounts of phosphorus in the urine (180) The tubular reabsorption of phosphate appears to be influenced by so many extrarenal factors that it may at times be impossibly difficult to establish the cause for a given instance of renal phosphaturia

It has been assumed apparently on the basis of observations made originally on a single subject (186) that phosphate reabsorption at high plasma levels of phosphate is limited by a stable maximum rate ( $T_m$ ) as it is in the dog (7) Smith (194 195) suggests that when the dietary intake is normal the plasma level of phosphate is such that the load of phosphate filtered is near to the maximal rate of reabsorption Recent observations on young adults (6) in which meticulous care was taken to maintain basal and constant conditions of study support the concept of a stable  $T_m$  Similar and equally careful experiments (129) in which conditions were *not* basal, revealed wide variations of  $T_m$  in the same subject phosphate reabsorption appeared to vary with the rate of glomerular filtration and the authors explain their results in terms of the perfusion of unpredictably varying numbers of nephrons These two groups of observations are of the utmost importance for they underline the fundamental difficulties involved in assessing the renal handling of phosphate in disease In placid patients it may be possible to make observations under reproducible and basal conditions by the use of these technics it has been claimed that the phosphate  $T_m$  of postmenopausal women is regularly reduced following the administration of oestrogens (155) But in most patients and especially in children the emotional effects of the investigative procedure and the infusion of phosphate salts itself are likely to influence renal haemodynamics in varying degree and the results obtained are correspondingly difficult of interpretation Effects on renal haemodynamics and accompanying changes in phosphate  $T_m$  are clearly evident in the experiments of Rupp and Swoboda (180 181) which were designed to explore the action of vitamin D in children with refractory rickets Similar haemodynamic effects produced when crude extracts of parathyroid gland (parathormone) are administered intravenously may account for the continued dispute as to whether or not the parathyroid glands influence phosphate excretion by varying the reabsorption of phosphate by the tubules This question is discussed by Nordin in this

volume on the basis of observations made on hypoparathyroid patients (101 144) the author will assume that a tubular effect of parathyroid hormone is established

In view of the difficulties experienced in investigating the renal excretion of phosphate by normal subjects it is not surprising that clinical appraisal of the same problem has given rise to considerable confusion. The following indices of the renal handling of phosphate have all been used by different workers in the clinical field

(1) The daily output of phosphorus in the urine (82 180 181)

(2) The renal clearance of phosphate as determined in short urinary collection periods (53 174)

(3) A 24 hour clearance calculated from the measured daily output of phosphorus in the urine and a single plasma level of phosphate obtained under varying and arbitrary conditions (65 139 180 181)

(4) A phosphate excretion index in which the reabsorption of phosphate is related to the simultaneous filtration rate of phosphate (35 47 125 147 157). The ratio of clearance of phosphate to glomerular filtration rate provides an index of the fraction of filtered phosphate which remains unabsorbed by the tubules. As originally used by Lambert (124 125) and by ourselves (147) the normal values were determined over a wide range of plasma phosphate levels and abnormal data were compared with this established normal. Others (158) by applying an incompletely valid mathematical treatment to the same data, have derived a convenient index which measures the deviation of an observed clearance ratio from the normal value expected with any particular level of plasma phosphate

(5) A somewhat similar index of tubular activity is provided by measurement of the absolute amount of phosphate reabsorbed per minute per 100 ml of glomerular filtrate formed (11 66). If this were measured at plasma levels that saturate the absorptive capacity of the tubules (181) it should minimize the effects of changing filtration rate on phosphate  $T_m$ .

(6) Measurement of the classic phosphate  $T_m$ , that is the absolute minute rate of phosphate reabsorption when the reabsorptive capacity has been saturated by artificial elevation of the plasma phosphate concentration

It may seem inappropriate to discuss methods of measurement in a review of tubular disorders but supposed renal phosphaturia frequently features in the description of these conditions and it is so

often diagnosed on inadequate grounds that some appraisal must be attempted

The first of the above indices is clearly of little value unless the dietary intake of phosphorus is stabilised and appropriate correction is applied for the varying weight or surface area of the subjects compared even constancy of intake does not ensure constant absorption of dietary phosphorus. Nonetheless the urine of normal individuals becomes virtually free of phosphate when the serum phosphate falls below about 2.2 mg per 100 ml (147) continued output of significant amounts of phosphorus then constitutes presumptive evidence of impaired renal conservation ✓

The second index, although it can be measured easily and accurately may provide the most misleading information. It is remarkable that a value of 4 to 6 ml per minute for the clearance of phosphate at normal plasma levels which was presented originally without supporting data (44) should be quoted uncritically in the clinical literature dealing with renal tubular disorders. In infants children and adults the phosphate clearance varies extremely (53 174) and in the same individual the clearance may vary through the day and from day to day (53). Even within the normal range of plasma phosphate levels the clearance varies with the plasma level (125) (Fig 2). The difficulties involved in obtaining a representative phosphate clearance can be illustrated by reference to Figure 2 which shows the regular but relatively enormous diurnal changes in the output and plasma level of phosphate. These data confirmatory of others published earlier (207) refute the opinion of Ollayos and Winkler (162) that the diurnal changes in phosphate excretion are unrelated to changes in the plasma phosphate level. Parenthetically some investigations of the phosphaturic action of parathormone have been made in the early morning at this time a spontaneous increase in the phosphate clearance is to be expected (Fig 2) and its occurrence can be detected in some of the published data (e.g. 117). From Figure 2 it is evident that there may be a threefold change in the clearance of phosphate within a single day and the average value is much higher than the supposedly normal figure quoted above. The glomerular filtration rate was not measured during the experiments recorded in Figure 2 but the output of creatinine fluctuated only slightly and previous experience (193 207) indicates that the glomerular filtration rate of resting subjects varies little during the day. It follows that the fourth index the clearance ratio

(phosphate clearance/glomerular filtration rate) will also change greatly in the course of the day and this figure is equally valueless unless related to the plasma level at which it was obtained (125-147-158). It may also be inferred from Figure 2 that the use of short urinary collection periods for calculating the clearance ratio has little advantage over the use of an "integrated" or "24 hour" clearance. The




FIG 2—Spontaneous changes of plasma phosphate level and of urinary output and renal clearance of phosphate during 24 hour period in 3 normal young adults resting and taking a small constant amount of fluid each hour. Urine was collected at hourly intervals and blood taken at midpoint of each clearance period. Subject 1 • subject 2 ○ subject 3 ○ (From unpublished data of Mills and Stanbury [148-149]). A Mean and SE of mean of the 3 subjects hour by hour (continued)

author calculates a 24 hour clearance of phosphate and creatinine from their respective daily outputs in the urine and plasma levels determined on a single blood specimen which is taken at midday 4 to 5 hours after the last meal or medicament. When it is used in the course of metabolic studies in which the patient is receiving a fixed dietary intake the 24 hour phosphate clearance/glomerular filtration rate ratio can provide a valuable index of changes in tubular activity (139). When used for comparison in this fashion the error that may occur from using the clearance of creatinine as a measure of glomerular filtration is minimized.




FIG 2 (cont) -B individual hourly clearance data related to corresponding plasma levels note increase of renal clearance with increase of plasma level Mean of hourly clearances was for subject 1 16.0 ml/min for subject 2 16.5 ml/min for subject 3 17.0 ml/min. Corresponding 24 hour clearances calculated from 24 hour urinary output of phosphorus and serum phosphate value at midday were for subject 1 15.2 ml/min for subject 2 17.0 ml/min for subject 3 16.9 ml/min The two grossly aberrant values of subject 2 the first of the series in this subject emphasize further the fallacies involved in using short collection periods

There is little room for dispute that measurement of phosphate  $T_m$  and calculation of the saturation thresholds as suggested by Anderson (6) provides the theoretic ideal in investigating disorders of the tubular handling of phosphate. The discomfort of the procedure and the experiences of Longson *et al* (129) militate against its general clinical use furthermore the infusion of large amounts of phosphate into pa

Patients with osteomalacia may give rise to severe tetany. There are two other theoretic disadvantages to its use. (1) The prolonged infusion of phosphate may itself appear to depress the measured phosphate  $T_m$  (103, 143, 160) an effect that may possibly be related to change in either the plasma level or body content of potassium (103) or to an induced change of parathyroid activity. (2) Certain factors may depress phosphate reabsorption at normal or slightly elevated plasma phosphate levels without having a demonstrable effect on phosphate  $T_m$ ; this appears to be the case with the phosphaturic effect of metabolic acidosis (186). Until these various difficulties have been circumvented there is much in favour of the continued clinical use of the third and fourth indices listed above.

The above considerations apply to the exploration of possible renal phosphaturia in patients without organic renal disease as for example in the so called phosphate diabetes of refractory rickets. Further difficulties arise in the presence of destructive renal disease. It is not known whether reduction of glomerular filtration and progressive loss of nephrons affects the handling of phosphate by the surviving renal tubules (Table 3). Conceivably measurement of the ratio of phosphate  $T_m$ /glomerular filtration rate would provide a suitable basis for assessing phosphate reabsorption in this circumstance but no data are available either for renal disease in general or for those apparently phosphaturic disorders in which progressive renal damage is the rule (e.g. the Lignac-Fanconi syndrome). It is also probable that the range of the clearance ratio established for normal individuals (120, 147, 157, 158) is not strictly transferable to patients with renal disease and significantly reduced glomerular filtration. This may account for the difficulties experienced when the clearance ratio is used in an attempt to detect primary hyperparathyroidism in patients with renal calculi (135). In the face of these uncertainties it may be advisable to resort to the indirect method of observing the effects on the phosphate clearance of eliminating influences which could be responsible for phosphaturia. By this means it has been possible to demonstrate that a severe deficiency of potassium was responsible for phosphaturia in a patient with chronic pyelonephritis (139) (see Fig. 5) and that the accompanying metabolic acidosis accounted for the increased phosphate clearance in the syndrome of renal tubular acidosis (9) and in a case of the adult Fanconi syndrome associated with myelomatosis (192). Assessment of the part played by secondary hyperparathyroidism in producing apparently high phosphate clearances in renal disease is

much more difficult and uncertain. Methods used in testing parathyroid activity have recently been reviewed (35)

It is probably only in the condition of refractory or vitamin D resistant rickets and osteomalacia that the presence of renal phosphaturia




FIG 3—Effects of phosphate deprivation (aluminium hydroxide gel, 120 ml. daily) and of administered phosphate in 56 year-old male patient with vitamin D resistant osteomalacia proved by bone biopsy. 11 of patient's relatives known to have same genetically determined disorder. Full metabolic data in Stanbury and Lumb (208)

has been established by all the criteria discussed above. Even in this genetically determined syndrome (60 215a) in which the serum phosphate level is usually very low and the urinary output of phosphorus relatively high, it has not been proved that the renal tubules are primarily at fault, and the fundamental nature of the disorder remains undecided. Three hypotheses have been proposed to account for the diminished tubular reabsorption of phosphate in refractory rickets:



(1) there is an innate defect of the mechanism responsible for phosphate transport in the tubules (56 82 91 176) (2) it results from some innate disturbance of vitamin D metabolism (10 60) (3) it is an effect of secondary hyperparathyroidism (1 2)

When it has been measured the glomerular filtration rate in refractory rickets has been found normal (82 114 126 180 181 208) and the patients exhibit no evidence of primary renal disease. Fanconi and Girardet (82) used the term "phosphate diabetes" for the syndrome and with others (56 102 111) they believe that renal glycosuria, refractory rickets and the Fanconi syndrome constitute a group of related and innate disorders of the proximal renal tubule. There is much to commend this hypothesis for some patients with refractory rickets or osteomalacia have renal glycosuria (126) and others have aminoaciduria with or without glycosuria (60 77 121). However there are certain objections to this concept. If the tubular transport mechanism for phosphate is congenitally defective it remains nonetheless responsive to physiologic stimulation and on deprivation of phosphorus or following its administration the pattern of tubular response is qualitatively the same as normal (Fig 3). When aluminum hydroxide gel was given all the dietary phosphorus remained in the faeces renal conservation was effected by a fall in phosphate clearance and the decrease in serum phosphate was only minor. When additional phosphorus was given most was absorbed from the bowel and the increase in its urinary excretion was through an increase in renal clearance. Creatinine output remained virtually unchanged. Moreover the presence in the tubules of the cellular components necessary for phosphate transfer is shown by the frequent fall of the phosphate clearance to normal after massive vitamin D therapy (Table 3) (132 176 180 181) and by the fact that normal values of phosphate  $T_m$  may be achieved after such treatment (181). Robertson *et al* (176) have tried to explain this therapeutic response by postulating "a functional defect of an enzyme system of which Vitamin D forms the prosthetic group and which is responsible for the absorption of phosphate from the intestine and its reabsorption from the glomerular filtrate." It seems possible to produce an adequate amount of the enzyme through the mass effect of large amounts of the vitamin. In criticism of this hypothesis it must be insisted that there is no demonstrable defect of phosphate absorption from the bowel (Fig 3) (208 222) although the absorption of dietary calcium is impaired (60 132 208 229). This failure of calcium utilisation, and the extremely low urinary output of calcium with

which it is usually associated, mimics precisely the findings in nutritional rickets when massive doses of vitamin D produce a satisfactory therapeutic effect, the metabolic response is the same as that which accompanies the healing of nutritional rickets (60 184 208) There is little doubt, therefore, that interference with the action of vitamin D is responsible for certain facets of this syndrome the intimate nature of the interference however remains unknown) As we have previously

TABLE 3—EFFECTS OF VITAMIN D IN SYNDROME OF VITAMIN D RESISTANT OSTEOMALACIA (208)

DATE	SERUM LEVELS OF			CLEARANCES OF		CLEARANCE RATIO P Cr <sup>cc</sup>
	Cal um, mg /100 ml.	Phosph t mg /100 ml.	C eat n mg /100 ml	Phosphate ml./min	C eat n n ml./m n	
2/27/57	89	37	0.79	16.3	73	22.3
3/13/57	88	33	0.74	17.8	72	24.2
<i>100 000 units calciferol daily started 3/13/57 increased to 300 000 units daily 3/23/57</i>						
3/26/57	96	43	0.85	11.4	65	17.4
4/ 2/57	10.3	52	0.90	8.9	50	18.0
4/ 9/57	12.2	53	1.26	10.8	39	28.9

P t i e n t was 56 y ld wom n h g h t 517 n. p n 537 weight 124 lb B n b o p e y r e v s i e d o s t e p o s e s w i t h m n d g r e e s o f o s t e o m a l a c i a 4 f p t n t b l n g s h a d t b i a l f m r a l o s t e o m a c i a i n h i l d h o o d y o u t h. D u r i n g o b s e r v a t n p e r i o d p t n t w a s r e c v i n g a n e s t a t d e t o n a n g 0.94 Gm. C l Gm. P Th 24 h u r r e n l c l e a r a n c e s w r e c a l c u l a t e d a s d e s c r i b e d i n t e x t

N t e t h t (1) r u m P w a s h g h t h n i s u s u l n t h i s s y n d r o m p o s s i b l y r e l t d t o p o s t m e n p u s l o s t e o p r o s s (2) f i r s t v l u e s f o r c l r a n c e r t w t h i g h e s t l i m t o f n r m a l (3) t i l l f a l l i n P e l r n w a s p p n t l y d u t o n r e a s s e d t u b u l a r e a b s o r p t i o n a n d t h e t h r d n d f u t h c l t o s e n o r m a l (4) v i t m n D n t x i t n l e d t o h y p c a l m a a n d g n f i a n t r e n a l d m g s t h t n p e c i s e s i g n f i c a n e c a n b e a t t a c h e d t o f i f t h l n t

pointed out (147) the phosphate clearance may be greatly increased in nutritional osteomalacia and as in rachitic dogs (100) vitamin D administration produces a fall toward normal values The analogous effects of high doses of vitamin D on the phosphate clearance in refractory rickets provide further evidence suggesting a probable extra renal origin of the renal phosphaturia In this context, it must be remembered that large doses of vitamin D may reduce the glomerular filtration rate in refractory rickets (177) and that a fall in phosphate clearance due to increased tubular reabsorption of phosphate must be distinguished from that produced by renal damage resulting from vitamin D intoxication (Table 3)

The occasional occurrence of glycosuria and amino-aciduria in pa

(1) there is an innate defect of the mechanism responsible for phosphate transport in the tubules (56 82 91 176) (2) it results from some innate disturbance of vitamin D metabolism (10 60) (3) it is an effect of secondary hyperparathyroidism (1 2)

When it has been measured the glomerular filtration rate in refractory rickets has been found normal (82 114 126 180 181 208) and the patients exhibit no evidence of primary renal disease. Fanconi and Girardet (82) used the term "phosphate diabetes" for the syndrome and with others (56 102 111) they believe that renal glycosuria, refractory rickets and the Fanconi syndrome constitute a group of related and innate disorders of the proximal renal tubule. There is much to commend this hypothesis for some patients with refractory rickets or osteomalacia have renal glycosuria (126) and others have aminoaciduria with or without glycosuria (60 77 121). However there are certain objections to this concept. If the tubular transport mechanism for phosphate is congenitally defective it remains nonetheless responsive to physiologic stimulation and on deprivation of phosphorus or following its administration the pattern of tubular response is qualitatively the same as normal (Fig 3). When aluminum hydroxide gel was given all the dietary phosphorus remained in the faeces renal conservation was effected by a fall in phosphate clearance and the decrease in serum phosphate was only minor. When additional phosphorus was given most was absorbed from the bowel and the increase in its urinary excretion was through an increase in renal clearance. Creatinine output remained virtually unchanged. Moreover the presence in the tubules of the cellular components necessary for phosphate transfer is shown by the frequent fall of the phosphate clearance to normal after massive vitamin D therapy (Table 3) (132 176 180 181) and by the fact that normal values of phosphate  $T_m$  may be achieved after such treatment (181). Robertson *et al* (176) have tried to explain this therapeutic response by postulating "a functional defect of an enzyme system of which Vitamin D forms the prosthetic group and which is responsible for the absorption of phosphate from the intestine and its reabsorption from the glomerular filtrate." It seems possible to produce an adequate amount of the enzyme through the mass effect of large amounts of the vitamin. In criticism of this hypothesis it must be insisted that there is no demonstrable defect of phosphate absorption from the bowel (Fig 3) (208 222) although the absorption of dietary calcium is impaired (60 132 208 229). This failure of calcium utilisation, and the extremely low urinary output of calcium with

which it is usually associated mimics precisely the findings in nutritional rickets when massive doses of vitamin D produce a satisfactory therapeutic effect the metabolic response is the same as that which accompanies the healing of nutritional rickets (60 184 208) There is little doubt therefore (that interference with the action of vitamin D is responsible for certain facets of this syndrome the intimate nature of the interference, however remains unknown) As we have previously

TABLE 3—EFFECTS OF VITAMIN D IN SYNDROME OF VITAMIN D RESISTANT OSTEOMALACIA (208)

DATE	SERUM LEVELS OF			CLEARANCES OF		CLEARANCE RATIO P/Ca %
	Cl um mg/100 ml	Phosph te mg/100 ml	C itinine mg/100 ml	Phosphate ml/min	C t n ml/min	
2/27/57	8.9	3.7	0.79	16.3	73	22.3
3/13/57	8.8	3.3	0.74	17.8	72	24.2
<i>100 000 units calciferol daily started 3/13/57 increased to 300 000 units daily 3/23/57</i>						
3/26/57	9.6	4.3	0.85	11.4	65	17.4
4/ 2/57	10.3	5.2	0.90	8.9	50	18.0
4/ 9/57	12.2	5.3	1.26	10.8	39	28.9

Patient was 56 yr old woman height 51 1/2 in span 53 7/8 in weight 124 lb Bone biopsy revealed osteoporosis with minor degrees of osteomalacia of patient's siblings had history of mild osteoporosis in childhood. During observation period patient was receiving a constant intake of 0.94 Gm. Ca 1 Gm. P. The 4-hour renal clearances were calculated as described in text.

Note that (1) serum P was high but this is usual in this syndrome possibly related to postmenopausal osteoporosis (2) first values of clearance ratio were at highest limit of normal (3) in this illness serum P level was apparently due to increased tubular reabsorption and the blood phosphate concentration was normal (4) vitamin D intoxication led to hypercalcaemia and significant renal damage so that no precise significance can be attributed to fifth laboratory rate.

pointed out (147) the phosphate clearance may be greatly increased in nutritional osteomalacia and as in rachitic dogs (100) vitamin D administration produces a fall toward normal values. The analogous effects of high doses of vitamin D on the phosphate clearance in refractory rickets provide further evidence suggesting a probable extra renal origin of the renal phosphaturia. In this context, it must be remembered that large doses of vitamin D may reduce the glomerular filtration rate in refractory rickets (177) and that a fall in phosphate clearance due to increased tubular reabsorption of phosphate must be distinguished from that produced by renal damage resulting from vitamin D intoxication (Table 3).

The occasional occurrence of glycosuria and amino aciduria in pa-

tients with refractory rickets provides at first sight, the strongest support for a primary renal defect in this disease. In 1 case however, glycosuria developed late in the course of the illness (10) an occurrence not readily explained in terms of an innate renal glycosuria. Moreover Dent and Harris (60) mention the disappearance of aminoaciduria in 1 patient after vitamin D treatment. Attention has already been directed to the disappearance of glycosuria and amino aciduria after vitamin D therapy in patients with the Lignac Fanconi syndrome and to the reversible amino aciduria of nutritional rickets. Although the pattern of amino aciduria is different in these 3 distinct syndromes the observed response to vitamin D suggests that it may play some role in the tubular reabsorption of substances other than phosphate. A critical step in the further elucidation of the nature of the renal defect in refractory rickets would be the quantitative study of amino aciduria and glycosuria preferably by saturation techniques before and after treatment with vitamin D. There is also scope for observation of the evolution of the renal disorders in a manner similar to that used by Bickel (17) in his neonatal observations on patients with the Lignac Fanconi syndrome.

The possibility remains that in refractory rickets the renal phosphaturia reflects a state of secondary hyperparathyroidism. This view originally proposed by Albright and associates (2) and subsequently championed by Albright and Reifenstein (1) is extremely difficult to confirm or refute. Since glycosuria and amino aciduria do not appear to develop in primary hyperparathyroidism functional hyperparathyroidism would not readily account for the occasional presence of these abnormalities in refractory rickets. Surgical exploration has demonstrated that there is both parathyroid hyperplasia and parathyroid hyperfunction in this syndrome as in the renal osteodystrophy syndrome (202). Linder and Vadas (127) removed 1 hyperplastic gland weighing 850 mg. Removal of a single hyperplastic gland from the patient observed by Albright *et al* (2) was followed by a rise in serum phosphate a fall in serum calcium and the clinical development of tetany. Moreover in the case reported by Lievre *et al* (126) the description of the roentgenographic osseous changes and the appearance of the single roentgenogram suggest that osteitis fibrosa was present, as well as osteomalacia. Here again the analogy with certain kinds of vitamin D deficiency is close the changes of osteitis fibrosa may occasionally be grafted on to the osteomalacia which complicates the mal

absorption syndrome (50 204a) Whether a deficiency of vitamin D produces parathyroid hyperfunction as a result of defective absorption of calcium as suggested by Albright and associates (1 2) or by some more direct means is undecided But it seems likely that a primary disorder of vitamin D metabolism will prove responsible directly or indirectly for most of the renal abnormalities of refractory rickets and osteomalacia.

### POTASSIUM DEFICIENCY AND RENAL TUBULAR DISORDERS

✓The development of a severe potassium deficiency in the experimental animal (153) or in man (70 172 188 204) may be accompanied by a decrease of the glomerular filtration rate and a moderate degree of nitrogen retention These changes are reversed after correction of the potassium deficit and nothing is known of the mechanisms immediately responsible for their production In addition to these apparently haemodynamic changes potassium depletion may cause various functional tubular disorders as well as structural changes in the renal tubular cells (146) The so called nephropathy of potassium depletion (172) is unique among the clinical disorders of renal tubular function in that many of its component functional abnormalities can be reproduced experimentally by inducing potassium depletion in man (37 76) rats (104 200) and dogs (151 198) Moreover considerable insight into the nature of the changes occurring in tubular cells of the potassium depleted kidney can be gained by the *in vitro* study of potassium depleted slices of renal tissue (4 214)

✓The various renal changes which have been ascribed to potassium deficiency are listed in Table 4 which is meant to be comprehensive As yet, not all the effects listed have been adequately verified and some of the findings in animals (e.g. renal hypertrophy and the reduced capacity to excrete a water load) may not be directly applicable to man Consequently discussion will be restricted to changes of clinical significance

It has been inferred, ✓from the results of metabolic balance studies in man (24) and in the rat (42), ✓that when an extracellular alkalosis develops with potassium deficiency it is associated with an intracellular acidosis The direct analysis of muscle from potassium depleted rats has revealed a decrease of intracellular pH (93) Recent *in vitro*

studies of the potassium and bicarbonate content of renal slices (4) indicate that the concentration of hydrogen ions within renal cells is increased by potassium depletion and it can be demonstrated that the secretion of hydrogen ion by the renal tubules is increased in potassium deficient states (175). In the light of these various studies it becomes possible to describe comprehensively if tentatively the metabolic state in potassium deficiency and to resolve some apparently anomalous features of renal function in this condition. The extracellular alkalosis is of extrarenal origin (163) and results from a shift of H from the extracellular fluids to cells in partial replacement of lost cellular K (42) the renal tubular cells sharing in the intracellular acidosis (4) increase the secretion of  $H^+$  in exchange for  $Na^+$  reabsorbed from the glomerular filtrate (16) the latter process effects the almost complete reabsorption of the greatly increased filtered load of  $HCO_3^-$  and thereby maintains the elevated plasma level of bicarbonate (175). It follows that a metabolic alkalosis of the extracellular fluid is associated with the excretion of what appears to be an inappropriately acid urine—the paradoxical aciduria found clinically with gastric alkalosis (115) and other conditions leading to the alimentary loss of potassium (32). This supposed paradox is to be regarded as a strictly physiologic response of the renal tubule that maintains the newly established ionic equilibrium between the intracellular and extracellular fluids.)

It has also been shown in man (76) and rat (43) that potassium depletion is associated with a reduced renal capacity to excrete an administered load of sodium bicarbonate the consumption of alkali in such circumstances may produce severe alkalosis. This observation may apply to patients with pyloric obstruction in whom a potassium deficiency commonly develops (51) and who may increase the alkali intake because of increasing pain. The ensuing severe alkalosis could conceivably be of importance in the production of renal damage, a combination of severe alkalosis with potassium deficiency may account for the mental symptoms sometimes seen with pyloric stenosis and which are not readily explained by the alkalosis alone (219a). Although the consumption of large amounts of alkali and the development of metabolic alkalosis appear to be without deleterious effects on the healthy kidney (219a) it cannot safely be assumed that the same is true of a kidney already damaged by potassium deficiency.)

The intracellular acidosis of potassium depletion appears to be directly responsible for two other changes of renal tubular function

(146) Of these the reduced urinary output of citric and other organic acids (43 76 87) seems to be without clinical significance (76) The other concerns the excretion of ammonia and it may be regarded as an adaptation whereby the kidney is enabled to excrete the acid products of metabolism despite a reduced capacity to produce urine of




FIG. 4—Metabolic alkalosis of potassium depletion and its spontaneous correction by retention of dietary potassium in patient with mitral valvulotomy potassium deficiency due to anorexia and use of mercurial diuretics. Fall in blood pH and serum total CO<sub>2</sub> was accompanied by fall in urinary ammonia output, urine was collected directly into acid to obtain accurate figures for ammonium output, and output of bicarbonate was therefore not measured (Unpublished observations of Mahler and Stanbury.)

maximal acidity. In potassium deficiency resulting from alimentary losses (188 228) in experimental potassium deficiency (37) and in primary aldosteronism (69 146) the urinary output of ammonia has been found disproportionately high for the pH of the urine excreted of the H<sup>+</sup> excreted a greater proportion than normal is excreted as NH<sub>4</sub><sup>+</sup> and less as titratable acid. Correction of the potassium deficiency is associated with a rapid fall in ammonia output, even though the pH



studies of the potassium and bicarbonate content of renal slices (4) indicate that the concentration of hydrogen ions within renal cells is increased by potassium depletion and it can be demonstrated that the secretion of hydrogen ion by the renal tubules is increased in potassium deficient states (175). In the light of these various studies it becomes possible to describe comprehensively if tentatively the metabolic state in potassium deficiency and to resolve some apparently anomalous features of renal function in this condition. The extracellular alkalosis is of extrarenal origin (163) and results from a shift of H from the extracellular fluids to cells in partial replacement of lost cellular K (42) the renal tubular cells sharing in the intracellular acidosis. (4) increase the secretion of  $H^+$  in exchange for  $Na^+$  reabsorbed from the glomerular filtrate (16) the latter process effects the almost complete reabsorption of the greatly increased filtered load of  $HCO_3^-$  and thereby maintains the elevated plasma level of bicarbonate (175). It follows that a metabolic alkalosis of the extracellular fluid is associated with the excretion of what appears to be an inappropriately acid urine—the paradoxical aciduria found clinically with gastric alkalosis (115) and other conditions leading to the alimentary loss of potassium (32). This supposed paradox is to be regarded as a strictly physiologic response of the renal tubule that maintains the newly established ionic equilibrium between the intracellular and extracellular fluids.)

It has also been shown in man (76) and rat (43) that potassium depletion is associated with a reduced renal capacity to excrete an administered load of sodium bicarbonate the consumption of alkali in such circumstances may produce severe alkalosis. This observation may apply to patients with pyloric obstruction in whom a potassium deficiency commonly develops (51) and who may increase the alkali intake because of increasing pain. The ensuing severe alkalosis could conceivably be of importance in the production of renal damage, a combination of severe alkalosis with potassium deficiency may account for the mental symptoms sometimes seen with pyloric stenosis and which are not readily explained by the alkalosis alone (219a). Although the consumption of large amounts of alkali and the development of metabolic alkalosis appear to be without deleterious effects on the healthy kidney (219a) it cannot safely be assumed that the same is true of a kidney already damaged by potassium deficiency.)

The intracellular acidosis of potassium depletion appears to be directly responsible for two other changes of renal tubular function

lar acidosis since an increase of phosphate clearance is usual with metabolic acidosis. Its rapid reversibility with potassium replacement would be compatible with this explanation but its origin in the structural changes of the proximal tubule cannot be excluded.

✓ Other renal effects of clinical significance appear to involve functions of both the proximal and distal parts of the nephron (146). Since they may be associated with clinical symptoms and with demonstrable histologic changes they are perhaps better regarded as pathologic rather than as adaptive sequels of the potassium depletion.

Although structural changes are frequently found in the proximal tubules evidence of impaired proximal tubular function is scanty. Elimination of p-aminohippurate (PAH) is depressed whether measured by its renal clearance, its extraction ratio or its maximal rate of excretion ( $T_m\text{PAH}$ ) (188). Replacement of potassium has been followed by an increase in the clearance of PAH (172). It is likely that the impaired PAH excretion is a direct result of a reduced intracellular potassium concentration and not of structural or haemodynamic renal changes. *In vitro* studies by Taggart and co-workers (214) indicate that renal slices leached of potassium accumulate little PAH when incubated in a potassium free medium; maximal accumulation depends on a normal tissue content of potassium.

✓ Polyuria accompanied by thirst may be a conspicuous feature of potassium deficiency in man (41, 75, 86, 139, 205) and it occurs regularly in the potassium depleted dog (151, 198) and rat (31, 104, 146, 200). It may also be inferred that development of potassium deficiency was involved in the production of the diabetes insipidus like syndrome in dogs treated with desoxycorticosterone acetate (DCA) (83, 152). Since the original observations of Schwartz and Relman (188) it has been established that the polyuria of potassium deficiency is due at least in part to an impaired renal capacity to produce osmotically concentrated urine and a hyposthenuria or isosthenuria that depends on the body content of potassium has been observed in a variety of conditions (Table 4). Our most impressive personal experience of this occurrence was in a patient with the genetically determined adult Fanconi syndrome who appeared to have a congenital water losing renal defect or renal diabetes insipidus and in whom osteomalacia and potassium deficiency developed at the age of 35 (Fig. 6). (The rapidity with which the osmolar concentrating capacity may improve after a positive potassium balance is established) may be seen in Figure 6.




FIG 5—Effects of potassium replacement on renal phosphaturia in patient with chronic pyelonephritis and potassium depletion (modified from ref 139). On administration of potassium bicarbonate plasma potassium level increased with its cumulative positive balance and serum phosphate level increased in roughly parallel fashion; creatinine clearance did not change materially. Renal clearance of phosphate normally increases with plasma phosphate level (see Fig 2); in this case converse relation obtained indicating that replacement of potassium changed renal tubular handling of phosphate.

of the extracellular fluid is falling simultaneously (Fig 4). The facilitation of ammonia excretion can probably be attributed to an increased content of glutaminase and D-amino oxidase in the cells of the renal tubule (109); there are reasons to believe that the adaptive enzymic changes are related to the reduced intracellular pH (49).

Conceivably the renal phosphaturia observed in 1 patient with severe potassium depletion (139) (Fig 5) was also a result of intracellu-

since the age of 12 but no other symptoms in early life osteomalacia and potassium deficiency were found at the age of 35 Osmolality of whole 24 hour urine specimen numbers in circles days of potassium replacement • Short urinary collection periods after intramuscular administration of 5 to 10 units of potassium tannate

When patient was potassium deficient there was no response to potassium as soon as potassium replacement began the osmolality of 24 hour specimens increased On day 11 when the potassium deficit was completely made up response to potassium was demonstrable although urinary osmolality remained below that of plasma (renal diabetes insipidus) Patient's younger sister with same type of renal lesion but without potassium deficiency responded in manner similar to that shown in right half of figure Full renal and metabolic data in Stanbury (204)




FIG. 8.—Water losing renal lesion in adult Fanconi syndrome in 36-year-old female patient with additional impairment of water conservation resulting from potassium deficiency. Patient in polydipsia and polyuria at least

## RENAL CHANGES

CLINICAL DISORDER RESPONSIBLE FOR DEFICIENCY OR  
EXPERIMENTAL METHOD

✓ Inability to establish minimal urinary pH relative increase in urinary $\text{NH}_4$	Experimental deficiency in man continued ingestion of $\text{NH}_4\text{Cl}$ and diabetic acidosis (37) steatorrhoea (228) primary aldosteronism (46 69 75 145)
Decreased urinary citric and other organic acids	Experimental deficiency in man (76 87) and in rat (43 76)
✓ Increased tubular re-absorption of $\text{HCO}$ and decreased capacity to excrete $\text{NaHCO}_3$ load	Experimental deficiency in man (76) and depletion in rat (43 76) various surgical conditions (175) gastric alkalosis (115) ulcerative colitis (32)
✓ Inversion of diurnal excretory rhythm	Chronic pyelonephritis (139) hyperaldosteronism with unilateral renal disease (227)
✓ Impaired capacity to conserve Na with low dietary Na	Renal tubular acidosis (139) Fanconi syndrome in adult (204)
✓ Renal phosphaturia	Renal tubular acidosis (139) (see Fig 5)
✓ Amino-aciduria (tubular?)	Alimentary losses (64)

*Structural changes in renal tubules*

Vacuolar (hydropic) nephropathy of proximal tubule	In various alimentary renal and adrenocortical disorders experimental deficiency in rat (84 85) ✓
Granular degeneration and atrophy of cells in distal and collecting tubules	Alimentary losses (119) experimental deficiency in rat (146 200)
Renal weight increase	Experimental depletion in rat (31 200)

*Histochemical changes in renal tubules*

Increased esterase in proximal tubules	} Experimental deficiency in rat (137)
Decreased DPN diaphorase and increased TPN diaphorase in medulla and papilla	

*Biochemical changes in renal tubules*

Decreased capacity to accumulate p-amino-hippurate	Kidney slices depleted of K by leaching (214)
Intracellular acidosis	Leached kidney slices reversible by metabolism (4)
Increased glutaminase d-amino oxidase and carbonic anhydrase	Experimental deficiency in rat (109)

Such rapid improvement appears to be usual (139 205) but it may be months before a completely normal concentrating capacity is regained (172 188)

It may be recalled that the diabetes insipidus like syndrome of DCA treated dogs was originally ascribed to a primary polydipsia (83 152). It is the author's clinical impression that a primary thirst, the mechanism of which is obscure can occur as a symptom of potassium deficiency (86 139) and that polydipsia may contribute to the production of the exceedingly high urinary volumes observed in certain cases. For instance it is difficult to explain the daily output of 4 to 6 litres in some patients with potassium depletion due to hyperaldosteronism (90 138 227) for most of these patients when tested with vasopressin, can elaborate urine with a specific gravity at least as high as 1.010. The situation may be compared with that found in the syndrome of renal tubular acidosis in which it is not uncommon to find isosthenuria (max sp gr 1.010) in association with normal or only slightly reduced glomerular filtration rates such patients virtually never produce so

TABLE 4—RENAL EFFECTS OF POTASSIUM DEFICIENCY

RENAL CHANGES	CLINICAL DISORDER RESPONSIBLE FOR DEFICIENCY OR EXPERIMENTAL METHOD
<i>Glomerular changes</i>	
✓ Lowered glomerular filtration rate and urea clearance	Alimentary losses (172 188) nephrotic syndrome treated with cation exchange resins (205) Fanconi syndrome in adult (204) renal disease of uncertain nature (70) primary aldosteronism (139) K depletion cause unknown (116) experimental K depletion in rat (153)
Proteinuria (?)	Present in most severe cases (Glomerular [?] tubular [?])
Impaired capacity to excrete water load	Experimental depletion in rat (31) but not necessarily in man (118 139)
<i>Functional changes in renal tubules</i>	
✓ Hyposthenuria or isosthenuria pitressin resistant	Alimentary losses (172 188) primary aldosteronism (41 69 76) renal tubular acidosis (139) nephrotic syndrome treated with cation exchange resins (205) Lignac Fanconi syndrome (see Table 1) Fanconi syndrome in adult (see Fig 6) experimental depletion in rat (104 146) and probably in dog (151 152 199)
Impaired p aminohippurate extraction and excretion	Alimentary losses (172 188)



PLATE 1—Vacuolar nephropathy of potassium depletion in male patient with malignant hypertension rendered fatally deficient in potassium by therapy with cation exchange resins ( $\times 320$ ) Appearance is identical with that of case of cystinosis reported by Gatzimos *et al* (94)



great an urinary volume. In contrast a patient with hyperaldosteronism studied in this laboratory by Wrong (227) excreted daily up to 45 litres of urine with an osmolarity between 180 and 210 mOsm per litre after deprivation of water or administration of vasopressin he was able to produce urine with an osmolarity of 310 mOsm per litre at a rate of about 1.2 ml per minute (equivalent to less than 2 litres daily). Were this degree of limitation of osmolar concentration alone responsible for the polyuria one would not expect the urinary volume to exceed 2 to 3 litres daily. This is a fascinating aspect of potassium deficiency to which more attention should be directed. It must be borne in mind that some symptoms of primary aldosteronism which we tend to ascribe to potassium deficiency may prove to be due to the abnormal production of aldosterone itself.

The pertinence of the last remark is evident on considering the mechanisms of defective urinary acidification in simple potassium deficiency and in primary aldosteronism. In a study of experimental potassium depletion Clarke and co workers (37) observed the response of the urinary pH to the administration of ammonium chloride. Subjects who were previously able to produce a minimal pH of 4.5 could not achieve values much lower than pH 5.4 when their potassium deficiency was 300 mEq. This constitutes a considerable reduction of the tubular (presumably distal) capacity to establish a gradient of hydrogen ion between the plasma and the urine and it accounts for the low urinary output of titratable acid in potassium deficiency. Defective acidification of this degree has been observed in potassium deficiency associated with various experimental and clinical states (Table 4). Several patients with hyperaldosteronism have shown a minimal urinary pH close to 6.5 after stimulation with ammonium chloride (46, 69, 75, 145, 227). It has been natural to ascribe the renal defect to the associated potassium depletion of this disease. It seems however that this assumption is unwarranted. In some patients it has proved possible to replenish body potassium without restoring a normal capacity for urinary acidification (69, 145) after removal of the aldosterone secreting tissue; this function was regained without change in the external potassium balance (69, 145, 227). It would thus appear possible that the more severe impairment of acidification in primary aldosteronism is due to aldosterone itself rather than to potassium deficiency. It may be assumed that aldosterone influences the cation exchange mechanism whereby sodium ion is reabsorbed in exchange for  $K^+$  or  $H^+$  secreted by



PLATE 1—Vacuolar nephropathy of potassium depletion in male patient with malignant hypertension rendered fatally deficient in potassium by therapy with cation exchange resins ( $\times 320$ ) Appearance is identical with that of case of cystinosis reported by Gatzimos *et al* (94)



the tubules (16) by facilitating the tubular secretion of potassium ion, it may inhibit the secretion of hydrogen ion and so prevent urinary acidification. This action of aldosterone may also account for the fact that patients with primary aldosteronism continue to excrete potassium despite established potassium depletion. In simple potassium deficiency urinary potassium excretion is minimal, and stimuli which normally promote its excretion become relatively ineffective (37-76).

The three renal tubular functions—excretion of PAH, establishment of a hydrogen ion gradient, and osmotic concentration of the urine—which are pathologically defective in potassium deficiency all necessitate the expenditure of energy by the tubular cells. We would agree with the suggestion (146) that impaired formation of phosphate bond energy by the potassium-deficient cells (see references in 139-169) may account for the tubular defects. The same factor could account for the impaired conservation of sodium chloride observed in 2 patients (139-206) and it is to be expected that other tubular defects will be found if assiduously sought. What is the significance of the structural changes developing in the renal tubules with potassium depletion? These will not be discussed in detail as many descriptions have been published of the lesions occurring in animals (84-85, 146-187, 199-200) and man (119-131, 164-172). They include granular hydropic vacuolar and desquamative lesions of the convoluted tubules and granular degeneration, atrophy and dilatation of the distal and collecting tubules. An example of the typical changes is shown in Plate 1. Some patients with potassium deficiency show no structural lesions in the tubules. It seems unlikely that the structural changes are the cause of the accompanying functional defects. There is evidence that the continued provision of phosphate bond energy is necessary to preserve the structural integrity of cells: the functional and structural changes of potassium deficiency are probably parallel, rather than consecutive and dependent, effects.)

It remains to be determined whether a severe and prolonged potassium deficiency can result in permanent renal changes. It seems likely that it can (205) but conclusive evidence is lacking. Several investigators have suggested that a potassium deficiency may predispose to the development of pyelonephritis (69-88, 146). This suggestion based partly on findings in a small number of patients with primary aldosteronism should be treated with caution. Pyelonephritis is the commonest of the chronic renal diseases: there is some evidence to suggest that

certain patterns of renal disease can produce an apparently irreversible secondary hyperaldosteronism (206 227) Primary renal disease is a prominent feature among the causes of potassium depletion (Table 4) and the latter may then be responsible for the production of additional renal changes (139 205) The interrelations between renal disease potassium deficiency, and primary and secondary adrenocortical hyperfunction are intricate and manifold some aspects of the problem are discussed elsewhere (209).

## REFERENCES

- 1 Albright F and Reifenstein E C Jr *The Parathyroid Glands and Metabolic Bone Disease* (Baltimore: Williams & Wilkins Company 1943)
- 2 Albright F Butler A M and Bloomberg E Rickets resistant to vitamin D therapy *Am J Dis Child* 54 529 1937
- 3 Albright F *et al* Osteomalacia and late rickets the various etiologies met in the United States *Medicine* 25 399 1946
- 4 Anderson H M and Mudge G H Effect of potassium on intracellular bicarbonate in slices of kidney cortex *J Clin Invest* 34 1691 1955
- 5 Anderson I A Miller A and Kenny A P Osteomalacia and renal glycosuria in adults metabolic investigation of case with particular reference to its relation to Fanconi syndrome and to treatment *Quart J Med* 21 33 1952
- 6 Anderson J Method for estimating  $T_m$  for phosphate in man *J Physiol* 130 268 1955
- 7 Ayer J L Schiess W A and Pitts R F Independence of phosphate reabsorption and glomerular filtration in dog *Am J Physiol* 151 168 1947
- 8 Baar H S and Bickel H Morbid anatomy histology and pathogenesis of Lignac Fanconi disease *Acta paediat* 42 Supp 90 1952
- 9 Baines G H Barclay J A and Cooke W T Nephrocalcinosis associated with hyperchloraemia and low plasma bicarbonate *Quart J Med* 54 113 1945
- 10 Bakwin H Bodansky O and Schorr R Refractory rickets *Am J Dis Child* 59 560 1940
- 11 Barclay J A Cooke W T and Kenney R A Concept of renal thresholds *Acta med scandinav* 128 578 1947
- 12 Baron D N *et al* Hereditary pellagra like skin rash with temporary cerebellar ataxia constant renal amino aciduria and other bizarre biochemical features *Lancet* 2 421 1956
- 13 Bearn A G Genetic and biochemical aspects of Wilson's disease *Am J Med* 15 442 1953
- 14 Bearn A G and Kunkel H G Abnormalities of copper metabolism in Wilson's disease and their relationship to the aminoaciduria *J Clin Invest* 33 400 1954
- 14a Bearn A G Yu T F and Cutman A B Renal function in Wilson's disease *J Clin Invest* 36 1107 1957
- 15 Bell E T *Renal Diseases* (London: Henry Kimpton 1946)
- 16 Berliner R W Kennedy T J Jr and Orloff J Relationship between acidification of urine and potassium metabolism effect of carbonic an

- hydrase inhibition on potassium excretion *Am J Med* 11 274 1951
- 17 Bickel H Die Entwicklung der biochemischen Läsion bei der Lignac Fanconischen Krankheit *Helvet paediat. acta* 10 259 1955
  - 18 Bickel H and Harris H Genetics of Lignac Fanconi disease *Acta paediat* 42 Supp 90 1952
  - 19 Bickel H and Hickmans E M Some biochemical aspects of Lignac Fanconi disease *Acta paediat* 42 Supp 90 1952
  - 20 Bickel H and Souchon F *Die Papierchromatographie in der Kinderheilkunde* (Stuttgart Ferdinand Enke 1955)
  - 21 Bickel H and Thursby Pelham D C Hyperamino aciduria in Lignac Fanconi disease in galactosaemia and in an obscure syndrome *Arch Dis Childhood* 29 224 1954
  - 22 Bickel H *et al* Clinical description factual analysis prognosis and treatment of Lignac Fanconi disease *Acta paediat Supp* 90 1952
  - 23 Black D A K and Emery E W Tubular secretion of potassium *Brit M Bull* 13 7 1957
  - 24 Black D A K and Milne M D Experimental potassium depletion in man *Clin Sc* 11 397 1952
  - 25 Blackman S S Intracellular inclusion bodies in kidney and liver caused by lead poisoning *Johns Hopkins Hosp Bull* 58 384 1936
  - 26 Blainey J D High protein diets in treatment of nephrotic syndrome *Clin Sc* 13 567 1954
  - 27 Blainey J D Personal communication
  - 28 Bradley S E Disorders of renal tubular function *Am J Med* 20 457 1956
  - 29 Bradley S E Nickel J F and Leifer E Distribution of nephron function in man *Tr A Am Physicians* 65 147 1952
  - 30 Bradley S E *et al* Renal function in renal disease *Am J Med* 9 100 1950
  - 31 Brakow A Renal hypertrophy and polydipsia in potassium depleted rats *Am J Physiol* 172 233 1952
  - 32 Broch O J Low potassium alkalosis with acid urine in ulcerative colitis *Scandinav J Clin & Lab Invest* 2 113 1950
  - 33 Carter C and Simpkins M "Carrier state in nephrogenic diabetes insipidus" *Lancet* 2 1069 1956
  - 34 Chalmers T C Iber F L and Uzman L L Hepatolenticular degeneration (Wilson's disease) as form of idiopathic cirrhosis *New England J Med* 256 235 1957
  - 35 Chambers E L *et al* Tests for hyperparathyroidism tubular reabsorption of phosphate phosphate deprivation and calcium infusion *J Clin Endocrinol* 16 1507 1956
  - 36 Chisolm J J *et al* Amino aciduria hypophosphatemia and rickets in lead poisoning A M A *Am J Dis Child* 89 159 1955
  - 37 Clarke E *et al* Acidosis in experimental electrolyte depletion *Clin Sc* 14 421 1955
  - 38 Clarkson T W and Kench J E Urinary excretion of amino acids by men absorbing heavy metals *Biochem J* 62 361 1956
  - 39 Clay R D Darmady E M and Hawkins M Nature of the renal lesion in Fanconi syndrome *J Path & Bact* 65 551 1953
  - 40 Cohen S I *et al* Polyuria in hyperparathyroidism, *Quart J Med* n s 26 423 1957
  - 41 Conn J W Primary aldosteronism a new clinical syndrome *J Lab & Clin Med* 45 3 661 1955

- 42 Cooke R E *et al* Extrarenal correction of alkalosis associated with potassium deficiency *J Clin Invest* 31 798 1952
- 43 Cooke R E *et al* Role of potassium in prevention of alkalosis *Am J Med* 17 180 1954
- 44 Cooke W T *et al* Osteoporosis associated with low serum phosphorus and renal glycosuria *Arch Int Med* 60 147 1947
- 45 Cooper A. M. *et al* Investigation of the aminoaciduria in Wilson's disease (hepatolenticular degeneration) Demonstration of defect of renal function *J Clin Invest* 29 265 1950
- 46 Corcoran A C Dustan H P and Page J H Renal function in primary aldosteronism *J Clin Invest* 35 1357 1956
- 47 Crawford J D *et al* Parathyroid glands and phosphorus homeostasis *J Clin Invest* 29 1448 1950
- 48 Crumpler H R *et al*  $\beta$  Aminoisobutyric acid ( $\alpha$  methyl  $\beta$  alanine)—new amino acid obtained from human urine *Nature* 167 307 1951
- 49 Davies B M A and Yudkin J Studies in biochemical adaptation organs of urinary ammonia as indicated by effect of chronic acidosis and alkalosis on some renal enzymes in rat *Biochem J* 52 407 1952
- 50 Davies D R Dent C E and Willcox Hyperparathyroidism and steatorrhoea *Brit M J* 2 1133 1946 1956
- 51 Davies H E F Jepson R P and Black D A K Some metabolic sequelae of gastric surgery in patients with and without pyloric stenosis *Clin Sc* 15 61 1956
- 52 Darmady E M Microdissection of the nephron in disease *Brit M Bull* 13 21 1957
- 53 Dean R F A and McCance R A Phosphate clearance in infants and adults *J Physiol* 107 182 1948
- 54 Dent C E Detection of amino acids in urine and other fluids *Lancet* 2 637 1916
- 55 Dent C E Amino aciduria in Fanconi syndrome a study making extensive use of techniques based on paper partition chromatography *Biochem J* 4 240 1947
- 56 Dent C E Rickets and osteomalacia from renal tubule defects *J Bone & Joint Surg* 34 B 266 1952
- 57 Dent C E Chromatography in the Study of Amino Acid Metabolism in *Lectures on the Scientific Basis of Medicine* 1952-53 (London Athlone Press 1954) Vol 2 pp 213-234
- 58 Dent C E Renal amino acidurias *Exper Med & Surg* 12 229 1954
- 59 Dent C E and Harris H Genetics of cystinuria *Ann Eugenics* 16 60 1951
- 60 Dent C E and Harris H Hereditary forms of rickets and osteomalacia *J Bone & Joint Surg* 38 B 204 1956
- 61 Dent C E and Rose G A Amino acid metabolism in cystinuria *Quart J Med* 20 205 1951
- 62 Dent C E and Senior B Studies on treatment of cystinuria *Brit J Urol* 27 317 1955
- 63 Dent C E Senior B and Walshe J M Pathogenesis of cystinuria polarographic studies of metabolism of sulphur containing amino acids *J Clin Invest* 33 1216 1954
- 64 Denton D A *et al* Renal Regulation of Extracellular Fluid II Renal Physiology in Electrolyte Subtraction *Acta med scandinav Supp* 261 1951
- 65 Dixon T F Discussion of Nordin and Fraser (1958) p 232

- 66 Dowdle E Jackson W P U and Hoffenberg R. Renal tubular activity  
Lancet 2 465 1956
- 67 Drablos A de Toni Fanconi syndrome with cystinosis Acta paediat 40 438  
1951
- 68 Dustin J P Moore S and Bigwood E J Chromatographic studies on  
excretion of amino acids in early infancy Metabolism 4 75 1955
- 69 Eales L and Linder G C Primary aldosteronism Quart J Med 25 539  
1956
- 70 Earle D P *et al* Low potassium syndrome due to defective renal tubular  
mechanisms for handling potassium Am J Med 11 283 1951
- 71 Edwards J G Renal tubule (nephron) as affected by mercury Am J  
Path 18 1011 1942
- 72 Emerson K Jr and Beckman W W Calcium metabolism in nephrosis  
description of abnormality in calcium metabolism in children with  
nephrosis J Clin Invest 24 564 1945
- 73 Emslie Smith D *et al* Amino aciduria in acute tubular necrosis Clin Sc  
15 171 1956
- 74 Engle R L and Wallis L A Multiple myeloma and adult Fanconi syn-  
drome report of case with crystal like deposits in tumour cells and in  
epithelial cells of kidney Am J Med 22 5 1957
- 75 Evans B M and Milne M D Potassium losing nephritis presenting as  
case of periodic paralysis Brit. M J 2 1067 1954
- 76 Evans B M MacIntyre I Macpherson C R and Milne M D Alka-  
losis in sodium and potassium depletion (with especial reference to or-  
ganic acid excretion) Clin Sc 16 53 1957
- 77 Evered D F Excretion of amino acids by the human quantitative study  
with ion exchange resins Biochem J 62 416 1956
- 78 Fanconi G Der fruhinfantile nephrotisch glykosurische Zwergwuchs mit  
hypophosphatamischer Rachitis Jahrb Kinderh. 147 299 1936
- 79 Fanconi G Neue Aspekte der Nierenpathologie chronische Aminoacidurie  
Diabetes salinus renalis "lower nephron nephrosis" Schweiz med  
Wchnschr 80 757 1950
- 80 Fanconi G Beitrage zur Nierenpathologie Acta paediat 40 409 1951
- 81 Fanconi G and Bickel H Die chronische Aminoacidurie (Aminosau-  
re diabetes oder nephrotisch glukosurischer Zwergwuchs) bei der Glyko-  
genose und der Cystinkrankheit, Helvet paediat. acta 4 359 1949
- 82 Fanconi, G and Girardet P Familiarer persistierender Phosphatdiabetes  
mit D vitamin resistenter Rachitis Helvet paediat acta 7 14 1952
- 83 Ferrebee J W *et al* Certain effects of desoxycorticosterone development  
of "diabetes insipidus" and replacement of muscle potassium by sodium in  
normal dogs Am. J Physiol 135 230 1941
- 84 Follis R H *The Pathology of Nutritional Disease Physiological and  
Morphological Changes Which Result From Deficiencies of the Essential  
Element Amino Acids Vitamins and Fatty Acids* (Springfield Ill.  
Charles C Thomas Publisher 1948)
- 85 Follis R H Orent Keles E and McCollum E V Production of cardiac  
and renal lesions in rats by diets extremely deficient in potassium Am  
J Path. 18 29 1942
- 86 Fourman P Depletion of potassium induced in man with an exchange  
resin, Clin Sc 13 93 1954
- 87 Fourman, P and Robinson J R Urinary excretion of citrate during  
potassium deficiency Lancet 2 656 1953
- 88 Fourman P McCance R A and Parker R A. Chronic renal disease in



- rats following temporary deficiency of potassium *Brit J Exper Path.* 37 40 1956
- 89 Fowler D I Harris H and Warren F L Plasma cystine levels in cystinuria *Lancet* 1 514 1952
  - 90 Foye L V and Feichtmeir T V Adrenal cortical carcinoma producing solely mineralocorticoid effect *Am J Med* 19 966 1955
  - 91 Freeman S and Dunskey I Resistant rickets *Am J Dis Child* 79 409 1950
  - 92 Freudenberg E Cystinosis Cystine disease (Lignac's disease) in Children in *Advances in Pediatrics* (Chicago The Year Book Publishers Inc 1949) Vol 4 pp 265-292
  - 93 Gardner L I MacLachlan E A and Berman H Effect of potassium deficiency on carbon dioxide cation and phosphate content of muscle *J Gen Physiol* 36 153 1952
  - 94 Gatzert C D Schulz D M and Neuman R L Cystinosis (Lignac-Fanconi disease) *Am J Path* 31 701 1955
  - 95 Goettsch E and Mason H H Glycosuria in lead poisoning report of a case and study of pathogenesis *Am J Dis Child* 59 118 1940
  - 96 Harris H *Genetic Aspects of Tubular Function* in Winston F R ed *Modern Views on the Secretion of Urine* (London J & A Churchill 1956)
  - 97 Harris H and Robson E B Variation in homozygous cystinuria *Acta genet* 5 381 1955
  - 98 Harris H and Warren F L Quantitative studies on urinary cystine in patients with cystine stone formation and their relatives *Ann Eugenics* 18 125 1953
  - 99 Harris H et al Pattern of amino acid excretion in cystinuria *Ann Human Genet* 20 57 1955
  - 100 Harrison H E and Harrison H C Renal excretion of inorganic phosphate in relation to action of vitamin D and parathyroid hormone *J Clin Invest* 20 47 1941
  - 101 Hiatt H H and Thompson D D Effects of parathyroid extract on renal function *J Clin Invest* 30 557 1955
  - 102 Hiltemann H Kublencordt F and Wenderoth H Generalisierte Knochenkrankung mit Funktionsstörungen im Tubulussystem der Niere *Deutsche Arch Klin Med* 199 538 1952
  - 103 Hogben C A M and Bollman J L Renal reabsorption of phosphate Normal and hypoparathyroidectomized dog *Am J Physiol* 164 670 1951
  - 104 Hollander W Jr et al Renal concentrating defect in potassium depleted rats *J Clin Invest* 35 713 1956
  - 105 Holzel A and Komrower G M Study of genetics of galactosaemia *Arch Dis Childhood* 30 155 1955
  - 106 Holzel A Komrower G M and Schwarz V Galactosemia *Am J Med* 22 703 1957
  - 107 Holzel A Komrower G M and Wilson V K Amino aciduria in galactosaemia *Brit. M J* 1 191 1952
  - 107a Hooft C and Vermassen A Syndrome de De Toni Dibré Fanconi chez un enfant atteint de néphrose lipidique *Ann paediat* 190 1 1958
  - 108 Hottinger A Zur Cystindialthese *Ann paediat* 169 272, 1947
  - 109 Jacobellis M Muntwyler C and Griffin G E Enzyme concentration changes in kidney of protein and/or potassium-deficient rats *Am J Physiol* 176 477 1954

- 110 Imperato C. Indurizzi attuali nella terapia della sindrome nefrosica del bambino *Lattante* 24 9 1953
- 111 Jackson, W P U., and Lander G C Innate functional defects of renal tubules with particular reference to Fanconi syndrome *Quart. J. Med.* 22 133 1953
- 112 Jackson W P U *et al* Syndrome of steatorrhea pseudohypoparathyroidism and amenorrhea observations on calcium infusion test, and effect of probenecid on calcium and phosphorus metabolism *J Clin. Endocrinol.* 16 1043 1956
- 113 Jonxis J H P Amino-aciduria and rickets *Helvet paediat. acta* 10 245 1955
- 114 Kajdi, L. Comparison of effects of vitamin D and citrates on mineral metabolism in late rickets *Am J Dis Child* 68 352, 1944
- 115 Kennedy T J Winkley J H and Dunning M F Gastric alkalosis with hypokalemia, *Am J Med* 6 790 1949
- 116 Kjerulf Jensen K. Krarup N B., and Warming Larsen, A Persistent hypokalaemia requiring constant potassium therapy *Lancet* 1 372 1951
- 117 Kleeman C R and Cooke R E Acute effects of parathyroid hormone on metabolism of endogenous phosphate *J Lab & Clin Med.* 38 112 1951
- 118 Komrower G M *et al.* Clinical and biochemical study of galactosaemia *Arch. Dis Childhood* 31 254 1956
- 119 Kulka J P Pearson C M and Robbins S L. Distinctive vacuolar nephropathy associated with intestinal disease *Am J Path* 26 349 1950
- 120 Kyle L H and Canary J J Renal response to ammonium chloride in glycosuric osteomalacia *J Clin Endocrinol.* 16 599 1956
- 121 Kyle L H Meroney W H. and Freeman M E Study of mechanism of bone disease in hypophosphatemic glycosuric osteomalacia *J Clin. Endocrinol* 14 365 1954
- 122 Lafitte A and Gross A Les lésions osseuses de l'intoxication chronique par le cadmium aspects radiologiques à type de syndrome de Milkman, *Presse med* 50 399 1942
- 123 Lambert, P P A Study of the Mechanism by which Toxic Tubular Damage Changes the Renal Threshold for Glucose in Lewis A A G and Wolstenholme G E W eds *The kidney* (Boston Little Brown & Co 1954 London J & A. Churchill, 1954) pp 79-95
- 124 Lambert, P P and de Braucourt, C H Syndrome de Fanconi un cas chez l'adulte *Acta clin belg* 6 13 1951
- 125 Lambert, P P van Kessel E. and Leplat, C Etude sur l'élimination des phosphates inorganiques chez l'homme *Acta med scandinav* 128 386 1947
- 126 Lievre J A. *et al* Le diabète renal phospho-glucidique (ostéoporose avec diabète renal chez l'adulte *Bull et mém Soc med. Hôp Paris* 64 769 1948
- 127 Lander G C and Vadas D G M Calcium and phosphorus metabolism in late rickets *Lancet* 2 1124 1931
- 128 Liu S H and Chu, H I Studies of calcium and phosphorus metabolism with special reference to pathogenesis and effects of dihydrotachysterol (A T 10) and iron, *Medicine* 22 103 1943
- 129 Longson, D *et al* Handling of phosphate by human kidney at high plasma concentrations *J Physiol.* 131 555 1956
- 130 Lowe C U Terrey M and MacLachlan, E A Organic aciduria decreased renal ammonia production hydrophthalmos and mental retardation A clinical entity *A. M. A. Am J Dis Child* 83 164 1952.
- 131 Luft, R. Ringertz, N and Sjogren B Two cases of cryptogenic hypokalaemia

- ma with pathological anatomical findings *Acta endocrinol* 7 196 1951
- 132 McCance R A Osteomalacia with Looser's nodes (Milkman's syndrome) due to raised resistance to vitamin D acquired about the age of 15 years *Quart J Med* 16 33 1947
- 133 MacNider W de B Review of acute experimental nephritis *Physiol Rev* 4 595 1924
- 134 McCune D J Mason H H and Clarke H T Intractable hypophosphatemic rickets with renal glycosuria and acidosis (Fanconi syndrome) report of case in which increased urinary organic acids were detected and identified with review of literature *Am J Dis Child* 65 81 1943
- 135 McGeown M G Normal standards of renal phosphate clearance and observations on calculus patients *Clin Sc* 16 297 1957
- 136 McManus J F A *Medical Diseases of the Kidney* (London Henry Kimpton 1950)
- 137 Macpherson C R and Pearse A G E Histochemical changes in potassium depleted kidney *Brit M Bull* 13 19 1957
- 138 Mader I J and Iseri L T Spontaneous hypopotassemia hypomagnesemia alkalosis and tetany due to hypersecretion of corticosterone like mineralo corticoid *Am J Med* 19 976 1955
- 139 Mahler R F and Stanbury S W Potassium losing renal disease *Quart J Med* 25 21 1956
- 140 Marsden H B and Wilson V K Lead poisoning in children correlation of clinical and pathological findings *Brit M J* 1 324 1955
- 141 Matthews W B Absorption and excretion of radiocopper in hepato lenticular degeneration (Wilson's disease) *J Neurol Neurosurg & Psychiat* 17 242 1954
- 142 Matthews W B Milne M D and Bell M Metabolic disorder in hepato lenticular degeneration *Quart J Med* 21 425 1952
- 142a Mees E J D Disturbed water reabsorption by renal tubules in two patients with hypercalcaemia *Acta med scandinav* 157 189 1957
- 143 Michie A J Effect of Parathyroid Hormone on Renal Excretion of Phosphate in *Symposium on Calcium and Phosphorus Metabolism* New York 1952 (Columbus Ohio M & R Laboratories 1952) Report of the Fourth M & R Pediatric Research Conference
- 144 Milne M D Observations on action of parathyroid hormone *Clin Sc* 10 471 1951
- 145 Milne M D Muehrcke R C and Aird I Primary aldosteronism *Quart. J Med n s* 26 317 1957
- 146 Milne M D Muehrcke R C and Heard F E Potassium deficiency and the kidney *Brit M Bull* 13 15 1957
- 147 Milne M D Stanbury S W and Thomson A E Observations on Fanconi syndrome and renal hyperchloraemic acidosis in adult, *Quart J Med* 21 61 1952
- 148 Mills J N and Stanbury S W Reciprocal relationship between K and H excretion in diurnal excretory rhythm in man *Clin Sc* 13 177 1954
- 149 Mills J N and Stanbury S W Rhythmic diurnal variations in behaviour of human renal tubule *Acta med scandinav Supp* 307 95 1955
- 150 Moore S and Stein W H Chromatography of amino acids on sulfonated polystyrene resins *J Biol Chem* 192 663 1951
- 151 Mudge G M and Hardin B Response to mercurial diuretics during alkalosis Comparison of acute metabolic and chronic hypokalemic alkalosis in dog *J Clin Invest* 35 155 1956

- 152 Mulinos M G Spingarn C L and Lojkin M E Diabetes insipidus like condition produced by small doses of desoxycorticosterone acetate in dogs *Am. J Physiol.* 135 102 1941
- 153 Muntwyler E and Griffin G E Creatinine clearance in normal and potassium-deficient rats *Am J Physiol* 173 145 1953
- 154 Myerson R M and Pastor B H Fanconi syndrome and its clinical variants *Am J M Sc* 228 378 1954
- 155 Nassim J R Saville P D and Mulligan L Effect of stilboestrol on urinary phosphate excretion *Clin Sc* 15 367 1956
- 156 Nicaud P *et al* Les lésions osseuses de l'intoxication chronique par le cadmium aspects radiologiques à type de syndrome de Milkman efficacité du traitement calcique et vitaminique *Bull et mem Soc med hôp Paris* 58 204 1942
- 157 Nordin B E C and Fraser R Effect of intravenous calcium on phosphate excretion *Clin Sc* 13 477 1954
- 158 Nordin B E C and Fraser R The Indirect Assessment of Parathyroid Function in Wolstenholme G E W and O'Connor C M eds *Bone Structure and Metabolism* (Boston Little Brown & Company 1956 London J & A Churchill 1956) pp 222-232
- 159 Oliver J McDowell, M and Lee Y C Cellular mechanisms of protein metabolism in nephron structural aspects of proteinuria Tubular absorption droplet formation and disposal of proteins *J Exper Med* 99 589 1954
- 160 Oliver J McDowell, M and Tracy A Pathogenesis of acute renal failure associated with traumatic and toxic injury renal ischemia nephrotic damage and ischemic episode *J Clin Invest* 30 1305 1951
- 161 Oliver J *et al* Cellular mechanisms of protein metabolism in the nephron histochemical characteristics of protein absorption droplets *J Exper Med* 99 605 1954
- 162 Ollayos R W and Winkler A W Urinary excretion and serum concentration of inorganic phosphate in man *J Clin Invest* 22 147 1943
- 163 Orloff J Kennedy T J Jr and Berliner R W Effect of potassium in nephrectomized rats with hypokalemic alkalosis *J Clin Invest* 32 538 1953
- 164 Perkins J G Petersen A B and Ruley J A Renal and cardiac lesions in potassium deficiency due to chronic diarrhea *Am J Med* 8 115 1950
- 165 Peters J P and Van Slyke D D *Quantitative Clinical Chemistry* (2d ed Baltimore Williams & Wilkins Company 1946)
- 166 Pitts R F Renal excretion of acid *Fed Proc* 7 418 1948
- 167 Platt, R Renal failure *Lancet* 1 1239 1951
- 168 Platt, R. Structural and functional adaptation in renal failure *Brit M J* 1 1313 1372 1952
- 169 Pranker T A J Effect of intracellular K on red cell metabolism *Clin Sc* 14 633 1955
- 170 Pranker T A J Communication to the Medical Research Society London (unpublished)
- 171 Protein metabolism in nephron *Lancet* 2 125 1954
- 172 Relman, A S and Schwartz W B Nephropathy of potassium depletion clinical and pathological entity *New England J Med* 255 195 1956
- 173 Reubi F C Glucose Titration in Renal Glycosuria in Lewis A. A G and Wolstenholme G E W eds *The Kidney* (Boston Little Brown & Company 1954 London J & A Churchill, 1954) pp 96-106
- 174 Richmond J B *et al* Renal clearance of endogenous phosphate in infants and children *Proc Soc Exper Biol. & Med* 77 83 1951

- 175 Roberts A E *et al* Effects of potassium on renal tubular reabsorption of bicarbonate *J Clin Invest* 34 666 1955
- 176 Robertson B R Harris R C and McCune D J Refractory rickets mechanism of therapeutic action of calciferol *Am J Dis Child* 64 948 1942
- 177 Robinson H W and Nelson W E Phosphorus clearances in children with vitamin D resistant rickets *Am J Dis Child* 69 323 1945
- 178 Robson E B and Rose G A Effect of intravenous lysine on renal clearances of cystine arginine and ornithine in normal subjects in patients with cystinuria and Fanconi syndrome and in their relatives *Clin Sc* 16 75 1957
- 179 Roussak N J and Oleesky S Water losing nephritis a syndrome simulating diabetes insipidus *Quart J Med* 23 147 1954
- 180 Rupp W and Swoboda W Untersuchungen des PO Stoffwechsels bei vitamin D resistenter Rachitis (Phosphat-diabetes) I *Helvet paediat. acta* 9 249 1954
- 181 Rupp W and Swoboda W Untersuchungen des PO Stoffwechsels bei vitamin D resistenter Rachitis ("Phosphat diabetes") II *Helvet paediat. acta* 10 135 1955
- 182 Salassa R M Ulrich J A and Hayles A B Observations on metabolic effects of vitamin D in Fanconi's syndrome *Proc Staff Meet Mayo Clin.* 29 214 1954
- 183 Saville P D *et al* Fanconi syndrome metabolic studies on treatment. *J Bone & Joint Surg* 37 B 529 1955
- 184 Saville P D *et al* Effect of A T 10 on calcium and phosphorus metabolism in resistant rickets *Clin Sc* 14 489 1955
- 185 Scheinberg I H and Gitlin D Deficiency of ceruloplasmin in patients with hepatolenticular degeneration *Science* 116 484 1952
- 186 Schiess W A *et al* Renal regulation of acid base balance in man factors affecting excretion of titratable acid by normal human subject *J Clin Invest.* 27 57 1948
- 187 Schrader G A Frickett C O and Salmon W D Symptomatology and pathology of potassium and magnesium deficiencies in rat *J Nutrition* 14 85 1937
- 188 Schwartz W B and Relman A S Metabolic and renal studies in chronic potassium depletion resulting from overuse of laxatives *J Clin Invest* 32 258 1953
- 189 Schwarz V *et al* Some disturbances of erythrocyte metabolism in galactosaemia *Biochem J* 62 34 1956
- 190 Short I A Personal communication
- 191 Singer M Fanconi's syndrome treatment by massive dosage of calciferol and two-stage osteotomy *J Bone & Joint Surg* 36-B 633 1954
- 192 Sirota J H and Hamerman D Renal function studies in adult subject with Fanconi syndrome *Am J Med* 16 138 1954
- 193 Sirota J H Baldwin D S and Villarreal H Diurnal variations of renal function in man *J Clin Invest* 29 187 1950
- 194 Smith H W *The Kidney Structure and Function in Health and Disease* (New York Oxford University Press 1951)
- 195 Smith H W *Principles of Renal Physiology* (New York Oxford University Press 1956)
- 196 Smith J C and Kench R E Personal communication
- 197 Smith, J C Kench R E and Laue R E Determination of cadmium in urine and observations on urinary cadmium and protein excretion in men exposed to cadmium oxide dust, *Biochem J* 61 698 1955

- 198 Smith S G and Lasater T E Diabetes insipidus like condition produced in dogs by potassium deficient diet, *Proc Soc Exper Biol & Med* 74 427 1950
- 199 Smith S G Black Schaffer B and Lasater T E Potassium deficiency syndrome in rat and dog description of muscle changes in potassium depleted dog *Arch Path* 49 185 1950
- 200 Spargo B Kidney changes in hypokalemic alkalosis in rat, *J Lab & Clin Med* 43 802 1954
- 201 Spencer A G and Franglen G T Gross amino aciduria following lysol burn *Lancet* 1 190 1952.
- 202 Stanbury S W Azotaemic renal osteodystrophy *Brit. M Bull* 13 57 1957
- 203 Stanbury S W Azotaemic renal osteodystrophy *Lancet* 1 253 1957
- 204 Stanbury S W Further observations on "Fanconi syndrome" of adult life In preparation
- 204a Stanbury S W Unpublished observations
- 205 Stanbury S W and Macaulay D Defects of renal tubular function in nephrotic syndrome observations on a nephrotic child with aminoaciduria, glycosuria polyuria tubular acidosis and potassium depletion *Quart. J Med* 26 7 1957
- 206 Stanbury S W and Mahler R F Renal salt wasting metabolic observations on chronic salt wasting renal disease "Quart J Med In press
- 207 Stanbury S W and Thomson A E Diurnal variations in electrolyte excretion *Clin Sc* 10 267 1951
- 208 Stanbury S W and Lumb G A. Refractory rickets and vitamin D resistant osteomalacia To be published
- 209 Stanbury S W Gowenlock, A H and Mahler R F Potassium Deficiency and Renal Disease in *An International Symposium on Aldosterone* (London J & A Churchill 1958)
- 210 Stern W H Excretion of amino acids in cystinuria *Proc Soc Exper Biol. & Med* 78 705 1951
- 211 Stern W H Bearn A G and Moore S Amino acid content of blood and urine in Wilson's disease *J Clin Invest* 33 410 1954
- 212 Stowers J M and Dent C E Studies on mechanism of Fanconi syndrome *Quart J Med* 16 275 1947
- 213 Taggart J V Disorders of renal tubular function *Am J Med* 20 448 1956
- 214 Taggart J V Silberman L and Trayner E M Influence of renal electrolyte composition on tubular excretion of *p* aminohippurate *Am J Physiol.* 173 345 1953
- 215 Tegelaers W H H and Tiddens H W Nephrotic glucosuric aminoaciduric dwarfism and electrolyte metabolism *Helvet paediat acta* 10 269 1955
- 215a Tobler A Prader A and Taillard W Die familiare vitamin D resistente Rachitis (Phosphat-diabetes) *Helvet paediat. acta* 11 209 1956
- 216 Uzman L L On relationship of urinary copper excretion to aminoaciduria in Wilson's disease (hepatolenticular degeneration) *Am J M Sc* 226 645 1953
- 217 Uzman L L and Denny Brown D Amino aciduria in hepatolenticular degeneration (Wilson's disease) *Am J M Sc* 215 599 1948
- 218 Uzman L L and Hood B Familial nature of amino aciduria of Wilson's disease (hepatolenticular degeneration) *Am J M Sc* 223 392 1952.
- 219 van Creveld S and Arons P Transitory renal osteoporosis with amino-aciduria and development of hypersensitivity to vitamin D *Ann paediat.* 173 299 1949
- 219a van Goidsenhoven G M T *et al* Effect of prolonged administration of

- large doses of sodium bicarbonate in man Clin Sc 13 383 1954
- 220 Warnock C G Hepatolenticular degeneration (Wilson's disease) Ulster M J 21 155 1952
- 221 Wilson V K Thomson M L and Dent C E Amino aciduria in lead poisoning case in childhood Lancet 2 66 1953
- 222 Winberg J *et al* Primary vitamin D refractory rickets report of two cases treated with high doses of vitamin D Acta paediat 43 347 1954
- 223 Wurz H Production of Hypertonic Urine by the Mammalian kidney in Lewis A A G and Wolstenholme G E W eds *The Kidney* (Boston Little Brown & Company 1954 London J & A Churchill 1954) pp 38-45
- 224 Wurz H The Location of Antidiuretic Action in the Mammalian kidney in Colston Research Society *The Neurohypophysis* (London Butterworths Scientific Publications 1957) pp 157-169 (Colston Papers No 8)
- 225 Woolf L I Paper chromatography Great Ormond St J 1 61 1951
- 226 Woolf L I and Giles H McC Urinary excretion of amino acids and sugar in nephrotic syndrome Acta paediat 45 489 1956
- 227 Wrong O M Renal potassium loss hypertension and unilateral renal disease To be published
- 228 Wrong O M and Davies H E F Excretion of acid in renal disease in preparation
- 229 Zetterstrom R and Winberg J Primary vitamin D refractory rickets metabolic studies during treatment with massive doses of vitamin D Acta paediat 44 45 1955
- 230 Zimdahl W T Hyman I and Cook D Metabolism of copper in hepatolenticular degeneration Neurology 3 589 1953

# Author Index

[Page numbers printed in italics indicate original contributions to this volume]

## A

Abernathy R. S. 73  
Ackroyd J. F. 158 166  
Adams D. 176  
Adams M. A. 166  
Addis T. 125 166  
Adlersberg D. 43  
Aggeler P. M. 166 177 178  
Ard I. 104 278  
Albright F. 81 86 94 96 101 103  
260 261 272  
Aldrich C. A. 183 201  
Aldrich R. A. 163 167  
Alexander B. 127 135 139 144 156  
157 158 160 162 167 170  
Alkjaersig N. 112 167 176  
Almerindo G. P. 202  
Alton H. G. 167  
Ambrus J. L. 76  
American Association for the Advance-  
ment of Science 227  
Amin, A. H. 227  
Anderson, D. 80  
Anderson, H. M. 272  
Anderson I. A. 272  
Anderson J. 255 272  
Anderson W. A. D. 101  
Andreassen, M. K. 133 167  
Angelopoulos B. 175  
Apt L. 38 43  
Archer W. H. 167  
Arends T. 172  
Arias I. M. 38  
Arkun S. N. 42  
Arnstein H. R. V. 38  
Aronovitch J. 40 43  
Arons P. 281  
Arons W. L. 101  
Asero B. 227

Ashby M. 73  
Ashton, N. 73  
Askanazy M. 101  
Astrup T. 113 167  
Atkins E. 73  
Atlas D. H. 101  
Atlas L. L. 73  
Avery R. C. 202  
Ayer J. L. 272

## B

Baar H. S. 272  
Bacos J. M. 73  
Badenoch J. 38 44  
Bailey K. 168  
Baues G. H. 272  
Baird I. M. 98 101  
Baker B. M. 101  
Baker M. 205  
Baker S. J. 38 42  
Baker S. L. 101  
Bakwin H. 272  
Balch H. H. 75  
Baldwin, D. S. 280  
Barclay J. A. 272  
Barnard C. 73  
Barnicot, N. A. 88 101  
Baron D. N. 272  
Barron, E. S. G. 73  
Barrow E. M. 171  
Bassett S. H. 99 102  
Bastrup-Madsen, P. 165 171  
Battle J. 160 171  
Bauer W. 101  
Beard, M. F. 38 43  
Bearn A. G. 272 281  
Beaumont, J. L. 167  
Beckman, W. W. 275  
Beeson, P. B. 74



Bein H J 78  
 Bell E T 192 201 272  
 Bell M 278  
 Bell W N 167  
 Benacerraf B 71 72 74 80  
 Bendien W M 125 167  
 Benditt E P 227  
 Benedek T C 51 74  
 Benjamin B 38  
 Bennett I L Jr 74 78  
 Bennis T 201  
 Berglund K. 64 70 74  
 Bergsagel D E 167  
 Bergstrand H 96 101  
 Berk L 38  
 Berliner R W 272 279  
 Berman H 276  
 Bernard J 167 168  
 Bernfeld P 168  
 Bertscher R W 38  
 Bertuccio M 164 179  
 Bethell E H 38  
 Bettelheim F R 168  
 Bevans M 201 204  
 Bickel H 238 239 240 241 246  
     247 260 272 273 275  
 Bidwell E 168 173  
 Bigelow F S 168 227  
 Biggs R 107 119 133 136 141  
     146 147 161 168 169 173  
 Bigwood E J 275  
 Billingham R E 74  
 Birch C LaF 124 131 132 168  
 Bjorkenheim G 39  
 Bjørneboe M 74 75  
 Black D A K 273 274  
 Black M A 101  
 Black, M M 80  
 Blackman, S C 273  
 Black Schaffer B 281  
 Blaney J D 273  
 Blans M M 178  
 Bloom W 101 103  
 Bloomberg E 272  
 Bodansky O 272  
 Boe J 95 104  
 Bogart R 173  
 Bogdonoff M D 101  
 Boger W P 39  
 Bollman J L 276  
 Booth C C 39

Borden, C W 74  
 Bordet J 112 168  
 Borges W H 162 168 170  
 Borrelli M S 229  
 Bottomley A C 179  
 Bowen H F 88 105  
 Boyer F 74  
 Bradfield A J 149 168  
 Bradley S E 273  
 Brannerd H 74  
 Brakow A 273  
 Brandberg L 41  
 Bratlund H 74  
 Braude A 189 201  
 Breckoff E 168  
 Briggs J D 40  
 Brill G 79  
 Brink, A J 168  
 Brinkhous K M 123 132 134 135  
     168 170 172 174 176 177  
 Broch O J 273  
 Brodie B B 227 228  
 Brody E A 11 39 44  
 Brooke M 74  
 Brown A 128 168  
 Browne J S L 74  
 Brun C 103  
 Brush B E 85 92 101  
 Buček A 168  
 Buchanan C D 105  
 Budtz Olsen O E 113 168  
 Bulkely W C M 74  
 Bull C M 84 103  
 Burkholder P R 39  
 Bush I E 74  
 Butler A M 272

## C

Caen J 168  
 Callender S T 16 39  
 Cameron D G 44  
 Campbell A C 229  
 Campbell D C 167  
 Campbell D H 203  
 Canary J J 277  
 Cargill W H 102  
 Carlsson A 95 102  
 Carnazzo S F 170  
 Carnes W H 102  
 Carroll R T 178  
 Carter C 273

- Case J 149 168  
 Castle W B 11 39 42  
 Catanzaro F J 201  
 Cavelti E S 201  
 Cavelti P A 201  
 Chalet, L 39  
 Chalmers T C 273  
 Chambers E L 85 92 102 273  
 Chang H 88 102  
 Chase W E 101  
 Chatterjea, J B 177  
 Chaudhuri S 39  
 Chedid L 74  
 Chevallier P 159 168 169  
 Chilcote M E 105  
 Chisolm J J 248 249 273  
 Chow B F 39 41  
 Choy D C 204  
 Christensen W R 101  
 Chu H I 277  
 Clarke E 270 273  
 Clarke H T 278  
 Clarkson T W 249 273  
 Clay R D 238 273  
 Coburn, A F 190 201  
 Cohen S 212 227  
 Cohen S I 273  
 Cohn E J 39  
 Colbert M J 43  
 Colopy J E 175  
 Commission on Acute Respiratory Diseases 201  
 Conley C L 39 43 125 169  
 Conn J W 273  
 Connor T B 103 105  
 Conroy E 205  
 Conway J P 123 175  
 Cook C 73  
 Cook D 282  
 Cooke A M 102  
 Cooke R E 274 277  
 Cooke W T 272 274  
 Coon R W 170  
 Cooper A M 250 274  
 Copeman W S C 74  
 Corbus H F 42  
 Corcoran A C 202 274  
 Cornell L L 74  
 Cornwell S 74  
 Cotler J 129 136 137 169  
 Cowles P B 76  
 Craddock, C G Jr 141 169 172  
 Crawford J C 92 102  
 Crawford, J D 274  
 Crawford R L 102  
 Crawford T 98 102  
 Crawford T B B 227  
 Crepea S B 74  
 Cretin A 89 102  
 Crockett C L Jr 160 169  
 Crosby W H 177  
 Cruickshank B 202  
 Crumpler H R 274  
 Culot Y 172  
 Cunliffe A C 205  
 Curtis R H 203
- D
- Dam H 177  
 Dameshek W 131 136 177  
 Damsch F 227  
 Darmady E M 273 274  
 Darte J M M 169  
 Daugherty G W 227  
 Davey W N 77  
 Davidson C S 128 129 137 140 169  
 Davidson L S P 40  
 Davies B M A 90 102 274  
 Davies D R 95 102 274  
 Davies H E F 233 274 282  
 Davis B D 40  
 Dean R F A 274  
 de Braucourt C H 277  
 Dees S C 164 171  
 de Nicola P 174  
 Denny F W Jr 52 74  
 Denny Brown D 250 281  
 den Ottolander G H 174  
 Denson, A W 177  
 Dent C E 87 90 102 234 235 236 237 260 274 281 282  
 Denton D A 274  
 De Palma A F 129 136 137 169  
 Desaulles P 75  
 DeShon H J 227  
 De Silva C C 169  
 de Vries A 167 169  
 Diamond L K 128 131 171  
 Didisheim P 169  
 Dingle J H 57 77 204  
 Dixon F J 205

Dixon T F 274  
 Donaldson G A 103  
 Doniach I 42  
 Dorfman R I 77  
 Doscherholmen A 40  
 Dougherty T F 75 76  
 Douglas A S 119 131 148 168 169  
 Douglas W W 75  
 Dowdle E 275  
 Drablos A 275  
 Drenick E J 40  
 Dreskin, O H 149 176  
 Duckert F 169  
 Duffy B J Jr 75  
 Duncan J G 102  
 Dunn F S 169  
 Dunning M F 277  
 Dunskey I 278  
 Dunstan H P 274  
 Duran Reynolds F 68 75  
 Dustin J P 275

## E

Eales L 275  
 Earle D B 182 202  
 Earle D P 275  
 Ebert R H 75  
 Ebert R V 75  
 Ecker E E 205  
 Edsall J R 75  
 Edwards J G 275  
 Ehrich W 202  
 Ehrich W E 192 202  
 Eisenberg H L 101  
 Eley R C 50 76  
 Ellsworth R 86 101 102  
 Elsbach P 75  
 Emerson K Jr 275  
 Emery B E 166 178  
 Emery E W 273  
 Emslie-Smith D 275  
 Engle R L 245 275  
 Epstein R D 170  
 Erdheim J 94 102  
 Erdman L A 103  
 Erdmann Ochlecker S 41  
 Erspamer V 208 213 226 227  
 Esplan D W 75  
 Estren S 11 39 40 43 41  
 Evans A S 75  
 Evans B M 275

Evans J R 16 39  
 Evered D F 234 237 275

## F

Fagraeus A 64 70 74  
 Fahey J L 157 169 178  
 Falkner S 227  
 Fanconi G 237 258 275  
 Fantl P 169  
 Farr L E 205  
 Favre Gilly J E 175  
 Fearnley M E 171  
 Feichtner T V 276  
 Fell C 169  
 Feng C T 104  
 Feng Y S L 78  
 Penninger L D 169  
 Ferguson J H 169 172  
 Ferrebee J W 275  
 Ferry J D 169  
 Feyrter F 227  
 Fiehrer A 168  
 Field R A 170  
 Falfus J 41  
 Finland M 45 70 75 77  
 Fischel E E 74 75 79 202  
 Fitzgerald P J 228  
 Flint A 11 40  
 Fluckinger P 169  
 Flynn J E 170  
 Foley E J 75  
 Follis R H 102 275  
 Fomo A 170  
 Foote F W Jr 203  
 Forbus W D 209 227  
 Ford J E 40  
 Forman C W 202  
 Fourman P 275  
 Fouts P 202  
 Fowler D I 276  
 Foy H 40  
 Foye L V 276  
 Francis A E 190 202  
 Franglen G T 281  
 Frankel G J 170  
 Franks R B 174  
 Fraser R 104 279  
 Fraser T R C 104  
 Freedberg A S 77  
 Freeman M E 277  
 Freeman S 276

Frei H 41  
 Frei M 174  
 Fresh, J W 172  
 Freudenberg E 276  
 Frick, P G 161 170  
 Frommeyer W B 140 170

## G

Gaberman, P 101  
 Gaddum J H 227  
 Gaffney G W 40  
 Gaillard P J 88 102  
 Gajdusek, 202  
 Galliard H 75  
 Ganley O H 75  
 Gardner L I 276  
 Garner E S 134 177  
 Gartland J J 173  
 Gasster M 40  
 Gatzimos C D 276  
 Gell P G H 75  
 Geller P 75  
 Gengou O 112 168  
 Germuth F G Jr 76 202  
 Gershenfeld L 76  
 Geschickter C F 208 228  
 Gilbertson, E 171  
 Giles H McC 282  
 Ginsberg V 41  
 Giordano A S 170  
 Girardet, P 258 275  
 Girdwood R H 28 40  
 Githin D 162 170 280  
 Gladstone J R 140 174  
 Glagov S 229  
 Glasden E S 43  
 Glass G B J 17 40  
 Glendenning M B 178  
 Gloor R 220 227  
 Gobel A J 219 227  
 Goettsch E 276  
 Gogdanski D F 229  
 Gold D 74  
 Goldfein S 171  
 Goldman R 99 102  
 Goldstein, M S 79  
 Goldstein R 144 156 167 170  
 Gonyea L M 161 170  
 Good, R A 76 170  
 Good T A 170  
 Goodale H D 104

Gordin, R 39  
 Gordon A H 90 102  
 Gordon, A S 78  
 Gordon L E 76  
 Gordon, P 76  
 Gosset A 208 211 227  
 Govaertz P 125 170  
 Gow R C 103  
 Gowenlock, A H 281  
 Graham J B 123 162 168 170 171  
 Graham R M 40  
 Grant H 73  
 Grata, A 125 170  
 Green A A 228  
 Greene A E 76  
 Greenspon S A 203  
 Griffeth H I 204  
 Griffin G E 276 279  
 Griggs R 170  
 Gross A 277  
 Grossowicz N 40 43  
 Guest M M 178  
 Guild W R 104  
 Gutman, A B 272

## H

Hackel D B 202  
 Hagen P S 40 161 170  
 Haggerty R J 50 76  
 Hagitte C 174  
 Hahn E O 76  
 Habne H J 76  
 Haeneed K A 227  
 Halberg F 73  
 Haldane J B S 122 170  
 Hall W H 74  
 Halsted J A 40 41 44  
 Ham A W 90 102  
 Ham T H 39  
 Hammerman D 280  
 Hamilton A 41  
 Hardin, B 278  
 Hardin, R A 202  
 Hardisty R M 162 170  
 Harris H 235 260 273 274 276  
 Harris J W 41  
 Harris R C 280  
 Harris T N 76  
 Harrison H C 276  
 Harrison H E 276  
 Hart E R. 228

Dixon T F 274  
 Donaldson C A 103  
 Doniach I 42  
 Dorfman R I 77  
 Doscherholmen A 40  
 Dougherty T F 75 76  
 Douglas A S 119 131 148 168 169  
 Douglas W W 75  
 Dowdle E 275  
 Drablos A 275  
 Drenick E J 40  
 Dreskin O H 149 176  
 Duckert F 169  
 Duffy B J Jr 75  
 Duncan J G 102  
 Dunn F S 169  
 Dunning M F 277  
 Dunsy I 276  
 Dunstan H P 274  
 Duran Reynolds F 68 75  
 Dustin J P 275

## E

Eales L 275  
 Earle D B 182 202  
 Earle D P 275  
 Ebert R H 75  
 Ebert R V 75  
 Ecker E E 205  
 Edsall J R 75  
 Edwards J G 275  
 Ehrich W 202  
 Ehrich W E 192 202  
 Eisenberg H L 101  
 Eley R C 50 76  
 Ellsworth R 86 101 102  
 Elsbach P 75  
 Emerson A Jr 275  
 Emery B E 169 178  
 Emery E W 273  
 Emshe Smith D 275  
 Engle R L 245 275  
 Epstein R D 170  
 Erdheim J 94 102  
 Erdman L A 103  
 Erdmann Oehlecker S 41  
 Erspamer V 208 213 226 227  
 Esplan D W 75  
 Estren S 11 39 40 43 44  
 Evans A S 75  
 Evans B M 275

Evans J R 16 39  
 Evered D F 234 237 275

## F

Fagraeus A 64 70 74  
 Fahey J L 157 169 178  
 Falkner S 227  
 Fanconi G 237 258 275  
 Fantl P 169  
 Farr L E 205  
 Favre-Gilly J E 175  
 Fearnley M E 171  
 Feichtmeier T V 276  
 Fell C 169  
 Feng C T 104  
 Feng Y S L 76  
 Fenninger L D 169  
 Ferguson J H 169 172  
 Ferrebee J W 275  
 Ferry J D 169  
 Feyrter F 227  
 Fiehrer A 168  
 Field R A 170  
 Filfus J 41  
 Finland M 45 70 75 77  
 Fischel E E 74 75 79 202  
 Fitzgerald P J 228  
 Flint A H 40  
 Fluckinger P 169  
 Flynn J E 170  
 Foley E J 75  
 Follos R H 102 275  
 Fonao A 170  
 Foote F W Jr 203  
 Forbus W D 209 227  
 Ford J E 40  
 Forman C W 202  
 Fourman P 275  
 Fouts P 202  
 Fowler D I 276  
 Foy H 40  
 Foye L V 276  
 Francis A E 190 202  
 Franglen C T 281  
 Frankel G J 170  
 Franks R B 174  
 Fraser R 104 279  
 Fraser T R C 104  
 Freedberg A S 77  
 Freeman M E 277  
 Freeman S 276

Jimenez-Casado M., 42  
 Johnson, J B., 139 140 171 172  
 Johnson, J R., 77  
 Johnson, S 76  
 Johnson, S A 127 171 176  
 Jones H. W., 172  
 Jones N W 228  
 Jonxis J H P., 277  
 Jordan, F L. J., 178  
 Jordan, W S 57 77  
 Josephson, A M 172  
 Jost, E L., 204  
 Jurgens J 172

## K

Kajdi, L. 277  
 Kaplan R. 201  
 Kark, R. M 78  
 Karlun R. 44  
 Kasbekar D K. 41  
 Kass E H 45 70 74, 75 77 78  
 Kass G H., 46 47 77  
 Kay C F., 202, 203  
 Kench, J E 249 273  
 Kench, R. E 249 280  
 Kendall E C 77  
 Kendrick, M I 70 77 78  
 Kennedy T J 277  
 Kennedy T J Jr 272 279  
 Kenney R A. 272  
 Kenny A P 272  
 Kessler W B 77  
 Key J A. 129 130 172  
 Khoobyarian, N 77  
 Kilbourne E D 77  
 Killough, J H 78  
 Kim M S 43  
 Kimball, D M 176  
 King B D 79  
 Kingsley C S 168 172  
 Kinney T D 202  
 Kinsell B G 177  
 Kit, S 73  
 Kjerulf Jensen, K. 277  
 Klayman, M J., 41  
 Kleeman C R 277  
 Klein, R. 103  
 Kleinman H 203  
 Klemola, E 50 77  
 Knowlton, A. I 79 80 203  
 Koch, F 172  
 Kodama, T 203

Koller F., 145 169 172  
 Komrower G M., 276 277  
 Kondi, A. 40  
 Kontz, S B., 77  
 Krantz, F W 105  
 Krakower C. A., 203  
 Krarup N B., 277  
 Krause R. M., 204  
 Krivit, W 161 170  
 Kroese W F S., 43  
 Krohn, P L. 74  
 Kruse I. 177  
 Krüsi, G 172  
 Kuhlencordt, F., 276  
 Kulka, J P., 277  
 Kunkel H G 272  
 Kurland, G S 77  
 Kuttner A. G 78  
 Kyle, L. H 92, 103 104 277

## L

Lafitte A 277  
 Lambert, P P., 103 252 277  
 Lanchantin, G F., 172  
 Landwehr G 127 139 167  
 Landy J A., 227  
 Lane, R. E 280  
 Lane, S 134 172  
 Lang F G 95 103  
 Langdell, R D 172  
 Langely L 44  
 Lapierre J., 75  
 Larnau M J 164 172, 177  
 Lasater T E 281  
 Lasch H G 112 172  
 Lavelle, J M., 172  
 Lawrence J S 140 141 169 172  
 Lawson, H A. 172  
 La Zerte G D 102  
 Lear A. A 41  
 Leatham J H 77  
 Lee Y C 279  
 Lees F 98 101  
 Leifer E 273  
 Lembeck F 213 228  
 Lemonde, P., 78  
 Lempert H 171  
 Lenman, J A N 40  
 Leplat C 103 277  
 Lepper M H 57 78  
 Lesh, J B 205  
 Levine P 138 172

Hartert H 114 170  
 Hartman J R 128 131 171  
 Hartmann R C 169  
 Hasson M W 204  
 Hawkins M 273  
 Hawn C V Z 202 205  
 Hay D R 227  
 Hayles A B 280  
 Heard B E 278  
 Hechter O 74 76  
 Heck F J 44  
 Hedinger C 220 227  
 Heidenhain R 207 227  
 Heilman D H 76  
 Heiman Hollander E 109  
 Heimark J J 227  
 Heindl S 171  
 Heinle R W 41 44  
 Heinrich H C 41  
 Heller J H 76  
 Heller Steinberg M 88 102  
 Henry E I 171  
 Heptinstall R H 202  
 Herbert F A 97 103  
 Herndon R F 98 103  
 Herrmann, W W 228  
 Herz, N 169  
 Herzog H L 76  
 Hewlett J 160 171  
 Heymann W 202 204  
 Hiatt H H 276  
 Hickmans E M 241 247 273  
 Hicks N D 171  
 Higinbotham R D 76  
 Higgins C M 103  
 Hill A C S 202  
 Hill J M 164 171  
 Hill R F 203  
 Hultemann H 276  
 Hinde I T 75  
 Hjort P 156 171  
 Hockenhull D J D 44  
 Hodgkin D C 41  
 Hoffenberg R 275  
 Hoffman, A 224 227  
 Hoffman I 171  
 Hogan, A G 173  
 Hogben C A M 276  
 Holburn R H 178  
 Hollander W Jr 276  
 Holten C 74  
 Holzel A 276

Honey G E 170  
 Honorato R 171  
 Hood B 250 281  
 Hooft, C 276  
 Hoorweg P G 174 178  
 Hopkins T R 87 103  
 Horder M H 171  
 Horrigan, D L 41  
 Horsfall F L Jr 77  
 Hottinger A 276  
 Houlie C 158 160 167 171  
 Howard J E 86 88 92 101 107  
 103 105  
 Howell D S 76  
 Hudson P 79  
 Humphrey J H 202  
 Humphreys E M 228  
 Huntley C L 164 171  
 Hussey C V 143 163 175  
 Hussey H H 176  
 Hutner S H 41  
 Hutt F B 170  
 Hyman I 282

## I

Iacobellis M 276  
 Iber F L 273  
 Imperato C 277  
 Ingalls T H 88 103  
 Ingbar S H 75 77  
 Ingle D J 76  
 Ingram G I C 151 164 171  
 Inverson P 103  
 Iserl L T 278  
 Israels M C C 143 171  
 Iversen T 165 171  
 Ivy A C 43

## J

Jackson W P U 275 277  
 Jacobs E 103  
 Jacox R F 171  
 Jacques L B 116 171  
 Jahn, J P 60 76  
 James P R 103  
 Janeway C A 202 205  
 Jansen L 41  
 Jasinski B 41  
 Jawetz E 54 75 77  
 Jenkins J S 171  
 Jepson, R P 274  
 Jum R T S 171

Jimenez Casado M 42  
 Johnson J B 139 140 171 172  
 Johnson, J R 77  
 Johnson, S 76  
 Johnson S A 127 171 176  
 Jones H W 172  
 Jones N W 228  
 Jonxis J H P 277  
 Jordan F L J 178  
 Jordan, W S 57 77  
 Josephson, A M 172  
 Jost E L 204  
 Jurgens J 172

## K

Kajdi L 277  
 Kaplan R 201  
 Kark, R M 78  
 Karlin R 44  
 Kasbekar D K 41  
 Kass E H 45 70 74 75 77 78  
 Kass G H 46 47 77  
 Kay C F 202 203  
 Kench J E 249 273  
 Kench R E 249 280  
 Kendall E C 77  
 Kendrick M I 70 77 78  
 Kennedy T J 277  
 Kennedy T J Jr 272 279  
 Kenney R A 272  
 Kenny A P 272  
 Kessler W B 77  
 Key J A 129 130 172  
 Khoobyaran N 77  
 Kilbourne E D 77  
 Killough, J H 78  
 Kim M S 43  
 Kimball D M 176  
 King B D 79  
 Kingsley C S 168 172  
 Kinney T D 202  
 Kinsell B G 177  
 Kit S 73  
 Kjerulf Jensen, K 277  
 Klayman M J 41  
 Kleeman C R 277  
 Klein, R 103  
 Kleinman H 203  
 Klemola E 50 77  
 Knowlton A I 79 80 203  
 Koch F 172  
 Kodama T 203

Koller F 145 169 172  
 Komrower G M 276 277  
 Kondo A 40  
 Koritz S B 77  
 Krautz F W 105  
 Krakower C A 203  
 Krarup N B 277  
 Krause R M 204  
 Krivit W 161 170  
 Kroese W F S 43  
 Krohn P L 74  
 Kruse I 177  
 Krusi G 172  
 Kuhlencordt F 278  
 Kulka J P 277  
 Kunkel H G 272  
 Kurland G S 77  
 Kuttner A G 78  
 Kyle L H 92 103 104 277

## L

Lafitte A 277  
 Lambert P P 103 252 277  
 Lanchantin G F 172  
 Landwehr G 127 139 167  
 Landy J A 227  
 Lane R E 280  
 Lane S 134 172  
 Lang F G 95 103  
 Langdell R D 172  
 Langely L 44  
 Lapiere J 75  
 Larnieu M J 164 172 177  
 Lasater T E 281  
 Lasch H C 112 172  
 Lavelle J M 172  
 Lawrence J S 140 141 169 172  
 Lawson H A 172  
 La Zerte G D 102  
 Lear A. A 41  
 Leatham J H 77  
 Lee Y C 279  
 Lees F 98 101  
 Leifer E 273  
 Lembeck F 213 228  
 Lemonde P 78  
 Lempert H 171  
 Lenman, J A N 40  
 Leplat, C 103 277  
 Lepper M H 57 78  
 Lesh J B 205  
 Levine P 138 172



- Levine R 79  
 Levitin H 78  
 Lewis D 208 228  
 Lewis J H 120 140 141 149 169  
     172 173  
 Lewis J L 78  
 Lewis M D 102  
 Li C H 78  
 Libby R L 44  
 Lichtman H 41  
 Lièvre J A 260 277  
 Linder G C 260 275 277  
 Lindquist B 95 102  
 Ling C T 41  
 Linneweh F 103  
 Lippman R W 203  
 Lipton M A 76  
 Lisker R 172  
 Little J A 44  
 Liu S H 103 277  
 Loeb E N 203  
 Lojkin M E 278  
 Longcope W T 203  
 Longson D 255 277  
 Lorand L 173  
 Loth E N 80  
 Lowe C U 277  
 Lowenstein L 41  
 Lubarsch O 209 228  
 Luchsinger G 172  
 Lucia S P 166  
 Ludemann H H 79  
 Luetscher J A Jr 203  
 Luft R 277  
 Lumb G A 257 281  
 Lund H Z 202  
 Lundgren M M 77  
 Lurie M B 78  
 Lyon E D 138 173  
 Lyster S C 78  
 Lyttle J D 203 204
- M
- McAlpine S G 131 148 169  
 McAusland, W R Jr 173  
 McCance R A 274 275 278  
 Macaulay D 244 281  
 McClaughry R I 171  
 McCollum E V 275  
 McCune D J 237 278 280  
 MacDonald R A 219 228  
 McDowell M 279  
 Macfarlane R G 107 124 133 136  
     138 141 168 173  
 McCauley W J 78  
 McGehee E H 78  
 McGeown M G 84 103 276  
 McGovern J J 124 173  
 MacGregor M E 103  
 MacIntyre I 275  
 McIntyre P A 42  
 MacLachlan E A 276 277  
 MacLagan N F 99 104  
 McLean C R 203  
 McLean F C 95 103  
 MacLean A 78  
 McLendon W W 170  
 McLeod N 205  
 Macklin C L 228  
 Macklin M T 228  
 McKusick V A 228  
 McManus J F A 278  
 McNeely R G D 228  
 MacNider W de B 278  
 Macpherson C R 275  
 Macpherson C R 278  
 McQuarrie J 170  
 Mader I J 278  
 Magill G B 78  
 Magnin G E 74  
 Mahler R F 278 281  
 Mann F D 126 173  
 Manser R W E 203  
 Marble A 101  
 Marcus S 75  
 Margolus A Jr 140 173 175 176  
 Markowitz M 78  
 Marmorston J 78  
 Marrazzi A S 228  
 Marsden H B 276  
 Marshall A H E 80  
 Marti H U 203  
 Martius C 173  
 Mason H H 276 278  
 Mason H L 79  
 Masson P 208 211 227  
 Mather H G 103  
 Matheson B H 204  
 Matoth Y 169  
 Matter M 144 145 173  
 Matthews W B 250 278  
 Mattingly T W 228

May C. D., 41 42  
 Medawar P B 74  
 Mees E J D 278  
 Meier R 75 78  
 Meites J 78  
 Melby J C., 78  
 Mellinger R C 79  
 Mellors R C 203  
 Mendeth A M 78  
 Meroney W 97 98 103  
 Meroney W H 277  
 Merrill, E R 75  
 Merrill J P 104  
 Merskey C 124 173  
 Meyer L M 38 42  
 Meyers M C 38  
 Meynell M S 42  
 Michie A J 278  
 Middlebrook, W R 173  
 Miles L M 104  
 Midler A 42 272  
 Miller C P 78  
 Miller E R 228  
 Miller H G 103  
 Miller M 169  
 Mills J N 253 278  
 Milne M D 82 83 104 273 275  
 278  
 Milosavljevic A 177  
 Mingos E S 40  
 Minor J 104  
 Minot G R 11 19 42 173  
 Mogabgab W J 78  
 Mollin D L 39 39 42 43  
 Montgomery M R 51 74  
 Monto R W 43  
 Moore A E 80  
 Moore M S 205  
 Moore S 275 278 281  
 More R H 203  
 Morgan A D 99 101  
 Morgan, H R 75  
 Morgan T E 80  
 Morrison F C Jr 168  
 Morse W I II 169  
 Mortimer E A 203  
 Movitt, E R 43  
 Mudge G H 272  
 Mudge G M 278  
 Muebreke R C 78 278  
 Mueller J F 28 43

Muhrer M E 168 173  
 Mulinos M G 279  
 Mulligan 279  
 Munro F L 141 173  
 Munro M P 141 173  
 Munson P L 90 104  
 Muntwyler E 276 279  
 Murard J 75  
 Murphy R C 178  
 Murphy W 11 19 42  
 Myerson, R M 279

## N

Nance M H 169  
 Nason A 179  
 Nassim J R 279  
 Neale A. V 203  
 Neligh R B 38  
 Nelson R S 75  
 Nelson W E 280  
 Neuman W F 104  
 Neunum R L 276  
 New York Academy of Medicine 78  
 Newcomb T 165 166 174  
 Nicaud P 279  
 Nickel J F 273  
 Nieweg H O., 43  
 Nitz Litrow D 173  
 Nonidez J F 104  
 Nordin, B E C 81 104 279  
 Nyberg W 43

## O

Oberndorfer S 209 228  
 Obrnsky W 79  
 O'Dell B L 43  
 Oehme J 174  
 Oert, J 164 174  
 Oleesky S 280  
 Oliver J 245 279  
 Ollayos R W 82 104 255 279  
 Opitz H 174  
 Orent Keles E 275  
 Orloff J 272 279  
 Ortega, L C 203  
 Ostling G 43  
 Ott, W H 79  
 Ottinger B 76 202  
 Owren O A 154 155 174  
 Owren P A. 156 171 174

- Levine R 79  
 Levinton H 78  
 Lewis D 208 228  
 Lewis J H 120 140 141 149 169  
     172 173  
 Lewis J L 78  
 Lewis M D 102  
 Li C H 78  
 Libby R L 44  
 Lichtman H 41  
 Lièvre J A 260 277  
 Linder G C 260 275 277  
 Lindquist B 95 162  
 Ling C T 41  
 Linneweh F 103  
 Lippman R W 203  
 Lipton M A 76  
 Lasker R 172  
 Little J A 44  
 Liu S H 103 277  
 Loeb E N 203  
 Lojkin M E 278  
 Longcope W T 203  
 Longson D 255 277  
 Lorand L 173  
 Loth E N 80  
 Lowe C U 277  
 Lowenstein L 41  
 Lubarsch O 209 228  
 Luchsinger G 172  
 Lucia S P 166  
 Ludemann H H 79  
 Luetscher J A Jr 203  
 Luft R 277  
 Lumb G A 257 281  
 Lund H Z 202  
 Lundgren M M 77  
 Lurie M B 78  
 Lyon E D 138 173  
 Lyster S C 78  
 Lytle J D 203 204
- M
- McAlpine S G 131 148 169  
 McAusland, W R Jr 173  
 McCance R A 274 275 278  
 Macaulay D 244 281  
 McClaughry R I 171  
 McCollum E V 275  
 McCune D J 237 278 280  
 MacDonald R A 219 228  
 McDowell M 279  
 Macfarlane R G 107 124 133 136  
     138 141 168 173  
 McGarity W J 78  
 McGehee E H 78  
 McGeown M G 84 103 278  
 McGovern J J 124 173  
 MacGregor M E 103  
 MacIntyre I 275  
 McIntyre P A 42  
 MacLachlan E A 276 277  
 MacLagan N F 99 104  
 McLean C R 203  
 McLean F C 95 103  
 MacLean A 78  
 McLendon W W 170  
 McLeod N 205  
 Macklin C L 228  
 Macklin M T 228  
 McKusick V A 228  
 McManus J F A 278  
 McNeely R C D 228  
 MacNider W de B 278  
 Macpherson C R 275  
 Macpherson C R 278  
 McQuarrie J 170  
 Mader I J 278  
 Magill C B 78  
 Magnin G E 74  
 Mahler R F 278 281  
 Mann F D 126 173  
 Manser R W E 203  
 Marble A 101  
 Marcus S 75  
 Margolus A Jr 140 173 175 178  
 Markowitz M 78  
 Marmorston J 78  
 Marrazzi A S 228  
 Marsden H B 278  
 Marshall A H E 80  
 Marti H U 203  
 Martinus C 173  
 Mason H H 270 278  
 Mason H L 79  
 Masson P 208 211 227  
 Mather H G 103  
 Matheson B H 204  
 Matoth Y 169  
 Matter M 144 145 173  
 Matthews W B 250 278  
 Mattingly T W 228

Ringertz N 277  
 Rinkel M 227  
 Rusak, E 175  
 Rutchie A. C 211 228  
 Rutchie G 228  
 Robbins L. L 94 105  
 Robbins S L 219 228 277  
 Roberts K. E 280  
 Roberts S 79  
 Robertson B R 258 280  
 Robertson, J S 79  
 Robinson H J 79  
 Robinson, H W 280  
 Robinson J R 275  
 Robson E B 235 237 276 280  
 Rogers H M 104  
 Roka L. 112, 172  
 Romanoff E B 79  
 Rose G A. 234 235 237 274 280  
 Rosenbaum P 79  
 Rosenblum C 39  
 Rosenfeld, C 79  
 Rosenthal H. L. 43  
 Rosenthal, M C 151 175  
 Rosenthal, N 149 176  
 Rosenthal R L. 149 150 151 171  
     176  
 Ross G I M 42 43 44  
 Roth, K. 179  
 Rothenberg M B 204  
 Rothlin E 228  
 Roussak, N J 280  
 Rowlands R A. 44  
 Royer P 44  
 Rupp J 79  
 Rupp W 251 280  
 Rutishauser E 101

## S

Said S I 78  
 St Goar W T 104  
 Salassa R M., 280  
 Salmon, W D 280  
 Salomon, E 161 175  
 Salomon, I. 177  
 Salvesen, H. A 95 104  
 Samama M 168  
 Sanders M 175  
 Sandler M 227  
 Sanneman E H 38  
 Sarett, H P 43  
 Saviard M 74

Saville P D 279 280  
 Sawers R. 176  
 Scaparone M 74  
 Schaaf M 92 103 104  
 Scheid H E 44  
 Scheinberg I H 280  
 Schuess W A 272 280  
 Schilling R. F 44 176  
 Schloessman H 178  
 Schmidt, Willard C 181  
 Schneebeli, G C 75  
 Schonholzer G 176  
 Schorr R 272  
 Schrader G A 280  
 Schrek, R 79  
 Schuler W 75  
 Schulman I 144 145 148 176  
 Schulz D M 276  
 Schuster A C 204  
 Schwab L. 204  
 Schwartz W B 265 279 280  
 Schwarz V 278 280  
 Schweigert, B S 44  
 Schweitzer A. 120 176  
 Seaman, A 176  
 Seastone C V 74  
 Seegal, B C 201 204  
 Seegal, D 186 191 204  
 Seegal E B C 204  
 Seegers W H 112 167 171 176  
     178  
 Seibert, R 176  
 Seifer J 202  
 Selberg W 228  
 Seldinger S L., 94 104  
 Selye H 78 79  
 Senior B 236 274  
 Shamir Z. 169  
 Shanberge J N 175  
 Shaw E., 228  
 Sheard C 103  
 Shelton, M 176  
 Sherrod T R 229  
 Sherry S 176  
 Shore P A. 227 228  
 Shorr E 80  
 Short, I A 280  
 Shulman, S 169 176  
 Siegel, A. C 204  
 Siegel, M 203  
 Silberman, L. 281  
 Simmons B 169

Orenhorn S 43  
Oyama J 76 202

## P

Pace M C 202  
Padawer J 78  
Page I H 202 213 223 228 229  
274  
Pantiset, M 78  
Pappenheimer A M 102 104  
Parken T W 227  
Parker R A 275  
Parker R T 78  
Paschlas A E 79  
Passet R 170  
Pastor B H 279  
Patek A J Jr 125 127 135 174  
Paton W D M 75  
Patrass M C 105  
Pauli R H 190 201  
Paulsen M 43  
Paulssen M M P 139 178  
Pavlovsky A 131 145 174  
Pearse A G E 278  
Pearson C M 228 277  
Peerman C G 78  
Pekarsky R L 174  
Penick G D 134 135 170 174  
Perkins J G 279  
Perla D 78  
Peters J P 279  
Petersdorf R G 78  
Petersen A B 279  
Peterson R H 78  
Pfander W H 43  
Philpott, N 41  
Pick C 41  
Pickering J W 140 174  
Piel, C F 203  
Pierce J M 104  
Pincus G 76 79  
Pinniger J L 162 170 174  
Pisciotta A V 175  
Pitney W R 38 43  
Pitts R F 104 272 279  
Platt, R 279  
Pletscher A 228  
Plotz C M 51 79  
Polley H F 79  
Pollycove M 38 43  
Pool, J G 174  
Porter J E 228

Potts A M 175  
Prader A 281  
Pranker T A J 279  
Pressman D 203  
Prichard R W 174  
Prickett C O 280  
Provasoli L 41  
Prunty F T C 162 174  
Pulaski E J 75  
Punt J 178

## Q

Quick A J 117 123 129 143 154  
163 174 175  
Quilter A R J 44  
Quinn R 202

## R

Rabe F 161 175  
Rachmilewitz M 40 43  
Ragan C 51 76 79  
Raiford T S 228  
Rake C 204  
Ramey E R 79  
Rammelkamp C H Jr 181 204  
Ramot, B 144 145 151 175 176  
Ransom W B 212 228  
Rapaport S I 156 171  
Rappaport M M 208 213 228  
Ratnoff O D 107 140 168 170  
173 175 176  
Rebuck J W 43 79  
Recant L 79  
Reed R W 204  
Rege D V 41  
Reifenstein, E 81 86 94 96 101  
Reifenstein E C Jr 260 272  
Reilly J 79  
Reisner E H Jr 43  
Reisman A S 204 265 279 280  
Reubs F C 279  
Rheault M H 40  
Rich A R 204  
Richards D G B 104  
Richards M D 175  
Richards P G 103  
Richardson G O 103  
Richmond J B 279  
Richter M A 227  
Richter O 43  
Rickard C G 170  
Ruley J A 279

Thorson A 216 229  
 Thorson A H 229  
 Thursby Pelham D C 240 273  
 Tiddens H W 244 281  
 Tippet J C 202  
 Titus E 229  
 Tobin J L 60 80  
 Tobler A 281  
 Tocantins L M 113 127 140 172  
     178  
 Tonutti E 80  
 Tournier P 79  
 Troll, W 178  
 Tracy A 279  
 Trayner E M 281  
 Turner R L 179  
 Twarog B M 223 229  
 Tweedy W R 105

## U

Udenfriend S 229  
 Ulrich J A 280  
 Ungley C C 44  
 Unna K 227  
 Updyke E L 205  
 Urst M R 103  
 Uzman L L 250 273 281

## V

Vadas D G M 260 277  
 van Buchem F S P 43  
 van Creveld S 125 139 167 178  
     281  
 Vandenbroucke J 140 164 178  
 van Goudsenhoven G M T 281  
 van Kessel E 103 277  
 Van Loon E J 43  
 Vann R L 174  
 Van Slyke D D 279  
 Vazquez J J 205  
 Veder H A 178  
 Verbanck M 103  
 Vermassen A 276  
 Vermier R L 76  
 Vernier R L 192 205  
 Verstraete M 140 164 178  
 Verwulghen R 178  
 Villarreal H 280  
 Vogel F 123 178  
 von Bonsdorff B 39  
 von Willebrand E A 145 179

## W

Wagner H N 80  
 Wagner R H 172  
 Wahrer C F 205  
 Waldenstrom J 225 239  
 Walker D L 77  
 Wallis L A 245 275  
 Walshe J M 274  
 Wang C C 105  
 Wannamaker L W 205  
 Wanzer S H 80  
 Ware A G 172 178  
 Warming Larsen A 277  
 Warner E D 177  
 Warnock C G 282  
 Warren F L 276  
 Wartelle O 177  
 Wasserman L R 11 39 40  
 Watson G M 44  
 Watson J 41  
 Waugh D 203  
 Weaver R S 204  
 Wechsler R L 79  
 Wedgewood R J 205  
 Weil E 134 178  
 Weissbach H 229  
 Welch A D 44  
 Welsh J H 229  
 Wenderoth H 276  
 Wertheim A R 205  
 Whelan C S 228  
 White R G 80  
 White S G 149 166 178  
 Whitehead T P 103  
 Wilkenson J F 179  
 Will J J 28 43  
 Willor A 102 274  
 Williams R E O 205  
 Wilmers M J 205  
 Wilson H E 205  
 Wilson M M 203  
 Wilson V K 276 278 282  
 Winberg J 282  
 Winkenwerder W L 183 205  
 Winkler A W 255 279  
 Winkler W 82 104  
 Winkley J H 277  
 Winston M E 179  
 Wintrobe M M 179  
 Wirz H 233 282  
 Wissler R W 205

- Simonsen M 204  
 Simpkins M 273  
 Simpson S L 44  
 Sinclair H M 44  
 Sinclair K 104  
 Singer A 143 144 145 175 176  
 Singer M 228 280  
 Sirota J H 85 104 280  
 Sise H S 176  
 Sjoerdsma A 216 229  
 Sjogren B 277  
 Sjolin K E 152 176  
 Skold E 122 176  
 Slaughter D P 229  
 Smadel J E 205  
 Smadel P E 205  
 Smith C H 148 176  
 Smith D T 61 73 80  
 Smith H W 251 280  
 Smith J C 249 280  
 Smith J P 229  
 Smith R T 76 79 80  
 Smith S G 281  
 Small K 205  
 Snow P J D 225 229  
 Snyder M J 78  
 Soffer L S 51 79  
 Sokal G 171  
 Sokoloff L 79  
 Solem J H 79  
 Solomon D H 205  
 Solomon H C 227  
 Somer P 50 77  
 Sørbye Ø 177  
 Sosman M C 101  
 Souchon F 273  
 Soulier J P 144 164 172 173 177  
 Southam C M 80  
 Spaet T H 134 152 166 174 175  
 177  
 Spain D M 207 229  
 Spargo B 281  
 Speer R J 164 171  
 Spencer A C 281  
 Spies H W 57 78  
 Spinazzola A J 229  
 Spingarn C L 279  
 Spink W W 73 80  
 Spray C H 39  
 Sprinz H 75  
 Sreenivasan A 41  
 Stafford W T 228  
 Stanbury S W 83 96 98 104 231  
 244 246 252 253 257 267 276  
 281  
 Stave U 103  
 Stavitsky A B 204 205  
 Stavitsky R 205  
 Stead E A Jr 75  
 Stefanini M 131 138 175 177  
 Stefanovic R 177  
 Stefanovic S 177  
 Stein W H 234 276 281  
 Steinberg A G 124 167 173  
 Steiner R E 94 104  
 Sternbeek I 228  
 Stetson C A 205  
 Stetson R P 125 127 174  
 Smith E L 44  
 Smith H P 176 177  
 Stevenson T D 44  
 Stewart C T 41  
 Stewart, G S 88 105  
 Stiefel G E 41  
 Stoerek H C 60  
 Stoerk H 75  
 Stoerk H C 74 102  
 Stone H H 39  
 Stout A P 211 229  
 Stowers J M 281  
 Sullivan J F 42  
 Swendsen M E 44  
 Swoboda W 251 280  
 Syverton J T 80  
 Szego C M 79  
  
 T  
 Taggart J V 265 281  
 Taillard W 281  
 Talmage R V 105  
 Taylor F H L 125 135 166 170  
 173 174 177  
 Tegelaers W H H 244 281  
 Telfer T P 160 177  
 Terrey M 277  
 Thanabalasundaram R S 169  
 Thomas H B 177  
 Thomas L 52 72 74 78 79 80 177  
 Thompson D D 276  
 Thompson R B 44  
 Thomson A E 83 104 278 281  
 Thomson M L 282

Thorson A 216 229  
 Thorson A H 229  
 Thursby Pelham D C 240 273  
 Tiddens H W 244 281  
 Tippet J C 202  
 Titus E 229  
 Tobin J L 60 80  
 Tobler A 281  
 Tocantins L M 113 127 140 172  
     178  
 Tonutti F 80  
 Tournier P 79  
 Troll, W 176  
 Tracy A 279  
 Trayner E M 281  
 Turner R L 179  
 Twarog B M 223 229  
 Tweedy W R 105

## U

Udenfriend S 229  
 Ulrich J A 280  
 Ungley C C 44  
 Unna K 227  
 Updyke E L 205  
 Urist M R 103  
 Uzman L L 250 273 281

## V

Vadas D G M 260 277  
 van Buchem F S P 43  
 van Creveld S 125 139 167 178  
     281  
 Vandenbroucke J 140 164 178  
 van Goudsenhoven G M T 281  
 van Kessel E 103 277  
 Van Loon E J 43  
 Vann R L 174  
 Van Slyke D D 279  
 Vazquez J J 205  
 Veder H A 178  
 Verbanck M 103  
 Vermassen A 276  
 Vermier R L 76  
 Vermier R L 192 205  
 Verstraete M 140 164 178  
 Verwulghen R 178  
 Villarreal H 280  
 Vogel F 123 178  
 von Bonsdorff B 39  
 von Willebrand E A 145 179

## W

Wagner H N 80  
 Wagner R H 172  
 Wahrer C F 205  
 Waldenstrom J 225 229  
 Walker D L 77  
 Wallis L A 245 275  
 Walshe J M 274  
 Wang C C 105  
 Wannamaker L W 205  
 Wanzer S H 80  
 Ware A G 172 178  
 Warming Larsen A 277  
 Warner E D 177  
 Warnock C G 282  
 Warren F L 276  
 Wartelle O 177  
 Wasserman L R 11 39 40  
 Watson G M 44  
 Watson J 41  
 Waugh D 203  
 Weaver R S 204  
 Wechsler R L 79  
 Wedgewood R J 205  
 Weil E 134 178  
 Weissbach H 229  
 Welch A D 44  
 Welsh J H 229  
 Wenderoth H 276  
 Wertheim A R 205  
 Whelan C S 228  
 White R G 80  
 White S G 149 166 178  
 Whitehead T P 103  
 Wilkenson J F 179  
 Will J J 28 43  
 Willcox A 102 274  
 Williams R E O 205  
 Wilmers M J 205  
 Wilson H E 205  
 Wilson M M 203  
 Wilson V K 276 278 282  
 Winberg J 282  
 Winkenwerder W L 183 205  
 Winkler A W 255 279  
 Winkler W 82 104  
 Winkley J H 277  
 Winston M E 179  
 Wintrobe M M 179  
 Wurz H 233 282  
 Wissler R W 205



- Witham A C 102  
 Witts L J 44  
 Wokes F 44  
 Wolf P 179  
 Wolf R 44  
 Wolff J A 164 179  
 Wolff R 44  
 Woltmann H W 44  
 Woodbury D T 39  
 Wooley D W 228  
 Woolf L I 282  
 Woolley E J S 179  
 Wosilant W D 179  
 Wright C S 179  
 Wnght, D R 177  
 Wrong O M 233 270 282  
 Wurzel H A 179  
 Wyman S M 94 105  
  
 Y  
 Yendt, E R 96 100 105  
 Yu, T F 272  
 Yuddkin J 274  
  
 Z  
 Zetterstrom R 282  
 Zindahl W T 282  
 Zubrow H J 167  
 Zubrow S 179  
 Zucker M B 229  
 Zweifach B E 80  
 Zweifach B W 80

# Subject Index

## A

- Abdomen in hemophilia 130 131
- Accelerator factor 155
- Accelerin 108 111 112 156
- Ac globulin, 108
- Achylia in pernicious anemia 32
- Acidosis
  - metabolic 239 243 244 246 247 256 269
  - in potassium deficiency 261 ff
  - renal tubular 233 247 248 256 268 269
- Acids organic
  - excretion in potassium deficiency 269
  - in serum 239
- ACTH
  - see also* Corticosteroids
  - and antibody production, 46 47 70
  - vs corticosteroids 61 ff
  - and experimental renal disease 195
  - for hemostasis in hemophilia 142
  - and pneumonia(s) 46-48
  - and resistance to infection 50 52
- Activated factor V 108
- Activated thromboplastin 108 109
- Addis count for glomerulonephritis
  - diagnosis 184 185
- Addisonian anemia *see* Anemia(s)
  - megaloblastic pernicious
- Adenoma
  - bronchial 210
  - parathyroid 84 85 93 94
- Adrenal glands
  - disease and potassium deficiency 269
  - insufficiency in infections 58 61
- Adrenocortical steroids *see* Corticosteroids
- Adrenocorticotropin *see* ACTH
- Afibrinogenemia 117 161 163
- Albuminuria
  - in acute glomerulonephritis 182 185 186 191
  - in streptococcal infections 188
- Aldosterone
  - and anti-inflammatory effect of corticosteroids 68
  - and cation exchange mechanism 270 271
  - excretion in Lignac Fanconi syndrome 241
- Aldosteronism 263 268 ff
- Alkali(s) and renal tubular disorders 238 247 248
- Alkalosis in potassium deficiency 261 ff 269
- Allergic reaction *see* Hypersensitivity
- Allergy and serotonin 217
- Amino acids
  - defective tubular reabsorption, *see* Amino aciduria renal
  - deficiency and megaloblastic anemias 30
- Amino aciduria
  - physiologic in newborn, 238
  - renal 232 233 250 258 ff
    - in celiac disease 243
    - in heavy metals poisoning 248
    - in hepatolenticular degeneration 249 250
    - in myelomatosis 244 245
    - in nephrotic syndrome 245
    - in nutritional rickets 243
    - in potassium deficiency 269
- p Aminohippuric acid excretion in potassium deficiency 265 268
- $\beta$  Aminoisobutyric aciduria 232 ff
- Aminophylline and proaccelerin in animals 157 158
- Ammonia
  - excretion in potassium deficiency 269

- Ammonia (*cont*)  
   in renal tubular disorders 239  
     241 ff 263 264
- Anaphylaxis  
   and animal antihemophilic factor 136  
   and serotonin 217
- Anemia(s)  
   with intestinal carcinoid 215  
   with liver disease 38  
   megaloblastic 11-41  
     clinical manifestations 29 30  
     of *Diphyllobothrium latum* infection 16 18 29 36-37  
     drug produced 16 29 38  
     of infancy 16 37-38  
       treatment 38  
   with intestinal blind loop 13 16  
     29 35-36  
   of malabsorption syndrome 14 16  
     18 19 25 34-35  
   nutritional macrocytic 13 16 29  
     30 31 32  
   pathogenetic classification 29  
   pernicious 11 ff 16 18 25 29  
     30 32 33  
     of pregnancy 14 16 21 37  
     treatment 20 32 33  
     vitamin B<sub>12</sub> levels 13 25  
   with total gastrectomy 16 18 25  
     29 30 33
- Anorexia  
   in acute glomerulonephritis 182  
   and corticosteroids 49  
   in Lignac Fanconi syndrome 241
- Antibiotic-corticosteroid therapy 53 ff
- Antibiotic prophylaxis with corticosteroid therapy 57
- Antibiotics  
   and blind loop syndrome 35 36  
   and pernicious anemia 32 36
- Antibodies 141  
   and corticosteroids 69 ff  
   *see also* Infection(s) resistance to  
   type specific after acute glomerulonephritis 188 189
- Anticoagulants circulating 136 140  
   142 149 152 157 159
- Anticonvulsants and megaloblastic anemia 29 38
- Antigen antibody reaction and experimental nephritis 194 195 196 198
- Antigen(s) nephrotic in glomerular tissue 197
- Antihemophilic factor 108 109 111  
   117 125 ff 156 165  
   deficiency *see* Blood clotting combined defects Hemophilia Hemophilia vascular  
   differentiation from other blood factors 125 126  
   for hemophilic bleeding episodes 134 135 136  
   inhibitor 127 128
- Antihemophilic factor B 108 146
- Antihemophilic globulin 108
- Antihyaluronidase in serum during tissue destruction 68
- Antikidney serum and experimental nephritis 195 ff
- Antiserum(s) and corticosteroids 53
- Antistreptolysin titer in acute glomerulonephritis 186
- Anuria  
   in nephritis 183  
   serum calcium-phosphate relation, 97
- Appendicitis simulated by hemophilic bleeding 165
- Appendix *see* Gastrointestinal tract
- Argentaffin cell(s) *see* Enterochromaffin cell(s)
- Argentaffinoma *see* Carcinoid(s)
- Arginine excretion 234 235
- Arteriography for hyperparathyroidism diagnosis 94
- Ascitic fluid vitamin B<sub>12</sub> content, 13 26
- Ascorbic acid  
   deficiency 14 29  
   for megaloblastic anemia of infancy 38  
   and vitamin B<sub>12</sub> 28
- Aspartic acid excretion 237
- Asphyxiation in hemophilia due to bleeding 130
- Atrophy soft tissue in hemophilia 130
- Aureomycin *see* Chlorotetracycline
- Autoprothrombin I 108
- Autoprothrombin II 108
- Azoospermia 50

**Azotemia**

- and bone lesions 96 247
- in experimental nephritis 194 196
- in nephritis 183
- in renal failure 232

**B**

Barium swallow for hyperparathyroidism diagnosis 94

Bicarbonate *see* Sodium bicarbonate

Bilateral renal cortical necrosis *see* Schwartzman phenomenon

**Biopsy**

- bone in hyperparathyroidism diagnosis 93-94
- kidney in nephritis diagnosis 192

Biothrombin, 108

Blastomycosis 49

Blind loop anemia *see* Anemia(s)  
megaloblastic with intestinal blind loop

**Blood**

- clotting 107 179
- combined defects 151 154 155 164 166
- in glass tubes 111 114 116 153
- glossary of terms 108 (table)
- inhibitors 112 113
- and serotonin 226
- in silicone-coated tubes 111 116
- physiology 109 114 156
- tests 114 120
  - in hemorrhagic disorders 115 133 134 135 148 150 153 156 157 158-159 162 163
- transfusion and circulating anticoagulant, 136 140 142
- for hemorrhagic disorders 134 136 149 151 157 159 163
- vitamin B<sub>12</sub> content 13 21 25

**Blood clot**

- lysis 113
- retraction, 113

**Bone**

- biopsy for hyperparathyroidism diagnosis 93-94
- disease and chronic amino aciduria, 236
- and renal tubular disorders 245 248

and serum phosphate levels 94 95

pain in hyperparathyroidism 91

and parathyroid hormone 88-89

pH and parathyroid hormone 88-89

Bone marrow vitamin B<sub>12</sub> content, 26

Brachial artery serotonin content, 219

Brain function, and serotonin 223-226

Bright's disease *see* Nephritis

Brucellosis 49 55

**C**

Cadmium poisoning *see* Heavy metals poisoning

Caeruloplasmin and hepatolenticular degeneration, 249

Calciferol, *see* Vitamin D

Calcification metastatic, in hyperparathyroidism 93

in uremia, 97 98

**Calcium**

and blood clotting 109 ff., 154 156

excretion, and bone disease 245 247

in parathyroid disorders 92

infusion, for hyperparathyroidism diagnosis 92 93

in renal failure 96 ff

in serum, in parathyroid disorders 84 87 ff 92

intestinal absorption and bone disease 245 ff

Calcium balance test, 94

Calcium-phosphate relation in renal failure 96 ff

**Calculi renal**

in cystinuria 234 236

in hyperparathyroidism 91 256

**Cancer**

and carcinoids 212

and fibrinolysis 113

Carbohydrate metabolism and vitamin B<sub>12</sub>, 28

**Carcinoid(s)**

clinical picture 214 215 216-218

histology 211 212

malignant 211 212 213 215 218

secretion, 213 214

sites of origin 209 210-211

staining properties 212

**Cardiovascular system**

abnormalities with carcinoids 212

with parahemophilia 155

- Cardiovascular system (*cont.*)  
   in malignant carcinoid syndrome 216 218 221
- Castle's extrinsic factor *see* Vitamin B<sub>12</sub>
- Cataracts 243
- Cauterization for hemophilic bleeding 136
- Cebac disease 243
- Cellulitis and corticosteroids 50
- Central nervous system  
   in hemorrhagic disorders 131 133 148 150 155 159 161 165  
   in megaloblastic anemias 30 33 35  
   *see also* Sclerosis posterolateral  
   vitamin B<sub>12</sub> content 26
- Cerebrospinal fluid vitamin B<sub>12</sub> content 13 26
- Chiari's network with carcinoids 212
- Chickenpox and corticosteroids 50 51
- Chloramphenicol-corticosteroid therapy 53
- Chlorides in serum in Fanconi syndrome 244
- Chlorpromazine and endotoxins 68
- Chlortetracycline *see* Antibiotics
- Choline and corticosteroids 63
- Christmas disease 115 120 145 149 156
- Christmas factor 108 109 111 112 125 126 146 ff 153 156 164 165
- Chronic lymphocytic leukemia *see* Leukemia(s)
- Chronic myelocytic leukemia *see* Leukemia(s)
- Citric acid  
   in bone and parathyroid hormone 89  
   excretion in potassium deficiency 269  
   in serum in renal failure 100
- Cleft palate with carcinoid 212
- Clostridia and corticosteroids 65
- Clot promoting factor 109
- Clotting time *see* Blood clotting tests
- Cobalamine *see* Vitamin B<sub>12</sub>
- Cobalt radioactive for vitamin B<sub>12</sub> study 14 17
- Coenzyme A and vitamin B<sub>12</sub> 28
- Cofactor V 108
- Cohn's Fraction I for hemophilic bleeding 135 136
- Colic in hemophilia 130 131
- Colitis ulcerative and potassium depletion 269
- Colon *see* Gastrointestinal tract
- Complement  
   digestion by plasmin, 113  
   fixation by circulating anticoagulants 141  
   titer in glomerulonephritis 195
- Component A, 108
- Compound B *see* Corticosterone
- Compound F *see* Cortisol
- Constipation in hyperparathyroidism 91
- Convertin 108
- Convulsions in nephritis 183
- Copper metabolism in hepatolenticular degeneration 249 250
- Corticosteroids 45 60  
   anti inflammatory effects 67 ff  
   dosage and effectiveness 60 61  
   and experimental renal disease 195  
   for hemophilia 142  
   potentiation effects 66 67  
   variations in effects 62  
   and vascular tone 67
- Corticosterone 62 ff  
   *see also* Corticosteroids
- Corticotropin *see* ACTH
- Cortisol, 62 ff  
   *see also* Corticosteroids
- Cortisone 62 ff
- Cortisone *see also* Corticosteroids
- Cothromoplastin 108 158
- Coumarin and blood clotting factors 112 153 158 160 165
- C reactive proteins 68
- Cushing's disease and infections 51 52
- Cyanocobalamine *see* Vitamin B<sub>12</sub>
- Cyanosis in malignant carcinoid syndrome 216 217
- Cylindruria in experimental nephritis 193 196
- Cystine lithiasis *see* Cystinuria  
   caliculi renal
- Cystine storage disease *see* Lignac  
   Fanconi syndrome
- Cystinelysturia *see* Cystinuria
- Cystinosis *see* Lignac Fanconi syndrome

Cystinuria 232 234 236 237  
 excretion of multiple amino acids  
 233 234  
 prophylaxis 236

## D

Decarboxylase and serotonin synthesis  
 216 223  
 Dermoid cyst and carcinoids 212  
 Desicote 116  
 Desoxycorticosterone  
 and anti inflammatory effect of cor-  
 ticosteroids 68  
 and experimental diabetes insipidus  
 265 268  
 Desoxyriboside(s) and vitamin B<sub>12</sub> 28  
 Dextrocardia *see* Cardiovascular sys-  
 tem abnormalities  
 Diabetes insipidus  
 experimental 265 268  
 renal in Fanconi syndrome 244 265  
 Diabetes phosphatic 256 258  
 Diarrhea in carcinoids 215 216 217  
 Dicumarol *see* Coumarin  
 Dihydrotachysterol *see* Vitamin D  
 Diphyllbothrium latum anemia 16  
 18 29 36 37  
 Diverticulosis and megaloblastic ane-  
 mia 35  
 Dry Film 116  
 Duodenum *see* Gastrointestinal tract  
 Dwarfism 242 243  
 Dyspepsia in hyperparathyroidism 91

## E

Ecchymoses in hemorrhagic disorders  
 129 150 165  
 Edema  
 in acute glomerulonephritis 182  
 183 191  
 in experimental nephritis 195 196  
 in malignant carcinoid syndrome 218  
 Endocarditis subacute bacterial and  
 corticosteroids 49 50  
 Endotoxins  
 and adrenal gland 59  
 and corticosteroids 64 66  
 and physiologic changes 66  
 Enteramine *see* Serotonin  
 Enterochromaffin cells 207 209  
 and serotonin 208 221

Enzymes in renal tubules in potas-  
 sium deficiency 269  
 Eosinopenia due to corticosteroids 69  
 Epidermolysis bullosa congenitalis  
 with parahemophilia 155  
 Epinephrine  
 and corticosteroids 66  
 and fibrinolysis 113  
 Epistaxis in hemorrhagic disorders  
 129 144 150 159 161  
 Ergot alkaloids 224  
 Erythrocyte casts in urine in acute  
 glomerulonephritis 182 184  
 Erythrocytes in urine *see* Hematuria  
 Erythropoiesis and nucleoprotein syn-  
 thesis 28  
 Escherichia coli for microbiologic as-  
 say of B<sub>12</sub> 12  
 Euglena gracilis var bacillaris for mi-  
 crobiologic assay of B<sub>12</sub> 12  
 Exercise and fibrinolysis 113  
 Exotoxins and corticosteroids 65  
 Extrinsic factor of Castle *see* Vitamin  
 B<sub>12</sub>

## F

Factor V 108 154  
 Factor VI 108 156  
 Factor VII 108  
 Factor VIII 108  
 Factor IV 108 146  
 Factor X 108  
 Factor XI 108  
 Familial disorders *see* Heredity  
 Fanconi syndrome 243 245 ff 256  
 265 ff  
*see also* Lignac Fanconi syndrome  
 Fat  
 impaired absorption 34  
 metabolism and vitamin B<sub>12</sub> 28  
 Fever  
 and corticosteroids 48 49 54 64  
 in experimental nephritis 193  
 Fibrin 109 110  
 Fibrin ferment 108  
 Fibrinogen 108 ff 126 153 154  
 deficiency 117 162 163  
*see also* Afibrinogenemia  
 Fibrinogenopenia 113  
 Fibrinolysin 108 113  
 Fibrinolysis 113  
 Fibrogenesis and corticosteroids 69

Fifth plasma thromboplastin precursor 108

Flushes in malignant carcinoid syndrome 216 217

Folic acid

deficiency 14 21 29 31 34

for drug induced megaloblastic anemia 38

for megaloblastic anemia of infancy 38

and nucleoprotein synthesis 28

for pernicious anemia of pregnancy 21 37

effect in pernicious anemia 32

in posterolateral sclerosis without anemia 34

for sprue 35

and vitamin B<sub>12</sub> 28 30 34

Folinic acid and vitamin B<sub>12</sub> 28

Fungus(es) infections and corticosteroids 49 ff

## G

Galactosemia 238 239

Gallbladder *see* Gastrointestinal tract

Gangrene in hemophilia 130

Gastrectomy and anemia *see* Anemia(s) megaloblastic with total gastrectomy

Gastrointestinal tract

carcinoid(s) 209 ff 216

in hemorrhagic disorders 128 129 143 159

Gelbe zelle *see* Enterochromaffin cell(s)

Gentian violet effect in blind loop syndrome 35

Gingivae bleeding in hemorrhagic disorders 129 150 159

Glass surfaces and blood clotting 111 114 116 153

Glass s method 17

Glaucoma 243

Globulin(s) and vitamin B<sub>12</sub> 20 21 24 25 29

Globulin substance 108

Glomerular failure *see* Kidney(s) failure

Glomerulonephritis 181 205

*see also* Nephritis

acute clinical picture 182 183 186

etiology 186 191

recurrence 189

chronic 182 186 ff

recurrence 189 190

experimental, 193

pathology 191 193

subacute 192

Glucagon and enterochromaffin cell 209

Glucose impaired absorption 14

Glutathione and vitamin B<sub>12</sub> 28

Glycogen storage disease 242

Glycosuria

in heavy metals poisoning 248

renal, 232 233 237 239 243 244 258 ff

and tubular reabsorption 231

Gram negative bacteria and corticosteroids 56 57 59 64

## H

Hageman factor 108 109 111 128 153 154

Hageman trait, 115 127 152 154

Harmine 224

Hartnup syndrome 234

Heart

disease in malignant carcinoid syndrome 216 218 221

vitamin B<sub>12</sub> content 27

Heavy metals poisoning and renal tubular disorders 248 250

Hemle Welch method 14 15

Hemarthrosis(es) in hemorrhagic disorders 126 129 130 136 137 143 150 159 161 165

Hematoma(s) in hemorrhagic disorders 128 144 148 150 155 159 161

Hematomesis in hemorrhagic disorders 165

Hematuria

in acute febrile diseases 184 185

in acute glomerulonephritis 182 ff 191

in experimental nephritis 193 196

in hemorrhagic disorders 130 154 165

in scarlet fever 185

in streptococcal infections 184 ff

Hemodynamics and serotonin 216 217 220 223

- Hemophilia 120 143 156  
*see also* Christmas disease  
 in animals 123 142 143  
 circulating anticoagulants 136 140 142  
 clinical picture 128 133  
 diagnosis 133 134  
 in females 142 143  
 heredity 120 125  
 identification of female carriers 123 125  
 incidence 120  
 prognosis 132 133  
 tests 115 118 119 126 133 134 135  
 theories 125 127  
 treatment 134 140  
   prophylactic 139 140  
 in twins 123  
 vascular 115 143 145  
 Hemophilia Foundation 139  
 Hemoptysis in hemorrhagic disorders 165  
 Hemostasis and serotonin 226  
 Hepatic uptake method for study of vitamin B *see* Glass's method  
 Hepatolenticular degeneration 233 239 242 249 250  
 Heredity  
   in cystinuria 235  
   in Fanconi syndrome 244  
   in hemorrhagic disorders 107 120 125 142 143 144 146 150 152 153 155 159 162 164 165  
   in hepatolenticular degeneration 249  
   in Lignac-Fanconi syndrome 236 238  
   in pernicious anemia 32  
 Hepatitis viral and corticosteroids 49 50  
 Heterologous protein nephritis 193 195 196  
 Histamine  
   in carcinoid 209  
   effect in malignant carcinoid syndrome 216  
   and enterochromaffin cell 209  
   in mast cell tumor 209  
 Histoplasmosis and corticosteroids 50  
 Homocystine and vitamin B 28  
 5 HT *see* Serotonin  
 Hyaluronidase use in hemophilia 136  
 Hydrocortisone anti-inflammatory effects 68  
 Hydronephrosis in cystinuria 236  
 5-Hydroxyindoleacetic acid 214 216 220  
 5-Hydroxytryptamine *see* Serotonin  
 Hyperaldosteronism *see* Aldosteronism  
 Hyperchloremia *see* Chlorides in serum  
 Hypercholesterolemia in experimental nephritis 195 196  
 Hypercorticoidism *see* Cushing's disease  
 Hyperheparinemia congenital 163  
 Hyperparathyroidism 81 105  
   clinical picture 91 ff  
   diagnostic methods 82 ff 92 ff 256  
   metastatic calcification 93  
   in renal failure 96 101  
   differential diagnosis 100 101  
   secondary 85 94 101 256 260  
 Hypersensitivity  
   to bacterial protein and nephritis 181 193  
   and experimental nephritis 193 ff  
 Hyperserotonemia *see* Serotonin in serum  
 Hypertension  
   in acute glomerulonephritis 182  
   in experimental nephritis 196  
   in nephritis 183  
   and serotonin 222  
 Hyperthyroidism and osteoclasts 88  
 Hypofibrinogenemia *see* Fibrinogen deficiency  
 Hypokalemia *see* Potassium in serum  
 Hypoparathyroidism 81 83 85  
 Hypophosphatemia *see* Phosphate in serum  
 Hypopotassemia *see* Potassium in serum  
 Hypoproteinemia *see* Protein(s) in serum  
 Hypoprothrombinemia *see* Prothrombin deficiency  
 Hyposthenuria in potassium depletion 241 261 265 ff  
 Hypothalamus and corticosteroids 64  
 Hypothermia after cortisone therapy 55 64  
 Hypotonia in hyperparathyroidism 91



## I

- Ileum *see* Gastrointestinal tract  
 Iliac crest biopsy for hyperparathyroidism diagnosis 93 94  
 Immobilization for hemophilic bleeding 136  
 Infection(s)  
   antibiotic corticosteroid therapy 53 57  
   and corticosteroids 45 80  
   resistance and corticosteroids 49 53 60 ff  
   streptococcal and acute glomerulonephritis *see* Glomerulonephritis acute  
 Inflammation(s) and corticosteroids 55 67 ff  
 Influenza virus and corticosteroids 65  
 Intestine(s) *see* Gastrointestinal tract  
 Intestinal blind loop anemia *see* Anemia(s) megaloblastic with intestinal blind loop  
 Intrinsic factor 18  
   absence congenital 18 29 33  
   and pernicious anemia 18 32  
   and vitamin B<sub>12</sub> absorption 14 ff 29  
 Iron deficiency in malabsorption syndrome 34  
 Isosthenuria  
   in potassium deficiency 268  
   in renal failure 232

## J

- Jaundice homologous serum after blood transfusions 139 149  
 Jejunum *see* Gastrointestinal tract  
 Joints in hemophilia 128 129 130

## K

- Kappa factor 108  
 Kidney(s)  
   biopsy in diagnosis of nephritis 192  
   and cortisone therapy 55  
   diseases *see* specific conditions  
   failure and dissolution of cystine calculi 236  
   and hyperparathyroidism 96 101  
   chronic 232  
   in Lignac Fanconi syndrome 238  
   function and serotonin 226

- glomerular tubular imbalance 232  
 and parathyroid hormone 86 87 251 252  
 pathology in experimental nephrotic nephritis 198 200  
   in glomerulonephritis 191 193  
   in Lignac Fanconi syndrome 241  
 phosphate turnover measurement, 251 252 ff  
 and potassium deficiency 268 269 (table)  
 tubules anatomic abnormalities 238 244  
   and homeostasis 231  
   and potassium deficiency 261 272  
 disorders 231 282  
   and bone lesions 245 248  
   phosphate reabsorption in parathyroid disorders 84 ff 246  
   vitamin B<sub>12</sub> content 13 26 27  
 Kultschitzky cell(s) *see* Enterochromaffin cell(s)

## L

- Labile factor 108 155  
 Lactobacillus leichmannii for microbiologic assay of B<sub>12</sub> 12  
 Lead poisoning 34 242 248  
 Lee White method 114 135  
 Leptospirosis 49  
 Leucine excretion 237  
 Leukemia(s) vitamin B<sub>12</sub> serum levels 21 23  
 Leukocytes and corticosteroids 67 68  
 Lignac Fanconi syndrome 233 234 236 241 247 256 260 268  
   complicating other disorders 241 ff  
 Lithiasis *see* Calculi renal  
 Liver  
   and blood clotting 110 112  
   carcinoid metastases 212 213 218 219  
   cirrhosis and chronic amino aciduria 236  
   in Fanconi syndrome 244  
   disease(s) *see also* Hepatitis viral  
   and fibrinolysis 113  
   and vitamin B<sub>12</sub> 23 24 26 29 38  
   vitamin B<sub>12</sub> storage 13 17 22 24 26 27  
 Liver extract and corticosteroids 63  
 LSD *see* Lysergic acid diethylamide

Lupus erythematosus and corticosteroids 51  
 Lymphocytic leukemia *see* Leukemia(s)  
 Lymphoid cells *see* Spleen Thymus  
 Lymphoma(s) *see* Leukemia(s)  
 Lymphocytes and corticosteroids 69  
 Lysergic acid diethylamide 217 224 225  
 Lysin 108  
 Lysine  
   excretion 234 235 237

## M

Malabsorption syndrome 14 16 18 19 25 34-35 260 261  
 Malaise and corticosteroids 49 64  
 Malaria and corticosteroids 49 71  
 Malignant carcinoid syndrome *see* Carcinoid(s) malignant with metastases  
 "Mass action" effect 14 19 32  
 Mast cell(s)  
   and serotonin 209  
   tumors 209  
 Meckel's diverticulum and carcinoid 210 212  
 Melena in hemorrhagic disorders 165  
 Meningitis  
   and corticosteroids 50  
   tuberculous antibiotic-corticosteroid therapy 55 57  
 Meningococcemia  
   and adrenal insufficiency 59-60  
   antibiotics-corticosteroid therapy 56 57  
 Menorrhagia in hemorrhagic disorders 143 144 150 159 165  
 Mental disturbances  
   in malignant carcinoid syndrome 218  
   in pyloric stenosis 262  
 Mental retardation 243  
 Mercury poisoning *see* Heavy metals poisoning  
 Methionine; and vitamin B<sub>12</sub> 28  
 Milk alkali syndrome 100  
 Moniliasis and corticosteroid therapy 50 51  
 Monoamine oxidase and serotonin metabolism 220 221 223

Mononucleosis infectious 49  
 Mucoproteins in serum during tissue destruction, 68  
 Mumps 49 50  
 Muscle vitamin B<sub>12</sub> content 13  
 Myalgia and corticosteroids 64  
 Mycoses and corticosteroids 50  
 Myelocytic leukemia *see* Leukemia(s)  
 Myeloma and vitamin B<sub>12</sub> binding 25  
 Myelomatosis and Fanconi syndrome, 244 256  
 Mysoline 38

## N

Nausea in hyperparathyroidism, 91  
 Necrosis bilateral renal cortical *see* Schwartzman phenomenon  
 Nephritis 181 183  
   *see also* Glomerulonephritis  
   chronic, 184  
   experimental, 193 201  
   *see also* specific types  
   hemorrhagic *see* Glomerulonephritis acute  
 Nephropathy potassium-depletion *see* Kidney(s) tubules and potassium depletion  
 Nephrosis 196  
 Nephrotic syndrome 195 199 242 244 268  
 Nephrotoxic experimental nephritis 195 200  
 Nervous system *see* Central nervous system  
 Neurologic abnormalities *see* Central nervous system specific conditions  
 Niacin deficiency with carcinoid 216  
 Nitrogen  
   retention in experimental nephritis 196  
   in potassium deficiency 261  
 Norepinephrine  
   and corticosteroids 66  
   for collapse in meningococcemia 60  
   release from pheochromocytoma 216  
 Nucleoproteins; synthesis 23 ff  
 Nutritional deficiencies  
   and nutritional macrocytic anemia 31-32  
   in malignant carcinoid syndrome 216

Nutritional macrocytic anemia *see* Anemia(s) megaloblastic nutritional macrocytic

## O

Obstruction intestinal, with carcinoid 215

Ochromonas malhamensis for microbiologic assay of B 12

Oliguria in acute glomerulonephritis 182

Ornithine excretion 234 235

Osteitis fibrosa 93 95 ff 100 260

Osteoclasts 88

Osteodystrophy renal 96 ff 243 245 247 248 260

Osteomalacia

and hyperparathyroidism 94 95

in renal tubular disorders 243 244 246 ff 256 258 260 265

in steatorrhea 95

phosphate-creatinine clearance ratio 83 85 95

Osteoporosis in hyperparathyroidism 93

Osteosclerosis in renal failure 98

Otitis media and nephritis 183

Ovary(ies) carcinoid 210 212

## P

Paget's disease and osteoclasts 88

PAH *see p* Aminohippuric acid

Pain

in acute glomerulonephritis 182

in hyperparathyroidism 91

in intestinal carcinoid 215

Pancytopenia in pernicious anemia 32

Paraneoplasia 115 154 158

differential diagnosis 157

treatment 157

Parathormone *see* Parathyroid hormone

Parathyroid glands 81 105

*see also* Hyperparathyroidism Hypoparathyroidism

activity and calcium ion level 90

hypertrophy in glomerular failure 96

in vitamin D deficiency 94 95 260

tumors *see* Adenoma parathyroid

Parathyroid hormone

and bone pH 88 89

and calcium in serum 84 87-89 92

and phosphate excretion 82 ff 86 87 251 ff

Pellagra with carcinoid 216

Penicillin effect in nutritional macrocytic anemia 32

Penicillin corticosteroid therapy 53 ff

Peptic ulcer *see* Ulcer peptic

Peripheral nerve lesions in hemorrhagic disorders 131 148

Peritonitis and corticosteroids 49 50

Pernicious anemia *see* Anemia(s)

Pharyngitis *see* Respiratory tract, infection

Phenindione 160

Phenylalanine excretion 237

Phenylketonuria 234

Pheochromocytoma 216

Phosphatase and renal tubular disorders 239

Phosphate

deprivation test in hyperparathyroidism 92

excretion and bone disease 245

and parathyroid hormone 86-87

in parathyroid disorders 84 ff

excretion in potassium deficiency 256 264 269

in refractory rickets 256 257

measurement 82 85

in serum 82 ff 256

after parathyroidectomy 84 ff 95 96

in osteomalacia 95 257 ff

in renal failure 96 ff

infusion and parathyroid glands 256

for diagnosis of tubular disorders 255 256

intestinal absorption and bone disease 245 ff

renal tubular reabsorption in parathyroid disorders 84 ff 246 256 257

turnover in kidney 250 ff

measurement 251 252 ff

Phosphate-creatinine clearance ratio 82 ff

in renal tubular disorders 237 245

246 250 261 269

in parathyroid disorders 84 ff

- in vitamin D resistant osteomalacia 259
- Phosphate diabetes *see* Diabetes phosphatic
- Phosphaturia *see* Phosphate excretion
- Pitressin resistance in potassium deficiency 241 267 268
- Pituitary gland vitamin B<sub>12</sub> content, 27
- Plasma lyophilized for hemophilia 135 140
- Plasma accelerator 108
- Plasma accelerator globulin 108 155
- Plasma proteolytic enzyme 108 113
- Plasma prothrombin conversion factor 108
- Plasma thromboplastic factor(s) 108 109
- Plasma thromboplastic factor A 108
- Plasma thromboplastic factor B 108
- Plasma thromboplastic factor C 108
- Plasma thromboplastin *see* Thromboplastin
- Plasma thromboplastin antecedent 108 109 111 153
  - deficiency 115 149 152
- Plasma thromboplastin component 108 111 146
- Plasmatic cofactor of thromboplastin 108
- Plasmin 108 113 154
- Plasminogen 108 113
  - activators 113
- Platlet cofactor I 108
- Platelet cofactor II 108
- Platelets 108 109 111 126 127 144 156 162 164 165 217 220 221 226
- Pleural effusion in malignant carcinoid syndrome 218
- Pneumococcus and acute glomerulonephritis 191
- Pneumonia
  - and nephritis 183 191
  - corticosteroid therapy 49 54 55
  - pneumococcal ACTH therapy 46-48
  - penicillin-cortisone therapy 54 55
- Poliomyelitis and corticosteroids 50
- Polydipsia
  - in Lignac Fanconi syndrome 239 240
- in potassium deficiency 265 266 268
- Polyuria
  - in hyperparathyroidism 91
  - in Lignac Fanconi syndrome 239 240
  - in potassium deficiency 265 266
- Posterolateral sclerosis *see* Sclerosis posterolateral
- Potassium
  - deficiency 241 242 246 256 261 272
  - effects on kidney 268 (table)
  - in serum in Fanconi syndrome 240 241 244
- Precursor of serum prothrombin conversion accelerator *see* Pro SPCA
- Prednisone anti inflammatory effects 68
- Pregnancy
  - and pernicious anemia 14 16 21 37
  - and vitamin B<sub>12</sub> levels 21
- Pruritus in hemorrhagic disorders 165
- Primidone 38
- Proaccelerin 108 109 112 117 126 153 155 156 165
  - deficiency 117 155 164 165
  - in bovine serum 156
- Proaccelerin accelerin 108
- Proconvertin 108 112 158 160 164
- Profibrin 108
- Profibrinolysin 108 113
- Proline excretion 237
- Proplasma 108
- Pro SPCA 108 109 112 125 147 153 156
  - deficiency 115 117 158 161 165
- Protein(s)
  - C reactive 68
  - deficiency and megaloblastic anemias 30 31 34
  - excretion *see also* Amino aciduria
    - in acute glomerulonephritis 182 183
    - in experimental nephritis 193 195 196
  - excretion in potassium deficiency 268
  - in renal tubular disorders 245

- Protein(s) (*cont*)  
 heterologous and experimental ne-  
 phritis 193 195  
 impaired absorption 14  
 in serum in experimental nephritis  
 195  
 Proteinuria *see* Proteins(s) excretion  
 Prothrombase 108  
 Prothrombin 108 ff 125 126 147 153  
 154 156  
 consumption test *see* Blood clot-  
 ting tests  
 deficiency 115 117 154 164 165  
 synthesis 110  
 Prothrombin A 108  
 Prothrombin B 108  
 Prothrombin accelerator 108  
 Prothrombin conversion factor 108  
 Prothrombin time *see* Blood clotting  
 tests  
 Prothromboknase 108  
 $\beta$  Prothromboplastin 146  
 Prower defect 106 108  
 Pseudohepophilia 145 226  
 Pseudohypoparathyroidism 233  
 PTA *see* Plasma thromboplastin ante-  
 cedent  
 Pulmonary artery  
 in malignant carcinoid syndrome  
 218 219  
 serotonin content 219  
 Pulmonic valves *see* Cardiovascular  
 system  
 Purines and vitamin B<sub>12</sub> 28  
 Pyelonephritis  
 and corticosteroids 50  
 in cystinuria 236  
 phosphate excretion 250 264  
 and potassium deficiency 269  
 Pylorus obstruction 262
- R**
- Recalcified clotting time *see* Blood  
 clotting tests  
 Rectum *see* Gastrointestinal tract  
 Renal ticks *see* Osteodystrophy renal  
 Reserpine 224 225  
 Respiratory tract  
 and serotonin, 222  
 infection and acute glomerulone-  
 phritis 181 ff  
 in malignant carcinoid syndrome  
 216 217  
 Reticuloendothelial system  
 and corticosteroids 71 73  
 cystine storage 239  
 Rheumatic fever and nephritis 183  
 Rickets  
 and hyperparathyroidism 95  
 nutritional 243 258  
 refractory 256 ff  
 renal, *see* Osteodystrophy renal  
 Rickettsiosis  
 antibiotic-corticosteroid therapy 55  
 corticosteroid therapy 49  
 Roentgenography in hyperparathyroid-  
 ism 93  
 Russell's viper venom use in hemor-  
 rhagic disorders 136 138 160  
 161
- S**
- Saprophytes and corticosteroids 50 52  
 Sarcoidosis and vitamin B<sub>12</sub> binding  
 25  
 Scarlet fever and acute glomerulo-  
 nephritis 183  
 Schilling's method 15 17  
 Schwartzman phenomenon 65 72  
 Sclerosis posterolateral in megaloblas-  
 tic anemias 30 33 34  
 Sepsis  
*see also* Endotoxins Infections  
 and adrenal insufficiency 59  
 and vascular tone 66  
 Serine excretion 237  
 Serotonin 208 213 214 216 217 219  
 221 226  
 and afibrinogenemia 162  
 antidiuretic action 226  
 antimetabolites 223 224  
 in carcinoids 209 213 214 216  
 and cerebral function, 223 ff  
 distribution in body 221  
 and endotoxins, 66  
 excretion, in carcinoid syndrome 215  
 216  
 in mast cell tumor 209  
 metabolism 217 220 ff

- and platelets, 127 217 220 221 226
- and pulmonary artery pressure, 220
- in serum in carcinoid syndrome 214 216
- toxicity 221 222
- Serum
  - prothrombic activity test, *see* Blood clotting tests
  - vitamin B<sub>12</sub> levels, *see* Blood vitamin B<sub>12</sub> content
- Serum accelerator 108
- Serum accelerator globulin 108 156
- Serum prothrombin conversion accelerator *see* SPCA
- Serum trypsin, 108
- Serum tryptogen, 108
- Shigella dysenteriae and corticosteroids, 65
- Shock and fibrinolysis, 113
- Silicone(s) use in blood clotting test, 116
- Sinusitis and nephritis, 183
- Skin
  - infections, and acute glomerulonephritis 181 ff
  - in malignant carcinoid syndrome 217
- Smallpox 49
- Sodium excretion, and tubular reabsorption, 231 232
- Sodium bicarbonate
  - excretion in Lignac Fanconi syndrome, 239
  - in potassium deficiency 269
- Somatotropin and corticosteroids, 63 68
- SPCA, 108
- Spinal cord, *see* Central nervous system
- Spleen
  - and corticosteroids, 64 71
  - in hemorrhagic disorders 128 144 148 161
- Sprue 13 14 16 17 30 34 35
  - see also* Anemia(s) megaloblastic
- Stable factor 108 112, 158
- Staphylococci infections, and corticosteroids, 49 ff.
- Steatorrhea
  - idiopathic, 34
  - and osteomalacia, 95
  - and potassium deficiency 269
- Steroids adrenocortical, *see* Corticosteroids specific substances
- Stomach, *see* Gastrointestinal tract
- Stool method for vitamin B<sub>12</sub> study *see* Heinle-Welch method
- Streptococci hemolytic A
  - and glomerulonephritis 181 182 ff
  - serologic types and glomerulonephritis 184 185 187 ff
  - hemolytic  $\beta$  and glomerulonephritis 190
  - nephritogenic, for experimental nephritis, 200-201
- Streptococciosis and corticosteroids 50 52
- Streptococcus kidney mixtures for experimental nephritis, 200-201
- Streptokinase, 113
- Streptomyces griseus for vitamin B<sub>12</sub> study 14
- Streptomycin-corticosteroid therapy 53-54
- Stuart factor 108 109 125 147 153 160
  - deficiency 115 117 160 165
- Subacute bacterial endocarditis *see* Endocarditis subacute bacterial
- Subacute combined degeneration, *see* Sclerosis, posterolateral
- Surgery in hemophilia, 137 139
- Swan neck, renal tubules *see* Kidney(s) tubules, anatomic abnormalities
- Sweating in malignant carcinoid syndrome, 217
- Swelling *see* Edema
- Syndactylism with parabemophilia, 155

## T

- Tachycardia and corticosteroids, 64
- Tachypnea and corticosteroids, 64
- Teeth
  - extraction, in hemophilia, 129 138-139
  - in hyperparathyroidism, 94
- Telangiectasia in malignant carcinoid syndrome, 217
- Teratoma(s) and carcinoids, 210 212

- Testes  
   carcinoid 210  
   after corticosteroid therapy of mumps orchitis 50  
 Tetanus and corticosteroids 49  
 Tetany  
   in osteomalacia after phosphate in fusion 256  
   in steatorrhea 95  
 Tetartoehemophilia 152  
 Tetracycline corticosteroid therapy 53 ff  
 Thirst *see* Polydipsia  
 Threonine excretion 237  
 Thrombase 108  
 Thrombin 108 ff 126 156  
   bovine for hemophilic bleeding 136 138  
 Thrombin time *see* Blood clotting tests  
 Thrombobene 108  
 Thrombocyte(s) 108  
 Thrombocytopathia serotonin levels 226  
 Thrombocytopenia *see* Thrombopenia  
 Thrombocytosis and serotonin 226  
 Thromboelastograph 114  
 Thrombogen 108  
 Thrombokinasase 108  
 Thrombopenia  
   congenital 115 118 156 162 163 164  
   after heterologous antihemophilic factor therapy 136  
   and serotonin 226  
 Thromboplastic plasma component 108  
 Thromboplastin 108 ff 126 154 155 156  
   generation test *see* Blood clotting tests  
 Thromboplastinogen 108  
 Thymus and corticosteroids 64 71  
 Thyroxine and corticosteroids 66  
 Tissue thromboplastin *see* Thromboplastin  
 Tonsillitis *see* Respiratory tract infection  
 Toxicity manifestations and corticosteroids 64 ff  
 Transfusion, *see* Blood transfusion  
 Trichinosis and corticosteroids 49  
 Trypsin 108  
 Tryptophan 216 221  
   depletion in malignant carcinoid syndrome 216 220  
 Tuberculosis  
   antibacterial corticosteroid therapy 55 56  
   and corticosteroids 49 ff 71  
 Tubular function *see* Kidney(s) tubules function  
 Tumors  
   *see also* specific tumors  
   and corticosteroids 68  
 Typhoid fever  
   antibiotic corticosteroid therapy 55  
   and corticosteroid 49  
 Tyrosine excretion 237
- ### U
- Ulcerative colitis *see* Colitis ulcerative  
 Ulcers peptic in hyperparathyroidism 91  
 Umbilical vein blood hemophilic defect, 128  
 Umbilicus bleeding in hemorrhagic disorders 128 161  
 Uranium poisoning *see* Heavy metals poisoning  
 Uremia  
   in experimental nephritis 196  
   and secondary hyperparathyroidism 94 ff  
 Uric acid excretion in Lignac Fanconi syndrome 243  
 Urinary excretion method for vitamin B<sub>12</sub> study *see* Schilling's method  
 Urinary tract in hemorrhagic disorders 130 143 154 165  
 Urine  
   in acute glomerulonephritis 182  
   specific gravity in Lignac Fanconi syndrome 239 ff  
   *see also* Isosthenuria Hyposthenuria
- ### V
- Valine excretion 237  
 Valves  
   cardiac *see* Cardiovascular system  
   pulmonic *see* Cardiovascular system  
 Varicella *see* Chickenpox

- Vascular hemophilia *see* Hemophilia  
vascular
- Vascular tone  
and corticosteroids 67 69  
in sepsis 66  
and serotonin 226
- Vegetarianism and nutritional macro  
cytic anemia 31
- Virus(es) infections and corticoste  
roids 49 ff 71
- Vitamin A impaired absorption 14 34
- Vitamin B<sub>12</sub>  
absorption 14 ff 18 20 21  
in American diet, 12  
binding 13 18 20 24 25 29  
in body 12 14 25 27  
and corticosteroids 63  
deficiency 12 ff 18 25 28 ff  
excretion 13 15 22 25 ff  
formation by colon bacteria 13 27  
intestinal 18 19  
due to intestinal bacteria 18 35 36  
metabolism in megaloblastic anemias  
11-44  
and nucleoprotein synthesis 28 ff  
radioactive studies 14 18  
*see also* specific organs and tissues  
storage 13 17 22 ff 25 27
- Vitamin D  
and bone 95
- deficiency and hyperparathyroidism  
94 96 261  
for hypoparathyroidism 81  
intoxication 88 97 242 259  
in renal failure 100 247  
and renal tubular disorders 238 246  
247  
resistance *see also* Rickets refrac  
tory  
and serum calcium 258 259  
and tubular phosphate clearance  
258 259
- Vitamin K  
and blood clotting 110 112  
for hemorrhagic disorders 154 158  
160 166  
impaired absorption 14 34
- Vomiting  
in acute glomerulonephritis 182  
in hyperparathyroidism 91
- W
- Waterhouse Friderichsen syndrome cor  
ticosteroid therapy 60
- Weakness in hyperparathyroidism 91
- Weight loss in intestinal carcinoid 215
- Wilson's disease *see* Hepatolenticular  
degeneration
- Y
- Yohimbine 224



- Testes  
   carcinoid 210  
   after corticosteroid therapy of mumps orchitis 50  
 Tetanus and corticosteroids 49  
 Tetany  
   in osteomalacia after phosphate in fusion 256  
   in steatorrhea 95  
 Tetartoheophilia 152  
 Tetracycline corticosteroid therapy 53 ff  
 Thirst *see* Polydipsia  
 Threonine excretion 237  
 Thrombase 108  
 Thrombin 108 ff 126 156  
   bovine for hemophilic bleeding 136 138  
 Thrombin time *see* Blood clotting tests  
 Thrombobene 108  
 Thrombocyte(s) 108  
 Thrombocytopathia serotonin levels 226  
 Thrombocytopenia *see* Thrombopenia  
 Thrombocytosis and serotonin 226  
 Thromboelastograph 114  
 Thrombogen 108  
 Thrombokinas 108  
 Thrombopenia  
   congenital 115 118 156 162 163 164  
   after heterologous antihemophilic factor therapy 136  
   and serotonin 226  
 Thromboplastic plasma component, 108  
 Thromboplastin 108 ff 126 154 155 156  
   generation test *see* Blood clotting tests  
 Thromboplastinogen 108  
 Thymus and corticosteroids 64 71  
 Thyroxine and corticosteroids 66  
 Tissue thromboplastin *see* Thromboplastin  
 Tonsillitis *see* Respiratory tract infection  
 Toxicity manifestations and corticosteroids 64 ff  
 Transfusion *see* Blood transfusion  
 Trichinosis and corticosteroids 49  
 Trypsin 108  
 Tryptophan 218 221  
   depletion in malignant carcinoid syndrome 216 220  
 Tuberculosis  
   antibacterial corticosteroid therapy 55 56  
   and corticosteroids 49 ff 71  
 Tubular function *see* kidney(s) tubules function  
 Tumors  
   *see also* specific tumors  
   and corticosteroids 68  
 Typhoid fever  
   antibiotic corticosteroid therapy 55  
   and corticosteroid 49  
 Tyrosine excretion 237
- ## U
- Ulcerative colitis *see* Colitis ulcerative  
 Ulcers peptic in hyperparathyroidism 91  
 Umbilical vein blood hemophilic defect, 128  
 Umbilicus bleeding in hemorrhagic disorders 128 161  
 Uranium poisoning *see* Heavy metals poisoning  
 Uremia  
   in experimental nephritis 196  
   and secondary hyperparathyroidism 94 ff  
 Uric acid excretion in Lignac Fanconi syndrome 243  
 Urinary excretion method for vitamin B<sub>12</sub> study *see* Schilling's method  
 Urinary tract in hemorrhagic disorders 130 143 154 165  
 Urine  
   in acute glomerulonephritis 182  
   specific gravity in Lignac Fanconi syndrome 239 ff  
   *see also* Isosthenuria Hyposthenuria
- ## V
- Valine excretion 237  
 Valves  
   cardiac *see* Cardiovascular system  
   pulmonic *see* Cardiovascular system  
 Varicella *see* Chickenpox

- Vascular hemophilia *see* Hemophilia  
vascular
- Vascular tone  
and corticosteroids 67 69  
in sepsis 66  
and serotonin 226
- Vegetarianism and nutritional macrocytic anemia 31
- Virus(es) infections and corticosteroids 49 ff 71
- Vitamin A impaired absorption, 14 34
- Vitamin B<sub>12</sub>  
absorption, 14 ff 18 20 21  
in American diet, 12  
binding 13 18 20 24 25 29  
in body 12 14 25 27  
and corticosteroids 63  
deficiency 12 ff 18 25 28 ff  
excretion 13 15 22 25 ff  
formation by colon bacteria 13 27  
intestinal 18 19  
due to intestinal bacteria 18 35 36  
metabolism in megaloblastic anemias 11-44  
and nucleoprotein synthesis 28 ff  
radioactive studies 14 18  
*see also* specific organs and tissues  
storage 13 17 22 ff 25 27
- Vitamin D  
and bone 95  
deficiency and hyperparathyroidism 94 96 261  
for hypoparathyroidism 81  
intoxication 88 97 242 259  
in renal failure 100 247  
and renal tubular disorders 238 246 247  
resistance *see also* Rickets refractory  
and serum calcium 258 259  
and tubular phosphate clearance 258 259
- Vitamin K  
and blood clotting 110 112  
for hemorrhagic disorders 154 158 160 166  
impaired absorption 14 34
- Vomiting  
in acute glomerulonephritis 182  
in hyperparathyroidism 91
- W
- Waterhouse Friderichsen syndrome corticosteroid therapy 60
- Weakness in hyperparathyroidism 91
- Weight loss in intestinal carcinoid 215
- Wilson's disease *see* Hepatolenticular degeneration
- Y
- Yohimbine 224